

15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



Con il Patrocinio di

Ministero della Salute



Consiglio Nazionale delle Ricerche



Promosso da



e da

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV

**ASA Onlus**, Associazione Solidarietà AIDS Onlus

**C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS

**EpaC Onlus**, Associazione EpaC Onlus

**LILA**, Lega Italiana per la Lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**Milano Check Point**, Associazione Milano Check Point

**NADIR**, Associazione Nadir

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS**, Rete persone LGBT+ sieropositive Aps

**Scientific Programme**

[www.icar2023.it](http://www.icar2023.it)

Seguici su #ICAR2023





Inquadra il **QRcode**  
 e scarica l'**App**



Inquadra il **QRcode**  
 e collegati al **sito web**

### **NOTA IMPORTANTE PER RELATORI E PRESENTING AUTHOR**

Il comitato scientifico di ICAR crede fermamente che il linguaggio sia un potente strumento per plasmare le convinzioni e influenzare i comportamenti, in particolare nell'affrontare lo stigma che circonda infezioni croniche come l'HIV e l'epatite virale. Pertanto, invitiamo tutti i partecipanti a dare la priorità al linguaggio centrato sulla persona e ad essere consapevoli di come il loro linguaggio e i materiali presentati siano in linea con questo principio. Per aiutare in questo sforzo, raccomandiamo l'adozione della terminologia approvata da UNAIDS, per esempio usando i termini "persone che vivono con HIV" piuttosto che "persone HIV-positive o sieropositive". Insieme, promuoviamo l'inclusività e il rispetto per tutti gli individui affetti da HIV ed altre infezioni croniche.

Seguici su



[www.icar2023.it](http://www.icar2023.it)

### **Sede Congressuale**

**Università degli Studi Aldo Moro**

Piazza Cesare Battisti, 3 - 70121 Bari

### **Provider e Segreteria Organizzativa**

**Effetti srl**

Via G.B. Giorgini, 16 - 20151 Milano

Tel. +39 02 3343281 - Fax +39 02 38002105 - [icar@effetti.it](mailto:icar@effetti.it) - [@ICARcongress](https://www.instagram.com/ICARcongress)



## Endorsement

### ISTITUZIONI

**Ministero della Salute**



**Consiglio Nazionale delle Ricerche**

**TOR VERGATA**  
UNIVERSITÀ DEGLI STUDI DI ROMA



con il patrocinio di  
**Università di Foggia**



### SOCIETÀ SCIENTIFICHE

- AIMI**, Associazione Infermieri Malattie Infettive
- AISF**, Associazione Italiana per lo Studio del Fegato
- AMCLI**, Associazione Microbiologi Clinici Italiani
- SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
- SIM**, Società Italiana di Microbiologia
- SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
- SIMIT**, Società Italiana di Malattie Infettive e Tropicali
- SITA**, Società italiana per la Terapia Antinfettiva
- SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology

### ASSOCIAZIONI PAZIENTI E DI COMUNITÀ

- ANLAIDS**, Associazione Nazionale per la lotta all'AIDS
- ARCIGAY**, Associazione LGBT+ Italiana
- ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV
- ASA Onlus**, Associazione Solidarietà AIDS Onlus
- CAMA LILA**
- C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS
- Differenza Lesbica**, Associazione culturale laica, antifascista, antirazzista per le donne lesbiche, bisessuali, transessuali
- EpaC Onlus**, EpaC Associazione Onlus
- Fondazione Villa Maraini Onlus**, Agenzia Nazionale di Croce Rossa Italiana per le dipendenze patologiche
- Gay Center**, casa di tutte le persone LGBT+ (lesbiche, gay, bisex e trans)
- IAPAC**, International Association of Providers of AIDS care
- LILA**, Lega Italiana per la Lotta contro l'AIDS
- MARIO MIELI**, Circolo di Cultura Omosessuale
- Medici con l'Africa - CUAMM**
- Milano Check Point**, Associazione Milano Check Point
- MIT**, Movimento Identità Trans
- NADIR**, Associazione Nadir
- NPS Italia aps**
- PLUS**, Rete persone LGBT+ sieropositive Aps



## Comitato Scientifico

### Presidenza del Congresso

**Francesca Ceccherini Silberstein**, Roma  
**Michele Formisano**, Taranto  
**Sergio Lo Caputo**, Foggia  
**Annalisa Saracino**, Bari

### Segreteria Scientifica

**Chiara Agrati**, Roma  
**Alessandra Bandera**, Milano  
**Mara Biasin**, Milano  
**Andrea Calcagno**, Torino  
**Giulia Valeria Calvino**, Roma  
**Daniele Calzavara**, Milano  
**Antonella Castagna**, Milano  
**Anna Maria Cattelan**, Padova  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Andrea Cossarizza**, Modena  
**Gabriella d'Ettore**, Roma  
**Nicoletta Frattini**, Milano  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Giovanni Guaraldi**, Modena  
**Miriam Lichtner**, Latina  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Caserta  
**Giulia Carla Marchetti**, Milano  
**Paolo Meli**, Bergamo  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Massimo Puoti**, Milano  
**Stefano Rusconi**, Milano  
**Maria Santoro**, Roma  
**Loredana Sarmati**, Roma  
**Valentina Svicher**, Roma  
**Carlo Torti**, Catanzaro  
**Ombretta Turriziani**, Roma  
**Maurizio Zazzi**, Siena

### Presidente ICAR

**Franco Maggiolo**, Bergamo

### Segreteria Corsi pregressuali

**Daniele Calzavara**, Milano  
**Mario Cascio**, Milano  
**Eugenio Nelson Cavallari**, Roma  
**Francesco Di Gennaro**, Bari  
**Giuseppe Lapadula**, Monza  
**Francesca Lombardi**, Roma

### Comitato Annuale di Programma (CAP)

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Antonella Castagna**, Milano  
**Maria Luisa Cosmaro**, Milano  
**Antonella d'Arminio Monforte**, Milano  
**Massimo Farinella**, Roma  
**Andrea Gori**, Milano  
**Franco Maggiolo**, Bergamo  
**Claudio Maria Mastroianni**, Roma  
**Cristina Mussini**, Modena  
**Carlo Federico Perno**, Roma

### SPC

(Scientific Programme Committee)

**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Guido Antonelli**, Roma  
**Matteo Bassetti**, Genova  
**Paolo Bonfanti**, Monza MB

### Coordinatore Abstract

**Antonio Di Biagio**, Genova

**Stefano Bonora**, Torino  
**Sergio Carbonara**, Bari  
**Arnaldo Caruso**, Brescia  
**Antonio Cascio**, Palermo  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Anna Maria Cattelan**, Padova  
**Benedetto Maurizio Cesesia**, Catania  
**Antonella Cingolani**, Roma  
**Massimo Clementi**, Milano  
**Andrea Cossarizza**, Modena  
**Marco Cusini**, Milano  
**Antonella d'Arminio Monforte**, Milano  
**Antonio Di Biagio**, Genova  
**Giovanni Di Perri**, Torino  
**Massimo Di Pietro**, Firenze  
**Vincenzo Esposito**, Napoli  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Sergio Lo Caputo**, Foggia  
**Fabrizio Maggi**, Varese  
**Paolo Maggi**, Napoli  
**Franco Maggiolo**, Bergamo  
**Giulia Carla Marchetti**, Milano  
**Claudio Maria Mastroianni**, Roma  
**Cristina Mussini**, Modena  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giustino Parruti**, Pescara  
**Carlo Federico Perno**, Roma  
**Massimo Puoti**, Milano  
**Giuliano Rizzardini**, Milano  
**Stefano Rusconi**, Legnano MI  
**Laura Sighinolfi**, Ferrara  
**Guido Silvestri**, Atlanta, USA  
**Barbara Suligoj**, Roma  
**Marcello Tavio**, Ancona  
**Carlo Torti**, Catanzaro  
**Maurizio Zazzi**, Siena



**CsC****(Community  
sub-Committee)****Alberto Bignardi**, Bologna  
**Maria Grazia Di Benedetto**, Catania**Ivan Gardini**, Forlì  
**Ada Moznich**, Milano  
**Giulia Valeria Calvino**, Roma  
**Massimo Farinella**, Roma  
**Sandro Mattioli**, Bologna**Stefano Patrucco**, Torino  
**Daniele Calzavara**, Milano  
**Nicoletta Frattini**, Milano  
**Paolo Meli**, Bergamo  
**Filippo Schloesser**, Roma**Faculty****Chiara Agrati**, Roma  
**Claudia Alteri**, Milano  
**Massimo Andreoni**, Roma  
**Gioacchino Angarano**, Bari  
**Andrea Antinori**, Roma  
**Spinello Antinori**, Milano  
**Guido Antonelli**, Roma  
**Daniele Armenia**, Roma  
**Sergio Babudieri**, Sassari  
**Alessandra Bandera**, Milano  
**Francesco Benedetti**, Milano  
**Dria Paola Betti**, Taranto  
**Mara Biasin**, Cernobbio CO  
**Teresa Bini**, Milano  
**Emiliano Bissio**, Madrid, Spain  
**Pierluigi Blanc**, Pistoia  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Luisa Broganzoli**, Milano  
**Bianca Bruzzone**, Genova  
**Giovanni Battista Buccoliero**, Taranto  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Giulia Valeria Calvino**, Roma  
**Daniele Calzavara**, Milano  
**Anna Caraglia**, Roma  
**Sergio Carbonara**, Bari  
**Elisabetta Carini**, Milano  
**Antonio Cascio**, Palermo  
**Mario Cascio**, Milano  
**Antonella Castagna**, Milano  
**Francesco Castelli**, Brescia  
**Anna Maria Cattelan**, Padova  
**Roberto Cauda**, Roma  
**Eugenio Nelson Cavallari**, Roma  
**Francesca Ceccherini Silberstein**, Roma  
**Salvatore Cecere**, Bologna  
**Benedetto Maurizio Cesia**, Catania  
**Giovanni Cenderello**, Sanremo IM**Massimo Cernuschi**, Milano  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Mario Salvatore Clerici**, Milano  
**Patrizia Elisa Comoli**, Pavia  
**Michele Conversano**, Taranto  
**Nicola Coppola**, Napoli  
**Maria Luisa Cosmaro**, Milano  
**Andrea Cossarizza**, Modena  
**Alessandro Cozzi-Lepri**, London, UK  
**Rosario Cultrera**, Ferrara  
**Antonella d'Arminio Monforte**, Milano  
**Gabriella d'Ettore**, Roma  
**Frederico da Silva**, Milano  
**Sara De Biasi**, Modena  
**Michele De Gennaro**, Lucca  
**Andrea De Maria**, Genova  
**Francesco Giuseppe De Rosa**, Torino  
**Elisabetta Degasperis**, Milano  
**Antonio Di Biagio**, Genova  
**Francesco Di Gennaro**, Bari  
**Simona Di Giambenedetto**, Roma  
**Giovanni Di Perri**, Torino  
**Margherita Errico**, Milano  
**Vincenzo Esposito**, Napoli  
**Massimo Farinella**, Roma  
**Sergio Ferrara**, Foggia  
**Paola Fiscaro**, Parma  
**Emanuele Focà**, Brescia  
**Michele Formisano**, Taranto  
**Antonina Franco**, Siracusa  
**Nicoletta Frattini**, Milano  
**Roberta Gagliardini**, Roma  
**Caitjan Gainty**, London, UK  
**Rosario Galipò**, Roma  
**Laura Galli**, Milano  
**Massimo Galli**, Milano  
**Martin Gartland**, Cary, USA**Ivan Gentile**, Napoli  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Foteini Gkalapi**, Brussels, Belgium  
**Daniele Gianfrilli**, Roma  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Giuseppina Giupponi**, Como  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Roberto Gulminetti**, Pavia  
**Roberto Paolo Iachetta**, Sassuolo MO  
**Giuseppe Ippolito**, Roma  
**Michele Lanza**, Milano  
**Giuseppe Lapadula**, Monza  
**Adriano Lazzarin**, Milano  
**Filippo Leserri**, Roma  
**Miriam Lichtner**, Latina  
**Sergio Lo Caputo**, Foggia  
**Riccardo Lolatto**, Milano  
**Francesca Lombardi**, Roma  
**Pier Luigi Lopalco**, Lecce  
**Giordano Madeddu**, Sassari  
**Fabrizio Maggi**, Roma  
**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Michele Manfredini**, Milano  
**Francesco Paolo Maraglino**, Roma  
**Giulia Carla Marchetti**, Milano  
**Bruno Marchini**, Roma  
**Matteo Marconi**, Roma  
**Claudio Maria Mastroianni**, Roma  
**Sandro Mattioli**, Bologna  
**Francesco Mazzotta**, Firenze  
**Valentina Mazzotta**, Roma  
**Davide Meli**, Bergamo  
**Paolo Meli**, Bergamo  
**Ilaria Mercurio**, Bergamo  
**Valeria Micheli**, Milano

**Sergio Milano**, Milano  
**Davide Moschese**, Milano  
**Ada Moznich**, Milano  
**Cristina Mussini**, Modena  
**Emanuele Nicastrì**, Roma  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Graziano Onder**, Milano  
**Giancarlo Orofino**, Torino  
**Antonella Palmitesta**, Roma  
**Saverio Parisi**, Padova  
**Roberto Parrella**, Napoli  
**Giustino Parruti**, Pescara  
**Stefano Patrucco**, Torino  
**Ilenia Pennini**, Padova  
**Carlo Federico Perno**, Roma  
**Marina Pierdominici**, Roma  
**Carmela Pinnetti**, Roma  
**Mariacristina Polisenò**, Foggia

**Gian Marco Prandi**, Roma  
**Tullio Salvatore Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Maria Eugenia Quiros Roldan**, Brescia  
**Laura Amelia Rachele Rancilio**, Roma  
**Marco Ridolfi**, Roma  
**Diego Ripamonti**, Bergamo  
**Giuliano Rizzardini**, Milano  
**Felipe Rogatto**, London, UK  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Legnano MI  
**Francesco Saladini**, Siena  
**Shayon Salehi**, Brentford, UK  
**Teresa Antonia Santantonio**, Foggia  
**Maria Santoro**, Roma  
**Luca Saracini**, Ancona  
**Annalisa Saracino**, Bari  
**Loredana Sarmati**, Roma  
**Carolina Scagnolari**, Roma

**Filippo Schloesser**, Roma  
**Vincenzo Spagnuolo**, Milano  
**Nicola Squillace**, Monza  
**Barbara Suligoj**, Roma  
**Valentina Svicher**, Roma  
**Chiara Taibi**, Roma  
**Alessandro Tavelli**, Milano  
**Marcello Tavio**, Ancona  
**Camilla Tincati**, Milano  
**Carlo Torti**, Catanzaro  
**Daria Lucia Trabattoni**, Milano  
**Ombretta Turriziani**, Roma  
**Emanuela Vaccher**, Aviano PN  
**Stefano Vella**, Roma  
**Serena Venturelli**, Bergamo  
**Ilaria Vicenti**, Siena  
**Francesca Vichi**, Firenze  
**Donatello Zagato**, Milano  
**Maurizio Zazzi**, Siena

## Abstract Reviewers

**Isabella Abbate**, Roma  
**Chiara Agrati**, Roma  
**Claudia Alteri**, Milano  
**Guido Antonelli**, Roma  
**Daniele Armenia**, Roma  
**Lorenzo Badia**, Imola BO  
**Alessandra Bandera**, Milano  
**Mara Biasin**, Cernobbio CO  
**Teresa Bini**, Milano  
**Paolo Bonfanti**, Monza  
**Stefano Bonora**, Torino  
**Andrea Calcagno**, Torino  
**Annapaola Callegaro**, Bergamo  
**Giulia Valeria Calvino**, Roma  
**Daniele Calzavara**, Milano  
**Antonella Castagna**, Milano  
**Dario Cattaneo**, Milano  
**Anna Maria Cattelan**, Padova  
**Benedetto M. Celesia**, Catania  
**Massimo Cernuschi**, Milano  
**Stefania Cicalini**, Roma  
**Antonella Cingolani**, Roma  
**Paola Cinque**, Milano  
**Nicola Coppola**, Napoli  
**Maria Luisa Cosmaro**, Milano

**Andrea Cossarizza**, Modena  
**Alessandro Cozzi-Lepri**, London, UK  
**Gabriella d'Ettore**, Roma  
**Antonio Di Biagio**, Genova  
**Carlo Ferrari**, Parma  
**Giorgia Fracca**, Milano  
**Nicoletta Frattini**, Milano  
**Roberta Gagliardini**, Roma  
**Anna Maria Geretti**, Roma  
**Cristina Gervasoni**, Milano  
**Andrea Giacomelli**, Milano  
**Nicola Gianotti**, Milano  
**Enrico Girardi**, Roma  
**Andrea Gori**, Milano  
**Giovanni Guaraldi**, Modena  
**Miriam Lichtner**, Latina  
**Giuseppina Liuzzi**, Roma  
**Sergio Lo Caputo**, Foggia  
**Lucia Lopalco**, Milano  
**Giordano Madeddu**, Sassari  
**Paolo Maggi**, Caserta  
**Franco Maggiolo**, Bergamo  
**Giulia C. Marchetti**, Milano  
**Maria Mazzitelli**, Padova  
**Valentina Mazzotta**, Roma

**Paolo Meli**, Bergamo  
**Valeria Micheli**, Milano  
**Ada Moznich**, Milano  
**Silvia Nozza**, Milano  
**Giuseppe Nunnari**, Messina  
**Giancarlo Orofino**, Torino  
**Carmela Pinnetti**, Roma  
**Tullio Salvatore Prestileo**, Palermo  
**Massimo Puoti**, Milano  
**Roberto Rossotti**, Milano  
**Stefano Rusconi**, Legnano MI  
**Francesco Saladini**, Siena  
**Maria Santoro**, Roma  
**Loredana Sarmati**, Roma  
**Vincenzo Spagnuolo**, Milano  
**Nicola Squillace**, Monza  
**Valentina Svicher**, Roma  
**Lucia Taramasso**, Genova  
**Camilla Tincati**, Milano  
**Carlo Torti**, Catanzaro  
**Ombretta Turriziani**, Roma  
**Alessandra Vergori**, Roma  
**Ilaria Vicenti**, Siena  
**Francesca Vichi**, Firenze  
**Maurizio Zazzi**, Siena



## Care Colleghe e Colleghi,

È con grande piacere che vi diamo il **Benvenuto a Bari** ad **ICAR 2023**.

**“From prevention to cure: ready for new challenges”** è il claim che sostiene questa **15° edizione del Congresso** e che caratterizza il programma scientifico, orientando la riflessione sulle attuali sfide ed opportunità per la promozione della salute nel campo delle infezioni virali.

Riteniamo sia il momento giusto per far emergere una riflessione matura dalla recente esperienza di pandemia Covid-19.

Il Congresso vuole dunque offrire la possibilità di far convergere e confrontare le migliori iniziative in campo scientifico e di ricerca medica, focalizzando l'attenzione sulla centralità della persona, sull'applicazione di un approccio multidisciplinare, su nuovi modelli organizzativi, sul rafforzamento degli interventi di sorveglianza epidemiologica e di prevenzione di HIV ma anche di altre malattie infettive.

Nelle tre giornate congressuali - caratterizzate da una forte interazione tra **ricerca di base, traslazionale, virologica, clinica e sociale** e da un approccio **abstract-driven** - i **temi HIV/AIDS, SARS-CoV-2, epatiti, infezioni sessualmente trasmesse, virus emergenti e/o riemergenti, vaccini, infezioni nell'immunocompromesso**, restano al centro del dibattito scientifico.

Con questo spirito, forti del percorso, dell'esperienza e del riscontro acquisiti in questi anni, manteniamo intatto l'impegno verso i nostri giovani ricercatori, il personale sanitario non-medico, la Community, la società civile, attraverso le **Scholarship, ICAR-CROI Awards, Contest RaccontART, il Community Village**.

Vi invitiamo a visitare la **Mostra Multimediale “Una storia positiva”**, il presidio destinato all'offerta gratuita per il **Test Rapido HIV-HCV** e la **Mostra** dedicata al bicentenario della nascita di **Louis Pasteur**, appositamente riaperta in occasione del Congresso.

Un ringraziamento speciale va al Comitato ed alla Segreteria Scientifica, al Coordinatore Abstract ed ai Revisori, agli Organismi di Governo ICAR, a SIMIT, alle Associazioni Pazienti e di Comunità, alle Istituzioni e Società Scientifiche, agli Studenti, le Scuole e le Giurie del Concorso RaccontART, alla Municipalità di Bari ed, infine, agli Sponsor che ci hanno consentito di ospitare centinaia di partecipanti.

## Nice to ICAR you!

### I Presidenti



Francesca  
Ceccherini Silberstein



Michele  
Formisano



Sergio  
Lo Caputo



Annalisa  
Saracino



15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



**PROGRAMME**  
**AT A GLANCE**



ORARI	AUDITORIUM ALDO MORO	AULA V	AULA IV	AULA III
15:00 17:30	PRE-CONFERENCE ADVANCED COURSE <b>Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer</b>	 SPECIAL SESSION <b>RaccontART</b> <b>Contest Awards: incontro con le scuole finaliste e premiazione</b>	PRE-CONFERENCE ADVANCED COURSE <b>Clinical virology: dealing with HIV infection today</b>	PRE-CONFERENCE ADVANCED COURSE <b>HIV infection in the migrant and refugee population</b>
	TEATRO PETRUZZELLI			
18:00 19:00	 SATELLITE SYMPOSIUM <b>HIV and COVID-19: where we are and where we are going</b>			
19:00 20:30	<p><b>ICAR 2023 Opening Session</b></p> <p><i>Chairs: F. Ceccherini Silberstein, M. Formisano, S. Lo Caputo, A. Saracino</i></p> <p>19:00-19:20 <b>Introducing ICAR 2023. Chairs and Authorities' welcome addresses</b></p> <p><b>RaccontART: the three Winners</b></p> <p>19:20-20:20 <b>Keynote Lectures</b></p> <p><i>Chairs: A. d'Arminio Monforte, G. Ippolito</i></p> <p>19:20-19:50 <b>Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"</b> <i>C. Gainty</i></p> <p><i>Chairs: G.V. Calvino, F. Schloesser</i></p> <p>19:50-20:20 <b>Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"</b> <i>M. Formisano</i></p> <p>20:20-20:30 <b>Closing remarks</b></p>			
20:30 23:30	<p><b>ICAR 2023 Welcome Reception</b></p>			

 CONFERENCE SESSIONS     ORAL COMMUNICATIONS     SATELLITE SESSIONS     SPONSORED SESSIONS     PARALLEL SESSIONS



ORARI	AUDITORIUM ALDO MORO	AULA V	AULA IV	AULA III	AULA II	AULA I
09:00 10:00	<b>Keynote Lectures</b>					
10:05 11:05	SYMPOSIUM <b>Controversies in HIV clinical virology</b>	SPONSORED SYMPOSIUM <b>Do mAbs still play a role in the early treatment of COVID-19 patients?</b>	EXPERT MEETING <b>Individualization and evolution of HIV management with the next generation of NNRTI: the future is now</b>	ORAL COMMUNICATIONS <b>Emerging immunological and virological concepts in viral hepatitis</b>	ORAL COMMUNICATIONS <b>Epidemiology trends in infections</b>	
11:10 12:10	SPONSORED SYMPOSIUM <b>HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV</b>	SATELLITE SYMPOSIUM <b>A new era of HDV treatment: relevance of HDV control in coinfectd patients</b>	ORAL COMMUNICATIONS <b>Immune response in SARS-CoV-2</b>	ORAL COMMUNICATIONS <b>Inflammation: a major pathogenetic process</b>		SPECIAL SESSION <b>Health and prevention in transgender people</b>
12:15 13:15	SYMPOSIUM <b>The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs</b>	ORAL COMMUNICATIONS <b>Outcome in first-line regimens</b>	EXPERT MEETING <b>Every left is lost, let's vaccinate</b>	ORAL COMMUNICATIONS <b>One size does not fit all</b>	ORAL COMMUNICATIONS <b>Early treatment for COVID-19</b>	PARALLEL SESSION <b>ARCA Scientific Board Meeting</b>
13:20 14:20	ORAL COMMUNICATIONS <b>Clinical issues blinking to laboratory</b>	ORAL COMMUNICATIONS <b>Viral infections old and new</b>	ORAL COMMUNICATIONS <b>Preferences limitations and long term outcomes</b>	ORAL COMMUNICATIONS <b>Immune response to viruses</b>	ORAL COMMUNICATIONS <b>COVID-19 outcome in special population</b>	
14:30 15:30	SPONSORED SYMPOSIUM <b>B/F/TAF: your trusted partner also in apparently un-complicated patients</b>	ORAL COMMUNICATIONS <b>Antiviral treatment in COVID-19</b>	EXPERT MEETING <b>Long-acting antimicrobial experiences in real world patients: toward paradigm change?</b>	ORAL COMMUNICATIONS <b>HIV: much left to do</b>	ORAL COMMUNICATIONS <b>Cardiovascular and malignancies</b>	
15:35 16:35	SYMPOSIUM <b>New issues on antiretroviral drug optimization</b>	SATELLITE SYMPOSIUM <b>From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy</b>	ORAL COMMUNICATIONS <b>Severe clinical issues in HIV-1 infection</b>	ORAL COMMUNICATIONS <b>Oral or injectable 2-drug regimens</b>	ORAL COMMUNICATIONS <b>Prevention, access and engagement</b>	SPECIAL SESSION <b>The Italian Fast-track Cities: strengths and weaknesses of a growing movement</b>
16:40 18:00	SYMPOSIUM <b>How to manage Heavily Treatment-Experienced patients (HTE)</b>	SYMPOSIUM <b>Immunotherapies in chronic viral infections: what will the future bring?</b> 16:40-17:40	ORAL COMMUNICATIONS <b>The increasing burden of STIs</b> 16:40-17:50	ORAL COMMUNICATIONS <b>Vaccine in frail patients</b> 16:40-17:50	ORAL COMMUNICATIONS <b>Clinical outcome of SARS-CoV-2 infection</b> 16:40-17:40	

LUNCH TIME 12:00-14:30



ORARI	AUDITORIUM ALDO MORO	AULA V	AULA IV	AULA III	AULA II	AULA I
08:30 09:00	SPECIAL SESSION <b>ICAR-CROI Awards 2023</b>					
09:00 10:30	<b>Keynote Lectures</b>					
10:35 11:35	SPONSORED SYMPOSIUM <b>Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV</b>	ORAL COMMUNICATIONS <b>Bench studies of viral infections</b>	ORAL COMMUNICATIONS <b>Liver, vessels and lipids</b>	ORAL COMMUNICATIONS <b>PACS: what to assess</b>		SPECIAL SESSION <b>U=U: Impossibile Sbagliare</b>
11:40 12:40	SYMPOSIUM <b>The battle between the virus and the host: an ongoing dynamic process</b>	ORAL COMMUNICATIONS <b>Innovative tools for diagnosis and monitoring of viral infections</b>	ORAL COMMUNICATIONS <b>The experience of PrEP in Italy</b>	ORAL COMMUNICATIONS <b>Virological topics in SARS-CoV-2 infection</b>		PARALLEL SESSION <b>Meeting Prestigio Registry</b>
12:45 13:45	SYMPOSIUM <b>Clinical COVID-19</b>	SPECIAL SESSION <b>Drug pipeline: a glimpse of the future</b>	ORAL COMMUNICATIONS <b>Education and knowledge to reduce the burden of HIV and STIs</b>	ORAL COMMUNICATIONS <b>Real world evidence in different treatment setting</b>		PARALLEL SESSION <b>HIV Outcomes in Europe</b> 12:50-14:00
14:00 15:00	SYMPOSIUM <b>Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection</b>	ORAL COMMUNICATIONS <b>Body and mind</b>	ORAL COMMUNICATIONS <b>PACS: clinical outcome</b>	ORAL COMMUNICATIONS <b>Viruses, resistance and drugs</b>	ORAL COMMUNICATIONS <b>Mpox and Immunopathogenic mechanisms</b>	PARALLEL SESSION <b>Investigator Meeting of EDOLAS Study</b> 14:05-15:35
15:05 16:05	SYMPOSIUM <b>Chemsex emergency - what happens in real life</b>	ORAL COMMUNICATIONS <b>Outcomes in treatment experienced PLWH</b>	ORAL COMMUNICATIONS <b>Clinical approach to COVID-19 in vulnerable populations</b>	ORAL COMMUNICATIONS <b>Emerging issues in HIV-1 infection</b>	ORAL COMMUNICATIONS <b>Novel clinical and epidemiological aspects of viral hepatitis</b>	
16:10 16:30	SPECIAL SESSION <b>ICAR 2023 Awards and Closing remarks</b>					

LUNCH TIME 12:00-14:30

PROGRAMME AT A GLANCE

Venerdì 16 giugno



15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



**PRE-CONFERENCE**  
**ADVANCED COURSES**


**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30 **AUDITORIUM ALDO MORO**
**Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer**

Chairs: D. Calzavara (Milano), E.N. Cavallari (Roma)

Sexually Transmitted Infections (STIs) represent a concern for sexually active individuals. If undiagnosed, STIs can eventually cause serious complications. Immunization and pharmacological prophylaxis are emerging, as adjunct to periodic screening of asymptomatic people, as new strategies for approaching STIs in addition to treatment once the infection is established. A thorough overview of the current state of the art will be offered to participants. The dynamic of HPV transmission and the pathogenesis of this infection differs from the other STIs. The relevance of anal HPV infection and HPV related anal cancer among MSM and PLWH is emerging. The ANCHOR study represents a milestone in this field and its publication in June 2022 opened the way to the definition of the first screening guidelines for the prevention of this neoplasm, with particular attention to PLWH. A review of current literature on anal HPV infection and anal cancer risk among several key populations and a focus on these novel screening guidelines will be offered to participants.

15.00-15.10	<b>Evaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)</b>	D. Calzavara, Milano E.N. Cavallari, Roma
15.10 -15.30	<b>New insights on vaccines to prevent STIs</b>	D. Moschese, Milano
15.30-15.50	<b>New insights on pharmacological approaches to prevent STIs</b>	S. Venturelli, Bergamo
15.50-16.15	<b>Discussion</b>	
16.15-16.35	<b>HPV and anal cancer risk among MSM and PLWH</b> Roberto	R.P. Iachetta, Sassuolo MO
16.35-16.55	<b>New screening guidelines for the prevention of HPV related anal cancer in MSM</b>	M. Ridolfi, Roma
16.55-17.20	<b>Discussion</b>	
17.20-17.30	<b>Revaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)</b>	D. Calzavara, Milano E.N. Cavallari, Roma


**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30
**AULA III**
**HIV infection in the migrant and refugee population**

Chairs: A. Caraglia (Roma), M. Cascio (Milano), T.S. Prestileo (Palermo)

There were around 281 million international migrants in the world in 2021, which equates to 3.6 per cent of the global population. Migrant populations are more likely to suffer from poor health in general and HIV infection in particular. This is due to the epidemiological burden in the country of origin, as well as the vulnerability conditions during travel and the poor living conditions once in Europe, which expose them to every vulnerability. In addition, as with other people living with HIV/AIDS, migrants who are HIV-positive are subject to stigmatization and discrimination, and therefore, they hide their HIV status as long as possible, thus making support services unavailable to them. Most migrant populations live in a legal vacuum, with no stay or work permit in the host country, making frequently this an element of non-access to health services.

The aim of this course is to deepen our understanding of the migration phenomenon and HIV pathology by highlighting epidemiological data, good practises of public and private entities, sharing difficulties, and approaching the problem with possible, applicable, and sustainable solutions.

15.00-15.20	<b>Migrant and refugees in Italy: current scenarios</b>	D.P. Betti, Taranto
15.20-15.40	<b>HIV infection in migrant population - Learning from each other</b>	C. Torti, Catanzaro
15.40-16.00	<b>NGOs as a first response for migrant integration and approach to the health system</b>	L.A.R. Rancilio, Roma
16.00-16.20	<b>Public health engagement of migrants: the role of Hospital and University</b>	F. Di Gennaro, Bari
16.20-17.30	<b>Round table Discussants:</b>	F. Di Gennaro, Bari; L.A.R. Rancilio, Roma; C. Torti, Catanzaro





**PRE-CONFERENCE ADVANCED COURSE** 15.00-17.30

**AULA IV**

## Clinical virology: dealing with HIV infection today

Chairs: G. Lapadula (Monza), F. Lombardi (Roma)

The scenario of HIV infection has dramatically changed in the last two decades. Since HIV became a treatable and "chronic" disease, people living with HIV (PLWH) require lifelong care and treatment. This is thanks to the progress of antiretroviral therapy (ART), which is increasingly effective, potent, tolerable and with a high genetic barrier.

Concomitantly, the strategy for treating/preventing HIV infection has also changed over time: possibility of starting ART immediately upon diagnosis (test-and-treat), likely (virtually) increasing the chance of detect acute infection; opportunity to simplify the regimen in virologically suppressed ART-experienced PLWH or prevent infection (pre-exposure prophylaxis, PrEP), using effective regimens with just two active components and/or based on long-acting injectable formulation. Both oral and injectable PrEP have been shown to greatly reduce the risk (incidence) of HIV infection.

In both ART-naïve and -experienced PLWH, these strategies can promote retention in care, treatment adherence and drug tolerability, ultimately improving the overall quality of life of PLWH.

Despite increasing evidence of the efficacy, safety and tolerability of these new strategies in both ART-naïve and -experienced PLWH, it is mandatory to evaluate them in clinical practice settings.

In this regard, it is crucial to strictly monitor and follow PLWH from the time of diagnosis, via: I) standard surrogate markers (CD4 and HIV-RNA); II) markers of inflammation/immune-activation panels; III) total HIV-DNA, as a marker of the reservoir; and IV) genotypic tests for detecting primary and secondary drug resistance.

To date, microfluidic technologies (microfluidic ELISA, digital droplet PCR and "next generation sequencing"), which have enhanced laboratory performances (higher sensitivity, higher throughput) could fulfil the needs of a routine practice in clinical virology improving, in turn, the management of "present-day" ART-naïve and virologically suppressed PLWH.

15.00-15.30	<b>Proviral DNA/transcription-competent reservoir as a marker for monitoring the efficacy of novel antiretroviral strategies (simplification/LA) in virologically suppressed PLWH:</b>	F. Saladini, Siena
	<ul style="list-style-type: none"> <li>• Clinical implication/interpretation of the results</li> </ul>	
15.30-16.00	<b>Diagnosis and Management of Acute HIV:</b>	V. Micheli, Milano
	<ul style="list-style-type: none"> <li>• Diagnostic algorithm</li> <li>• Clinical relevance of early detection</li> </ul>	
16.00-16.30	<b>NGS in HIV: present and future challenges:</b>	D. Armenia, Roma
	<ul style="list-style-type: none"> <li>• Understand the cut-off for detection of the minority variants (clinical interpretation)</li> <li>• Whole genome sequencing (WGS) in the light of new strategies based on antiretrovirals acting on several different targets</li> </ul>	
16.30-17.00	<b>A new paradigm for antiretroviral delivery: long-acting new antivirals and strategies for the treatment and prevention of HIV:</b>	R. Rossotti, Milano
	<ul style="list-style-type: none"> <li>• Clinical and virological perspectives</li> </ul>	
17.00-17.30	<b>Discussion</b>	



15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



**SCIENTIFIC**  
**PROGRAMME**



SPECIAL SESSION 15.00-17.30

AULA V

## "RACCONTART" CONTEST AWARDS: INCONTRO CON LE SCUOLE FINALISTE E PREMIAZIONE

Chairs: F. Ceccherini Silberstein (Roma), M. Formisano (Taranto), S. Lo Caputo (Foggia), A. Saracino (Bari)

Con la sponsorizzazione non condizionante di Gilead Sciences

Giunto alla nona edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.

15.00-15.15 **Benvenuto dei Presidenti ICAR 2023**

F. Ceccherini Silberstein (Roma), M. Formisano (Taranto),  
S. Lo Caputo (Foggia), A. Saracino (Bari)

15.15-15.30 **Introduzione e presentazione della Giuria Artistica  
e Tecnico-Scientifica**

F. Ceccherini Silberstein (Roma), M. Errico (Milano)

### La Giuria Artistica

- **Anna Maria Bonsante** Professoressa di storia della musica
- **Elena Capparelli** Direttrice di RaiPlay e Digital
- **Alessandro Castellano** Graphic Designer
- **Nefeli Misuraca** Montatrice e regista di cortometraggi
- **Francesco Suriano** Scrittore di teatro, sceneggiatore e regista
- **Vincenzo Porcelli** Produttore cinematografico

### La Giuria Tecnico-Scientifica

- **Giulia Valeria Calvino** ANLAIDS, Roma
- **Daniele Calzavara** Milano Check Point, Milano
- **Anna Caraglia** Direzione prevenzione sanitaria – Ministero della Salute, Roma
- **Francesca Ceccherini Silberstein** Università degli Studi di Roma Tor Vergata, Roma
- **Antonella Cingolani** Fondazione Policlinico Universitario Agostino Gemelli, Roma
- **Paola Maria Cinque** Università Vita-Salute San Raffaele, Milano
- **Maria Luisa Cosmaro** LILA, Milano
- **Giovanni Del Bene** ANLAIDS, Milano
- **Antonio Di Biagio** Ospedale Policlinico San Martino, Genova
- **Margherita Errico** NPS Italia, Milano
- **Massimo Farinella** Circolo di Cultura Omosessuale Mario Mieli, Roma
- **Michele Formisano** NPS Puglia, Taranto





- **Nicoletta Frattini** A.S.A. Onlus - Associazione Solidarietà AIDS, Milano
- **Rosario Galipò** ANLAIDS Lazio, Roma
- **Giuseppina Giupponi** LILA Nazionale, Como
- **Sergio Lo Caputo** A.O.U. Policlinico Foggia, Università di Foggia
- **Donatella Mainieri** ANLAIDS, Milano
- **Paolo Meli** Associazione Comunità Emmaus, Bergamo
- **Silvia Nozza** IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Annalisa Saracino** Università degli Studi Aldo Moro, Bari
- **Donatello Zagato** A.S.A. Onlus - Associazione Solidarietà AIDS, Milano

15.30-17.00 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

F. Ceccherini Silberstein (Roma), M. Errico (Milano)

#### **Gli Istituti Scolastici e le opere finaliste**

- **Centro Studi Casnati - Liceo Artistico Giuseppe Terragni** Como
- **I.I.S. "E. Majorana"**, San Lazzaro di Savena (BO)
- **Liceo G. Bianchi Dottula**, Bari
- **Istituto Caterina Caniana**, Bergamo
- **Istituto Carlo Emery**, Roma
- **Istituto Gorjux Tridente**, Bari
- **I.I.S. "E. Majorana"**, Bari
- **Istituto Superiore "Lorenzo Lotto"**, Trescore (BG)
- **ITET De Viti De Marco**, Valenza (BA)
- **Liceo Simone Morea**, Conversano (BA)
- **Liceo Artistico F. Orioli**, Viterbo
- **Liceo Don L. Milani**, Romano di Lombardia (BG)
- **Liceo Artistico De Nittis**, Bari
- **Liceo S. Simone**, Conversano (BA)
- **Liceo Don Lorenzo Milani**, Napoli
- **Progetto YAU**, Perugia

17.00-17.15 **Premiazione primi 3 classificati**

A. Caraglia (Roma), M. Formisano (Taranto), A. Saracino (Bari)

17.15-17.30 **Conclusioni**




**SATELLITE SYMPOSIUM** 18.00-19.00

**TEATRO PETRUZZELLI**
**HIV and COVID-19: where we are and where we are going**

Chairs: G. Di Perri (Torino), C. Mussini (Modena)

Con la sponsorizzazione non condizionante di Gilead Sciences

The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative individuals. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), by providing new antiretroviral regimens providing high efficacy, genetic barrier, forgiveness, tolerability, and convenience. However, a "tailored" approach has to satisfy also needs and expectations of PLWH, in order to guarantee them a therapeutic success for long-term. The symposium is also aimed at providing new insights on SARS-CoV-2 infection, especially in high-risk populations, such as comorbid and immunocompromised individuals. Through an interactive talk, experts will discuss on challenges and current and future innovative strategies that can fill the unmet needs of people living with HIV and SARS-CoV-2, supporting individuals to overcome treatment barriers and improve their quality of life.

**Talk-show debate based on the following topics:**

18.00-18.15	<b>What we need in HIV treatment today to achieve long term success?</b>	S. Lo Caputo, Foggia
18.15-18.30	<b>What are the patients' needs in terms of adherence and forgiveness in HIV?</b>	F. Maggiolo, Bergamo
18.30-18.45	<b>COVID-19 and comorbidities. What challenges we need to face?</b>	E. Nicastrì, Roma
18.45-19.00	<b>Discussion and final consideration</b>	All





## ICAR 2023 OPENING SESSION

TEATRO PETRUZZELLI

19.00-19.20

### Introducing ICAR 2023. Chairs and Authorities' welcome addresses

Chairs: F. Ceccherini Silberstein (Roma), M. Formisano (Taranto), S. Lo Caputo (Foggia), A. Saracino (Bari)

### RaccontART: the three Winners

19.20-20.20 **Keynote Lectures**

19.20-19.50

Chairs: A. d'Arminio Monforte (Milano), G. Ippolito (Roma)

#### Mauro Moroni Memorial Lecture

### Vaccine Hesitancy - A Story as Old as Vaccines Themselves

Caitjan Gainty (London, UK)

*A historical & sociological perspective on vaccine hesitancy through the decades, starting with smallpox and progressing through various vaccines such as MMR and finally C-19. This aims to be a historical (rather than political or clinical) perspective, to be given by an historian.*

19.50-20.20

Chairs: G.V. Calvino (Roma), F. Schloesser (Roma)

#### Giulio Maria Corbelli Memorial Lecture

### Health pathways in transgender people. The denied rights of invisible people

M. Formisano (Taranto)

*Transgender people are a neglected population as their history is not known and there are few studies concerning the health of 'nonconforming' bodies. The lecture aims to provide incentives to explore these issues, both from a historical and a clinical point of view.*

20.20-20.30

### Closing remarks

F. Ceccherini Silberstein (Roma), M. Formisano (Taranto), S. Lo Caputo (Foggia), A. Saracino (Bari)

20.30-23.30

### ICAR 2023 Welcome Reception





## KEYNOTE LECTURES 09.00-10.00

## AUDITORIUM ALDO MORO

Chairs: G. Antonelli (Roma), F. Castelli (Brescia), A. Gori (Milano)

09.00-09.30 **All you always wanted to know about clinical pharmacology but were afraid to ask** S. Bonora, Torino

The lecture will focus on pharmacological issues and characteristics of different antiviral treatments (HIV, hepatitis, COVID) which awareness could be useful to clinicians in the daily management of patients. Knowledge of some key principle of clinical pharmacology could help the clinicians to overcome the therapeutic pitfalls of real life setting.

09.30-10.00 **Simplifying a complex issue: how to tailor drug resistance into clinical practice** A.M. Geretti, Roma

Despite great advancements in HIV treatment, new and existing antiretrovirals remain vulnerable to viral escape. Preventing and managing antiretroviral drug resistance is central to ensuring optimal outcomes over the life time of our patients. This is a continuously evolving field and new understandings have recently emerged that can have a profound impact on clinical care.



## SYMPOSIUM 10.05-11.05

## AUDITORIUM ALDO MORO

### Controversies in HIV clinical virology

Chairs: A. Callegaro (Bergamo), A. Lazzarin (Milano)

While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This symposium focuses on two specific issues, namely HIV drug resistance and low-level viremia, through an attractive clinician vs. virologist format. The incidence of HIV drug resistance has been decreasing due to expanded use of high genetic barrier drugs and lower rates of virological failure. However, a proportion of PLWH still develop or harbour drug resistance patterns which can challenge treatment options. In addition, people with controlled viremia can benefit from HIV DNA drug resistance testing and the advent of high-resolution sequencing methods have recently added a new layer of opportunities and challenges. On the other hand, how to deal with low-level viremia remains an open debate requiring an integrated view on antiretroviral pharmacology, adherence and the risk of emergent resistance.

10.05-10.35 **Round Table: Should we still care about drug resistance? The clinician's and virologist's view** V. Micheli, Milano; S. Rusconi, Legnano MI

10.35-11.05 **Round Table: How to deal with low-level viraemia. Clinician and biologist in comparison** F. Lombardi, Roma; F. Maggiolo, Bergamo



## SPONSORED SYMPOSIUM 10.05-11.05

## AULA V

### Do mAbs still play a role in the early treatment of COVID-19 patients?

Chairs: C.F. Perno (Roma), A. Saracino (Bari)

Simposio promozionale di GSK

Even if the epidemiology of COVID-19 has a significant decline there is still a significant unmet need related to the management of fragile patients with COVID-19 that despite vaccination can not build an immune response that can stop SARS-CoV2 reducing hospitalization or death progression in particular in the Early Treatment setting. Actually, in Italy the weekly mortality rate of patients with COVID-19 is still high ranging from 200 to 250 patients. The evolution of the VOCs resulting in the actual omicron soup has increased COVID-19 immune escape to mAbs generally, dramatically reducing in vitro neutralizing efficacy of the majority of mAbs and only sotrovimab maintain a moderate fold reduction in vitro and vivo that can be compensated by pharmacodynamic (effector functions) and pharmacokinetic properties such as blood concentration and pulmonary system persistency. In addition, recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So the question is the title of this Symposia "Do mAbs still play a role in the ET of COVID-19 patients?" and the answer is yes and in particular sotrovimab going beyond in vitro data that with an evidence and experience based approach has the most robust Real World Evidences even in the most difficult to treat patient by fulfilling the unmet clinical needs of the three fragile patients' dimensions: aging, impact of comorbid condition and immunocompromised patients illness or treatment related. The talk show format and the shoot the piano player final session are going to animate discussion with experts and attendees.



- 10.05-10.20 **Rational criteria for evaluating mAbs efficacy: beyond in vitro data** C.F. Perno, Roma  
**Talk Show Tailored experience-based approach on at risk COVID-19 patient dimensions:**
- 10.20-10.30 **Aging** G. Madeddu, Sassari  
o Why can aging influence immune response of COVID-19 patients?  
o How aging is correlated with COVID-19 mortality?  
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
- 10.30-10.40 **Frailty** A.M. Cattelan, Padova  
o Which chronic comorbidities are more associated with higher risk of COVID-19 patients' progression?  
o How multimorbidities and related treatments can worsen clinical outcomes of COVID-19 patients?  
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
- 10.40-10.50 **Vulnerability** V. Mazzotta, Roma  
o Why immunocompromised patients are more associated with higher risk of COVID-19 patients' progression?  
o Which pharmacological and surgical immunosuppressive treatments can worsen clinical outcomes of COVID-19 patients? (positivity, viral load, symptoms)  
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
- 10.50-11.05 **Shoot the Piano Player Experts "Q&A session"** A. Saracino, Bari



**EXPERT MEETING** 10.05-11.05

**AULA IV**

## Individualization and evolution of HIV management with the next generation of NNRTI: the future is now

Chair: A. Castagna (Milano)

Con la sponsorizzazione non condizionante di MSD Italia

Discussants: B.M. Celesia (Catania), R. Gagliardini (Roma), C. Gervasoni (Milano), P. Maggi (Caserta)

One size doesn't fit all. Prevention and management of comorbidities. How does it impact your practice? Interactive discussion on cardio-metabolic disorders, DDI and polypharmacy and resistance to support PLWH with the first of the new generation of NNRTI.



**ORAL COMMUNICATIONS** 10.05-11.05

**AULA III**

## Emerging immunological and virological concepts in viral hepatitis

Chairs: N. Coppola (Napoli), V. Svicher (Roma)

10.05-10.10 **Introduction**

N. Coppola, Napoli; V. Svicher, Roma

**OC 1 10.10-10.20 Ultrasensitive HBV-RNA quantification as a promising biomarker to optimize the staging of chronic HBV infection and to detect minimal viral activity under prolonged virological suppression and occult HBV infection**

L. Piermatteo<sup>1,2</sup>, S. D'Anna<sup>1</sup>, L. Duca<sup>1</sup>, G. Torre<sup>1</sup>, A.F. Guerra<sup>3</sup>, C. Boarini<sup>3</sup>, A. Tavelli<sup>4</sup>, P. Ventura<sup>3</sup>, F. Ceccherini Silberstein<sup>1</sup>, A. Pietrangelo<sup>3</sup>, A. D'Arminio Monforte<sup>4</sup>, G. Abbati<sup>3</sup>, U. Gill<sup>5</sup>, P. Kennedy<sup>5</sup>, V. Svicher<sup>1,2</sup>, R. Salpini<sup>1</sup>

<sup>1</sup>University of Rome "Tor Vergata", Department of Experimental Medicine, Rome, Italy, <sup>2</sup>University of Rome "Tor Vergata", Department of Biology, Rome, Italy, <sup>3</sup>Internal Medicine and Centre for Hemochromatosis, University Hospital of Modena, University of Modena and Reggio Emilia, Italy, <sup>4</sup>ICONA Foundation, Milan, Italy, <sup>5</sup>Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom



- OC 2** 10.22-10.32 **Functional and transcriptional restoration of exhausted virus-specific T lymphocytes from patients with chronic hepatitis B**  
*C. Ceccatelli Berti<sup>1</sup>, I. Montali<sup>1</sup>, M. Morselli<sup>2</sup>, C. Boni<sup>3</sup>, A. Penna<sup>3</sup>, D. Laccabue<sup>1,3</sup>, A. Vecchi<sup>3</sup>, M. Rossi<sup>1</sup>, C. Tiezzi<sup>1,3</sup>, V. Reverberi<sup>3</sup>, A. Montali<sup>1</sup>, S. Doselli<sup>3</sup>, S. Schivazappa<sup>3</sup>, C. Boarini<sup>4</sup>, G. Abbati<sup>4</sup>, G. Missale<sup>1,3</sup>, C. Ferrari<sup>1,3</sup>, P. Fiscaro<sup>3</sup>*  
<sup>1</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy, <sup>2</sup>Laboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy, <sup>3</sup>Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, <sup>4</sup>Division of Internal Medicine 2 and Center for Hemochromatosis, University of Modena and Reggio Emilia, Modena, Italy
- OC 3** 10.34-10.44 **HDV viral decline in HIV-infected and uninfected subjects with HBV/HDV-related cirrhosis during "real world" bulevirtide compassionate use program at INMI Spallanzani in Rome, Italy**  
*U.V. Comandini<sup>1</sup>, C. Taibi<sup>1</sup>, E. De Santis<sup>2</sup>, F. De Maria<sup>1</sup>, R. Lionetti<sup>1</sup>, M. Montalbano<sup>1</sup>, A. Rianda<sup>1</sup>, P. Piccolo<sup>3</sup>, C. De Ponte<sup>4</sup>, S. Mazzotta<sup>4</sup>, A.R. Garbuglia<sup>5</sup>, F. Maggi<sup>5</sup>, G. D'Offizi<sup>1</sup>*  
<sup>1</sup>Infectious Diseases and Hepatology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy (INMI), <sup>2</sup>La Sapienza University of Rome, Italy, <sup>3</sup>Internal Medicine Unit, Fatebenefratelli Isola Tiberina Hospital – Gemelli Isola, Rome, Italy, <sup>4</sup>Pharmacy Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>5</sup>Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- OC 4** 10.46-10.56 **Successful treatment of resistant HCV in ten patients, failed for other DAA, with glecaprevir/pibrentasvir and sofosbuvir**  
*M. Migliorati<sup>1</sup>, L. Zeneli<sup>1</sup>, F. Compostella<sup>1</sup>, A. Cambianica<sup>1</sup>, F. Pennati<sup>1</sup>, F. Gottardi<sup>1</sup>, S. Zaltron<sup>1</sup>, F. Castelli<sup>1</sup>, A. Spinetti<sup>1</sup>*  
 Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy

10.58-11.05 **Conclusion**

N. Coppola, Napoli; V. Svicher, Roma

**ORAL COMMUNICATIONS** 10.05-11.05**AULA II****Epidemiology trends in infections**

Chairs: E. Girardi (Roma), B. Marchini (Roma)

10.05-10.10 **Introduction**

E. Girardi, Roma; B. Marchini, Roma

- OC 5** 10.10-10.20 **HIV-1 Transmitted Drug Resistance in Newly Diagnosed Individuals in Italy Over the Period 2015-2021**  
*L. Fabeni<sup>1</sup>, D. Armenia<sup>2</sup>, I. Abbate<sup>1</sup>, R. Gagliardini<sup>1</sup>, V. Mazzotta<sup>1</sup>, N. Orchi<sup>1</sup>, A. Bertoli<sup>3</sup>, W. Gennari<sup>4</sup>, F. Forbici<sup>1</sup>, G. Berno<sup>1</sup>, L. Piermatteo<sup>5</sup>, V. Borghi<sup>4</sup>, S. Pittalis<sup>1</sup>, C. Pinnetti<sup>1</sup>, A. Vergori<sup>1</sup>, A. Mondì<sup>1</sup>, G. Parruti<sup>6</sup>, F. Di Sora<sup>7</sup>, M. Iannetta<sup>3</sup>, M. Lichtner<sup>8</sup>, A. Latini<sup>9</sup>, C. Mussini<sup>4</sup>, L. Sarmati<sup>3</sup>, C.F. Perno<sup>10</sup>, E. Girardi<sup>1</sup>, A. Antinori<sup>1</sup>, F. Ceccherini-Silberstein<sup>5</sup>, F. Maggi<sup>1</sup>, M.M. Santoro<sup>5</sup>, The Italian Resistance group*  
<sup>1</sup>National Institute for Infectious Diseases L Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>3</sup>Polyclinic of Rome "Tor Vergata", Rome, Italy, <sup>4</sup>Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>6</sup>Pescara General Hospital, Pescara, Italy, <sup>7</sup>S. Giovanni Addolorata Hospital, Rome, Italy, <sup>8</sup>Sapienza University, Latina, Italy, <sup>9</sup>San Gallicano Dermatological Institute, IRCCS, Rome, Italy, <sup>10</sup>Bambino Gesù Children's Hospital, Rome, Italy
- OC 6** 10.22-10.32 **Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy in 2020 and 2021 period**  
*A. Bergna<sup>1</sup>, A. Lai<sup>1</sup>, C. della Ventura<sup>1</sup>, A. Weisz<sup>2</sup>, B. Bruzzone<sup>3</sup>, F. Sagradi<sup>4</sup>, G. Brindicci<sup>5</sup>, D. Francisci<sup>6</sup>, N. Clementi<sup>7</sup>, I. Vicenti<sup>8</sup>, A. Callegaro<sup>9</sup>, S. Menzo<sup>10</sup>, E. Venanzi Rullo<sup>11</sup>, G. Giurato<sup>2</sup>, F. Rizzo<sup>2</sup>, T. Rocco<sup>2</sup>, V. De Pace<sup>3</sup>, C. Fracalvieri<sup>3</sup>, S. Testa<sup>4</sup>, L. Lanfranchi<sup>4</sup>, A. Saracino<sup>5</sup>, S. Caucci<sup>10</sup>, G. Nunnari<sup>11</sup>, M. Clementi<sup>7</sup>, M. Galli<sup>1</sup>, A. Riva<sup>1</sup>, S. Antinori<sup>1</sup>, G. Zehender<sup>1</sup> and SARS-CoV-2 ITALIAN RESEARCH ENTERPRISE – (SCIRE) collaborative Group 1*  
<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, <sup>3</sup>Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, <sup>4</sup>Unit of Infectious Diseases, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy, <sup>5</sup>Infectious Diseases Unit, University of Bari, Bari, Italy, <sup>6</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>7</sup>Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy, <sup>8</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>9</sup>Microbiology and Virology Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>10</sup>Department of Biomedical Sciences and Public Health, Virology Unit, Polytechnic University of Marche, Ancona, Italy, <sup>11</sup>Unit of Infectious Diseases, Department of Experimental and Clinical Medicine, University of Messina, Messina, Italy



**OC 7 10.34-10.44 Trends of testing for HIV and syphilis in community based voluntary counselling and testing (CBVCT) services in the period 2019-2022: are there people more at risk?**

A. Soria<sup>1,2</sup>, D. Calzavara<sup>2</sup>, R. Rossotti<sup>2,3</sup>, R. Reposs<sup>2,4</sup>, A. Bianchi<sup>2,4</sup>, D. Zagato<sup>4</sup>, N. Frattini<sup>2,4</sup>, M. L. Cosmaro<sup>2,5</sup>, P. Russo<sup>2,6</sup>, S. Penon<sup>5</sup>, S. Curridori<sup>5</sup>, A. Antonino<sup>2,4</sup>, D. Savarino<sup>5</sup>, G. Lapadula<sup>1,2</sup>, S. Bossolasca<sup>2,7</sup>, A. De Bona<sup>2,8</sup>, A. d'Arminio Monforte<sup>2,9</sup>, M. Cernuschi<sup>2,4,7</sup>

<sup>1</sup>Fondazione IRCCS San Gerardo dei Tintori, Monza, <sup>2</sup>Milano Check Point ETS, Milano, <sup>3</sup>Grande Ospedale Metropolitano Niguarda, Milano, <sup>4</sup>ASA Milano ODV, Milano, <sup>5</sup>Fondazione Lila Milano Onlus, Milano, <sup>6</sup>CIG – Arcigay Milano ODV, Milano, <sup>7</sup>IRCCS Ospedale San Raffaele, Milano, <sup>8</sup>ASST Santi Paolo e Carlo, Milano, <sup>9</sup>Fondazione ICONA, Milano

**OC 8 10.46-10.56 Epidemiological and perceived health status determinants of early access to vaccine in Latium region Mpox vaccination (MpoxV) campaign**

G. Del Duca<sup>1</sup>, A. Tavelli<sup>2</sup>, I. Mastroiosa<sup>1</sup>, V. Mazzotta<sup>1</sup>, C. Aguglia<sup>1</sup>, S. Lanini<sup>1</sup>, A.C. Brita<sup>1</sup>, R. Gagliardini<sup>1</sup>, M.L. Giancola<sup>1</sup>, S. Vita<sup>1</sup>, A. Beccacece<sup>1</sup>, A. Vergori<sup>1</sup>, J. Paulicelli<sup>1</sup>, G. Natalini<sup>1</sup>, A. D'Urso<sup>1</sup>, P. Piselli<sup>3</sup>, C. Cimaglia<sup>3</sup>, P. Galli<sup>4</sup>, V. Mondillo<sup>4</sup>, M. Ridolfi<sup>5</sup>, G. D'Ettore<sup>5</sup>, E. Tamburrini<sup>6</sup>, L. Coppola<sup>7</sup>, A. Latini<sup>8</sup>, M. Lichtner<sup>9</sup>, V. Puro<sup>1</sup>, M. Farinella<sup>10</sup>, G.M. Corbelli<sup>11</sup>, A. d'Arminio Monforte<sup>2</sup>, F. Vairo<sup>1</sup>, A. Barca<sup>12</sup>, E. Nicastri<sup>1</sup>, F. Vaia<sup>1</sup>, E. Girardi<sup>1</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, <sup>2</sup>ASST Santi Paolo e Carlo, Unimi Milan, <sup>3</sup>Clinical Epidemiology, INMI Rome, <sup>4</sup>Health Management, INMI Rome, <sup>5</sup>Umberto I, Rome, <sup>6</sup>Clinical Infectious Diseases, A. Gemelli Rome, <sup>7</sup>Clinical Infectious Diseases, Tor Vergata Rome, <sup>8</sup>STD/HIV San Gallicano Dermatologic Unit IFO Rome, <sup>9</sup>Infectious Disease, La Sapienza University Santa Maria Goretti Hospital, Latina, <sup>10</sup>Circle of homosexual culture Mario Mieli Rome, <sup>11</sup>Plus Rome, Rome, <sup>12</sup>Regional Directorate of Health and Social Health Integration, Latium region

10.58-11.05 **Conclusion**

E. Girardi, Roma; B. Marchini, Roma

**SPONSORED SYMPOSIUM** 11.10-12.10**AUDITORIUM ALDO MORO****HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV**

Chairs: S. Rusconi (Legnano MI), M. Santoro (Roma)

Simposio promozionale di ViiV Healthcare

DTG/3TC has now demonstrated durable efficacy and tolerability both as a first-line regimen as well as in the setting of treatment optimization for experienced patients, at the same time reducing the number of antiretrovirals (compared to 3-4DR). In the setting of naive patients, it is key to understand the criteria driving the treatment choice and the concerns associated with starting treatment with a 2DR such as DTG/3TC to compare them with the evidences available both from RCTs and real-world experiences.

On the other hand, proactive treatment optimization and simplification in the experienced patient is becoming much more relevant as we focus on a preventive approach to improve the quality of life in the context of a lifelong therapy. Therefore, the aim of this symposium is discussing the most recent evidences available that supports the use of DTG/3TC in these settings.

11.10-11.20 **Opening: relevance of long term perspectives in current HIV care** S. Rusconi, Legnano MI; M. Santoro, Roma**Round table**11.20-11.35 **Decision criteria and concerns around DTG/3TC usage in naive patients** N. Gianotti, Milano11.35-11.50 **Long-term outcomes of treatment simplification: the role of DTG/3TC** S. Di Giambenedetto, Roma11.50-12.05 **DTG/3TC and metabolic health** N. Squillace, Monza12.05-12.10 **Closing and take home messages** S. Rusconi, Legnano MI; M. Santoro, Roma


**SATELLITE SYMPOSIUM** 11.10-12.10

**AULA V**
**A new era of HDV treatment: relevance of HDV control in coinfecting patients**

Chairs: A. d'Arminio Monforte (Milano), T.A. Santantonio (Foggia)

Con la sponsorizzazione non condizionante di Gilead Sciences

Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5-10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15-25 million people. Hepatitis delta is the most severe of all chronic viral hepatitis, leading to cirrhosis, liver cancer and/or transplantation in most patients. The only treatment available until recently was peginterferon alfa, with poor results and significant side effects. The recent approval of bulevirtide, a lipopeptide that blocks HBV/HDV entry, has revolutionized the field. Given that sexual and parenteral transmission routes are the most frequent for the acquisition of HBV and HDV, shared with HIV infection and HBV/HDV and HIV coinfection. The clinical outcome of hepatitis delta is worst in the HIV setting, with more frequent liver complications.

- 11.10-11.30 **New therapeutic options for HDV: from RCT to Real world** E. Degaspero, Milano
- 11.30-11.50 **HIV-HBV-HDV coinfecting patients in ICONA Cohort: practical management recommendations** M. Puoti, Milano
- 11.50-12.00 **Discussion**
- 12.00-12.10 **The patient voice** C. Taibi, Roma


**ORAL COMMUNICATIONS** 11.10-12.10

**AULA IV**
**Immune response in SARS-CoV-2**

Chairs: M. Biasin (Cernobbio CO), C. Tincati (Milano)

- 11.10-11.15 **Introduction** M. Biasin, Cernobbio CO; C. Tincati, Milano

**OC 9 11.15-11.25 Monocytes and NK cell subsets frequencies after anti-S monoclonal antibodies treatment in COVID-19 patients**

 L. Maddaloni<sup>1</sup>, L. Santinelli<sup>1</sup>, G. Bugani<sup>1</sup>, A. Lazzaro<sup>1</sup>, C.M. Lofaro<sup>1</sup>, L. Sorrentino<sup>2</sup>, M. Fracella<sup>2</sup>, A. D'Auria<sup>2</sup>, C. Ajassa<sup>1</sup>, C. Leanza<sup>1</sup>, A. Napoli<sup>3</sup>, G. Antonelli<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, G. Ceccarelli<sup>1</sup>, C. Scagnolari<sup>2</sup>, G. d'Ettore<sup>1</sup>
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, <sup>3</sup>Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Italy

**OC 10 11.27-11.37 ERAPs control In Vitro SARS-CoV-2 Infection by triggering NK and Neutrophil activation**

 I. Saulle<sup>1,2</sup>, M.L. Murno<sup>2</sup>, F. Limanaqi<sup>1,2</sup>, M. Garziano<sup>1,2</sup>, S. Strizzi<sup>2</sup>, C. Vanetti<sup>2</sup>, S. Lo Caputo<sup>3</sup>, M. Polisenò<sup>3</sup>, T.A. Santantonio<sup>3</sup>, M. Clerici<sup>1,4</sup>, M. Biasin<sup>2</sup>
<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>4</sup>Don C. Gnocchi Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy

**OC 11 11.39-11.49 A novel enhancing effect of SARS-CoV-2 mutations on anti-viral CD8 T cell responses**

 C. Tiezzi<sup>1,2</sup>, A. Vecchi<sup>1</sup>, M. Rossi<sup>2</sup>, D. Cavazzini<sup>3</sup>, A. Bolchi<sup>3,4</sup>, D. Laccabue<sup>2</sup>, A. Penna<sup>1</sup>, T. Meschi<sup>2,5</sup>, A. Ticinesi<sup>2,5</sup>, A. Nougues<sup>5</sup>, G. Donofrio<sup>6</sup>, P. Fiscaro<sup>1</sup>, I. Montali<sup>2</sup>, C. Ceccatelli Berti<sup>1</sup>, V. Reverberi<sup>1</sup>, A. Montali<sup>2</sup>, S. Doselli<sup>1</sup>, G. Pedrazzi<sup>7</sup>, G. Missale<sup>1,2</sup>, S. Ottonello<sup>3,4</sup>, C. Ferrari<sup>1,2</sup>, C. Boni<sup>1</sup>
<sup>1</sup>Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda-Ospedaliero-Universitaria di Parma, Parma, Italy, <sup>2</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy, <sup>3</sup>Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy, <sup>4</sup>Interdepartmental Center Biopharmantec-Tec, University of Parma, Parma, Italy, <sup>5</sup>Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, <sup>6</sup>Department of Veterinary Science, University of Parma, Parma, Italy, <sup>7</sup>Department of Neuroscience - Biophysics and Medical Physics Unit, University of Parma, Parma, Italy

**OC 12 11.51-12.01 Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination**

 I. Varasi<sup>1</sup>, A. Lai<sup>2</sup>, A. Bergna<sup>2</sup>, L. Fiaschi<sup>1</sup>, A. Gatti<sup>3</sup>, B. Caimi<sup>3</sup>, C. Balotta<sup>3</sup>, C. Biba<sup>1</sup>, A. Riva<sup>2</sup>, G. Zehender<sup>2</sup>, M. Zazzi<sup>1</sup>, I. Vicenti<sup>1</sup>
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>3</sup>Azienda di Servizi alla Persona, Istituto Milanese Martinotti e Stelline e Pio Albergo Trivulzio, Milan, Italy

- 12.03-12.10 **Conclusion** M. Biasin, Cernobbio CO; C. Tincati, Milano







ORAL COMMUNICATIONS 11.10-12.10

AULA III

**Inflammation: a major pathogenetic process**

Chairs: A. De Maria (Genova), D. Trabattoni (Milano)

11.10-11.15 **Introduction**

A. De Maria, Genova; D. Trabattoni, Milano

**OC 13 11.15-11.25 Effects of cART on residual inflammation and HIV reservoirs in Primary and Chronic HIV infection**  
*V. Bono<sup>1</sup>, C. Tincati<sup>1</sup>, M. Augello<sup>1</sup>, R. Rovito<sup>1</sup>, S. Rusconi<sup>2</sup>, A. Gabrieli<sup>2</sup>, S. Nozza<sup>3</sup>, E. Bruzzesi<sup>3</sup>, A. Gori<sup>4</sup>, A. Calcagno<sup>5</sup>, A. Giacomelli<sup>6</sup>, G. Marchetti for the Inaction (Italian Network of Acute HIV Infection) Study Group*

<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>2</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, DIBIC, University of Milan, ASST Ovest Milanese, Legnano, <sup>3</sup>Vita-Salute San Raffaele University, Milan, <sup>4</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, <sup>5</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, <sup>6</sup>Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan

**OC 14 11.27-11.37 Switching to doravirine reduces chronic inflammation among virologically controlled PLWH: 48 weeks results from the DORAGE cohort***A. Lazzaro<sup>1</sup>, R.A. Valia<sup>1</sup>, G. Recchia<sup>1</sup>, L. Battistini<sup>1</sup>, S. Caruso<sup>1</sup>, M. D'Amico<sup>1</sup>, I. Mezzaroma<sup>2</sup>, M. Falciano<sup>1</sup>, C. Andreoni<sup>1</sup>, C. Fimiani<sup>1</sup>, L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, G. Bugani<sup>1</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, <sup>2</sup>Department of Translational and Precision Medicine; Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy

**OC 15 11.39-11.49 Antiretroviral therapy partially restores phenotypic and metabolic immunosenescence features of T cells in HIV infected individuals***B. Dallan<sup>1</sup>, M. Campagnaro<sup>1</sup>, E. Gallerani<sup>1</sup>, D. Proietto<sup>1</sup>, R. Cultrera<sup>3</sup>, M. Libanore<sup>4</sup>, L. Sighinolfi<sup>4</sup>, F. Nicoli<sup>1</sup>, A. Caputo<sup>1</sup>, D. Segala<sup>2</sup>*

<sup>1</sup>Laboratory of Biochemistry, Immunology and Microbiology (BIM), Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy, <sup>2</sup>Department of Translational Medicine, University of Ferrara, Italy Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy, <sup>3</sup>Department of Translational Medicine, University of Ferrara, Italy Infectious Diseases-Primary and Community Health Care Dept, Azienda Unità Sanitaria Locale di Ferrara, Italy, <sup>4</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy

**OC 16 11.51-12.01 Human endogenous retroviruses expression correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients***V. Petrone<sup>1</sup>, R. Scutari<sup>1</sup>, V. Malagnino<sup>2,3</sup>, L. Piermatteo<sup>1</sup>, M. Compagno<sup>2,3</sup>, R. Salpini<sup>1</sup>, E. Teti<sup>2,3</sup>, M. Iannetta<sup>2,3</sup>, A. Minutolo<sup>1</sup>, M.M. Santoro<sup>1</sup>, V. Sviche<sup>1</sup>, M. Andreoni<sup>2,3</sup>, Balestrieri<sup>1</sup>, L. Sarmati<sup>2,3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, S. Grelli<sup>1,4</sup>, C. Matteucci<sup>1</sup>*

<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Italy, <sup>2</sup>Department of Systems Medicine, University of Rome Tor Vergata, Italy, <sup>3</sup>Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, <sup>4</sup>Virology Unit, Policlinic of Tor Vergata, Rome, Italy

12.03-12.10 **Conclusion**

A. De Maria, Genova; D. Trabattoni, Milano




**SPECIAL SESSION** 11.10-12.10

**AULA I**

## Health and prevention in transgender people

Chair: A. Palmitesta (Roma)

Studies carried out across a variety of different contexts have shown that transgender and gender diverse (TGD) people face significant barriers to accessing health care and health-determining resources, such as education, employment and housing. Harassment and discrimination contribute to high rates of stress and make transgender individuals significantly more likely to experience poor health outcomes (e.g., high risk for mental health morbidity, STI, cardiac disease, etc). Thus, it is urgently warranted to provide an effective and appropriate evidence-based prevention and care so as to ensure health equity for transgender people. In particular, TGD people are at high risk for HIV infection but prevention efforts targeting these people have been minimal. HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV, however PrEP use among TGD people remains low. In this section, an overview of the main barriers that TGD people have to face accessing healthcare services will be given and possible future strategies will be discussed.

11.10-11.25	<b>In-practice policies to promote an inclusive health care for transgender People</b>	M. Pierdominici, Roma
11.25-11.40	<b>Transgender health and communication strategies: the website Infotrans.it</b>	M. Marconi, Roma
11.40-11.55	<b>Sociosanitary conditions of transgender PWHIV: photography and possible inclusion tools</b>	L. Brogonzoli, Milano
11.55-12.10	<b>Barriers in the use HIV prophylaxis in transgender individuals</b>	T. Bini, Milano


**SYMPOSIUM** 12.15-13.15

**AUDITORIUM ALDO MORO**

## The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONS

Chairs: P. Bonfanti (Monza), F. Vichi (Firenze)

Weight gain in people on antiretroviral treatment has been observed in numerous cohorts and continues to be an issue of intense debate. Indeed, several aspects are not yet clear: how weight gain is affected by specific antiretroviral treatments, pre-existing body weight or other factors, what are the underlying mechanisms, and to what extent is this a clinically relevant issue, depending on actual rate and extent and associations with metabolic disorders and other conditions. This symposium aims to weight pros and cons from ID and other specialists on whether weight gain is clinically relevant in PWH and gain knowledge towards optimal management.

12.15-12.20	<b>Introduction</b>	G. Madeddu, Sassari
12.20-12.30	<b>YES, weight gain is a truly relevant issue</b>	P. Maggi, Caserta
12.30-12.40	<b>NO, weight gain is not that much relevant afterall</b>	S. Cicalini, Roma
12.40-12.50	<b>The association of weight gain with (diabetes and) metabolic alterations: an endocrinological view</b>	D. Gianfrilli, Roma
12.50-13.00	<b>Increased CV risk related to minimal to substantial weight gain: a cardiovascular view</b>	G. d'Ettore, Roma
13.00-13.15	<b>Round Table and conclusion</b>	P.M. Cinque, Milano; F. Vichi, Firenze





ORAL COMMUNICATIONS 12.15-13.15

AULA V

## Outcome in first-line regimens

Chairs: S. Ferrara (Foggia), N. Gianotti (Milano)

12.15-12.20 **Introduction**

S. Ferrara, Foggia; N. Gianotti, Milano

**OC 17 12.20-12.30 Effectiveness of bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in real-world setting in ART-naïve patients: data from the Icona cohort**

*A. Tavelli<sup>1</sup>, G. Marchetti<sup>2</sup>, A. Vergori<sup>3</sup>, E. Quiros Roldan<sup>4</sup>, V. Malagnino<sup>5</sup>, F. Vichi<sup>6</sup>, M. Lichtner<sup>7</sup>, S. Nozza<sup>8</sup>, R. Rossotti<sup>9</sup>, L. Sarmati<sup>5</sup>, F. Bai<sup>2</sup>, A. Di Biagio<sup>10</sup>, A. Antinori<sup>3</sup>, A. d'Arminio Monforte<sup>1</sup> for the Icona Foundation Study Group*

<sup>1</sup>Icona Foundation, Milan, Italy, <sup>2</sup>Department of Health Sciences, Unit of Infectious Diseases, ASST Santi Paolo e Carlo, 'San Paolo' Hospital, University of Milan, Milan, Italy, <sup>3</sup>Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>4</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>5</sup>Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>6</sup>Infectious Diseases Unit I, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy, <sup>7</sup>Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>8</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>9</sup>Department of Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>10</sup>Ospedale Policlinico San Martino IRCCS, University of Genoa, Genoa, Italy

**OC 18 12.32-12.42 Effectiveness of first-line lamivudine-dolutegravir (3TC-DTG) antiretroviral therapy (ART) in persons living with HIV (PLWH): real-life data from the ICONA Foundation cohort**

*S. Lo Caputo<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, R. Gagliardini<sup>3</sup>, E. Schiaroli<sup>4</sup>, G. Orofino<sup>5</sup>, A. Vergori<sup>3</sup>, F. Maggiolo<sup>6</sup>, N. Gianotti<sup>7</sup>, A. Castagna<sup>8</sup>, A. Cingolani<sup>9</sup>, A. Antinori<sup>3</sup>, A. d'Arminio Monforte<sup>10</sup> for the Icona Foundation Study Group*

<sup>1</sup>Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Clinical and Research Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy, <sup>4</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>5</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>6</sup>UOC Infectious Diseases, ASST Papa Giovanni XXII, Bergamo, Italy, <sup>7</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>8</sup>Infectious and Tropical Diseases Department, Vita-Salute San Raffaele University, Milan, Italy, <sup>9</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, <sup>10</sup>Icona Foundation, Milan, Italy

**OC 19 12.44-12.54 Body weight and plasma lipids changes in person living with HIV (PLWH) starting double or triple INSTI-based cART regimens**

*F. Bai<sup>1</sup>, M. Ponzano<sup>2</sup>, F. Bovis<sup>2</sup>, A. di Biagio<sup>3</sup>, G. Guaraldi<sup>4</sup>, A. Rodanò<sup>5</sup>, C. Stingone<sup>6</sup>, R. Marocco<sup>7</sup>, D. Leoni<sup>8</sup>, A. Cozzi-Lepri<sup>9</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>*

<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>2</sup>Department of Health Sciences, University of Genoa, Genoa, <sup>3</sup>Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Department of Health Sciences (DISSAL), University of Genoa, Genoa, <sup>4</sup>Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, <sup>5</sup>Icona Foundation, <sup>6</sup>STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, <sup>7</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, <sup>8</sup>Infectious and Tropical Diseases Unit, Department of Medical Sciences, Padua University Hospital, Padua, <sup>9</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, United Kingdom

**OC 20 12.56-13.06 HIV-DNA decay in ART-naïve PLWH starting dolutegravir plus lamivudine vs triple therapy: 48-week results in a real-life setting**

*F. Lombardi<sup>1,2</sup>, A. Sanfilippo<sup>3</sup>, N. Bartolini<sup>3</sup>, C. Paletti<sup>3</sup>, I. Vicenti<sup>3</sup>, P. Salvo<sup>2</sup>, F. Lamanna<sup>2</sup>, F. Saladini<sup>3</sup>, A. Ciccullo<sup>4</sup>, A. Borghetti<sup>1</sup>, M. Zazzi<sup>3</sup>, S. Di Giambenedetto<sup>1,2</sup>*

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>2</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>3</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>4</sup>Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

13.08-13.15 **Conclusion**

S. Ferrara, Foggia; N. Gianotti, Milano




**EXPERT MEETING** 12.15-13.15

**AULA IV**

## Every left is lost, let's vaccinate

Chairs: C.M. Mastroianni (Roma), O. Turriziani (Roma)

Discussants: M. Andreoni (Roma), M. Conversano (Taranto), I. Gentile (Napoli)

Some infectious diseases are preventable, and vaccination is one of the most effective and safe measure in Public Health for their primary prevention. Over time, the introduction of vaccinations has made it possible to reduce the spread of some serious and deadly diseases, or even to eliminate them. Although, paradoxically, it is precisely the success of vaccinations that creates problems in their acceptance, since the decrease in the frequency of these preventable diseases has led to a decrease in the perception of their severity. The immunocompromised patient is among the ones at greater risk of infections, and therefore vaccinations become fundamental for its management. Among vaccinations recommended for immunocompromised patients the main are against: flu, herpes zoster, pneumococcus and meningococcus. In this process, the infectious disease specialist has a central role for both the patient and the other specialists involved.


**ORAL COMMUNICATIONS** 12.15-13.15

**AULA III**

## One size does not fit all

Chairs: S. Babudieri (Sassari), I. Pennini (Padova)

 12.15-12.20 **Introduction**

S. Babudieri, Sassari; I. Pennini, Padova

**OC 21** 12.20-12.30 **Sexual and reproductive unmet clinical needs in Italian women living with HIV: results from Marilyn study**

 G.V. Calvino<sup>1</sup>, M. Errico<sup>2</sup>, A. Tavelli<sup>3</sup>, M.L. Cosmaro<sup>4</sup>, A. Perziano<sup>5</sup>, A. Bove<sup>6</sup>, L. Taramasso<sup>7</sup>, I. Mastroianni<sup>8</sup>, M. Di Gaetano<sup>9</sup>, M. Ferrara<sup>10</sup>, M. Cernuschi<sup>11</sup>, M. Lichtner<sup>12</sup>, A.d'Arminio Monforte<sup>3</sup>, A. Cingolani<sup>13</sup> for Icona Foundation Study Group

<sup>1</sup>Anlaidis Onlus-ETS, Rome, Italy, <sup>2</sup>Network Persone Sieropositive Italia APS, Milan, Italy, <sup>3</sup>Icona Foundation, Milan, Italy, <sup>4</sup>Fondazione LILA Milano, Milan, Italy, <sup>5</sup>Associazione Arcobaleno AIDS ODV, Turin, Italy, <sup>6</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, Italy, <sup>7</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy, <sup>8</sup>Clinical and Research Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy, <sup>9</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>11</sup>Associazione Solidarietà AIDS ODV, Milan, Italy, <sup>12</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>13</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy

**OC 22** 12.32-12.42 **COVID perceptions among pregnant women living in a malaria hyperendemic rural region in Uganda: a cross-sectional study**

 F.V. Segala<sup>1</sup>, F. Di Gennaro<sup>2</sup>, J. Ichho<sup>2</sup>, M. L'Episcopia<sup>3</sup>, E. Onapa<sup>2</sup>, E. De Vita<sup>1</sup>, R. Novara<sup>1</sup>, N. Olung<sup>4</sup>, V. Totaro<sup>1</sup>, L. Olal<sup>5</sup>, G. Patti<sup>1</sup>, C. Bingom<sup>2</sup>, U. Farina<sup>6</sup>, R. Papagni<sup>1</sup>, C. Agaro<sup>7</sup>, J. Amoné<sup>4</sup>, G. Dall'Oglio<sup>2</sup>, B. Ngole<sup>5</sup>, C. Marotta<sup>8</sup>, S. Okori<sup>4</sup>, C. Severini<sup>3</sup>, P. Lochoro<sup>2</sup>, G. Putoto<sup>8</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Doctors with Africa, CUAMM, Kampala, Uganda, <sup>3</sup>Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, <sup>4</sup>St. John's XXIII Hospital Aber, Jaber, Uganda, <sup>5</sup>African Network for Change, Kampala, Uganda, <sup>6</sup>Hygiene Unit, Policlinico Riuniti Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>7</sup>District Health Office, Oyam District Local Government, Loro, Uganda, <sup>8</sup>Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy

**OC 23** 12.44-12.54 **Life quality and psychological health of women living with HIV: insight from a single centre in Sassari, Italy**

 A. Colpani<sup>1</sup>, A. De Vito<sup>1</sup>, C. Poggiu<sup>1</sup>, F. Cherchi<sup>1</sup>, A. Bitti<sup>1</sup>, M.C. Meloni<sup>1</sup>, B. Zauli<sup>1</sup>, M. Fois<sup>1</sup>, S. Bacciu<sup>1</sup>, S. Ruiu<sup>1</sup>, G. Moi<sup>1</sup>, A. Nivoli<sup>2</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, <sup>2</sup>Psychiatric Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy

**OC 24** 12.56-13.06 **HIV in prison setting: what about inmates? The four-years experience including SARS-CoV2 pandemic period in Florence**

 E. Salomoni<sup>1</sup>, C. Tozzi<sup>2</sup>, A. Gabbuti<sup>1</sup>, L.G. Gragnoli<sup>2</sup>, M. Pusceddu<sup>2</sup>, M. Brogi<sup>1</sup>, C.P. Rendo<sup>3</sup>, M.A. Di Pietro<sup>1</sup>

<sup>1</sup>SOC Malattie Infettive I Firenze-Empoli, Azienda USL Toscana Centro, <sup>2</sup>SOS Infermieristica Firenze Nord-Ovest, Presidio Sanitario C.C. Sollicciano-Firenze, Azienda USL Toscana Centro, <sup>3</sup>SOC Salute in Carcere, Presidio Sanitario C.C. Sollicciano-Firenze, Azienda USL Toscana Centro

 13.08-13.15 **Conclusion**

S. Babudieri, Sassari; I. Pennini, Padova





ORAL COMMUNICATIONS 12.15-13.15

AULA II

**Early treatment for COVID-19**

Chairs: E. Nicastrì (Roma), M. Tavio (Ancona)

12.15-12.20 **Introduction**

E. Nicastrì, Roma; M. Tavio, Ancona

**OC 25 12.20-12.30 Incidence and predictors of clinical progression in an early treated COVID-19 multicentric cohort of an Italian Region**

V. Mazzotta<sup>1,2</sup>, A. Cozzi Lepri<sup>3</sup>, C. Del Borgo<sup>4</sup>, S. Lanini<sup>1</sup>, S. Meschi<sup>1</sup>, S. Garattini<sup>4</sup>, S. Rosati<sup>1</sup>, V. Siciliano<sup>5</sup>, A. Vergori<sup>1</sup>, L. Coppola<sup>6</sup>, A. Falletta<sup>7</sup>, A. Carraro<sup>4</sup>, G. Gramigna<sup>1</sup>, A. Oliva<sup>1</sup>, E. Matteini<sup>5</sup>, A. Gasperin<sup>4</sup>, G. Giannico<sup>1</sup>, A. D'Abramo<sup>1</sup>, R. Marocco<sup>4</sup>, E. Milozzi<sup>1</sup>, C. Cerva<sup>1</sup>, F. Gavaruzzi<sup>1</sup>, M. Rueca<sup>1</sup>, C. Cimaglia<sup>1</sup>, P. Piselli<sup>1</sup>, E. Girardi<sup>1</sup>, L. Sarmati<sup>6</sup>, C. Mastroianni<sup>7</sup>, M. Andreoni<sup>6</sup>, M. Fantoni<sup>5</sup>, F. Vaia<sup>1</sup>, F. Maggi<sup>1</sup>, E. Nicastrì<sup>1</sup>, M. Lichtner<sup>4</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>4</sup>Università La Sapienza Polo pontino, Latina, Italy, <sup>5</sup>Fondazione Universitaria Policlinico Agostino Gemelli, Rome, Italy, <sup>6</sup>University of Rome Tor Vergata, Rome, Italy, <sup>7</sup>Università La Sapienza Roma Italy

**OC 26 12.32-12.42 Impact of active and passive SARS-CoV-2 immunization on CAR-T patients: an Italian experience**

I. Pansini<sup>1</sup>, F. Frondizi<sup>2</sup>, E. Galli<sup>3</sup>, A. Di Rocco<sup>4</sup>, A. Cingolani<sup>2,5</sup>, M. Di Palma<sup>4</sup>, E. Metafuni<sup>3</sup>, S. Hohaus<sup>1,3</sup>, P. Chiusolo<sup>1,3</sup>, A.P. Iori<sup>4</sup>, S. Sica<sup>1,3</sup>, M. Martelli<sup>4</sup>, F. Sorà<sup>1,3</sup>

<sup>1</sup>Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome (IT), <sup>2</sup>Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome (IT), <sup>3</sup>Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (IT), <sup>4</sup>Dipartimento di Medicina Traslazionale e di Precisione, Università di Roma Sapienza, Roma (IT), <sup>5</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (IT)

**OC 27 12.44-12.54 Oral Antivirals against SARS-CoV-2: a Comparison between Molnupiravir and Nirmatrelvir/Ritonavir in a Real Life Setting**

N. Braccialarghe<sup>1</sup>, R.A. Cavasio<sup>1</sup>, D. Zaçe<sup>1</sup>, L. Alborghetti<sup>1</sup>, A. Cekrezi<sup>1</sup>, A.C. Epifani<sup>1</sup>, G. Montagnari<sup>1</sup>, F. Nina<sup>1</sup>, L. Coppola<sup>2</sup>, M. Iannetta<sup>1,2</sup>, L. Sarmati<sup>1,2</sup> and the Tor Vergata Hospital group

<sup>1</sup>Department of System Medicine Tor Vergata, University of Rome, Rome, Italy, <sup>2</sup>Infectious Disease Clinic, Policlinico Tor Vergata University Hospital, Rome, Italy

**OC 28 12.56-13.06 Efficacy, tolerability and prescribing choice in patients undergoing early therapy for COVID19: a single-center 2-years real life experience**

D. Di Trento<sup>1</sup>, A. Gasperin<sup>1</sup>, S. Garattini<sup>1,2</sup>, A. Carraro<sup>2</sup>, A. Grimaldi<sup>1</sup>, S.G. De Maria<sup>1</sup>, S. Corazza<sup>1</sup>, G. Mancarella<sup>1,2</sup>, F. Izzo<sup>1</sup>, M. De Masi<sup>2</sup>, B. Kertusha<sup>2</sup>, A. Parente<sup>1,2</sup>, T. Tieghi<sup>2</sup>, P. Fabietti<sup>2</sup>, C. Bortignon<sup>1</sup>, O. D'Onofrio<sup>1,2</sup>, G. Bagagli<sup>3</sup>, G. Bonanni<sup>3</sup>, C. Del Borgo<sup>2</sup>, M. Lichtner<sup>1,2</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, "La Sapienza" University, Rome, <sup>2</sup>Infectious Diseases Unit, SM Goretti Hospital Latina; <sup>3</sup>Pharmacy Service Unit, SM Goretti Hospital Latina

13.08-13.15 **Conclusion**

E. Nicastrì, Roma; M. Tavio, Ancona



PARALLEL SESSION 12.15-13.15

AULA I

**ARCA Scientific Board**

La riunione del Board Scientifico tratterà lo stato attuale della Coorte con un update sulle attività in corso e le prospettive progettuali, incluso il prossimo meeting ARCA Mentor School in programma a settembre a Siena.




**ORAL COMMUNICATIONS** 13.20-14.20

**Clinical issues blinking to laboratory**
**AUDITORIUM ALDO MORO**

Chairs: S. Cicalini (Roma), C. Gervasoni (Milano)

 13.20-13.25 **Introduction**

S. Cicalini, Roma; C. Gervasoni, Milano

**OC 29 13.25-13.35 Weight gain and loss and stable weight in relation to fat and lean mass in PWH**

 L. Taramasso<sup>1</sup>, N. Barp<sup>2</sup>, J. Milic<sup>2</sup>, F. Bovis<sup>1</sup>, F. Motta<sup>2</sup>, G. Mancini<sup>3</sup>, F. Mediolini<sup>2</sup>, J. Conti<sup>2</sup>, M. Faltoni<sup>2</sup>, G. Burastero<sup>2</sup>, S. Volpi<sup>2</sup>, M. Belli<sup>2</sup>, A. Di Biagio<sup>1</sup>, M. Bassetti<sup>1</sup>, C. Mussini<sup>2,3</sup>, G. Guaraldi<sup>2,3</sup>
<sup>1</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>University of Modena and Reggio Emilia, Modena, Italy,

<sup>3</sup>Infectious Diseases Unit, Policlinico di Modena, Università Degli Studi di Modena e Reggio Emilia, Modena, Italy

**OC 30 13.37-13.47 Predicting Major Cardiovascular Events in People Living with HIV: a Prospective Observational Study**

E. Drappero, A. Bosio, M.C. Tettoni, M. Ferrara, F. Alladio, G. Accardo, S. Fantino, G. Trevisan, G. Di Perri, S. Bonora, A. Calcagno

Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

**OC 31 13.49-13.59 Long-term CD4+ cells recovery in PLWH on active antiretroviral treatment**

 F. Maggiolo<sup>1</sup>, L. Comi<sup>1</sup>, D. Valenti<sup>1,2</sup>, R. Teocchi<sup>3</sup>, E. Di Filippo<sup>1</sup>, S. Venturelli<sup>1</sup>
<sup>1</sup>UOC Infectious Diseases, <sup>2</sup>FROM foundation, <sup>3</sup>Informatics department, ASST Papa Giovanni XXII, Bergamo Italy

**OC 32 14.01-14.11 A comprehensive analysis of total and integrated HIV DNA, CD4 and CD8 T cell response, and survival, quiescence, and stemness signaling at different stages of HIV infection**

 L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, Z. Michelini<sup>2</sup>, M. Fracella<sup>3</sup>, L. Sorrentino<sup>3</sup>, M. Andreotti<sup>2</sup>, G. Bugani<sup>1</sup>, A. Lazzaro<sup>1</sup>, F. Frasca<sup>3</sup>, C. Lofaro<sup>1</sup>, G. Antonelli<sup>3</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, C. Scagnolari<sup>3</sup>, G. d'Ettore<sup>1</sup>
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>National Center for Global Health, Istituto

 Superiore di Sanità, Rome, Italy, <sup>3</sup>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia, Sapienza University, Rome

 14.13-14.20 **Conclusion**

S. Cicalini, Roma, C. Gervasoni, Milano


**ORAL COMMUNICATIONS** 13.20-14.20

**Viral infections old and new**
**AULA V**

Chairs: V. Micheli (Milano), L. Sarmati (Roma)

 13.20-13.25 **Introduction**

V. Micheli, Milano; L. Sarmati, Roma

**OC 33 13.25-13.35 APRI and FIB-4 scores predict mortality and morbidity in HCV infected subjects after sustained virologic response over the longterm**

C. Costa, H.L. Morrone, B. Tassone, M.T. Tassone, G. Bruno, F. Valente, S. Rotundo, G. Marino, P. Fusco, A. Russo, E.M. Treçarichi, C. Torti

Department of Medical and Surgical Sciences, Chair of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro, Italy

**OC 34 13.37-13.47 Common seasonal respiratory viral infections during nine consecutive seasons (2014-2023), including Coronavirus disease (COVID-19) pandemic**

 I. Giberti<sup>1</sup>, E. Costa<sup>1</sup>, V. Ricucci<sup>2</sup>, B. Galano<sup>2</sup>, N. Nigro<sup>2</sup>, G. Guarona<sup>1,2</sup>, B. Bruzzone<sup>2</sup>, A. Orsi<sup>1,2</sup>, G. Icardi<sup>1,2</sup>
<sup>1</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>2</sup>Hygiene Laboratory Unit, IRCCS, Policlinico San Martino Hospital, Genoa, Italy

**OC 35 13.49-13.59 Seroprevalence of Monkeypox (MPX) IgG antibodies in a cohort of PLWH in Rome, during the 2022 outbreak**

 P.F. Salvo<sup>1</sup>, D. Farinacci<sup>2</sup>, R. Jo Steiner<sup>1</sup>, V. Iannone<sup>1</sup>, F. Lamanna<sup>1</sup>, R.A. Passerotto<sup>1</sup>, G. Placidi<sup>3</sup>, A. Carbone<sup>1</sup>, A. Borghetti<sup>4</sup>, S. Di Giambenedetto<sup>1,4</sup>, F. Lombardi<sup>4</sup>
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>UOC Medicina Protetta - ASL Viterbo, Viterbo, <sup>3</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma


**OC 36 14.01-14.11 Case series of Monkeypox in a sexual health clinic in Milan**G. Pozza<sup>1</sup>, D. Moschese<sup>1</sup>, A. Giacomelli<sup>1</sup>, A. Chiesa<sup>1</sup>, D. Mileto<sup>2</sup>, G. Rizzardini<sup>1</sup>, S. Antinori<sup>1</sup><sup>1</sup>Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>Clinical Microbiology, Virology and Bioemergency Diagnostics, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy14.13-14.20 **Conclusion**

V. Micheli, Milano; L. Sarmati, Roma

**ORAL COMMUNICATIONS** 13.20-14.20**AULA IV****Preferences limitations and long term outcomes**

Chairs: A. Cascio (Palermo), E. Girardi (Roma)

13.20-13.25 **Introduction**

A. Cascio, Palermo; E. Girardi, Roma

**OC 37 13.25-13.35 Real world data on PROs and pharmacokinetics in PLWH starting long-acting injectable antiretroviral therapy (LAI-ART)**D. Tomasoni<sup>1</sup>, L. Gazzola<sup>1</sup>, R. Nardo<sup>1</sup>, M. Sala<sup>1</sup>, G. Brambilla<sup>1</sup>, D. Cattaneo<sup>2</sup>, T. Bini<sup>1</sup>, G. Marchetti<sup>1</sup><sup>1</sup>Infectious Disease and Tropical Medicine, San Paolo University Hospital, Milan, <sup>2</sup>Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan**OC 38 13.37-13.47 Perceived health discrimination and normative stigma: health consequences in a cohort of People living with HIV**V. Massaroni<sup>1</sup>, V. Iannone<sup>1,2</sup>, V. Delle Donne<sup>1</sup>, A. D'Angelillo<sup>1,2</sup>, G. Baldin<sup>2</sup>, R. Passerotto<sup>1,2</sup>, F. Sangiorgi<sup>1,2</sup>, R. Jo Steiner<sup>1,2</sup>, E. Visconti<sup>2</sup>, S. Di Giambenedetto<sup>1,2</sup>, A. Ciccullo<sup>3</sup><sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>3</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila; Italy**OC 39 13.49-13.59 Outcome of tenofovir and integrase inhibitors-including ART in PLWH and HBV: data from the SCOLTA cohort**L.A. Nicolini<sup>1</sup>, B. Menzaghi<sup>2</sup>, E. Ricci<sup>3</sup>, N. Squillace<sup>4</sup>, G.V. De Socio<sup>5</sup>, P. Maggi<sup>6</sup>, S. Piconi<sup>7</sup>, G. Orofino<sup>8</sup>, G. Madeddu<sup>9</sup>, B.M. Celesia<sup>10</sup>, G.F. Pellicanò<sup>11</sup>, L. Valsecchi<sup>12</sup>, E. Sarchi<sup>13</sup>, F. Vichi<sup>14</sup>, F. Lagi<sup>15</sup>, K. Falasca<sup>16</sup>, R. Gulminetti<sup>17</sup>, A. Bandera<sup>18,19</sup>, L. Calza<sup>20</sup>, P. Bonfanti<sup>4,21</sup>, A. Di Biagio<sup>1,21</sup><sup>1</sup>Unit of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>2</sup>Unit of Infectious Diseases, ASST Della Valle Olona-Busto Arsizio (VA), Busto Arsizio, <sup>3</sup>Fondazione ASIA Onlus, Milan, Italy, <sup>4</sup>Unit of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>5</sup>Unit of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, <sup>6</sup>Infectious and Tropical Diseases Clinic, AORN Sant'Anna and San Sebastiano, Caserta, Italy, <sup>7</sup>Infectious Diseases, Azienda Ospedaliera di Lecco, Lecco, Italy, <sup>8</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>9</sup>Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, <sup>10</sup>Unit of Infectious Diseases, University of Catania, Catania, Italy, <sup>11</sup>Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', Unit of Infectious Diseases, University of Messina, <sup>12</sup>Infectious Disease Unit (I Division), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>13</sup>Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>14</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, <sup>15</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>16</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy, <sup>17</sup>Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, <sup>18</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, <sup>19</sup>Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy, <sup>20</sup>Unit of Infectious Diseases; Unit of Microbiology; and Hospital Pharmacy, S. Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, <sup>21</sup>University of Milano-Bicocca, Milan, Italy, <sup>22</sup>Department of Health Science (Dissal), University of Genoa, Genoa, Italy**OC 40 14.01-14.11 Missing data generate missing opportunities: frailty phenotype assessment in the GEPPPO cohort**E. Focà<sup>1</sup>, S. Arsuffi<sup>1</sup>, S. Calza<sup>2</sup>, J. Milic<sup>3</sup>, C. Mussi<sup>4</sup>, A. Marengoni<sup>5</sup>, M. Ferrara<sup>6</sup>, B.M. Celesia<sup>7</sup>, G. Madeddu<sup>8</sup>, A.M. Cattelan<sup>9</sup>, G. Di Perri<sup>6</sup>, A. Calcagno<sup>6</sup>, G. Guaraldi<sup>3</sup><sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious Diseases, University of Brescia and Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>3</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, <sup>4</sup>Department of Biomedical, Metabolic and Neural Sciences, Center for Gerontological Evaluation and Research, University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>Department of Clinical and Experimental Sciences, Unit of Geriatrics, University of Brescia and Spedali Civili Hospital, Brescia, Italy, <sup>6</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>7</sup>Division of Infectious Diseases, ARNAS Garibaldi, Catania, Italy, <sup>8</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Science, University of Sassari, Sassari, Italy, <sup>9</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy14.13-14.20 **Conclusion**

A. Cascio, Palermo; E. Girardi, Roma





ORAL COMMUNICATIONS 13.20-14.20

AULA III

## Immune response to viruses

Chairs: C. Agrati (Roma), I. Vicenti (Siena)

13.20-13.25 **Introduction**

C. Agrati, Roma; I. Vicenti, Siena

### OC 41 13.25-13.35 Humoral and cell-mediated immunity against SARS-CoV-2 in dialysis patients after the vaccination with mRNA-1273 and BNT162b2 vaccines

*M. Tarkowski<sup>1</sup>, N. Landriani<sup>2</sup>, C. Costanza<sup>1</sup>, C. Airaghi<sup>2</sup>, E. Sabadini<sup>3</sup>, R. Gingis<sup>3</sup>, C. De Salvo<sup>3</sup>, A. Gabrielli<sup>1</sup>, M. Gallieni<sup>1</sup>, A. Riva<sup>1</sup>*  
CoVICIS EU Horizon grant nr 101046041

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>L. Sacco Hospital, Milan, Italy, <sup>3</sup>Fattebenefratelli Hospital, Milan, Italy

### OC 42 13.37-13.47 Immune response triggered by a candidate vaccine based on a clone of Leishmania tarentolae expressing the SARS-CoV-2 Spike protein

*M. Garziano<sup>1,2</sup>, I. Varotto-Boccazzi<sup>3,4</sup>, C. Conforti<sup>1</sup>, G.M. Cattaneo<sup>3</sup>, M. Clerici<sup>2,5</sup>, C. Vanetti<sup>1</sup>, S. Epis<sup>3,4</sup>, M. Biasin<sup>1</sup>, C. Bandi<sup>3,4</sup>, D. Trabattoni<sup>1</sup>*

<sup>1</sup>Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>3</sup>Department of Biosciences, University of Milan, Milan, Italy, <sup>4</sup>Pediatric CRC "Romeo ed Enrica Invernizzi", University of Milan, Milan, Italy, <sup>5</sup>IRCCS Fondazione don Carlo Gnocchi, Milan, Italy

### OC 43 13.49-13.59 Specific T-cell responses to Varicella Zoster Virus glycoprotein E are elicited after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments

*M. Iannetta<sup>1,2</sup>, L. Benedetti<sup>1</sup>, D. Landi<sup>3</sup>, F. Napoli<sup>3</sup>, I. Fato<sup>1</sup>, G. Alessio<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, A. Imeneo<sup>1</sup>, B. Massa<sup>1</sup>, V. Barchi<sup>1</sup>, C. Picarelli<sup>1</sup>, F. Angelone<sup>1</sup>, A.C. Epifani<sup>1</sup>, G. Mataluni<sup>3</sup>, C.G. Nicoletti<sup>3</sup>, E. Teti<sup>2</sup>, G.A. Marfia<sup>3,4</sup>, L. Sarmati<sup>1,2</sup>*

<sup>1</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Rome, Italy, <sup>4</sup>IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy

### OC 44 14.01-14.11 Interferon and inflammatory response in SARS-CoV-2 infected patients treated with anti-S monoclonal antibodies

*L. Maddaloni<sup>1</sup>, L. Santinelli<sup>1</sup>, G. Bugani<sup>1</sup>, A. Lazzaro<sup>1</sup>, E. Gentilini Cacciola<sup>1</sup>, C.M. Lofaro<sup>1</sup>, A. D'Auria<sup>2</sup>, F. Frasca<sup>1</sup>, C. Leanza<sup>1</sup>, C. Ajassa<sup>1</sup>, G. Antonelli<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, G. Ceccarelli<sup>1</sup>, C. Scagnolari<sup>2</sup>, G. d'Ettore<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy

14.13-14.20 **Conclusion**

C. Agrati, Roma; I. Vicenti, Siena



ORAL COMMUNICATIONS 13.20-14.20

AULA II

## COVID-19 outcome in special population

Chairs: G.B. Buccoliero (Taranto), R. Rossotti (Milano)

13.20-13.25 **Introduction**

G.B. Buccoliero, Taranto; R. Rossotti, Milano

### OC 45 13.25-13.35 Efficacy of Tixagevimab/Cilgavimab pre-exposure prophylaxis of COVID-19 in severely immunocompromised individuals: data from the OCTOPUS study

*A. Vergori<sup>1</sup>, G. Matusali<sup>2</sup>, E. Cimini<sup>3</sup>, L. Bordi<sup>2</sup>, P. Borrelli<sup>4</sup>, S. Lanini<sup>1</sup>, R. Palazzi<sup>5</sup>, J. Paulicelli<sup>1</sup>, D. Mariotti<sup>2</sup>, V. Mazzotta<sup>1</sup>, S. Notari<sup>3</sup>, R. Casetti<sup>3</sup>, M. Francalancia<sup>2</sup>, S. Rosati<sup>6</sup>, A. D'Abramo<sup>6</sup>, C. Mija<sup>2</sup>, P. Mencarini<sup>7</sup>, S. Sica<sup>8</sup>, E. Metafuni<sup>8</sup>, F. Sorà<sup>8</sup>, A. Rago<sup>9</sup>, A. Siniscalchi<sup>9</sup>, E. Abruzzese<sup>10</sup>, M.G. Garzia<sup>11</sup>, G. Luzi<sup>11</sup>, R. Battistini<sup>11</sup>, L. Prosperini<sup>12</sup>, E. Girardi<sup>13</sup>, F. Vaia<sup>14</sup>, A. Cingolani<sup>15</sup>, F. Maggi<sup>2</sup>, E. Nicastrì<sup>6</sup>, A. Antinori<sup>1</sup> on behalf of the Octopus Study group*

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Laboratory of Virology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>3</sup>Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" of Chieti- Pescara, Chieti, Italy, <sup>5</sup>Accettazione e Teleconsulto Rete Regionale Malattie Infettive, National Institute for





Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>Emerging Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>7</sup>Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy, <sup>8</sup>Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica e Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome Italy, <sup>9</sup>UOSD Ematologia ASL Roma 1, San Filippo Neri Hospital, Rome, Italy, <sup>10</sup>UOC Ematologia, Sant'Eugenio Hospital, Rome, Italy, <sup>11</sup>UOC Ematologia e Trapianto di Cellule Staminali, San Camillo-Forlanini Hospital, Rome, Italy, <sup>12</sup>UOC Neurologia e Neurofisiopatologia, San Camillo-Forlanini Hospital, Rome, Italy, <sup>13</sup>Scientific Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>14</sup>General Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>15</sup>Infectious Diseases Institute, Policlinico A. Gemelli, Rome, Italy

**OC 46 13.37-13.47 Outcomes and clinical features of COVID-19 patients with haematological malignancies in the Omicron era**

A. Oliva<sup>1</sup>, S. Valeri<sup>1</sup>, G. Savelloni<sup>1</sup>, F. Cogliati Dezza<sup>1</sup>, F. Iannazzo<sup>1</sup>, F. Infante<sup>1</sup>, A. Iacovelli<sup>2</sup>, F. Cancelli<sup>1</sup>, M. Venditti<sup>1</sup>, P. Palange<sup>2</sup>, C.M. Mastroianni<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome

**OC 47 13.49-13.59 COVID-19 in PLWH: clinical outcomes, a single center analysis**

C. Grillo, A. Narducci, M. Caggese, E.P. Drago, C. Muscatiello, S. Ferrara, T.A. Santantonio, S. Lo Caputo

Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

**OC 48 14.01-14.11 Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children**

R. Scutari<sup>1,2</sup>, V. Fox<sup>1,2</sup>, V. Fini<sup>2</sup>, A. Granaglia<sup>2</sup>, P. Bernaschi<sup>3</sup>, C. Russo<sup>3</sup>, A. Campana<sup>4</sup>, S. Bernardi<sup>4</sup>, A. Villani<sup>4</sup>, C.F. Perno<sup>2,3</sup>, C. Alteri<sup>1,2</sup>

<sup>1</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>2</sup>Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>3</sup>Microbiology and Diagnostics in Immunology, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>4</sup>Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

14.13-14.20 **Conclusion**

G.B. Buccoliero, Taranto; R. Rossotti, Milano



**SPONSORED SYMPOSIUM** 14.30-15.30

**AUDITORIUM ALDO MORO**

**B/F/TAF: your trusted partner also in apparently un-complicated patients**

Chair: G.C. Marchetti (Milano)

Simposio promozionale Gilead Sciences

Gilead, a historical company involved in advancing HIV therapy, will host a promotional symposium called "B/F/TAF: Your trusted partner also in apparently uncomplicated patients." The symposium will focus on apparently uncomplicated patients in order to better understand their characteristics and raise awareness of the complexity of HIV. Through an analysis of patients' clinical needs, the often-overlooked CNS adverse events, the importance of long-term safety in therapy, and the need to control viral replication for as long as possible, we will draw on the experience of B/F/TAF to present key data on long-term safety and maximal and durable viral suppression, with the aim of identifying the optimal treatment choices for these patients.

14.30-14.35	<b>Introduction</b>	G.C. Marchetti, Milano
14.35-14.45	<b>Gilead's commitment in HIV</b>	F. da Silva, Milano
14.45-15.05	<b>Maximal and durable viral suppression in apparently un-complicated HIV Patients: the role of B/F/TAF</b>	S. Bonora, Torino
15.05-15.25	<b>The confidence of B/F/TAF Long-Term Safety in HIV Treatment</b>	G. Madeddu, Sassari
15.25-15.30	<b>Q&amp;A</b>	G.C. Marchetti, Milano





ORAL COMMUNICATIONS 14.30-15.30

AULA V

**Antiviral treatment in COVID-19**

Chairs: A. Franco (Siracusa), M. Lichtner (Latina)

14.30-14.35 **Introduction**

A. Franco, Siracusa; M. Lichtner, Latina

**OC 49 14.35-14.45 Prolonged antiviral therapy combined with neutralizing monoclonal antibodies as a treatment strategy for COVID-19 in severely immunocompromised patients during the Omicron wave: a quasi-experimental multicentre cohort study**D.F. Bavaro<sup>1</sup>, C. Pellegrino<sup>1</sup>, F. Balena<sup>1</sup>, A. Belati<sup>1</sup>, L. Diella<sup>1</sup>, G. Metrangola<sup>1</sup>, V. Totaro<sup>1</sup>, L. Frallonardo<sup>1</sup>, E. Pallara<sup>1,3</sup>, G. Bruno<sup>2</sup>, C. Muscatiello<sup>3,4</sup>, F. Di Gennaro<sup>1</sup>, N. Giovine<sup>5</sup>, F. Pomarico<sup>5</sup>, M. Dell'Aera<sup>5</sup>, G.B. Buccoliero<sup>2</sup>, S. Carbonara<sup>3</sup>, A. Saracino<sup>1</sup><sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University Hospital of Bari, Bari, Italy, <sup>2</sup>Infectious Diseases Unit, "San Giuseppe Moscati" Hospital, Taranto, Italy, <sup>3</sup>U.O.C. Malattie Infettive, ASL BAT, P.O. V. Emanuele II, Bisceglie, Italy, <sup>4</sup>Department of Medical and Surgical Science, University of Foggia, Foggia, Italy, <sup>5</sup>Pharmacy Unit, University Hospital Polyclinic of Bari, Bari, Italy**OC 50 14.47-14.57 Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: final analysis of an observational multicenter study (CONDIVIDIAMO)**G. Ghilardi<sup>1</sup>, A. Soria<sup>1</sup>, F. Graziano<sup>1</sup>, G. Lapadula<sup>1,2</sup>, D. Dalla Gasperina<sup>3</sup>, S.V. Benatti<sup>4</sup>, M.E. Quiros Roldan<sup>5</sup>, P. Brambilla<sup>6</sup>, F. Bai<sup>7</sup>, M. Merli<sup>8</sup>, D. Minisci<sup>9</sup>, M. Franzetti<sup>10</sup>, E. Asperges<sup>11</sup>, D. Pocaterra<sup>12</sup>, A. Pandolfo<sup>13</sup>, F. Zanini<sup>14</sup>, D. Lombardi<sup>15</sup>, A. Cappelletti<sup>1</sup>, A. Rugova<sup>1</sup>, M. L. Borghesi<sup>1</sup>, L. Pusterla<sup>15</sup>, S. Piconi<sup>13</sup>, P. Morelli<sup>12</sup>, P. Rovere<sup>16</sup>, R. Bruno<sup>11</sup>, S. Rusconi<sup>10</sup>, S. Casari<sup>9</sup>, A. Bandera<sup>17</sup>, F. Franzetti<sup>18</sup>, M. Puoti<sup>2,8</sup>, A. d'Arminio Monforte<sup>7</sup>, G. Marchetti<sup>7</sup>, M. Milesi<sup>6</sup>, F. Castelli<sup>2</sup>, M. Rizzi<sup>4</sup>, F. Dentali<sup>3</sup>, M. Mallardo<sup>2</sup>, E. Rossi<sup>2</sup>, M.G. Valsecchi<sup>2</sup>, S. Galimberti<sup>2</sup>, P. Bonfanti<sup>1,2</sup><sup>1</sup>IRCCS San Gerardo dei Tintori, Monza MB, Italy, <sup>2</sup>University of Milano-Bicocca, Monza MB, Italy, <sup>3</sup>ASST Sette Laghi, Varese, Italy, <sup>4</sup>ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>5</sup>University of Brescia, Brescia, Italy, <sup>6</sup>ASST Cremona, Cremona, Italy, <sup>7</sup>ASST Santi Paolo e Carlo, <sup>8</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>9</sup>ASST Mantova, Mantova, Italy, <sup>10</sup>ASST Ovest Milano, Legnano VA, Italy, <sup>11</sup>IRCCS Policlinico San Matteo, Pavia, Italy, <sup>12</sup>IRCCS Humanitas, Rozzano, <sup>13</sup>ASST Lecco, Italy, <sup>14</sup>ASST Nord Milano, Cinisello Balsamo MI, Italy, <sup>15</sup>ASST Lariana Como, Italy, <sup>16</sup>IRCCS San Raffaele, Milan, Italy, <sup>17</sup>IRCCS Ca' Granda Policlinico, Milan, Italy, <sup>18</sup>ASST Valle Olona, Busto Arsizio VA, Italy**OC 51 14.59-15.09 Clinical efficacy of tixagevimab/cilgavimab pre-exposure prophylaxis in immunocompromised patients treated during Omicron sublineages diffusion. Real life experience from ASST Lecco**V. Morena<sup>1</sup>, S. Pontiggia<sup>1</sup>, F. Alberton<sup>2</sup>, F. Badalucco<sup>2</sup>, C. Molteni<sup>1</sup>, L. Bradanini<sup>1</sup>, F. Conti<sup>1</sup>, A. Pandolfo<sup>1</sup>, A. Castagna<sup>2</sup>, S. Piconi<sup>1</sup><sup>1</sup>Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, <sup>2</sup>University Vita-Salute IRCCS San Raffaele Hospital, Milan, Italy**OC 52 15.11-15.21 Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study**A. De Vito<sup>1</sup>, G. Moi<sup>1</sup>, L. Saderi<sup>2</sup>, M. Puci<sup>2</sup>, A. Colpani<sup>1</sup>, B. Zauli<sup>1</sup>, V. Fiore<sup>1</sup>, M. Fois<sup>1</sup>, A. Bitti<sup>1</sup>, B. Zauli<sup>1</sup>, I. Maida<sup>1</sup>, S. Babudieri<sup>1</sup>, G. Sotgiu<sup>2</sup>, G. Madeddu<sup>1</sup><sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, <sup>2</sup>Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy15.23-15.30 **Conclusion**

A. Franco, Siracusa; M. Lichtner, Latina



**EXPERT MEETING** 14.30-15.30**AULA IV****Long-acting antimicrobial experiences in real world patients: toward paradigm change?**

Chairs: S. Carbonara (Bari), A.M. Cattelan (Padova)

The long-acting lipoglycopeptides (LGP) are antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved for acute bacterial skin and soft tissue infections (ABSSSI), their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as diabetic foot, bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and multidrug-resistant bacteria are suspected.

14.30-14.45	<b>In the diabetic patient</b>	F.G. De Rosa, Torino
14.45-15.00	<b>In bacterial coinfection</b>	G. Parruti, Pescara
15.00-15.15	<b>Clinical practice and pharmaco-economic aspects</b>	R. Cultrera, Ferrara
15.15-15.30	<b>Discussion</b>	

**ORAL COMMUNICATIONS** 14.30-15.30**AULA III****HIV: much left to do**

Chairs: M. Farinella (Roma), S. Mattioli (Bologna)

14.30-14.35 **Introduction** M. Farinella, Roma; S. Mattioli, Bologna**OC 53** 14.35-14.45 **HIV and hospitals: an evolving relationship***L. Brogonzoli<sup>1</sup>, M. Cascio<sup>2</sup>, E. Sala<sup>1</sup>, C. Crepaldi<sup>1</sup>, R. Iardino<sup>1</sup>, A. d'Arminio Monforte<sup>3</sup>*<sup>1</sup>Fondazione The Bridge, Milano, <sup>2</sup>European AIDS Treatment Group (EATG), Palermo, <sup>3</sup>University of Milan, Milano, Fondazione Icona, Milano**OC 54** 14.47-14.57 **Achieving the third 95 in our HIV clinics: it is possible, but there is still a lot to do***E. Teti<sup>1</sup>, A. Crea<sup>1</sup>, B. Rossi<sup>1</sup>, D. Checchi<sup>1</sup>, M. Compagno<sup>1</sup>, L. Sarmati<sup>2</sup>, A.M. Geretti<sup>2</sup>*<sup>1</sup>Clinical Infectious Diseases, Tor Vergata Hospital, Rome, Italy, <sup>2</sup>Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy**OC 55** 14.59-15.09 **Implementation of the Regional DCA 401/2016 in Latium: an example of a coordinated, multidisciplinary and individualized approach to PLWH territorial healthcare, forerunner of the National Recovery and Resilience Plan (PNRR) indications***A. Faticoni, A. Agresta, R. Casa, R. Esvan, V. Puro, N. Orchi*

INMI L. Spallanzani - IRCCS, Roma

**OC 56** 15.11-15.21 **BELONG – Why people living with HIV must be included in non-HIV Clinical Trials. A community-led initiative for an inclusive approach to clinical research***R. Pignata, R. Tatoud, G. Barbareschi, F. Greenhalgh*

European AIDS Treatment Group, Brussels

15.23-15.30 **Conclusion** M. Farinella, Roma; S. Mattioli, Bologna


**ORAL COMMUNICATIONS** 14.30-15.30

**AULA II**
**Cardiovascular and malignancies**

Chairs: F. Mazzotta (Firenze), M.E. Quiros Roldan (Brescia)

 14.30-14.35 **Introduction**

F. Mazzotta, Firenze; M.E. Quiros Roldan, Brescia

**OC 57 14.35-14.45 Malignancies and MACEs in the PRESTIGIO Registry**

 T. Clemente<sup>1,2</sup>, D. Pontillo<sup>2</sup>, D. Minisci<sup>3</sup>, A. Di Biagio<sup>4</sup>, A. Galli<sup>2</sup>, L. Attala<sup>5</sup>, G. Cenderello<sup>6</sup>, V. Malagnino<sup>7</sup>, S. Lo Caputo<sup>8</sup>, M. Tavio<sup>9</sup>, A. Giacomelli<sup>10</sup>, A. Castagna<sup>1,2</sup>, V. Spagnuolo<sup>2</sup> on behalf of the PRESTIGIO Study Group

<sup>1</sup>Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, <sup>4</sup>Unit of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>5</sup>Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Italy, <sup>6</sup>Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, <sup>7</sup>Infectious Disease Clinic, Policlinico Tor Vergata University Hospital, Rome, Italy, <sup>8</sup>Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>9</sup>Infective Diseases, AOU Ospedali Riuniti, Ancona, Italy, <sup>10</sup>III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy

**OC 58 14.47-14.57 Cardiovascular events on integrase strand-transfer inhibitors treatment**

 P. Bonfanti<sup>1</sup>, E. Ricci<sup>2</sup>, G.V. De Socio<sup>3</sup>, P. Maggi<sup>4</sup>, N. Squillace<sup>1</sup>, L. Taramasso<sup>5</sup>, L.A. Nicolini<sup>5</sup>, G. Orofino<sup>6</sup>, M.B. Celesia<sup>7</sup>, G. Madeddu<sup>8</sup>, B. Menzaghi<sup>9</sup>, F. Vichi<sup>10</sup>, A. Di Biagio<sup>5</sup> on behalf of CISAI Study Group

<sup>1</sup>Fondazione IRCCS San Gerardo dei Tintori-University of Milano-Bicocca, Monza, <sup>2</sup>Fondazione ASIA Onlus, <sup>3</sup>Santa Maria Hospital, Perugia, <sup>4</sup>AORN Sant'Anna e San Sebastiano - University L.Vanvitelli, Caserta, <sup>5</sup>IRCCS Policlinico San Martino Hospital - University of Genova, Genova, <sup>6</sup>Amedeo di Savoia Hospital, Torino, <sup>7</sup>A. Garibaldi Hospital, Catania, <sup>8</sup>Università di Sassari, Sassari, <sup>9</sup>Busto Arsizio Hospital, Busto Arsizio (VA), <sup>10</sup>Sant'Annunziata Hospital, Firenze

**OC 59 14.59-15.09 Multidimensional evaluation of switching from a first generation 3 drug (DR) INSTI regimen to a second generation 3DR- or 2DR INSTI regimen: a single Center retrospective Desirability of Outcome Ranking (DOOR) analysis**

N. De Gennaro, F. Balena, D. Fiordelisi, L. Frallonardo, G. Guido, D. Cassano, V. Guerra, V. Spada, A. Dargeni, G. Romito, G. Manco Cesari, V. Totaro, C. Pellegrino, D.F. Bavaro, A. Saracino

Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari "Aldo Moro", Bari, Italy

**OC 60 15.11-15.21 Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL**

 A. Cozzi-Lepri<sup>1</sup>, A. Tavelli<sup>2</sup>, L. Taramasso<sup>3</sup>, D. Barbanotti<sup>4</sup>, G. Lapadula<sup>5</sup>, N. Bobbio<sup>6</sup>, S. Piconi<sup>7</sup>, G. Guaraldi<sup>8</sup>, A. Di Biagio<sup>3</sup>, C. Muccini<sup>9</sup>, A. Antinori<sup>10</sup>, A. d'Arminio Monforte<sup>2</sup>, on behalf of the Icona Foundation Study group

<sup>1</sup>IGH University College London, CREME Center, London, United Kingdom, <sup>2</sup>Icona Foundation Study, Milano, Italy, <sup>3</sup>San Martino Hospital, Genova, Italy, <sup>4</sup>San Paolo Hospital, Milano, Italy, <sup>5</sup>Fondazione IRCCS "San Gerardo" and Bicocca University, Monza/Milano, Italy, <sup>6</sup>Galliera Hospital, Genova, Italy, <sup>7</sup>Unità Operativa Complessa ASST Lecco, Lecco, Italy, <sup>8</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>9</sup>San Raffaele Hospital, Milano, Italy, <sup>10</sup>INMI Lazzaro Spallanzani, Roma, Italy

 15.23-15.30 **Conclusion**

F. Mazzotta, Firenze; M.E. Quiros Roldan, Brescia


**SYMPOSIUM** 15.35-16.35

**AUDITORIUM ALDO MORO**
**New issues on antiretroviral drug optimization**

Chairs: S. Di Giambenedetto (Roma), G. Rizzardini (Milano)

With currently available antiretroviral therapy, most people with HIV infection can achieve and maintain HIV viral suppression. Advances in antiretroviral treatment and a better understanding of drug resistance have made it possible to consider switching a person with HIV from an effective regimen to another in defined circumstances. New burning topics including the significance of the archived and resistant HIV, will be discussed

 15.35-15.50 **Role and impact of drug-resistant and archived HIV**

M. Zazzi, Siena

 15.50-16.05 **How much adherence is necessary to avoid drug-resistance with modern ART 2DRs and 3DRs?**

A. Di Biagio, Genova

 16.05-16.20 **Pharmacological interactions: ART and the rest of world**

A. Calcagno, Torino

 16.20-16.35 **Discussion**


**SATELLITE SYMPOSIUM** 15.35-16.35**AULA V****From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy**

Chairs: A. Cingolani (Roma), R. Parrella (Napoli)

Con la sponsorizzazione non condizionante di Pfizer

COVID-19 places tremendous burden to public health and economy system. The roll-out of COVID-19 vaccines at the beginning of 2021 marked a key turning point in the fight against the global pandemic by limiting disease transmission and progression to death, albeit variable vaccination coverage. Early antiviral treatments can help reduce the risk of serious illness especially in adults at high risk of progressing to severe COVID-19 (as immunocompromised individuals) and may continue to shed virus and remain symptomatic for a longer period.

15.35-15.50	<b>SARS-CoV-2 early antiviral treatment: in which patients?</b>	M. Andreoni, Roma
15.50-16.05	<b>Antiviral therapy in COVID-19 patients</b>	A. Antinori, Roma
16.05-16.15	<b>Discussion</b>	
16.15-16.30	<b>SARS-CoV-2 bivalent vaccines efficacy in today's epidemiological scenario</b>	P.L. Lopalco, Lecce
16.30-16.35	<b>Discussion</b>	

**ORAL COMMUNICATIONS** 15.35-16.35**AULA IV****Severe clinical issues in HIV-1 infection**

Chairs: A. Cozzi-Lepri (London, UK), M. De Gennaro (Lucca)

15.35-15.40	<b>Introduction</b>	A. Cozzi-Lepri, London, UK; M. De Gennaro, Lucca
<b>OC 61</b>	<b>15.40-15.50 Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO registry</b> <i>R. Papaioannu Borjesson<sup>1</sup>, L. Galli<sup>2</sup>, R. Lolatto<sup>2</sup>, B. Menzaghi<sup>3</sup>, M. Feasi<sup>4</sup>, R. Gulminetti<sup>5</sup>, C. Fornabaio<sup>6</sup>, A.M. Cattelan<sup>7</sup>, S. Bonora<sup>8</sup>, F. Lagi<sup>9</sup>, M. Zazzi<sup>10</sup>, A. Castagna<sup>1,2</sup>, on behalf of PRESTIGIO Study Group</i> <sup>1</sup> San Raffaele Vita-Salute University, Milan, Italy, <sup>2</sup> Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup> Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, <sup>4</sup> Ente Ospedaliero Ospedali Galliera, Genova, Italy, <sup>5</sup> Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>6</sup> ASST Cremona, Cremona, Italy, <sup>7</sup> Azienda Ospedale-Università Padova, Padova, Italy, <sup>8</sup> Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Torino, Italy, <sup>9</sup> Infectious and Tropical diseases Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, <sup>10</sup> Department of Medical Biotechnologies, University of Siena, Siena, Italy	
<b>OC 62</b>	<b>15.52-16.02 Malignancies in PLWH: a 20-year experience in Perugia and Ancona hospitals</b> <i>L. Curci, C. Papalini, L. Brescini, F. Barchiesi, A. Giacometti, D. Francisci</i> Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy, Biomedical Sciences and Public Health Department, University Politecnica delle Marche, Ancona, Italy	
<b>OC 63</b>	<b>16.04-16.14 Clinical presentation and neuroimaging in newly diagnosed AIDS patients in the last 6 years</b> <i>L. Carani<sup>1</sup>, A. Calcagno<sup>1</sup>, G.C. Orofino<sup>2</sup>, G. Calleri<sup>2</sup>, P. Busolli<sup>3</sup></i> <sup>1</sup> Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino, <sup>2</sup> Divisione A Malattie Infettive e Tropicali, Ospedale Amedeo di Savoia, Torino, <sup>3</sup> SS Imaging Neuroncologico, Ospedale Giovanni Bosco, Torino	
<b>OC 64</b>	<b>16.16-16.26 Prolonged survival in HIV-associated progressive multifocal leukoencephalopathy (PML) treated with Pembrolizumab: a case series on treatment and long-term follow-up</b> <i>M. Chiuchiarelli<sup>1</sup>, F.V. Segala<sup>2</sup>, G. Giuliano<sup>3</sup>, P. Del Giacomo<sup>4</sup>, A. Dusina<sup>4</sup>, G. Maiuro<sup>4</sup>, E. Matteini<sup>1</sup>, F. Frondizi<sup>1</sup>, S. Gaudino<sup>5</sup>, E. Cimini<sup>6</sup>, R. Santangelo<sup>4,7</sup>, C. Agrati<sup>6</sup>, A.Cingolani<sup>4</sup></i> <sup>1</sup> Department of Bioethics and security, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>2</sup> Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>3</sup> Dipartimento Scienze di Laboratorio e Infettivologiche - Fondazione Policlinico Gemelli IRCCS, Roma, Italy, <sup>4</sup> Department of Radiological Sciences, Catholic University, School of Medicine, Rome, Italy, <sup>5</sup> Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>6</sup> Department of Basic Biotechnological, Clinical Intensivological and Perioperative Sciences, Catholic University of the Sacred Heart, Rome, Italy	
16.28-16.35	<b>Conclusion</b>	A. Cozzi-Lepri, London, UK; M. De Gennaro, Lucca




**ORAL COMMUNICATIONS** 15.35-16.35

**AULA III**
**Oral or injectable 2-drug regimens**

Chairs: V. Esposito (Napoli), A. Tavelli (Milano)

 15.35-15.40 **Introduction**

V. Esposito, Napoli; A. Tavelli, Milano

**OC 65 15.40-15.50 "With age comes wisdom": efficacy and tolerability of dolutegravir+lamivudine in virologically-suppressed PLWH**

 G. Baldin<sup>1</sup>, A. Ciccullo<sup>2</sup>, R. Passerotto<sup>3</sup>, A. Dusina<sup>1</sup>, V. Iannone<sup>3</sup>, A. Lamanna<sup>3</sup>, A. Carbone<sup>3</sup>, I. Mozzetta<sup>1</sup>, E. Visconti<sup>1</sup>, S. Di Giambenedetto<sup>1,3</sup>, A. Borghetti<sup>1</sup>
<sup>1</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>2</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italy, <sup>3</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy

**OC 66 15.52-16.02 Assessing long-term risk of virological failure in PLWHIV starting dolutegravir+lamivudine as a switch strategy**

 A. Ciccullo<sup>1</sup>, G. Baldin<sup>2</sup>, F. Lombardi<sup>2</sup>, A. Carbone<sup>3</sup>, D. Farinacci<sup>4</sup>, G. Placidi<sup>2</sup>, A. Dusina<sup>2</sup>, E. Visconti<sup>2</sup>, A. Borghetti<sup>2</sup>, S. Di Giambenedetto<sup>2,3</sup>
<sup>1</sup>UOC Malattie Infettive, PO San Salvatore, L'Aquila, Italia, <sup>2</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, <sup>3</sup>Università Cattolica del Sacro Cuore, Roma, Italia, <sup>4</sup>UO Medicina Protetta - Malattie Infettive, ASL Viterbo, Italia

**OC 67 16.04-16.14 Characteristics and clinical features of patients receiving LA CAB/RPV in a large clinical centre**

 M.V. Cossu<sup>1</sup>, D. Moschese<sup>1</sup>, M. Piscaglia<sup>1,3</sup>, F. Caruso<sup>2,3</sup>, C. Fusetti<sup>2,3</sup>, M. Matone<sup>1,3</sup>, C. De Luca<sup>1</sup>, M. Faenzi<sup>1</sup>, S. Sportoletti<sup>1</sup>, A.F. Capetti<sup>1</sup>, P.R. Meraviglia<sup>2</sup>, A. Gori<sup>2,3</sup>, G. Rizzardini<sup>1</sup>
<sup>1</sup>Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>II Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>3</sup>University of Milano, Milan, Italy

**OC 68 16.16-16.26 3-month outcome of long-acting cabotegravir and rilpivirine: preliminary results from the SCohLART Study**

 C. Candela<sup>1,2</sup>, V. Gordo<sup>1</sup>, L. Galli<sup>1</sup>, T. Clemente<sup>1,2</sup>, B. Trentacapilli<sup>1,2</sup>, M.F. Lucente<sup>1,2</sup>, R. Monardo<sup>1,2</sup>, F. Alberton<sup>1,2</sup>, R. Lolatto<sup>1</sup>, M. Lavall<sup>1</sup>, A. Lettieri<sup>1</sup>, R. Melzi<sup>1</sup>, P. Striglia<sup>1</sup>, D. Zandonà<sup>1</sup>, S. Bagaglio<sup>1</sup>, E. Carini<sup>1</sup>, A. Castagna<sup>1,2</sup>, N. Gianotti<sup>1</sup>
<sup>1</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milano, Italy

 16.28-16.35 **Conclusion**

V. Esposito, Napoli; A. Tavelli, Milano


**ORAL COMMUNICATIONS** 15.35-16.35

**AULA II**
**Prevention, access and engagement**

Chairs: M.L. Cosmaro (Milano), E. Girardi (Roma)

 15.35-15.40 **Introduction**

M.L. Cosmaro, Milano; E. Girardi, Roma

**OC 69 15.40-15.50 A nurse-led HIV/STI prevention program in a Voluntary Counselling and Testing site in the metropolitan area of Rome**

 E. Gennaro, R. Esvan, O. Bruzzi, A. Faticoni, G. Iannicelli, A. Navarra, N. Orchi, E. Piscitelli, S. Pittalis, D. Tonnini, V. Puro  
 Centro di Riferimento AIDS, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani", Roma

**OC 70 15.52-16.02 Epidemiological impact of pre-exposure prophylaxis in HIV prevention: a single center observational experience in pre and post prophylaxis era**

 L.F. Rezzonico<sup>1,2</sup>, C. Baiguera<sup>1</sup>, A. Raimondi<sup>1</sup>, C. Rogati<sup>1</sup>, L. Baldassari<sup>1,3</sup>, F. Peracchi<sup>1,3</sup>, F. D'Amico<sup>1</sup>, D. Calzavara<sup>4</sup>, M.C. Moiola<sup>1</sup>, L.G. Chianura<sup>1</sup>, M. Puoti<sup>1,3</sup>, R. Rossotti<sup>1</sup>
<sup>1</sup>Department of Infectious Disease, ASST Grande Ospedale Metropolitano Niguarda, Milan, <sup>2</sup>School of Medicine, University of Pavia, Pavia, <sup>3</sup>School of Medicine, University of Milano-Bicocca, Milan, <sup>4</sup>Associazione Milano Check Point, Milan

**OC 71 16.04-16.14 Late HIV diagnosis: the new consensus definition reduces the proportion of late presentations**

V. Regine, L. Pugliese, B. Suligoj

Istituto Superiore di Sanità, Rome



**OC 72 16.16-16.26 Impact of COVID-19 pandemic on retention in care of native and migrant PLWH in the ICONA cohort**  
**R. Gagliardini<sup>1</sup>, A. Giacomelli<sup>2</sup>, G. Bozzi<sup>3</sup>, A. D'Arminio Monforte<sup>4</sup>, A. Tavelli<sup>4</sup>, V. Mazzotta<sup>1</sup>, E. Bruzzeri<sup>5</sup>, A. Cervo<sup>6</sup>, A. Saracino<sup>7</sup>,  
 C. Mussini<sup>8</sup>, E. Girardi<sup>9</sup>, A. Cozzi-Lepri<sup>9</sup>, A. Antinori<sup>1</sup>, on behalf of COVID-19 ICONA study group**

<sup>1</sup>Clinical and Research Infectious Diseases Department, National Institute of Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>III Infectious Disease Unit, ASST-Fatebenefratelli Sacco, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, <sup>4</sup>Icona Foundation, Milan, Italy, <sup>5</sup>UO Malattie Infettive, IRCCS Ospedale San Raffaele, <sup>6</sup>Division of Infectious Diseases, University of Modena, Modena, Italy, <sup>7</sup>Clinic of Infectious Diseases, University Hospital, University of Bari, Bari, Italy, <sup>8</sup>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>9</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK

16.28-16.35 **Conclusion**

M.L. Cosmaro, Milano; E. Girardi, Roma



**SPECIAL SESSION** 15.35-16.35

**AULA I**

**The Italian Fast-track Cities: strengths and weaknesses of a growing movement**

Chairs: P. Meli (Bergamo), G. Orofino (Torino)

Since December 2018, when Milan, the first Italian city, joined the global network of Fast-track Cities Initiative, the number of participating cities has steadily increased. This movement is one of the most important innovation in the national overview of territorial actions to reach the UNAIDS 95-95-95 goal by 2030. However, this growth is characterized by light and shadow. Some cities are blocked in their first declaration of intent or have difficulties in developing necessary collaboration between public institutions and social organisations in order to achieve tangible actions. Others cities are totally changing the face of fight against HIV in their own territories. A further difficulty, but which is also a possibility, concerns the sharing of good practices and the most effective actions between Italian Fast-track Cities.

15.35-15.45	<b>Activities in the last year of the Italian FTCs</b>	I. Mercurio, Bergamo
15.45-15.55	<b>The U=U campaign of the city of Turin</b>	S. Patrucco, Torino
15.55-16.05	<b>The first steps of the city of Ancona</b>	L. Saracini, Ancona
16.05-16.15	<b>A project for the most vulnerable people in the city of Bergamo</b>	D. Meli, Bergamo
16.15-16.35	<b>Common projects and actions are possible?</b>	FTCI delegates



**SYMPOSIUM** 16.40-18.00

**AUDITORIUM ALDO MORO**

**How to manage Heavily Treatment-Experienced patients (HTE)**

Chairs: M. Galli (Milano), F. Maggiolo (Bergamo), M. Santoro (Roma)

Con la sponsorizzazione non condizionante di Gilead Sciences e ViiV Healthcare

Immunotherapies, already well established in the management of cancer, are emerging as important tools in the control of chronic viral infections. There are challenges: we need to understand whether stimulating a sluggish immune response, tackling immune inhibition, or directly transferring immune mediators is the best approach; we must carefully consider potential safety liabilities; and we wish for improved biomarkers to optimise patient stratification and monitoring. We will discuss two different scenarios that pose different risk/benefit considerations but are equally challenging. Firstly, we will talk about the initial hopes, subsequent disappointments and current promising approaches that bring us closer to curing chronic HBV infection. A brief case history will then highlight the problem of CMV infection unresponsive to traditional interventions in the setting of immunodeficiency, followed by a lecture on how transfer of CMV-specific T-cells can restore protective antiviral immunity in transplant recipients patients. Come along to this exciting symposium to hear how cutting-edge science is being translated into clinical practice!

16.40-16.55	<b>Who are the HTE patients?</b>	S. Lo Caputo, Foggia
	<b>New classes of antiretroviral drugs with novel mechanisms of action:</b>	
16.55-17.10	<b>Fostemsavir, the HIV-1 attachment inhibitor</b>	S. Rusconi, Legnano MI
17.10-17.25	<b>Lenacapavir, the inhibitor of HIV capsid function</b>	A. Di Biagio, Genova
17.25-17.40	<b>U=U in HTE patients: myth or reality?</b>	A. Castagna, Milano
17.40-18.00	<b>Q&amp;A and Panel Discussion</b>	Moderators: M. Galli, Milano; F. Maggiolo, Bergamo; M. Santoro, Roma Discussants: A. Castagna, Milano; A. Di Biagio, Genova; S. Lo Caputo, Foggia; S. Rusconi, Legnano MI




**SYMPOSIUM** 16.40-17.40

**AULA V**

## Immunotherapies in chronic viral infections: what will the future bring?

Chairs: N. Coppola (Napoli), V. Svicher (Roma)

Immunotherapies, already well established in the management of cancer, are emerging as important tools in the control of chronic viral infections. There are challenges: we need to understand whether stimulating a sluggish immune response, tackling immune inhibition, or directly transferring immune mediators is the best approach; we must carefully consider potential safety liabilities; and we wish for improved biomarkers to optimise patient stratification and monitoring. We will discuss two different scenarios that pose different risk/benefit considerations but are equally challenging. Firstly, we will talk about the initial hopes, subsequent disappointments and current promising approaches that bring us closer to curing chronic HBV infection. A brief case history will then highlight the problem of CMV infection unresponsive to traditional interventions in the setting of immunodeficiency, followed by a lecture on how transfer of CMV-specific T-cells can restore protective antiviral immunity in transplant recipients patients. Come along to this exciting symposium to hear how cutting-edge science is being translated into clinical practice!

16.40-17.00	<b>Immunotherapies to cure chronic HBV infection</b>	P. Fiscaro, Parma
17.00-17.05	<b>Case history: the challenge of unresponsive CMV infection</b>	M. Lichtner, Latina
17.05-17.25	<b>Adoptive immunotherapies for CMV and other viruses in the transplant setting</b>	P.E. Comoli, Pavia
17.25-17.40	<b>Q&amp;A and Panel Discussion</b>	Discussants: P.E. Comoli, Pavia; N. Coppola, Napoli; P. Fiscaro, Parma; A.M. Geretti, Roma; M. Lichtner, Latina; V. Svicher, Roma


**ORAL COMMUNICATIONS** 16.40-17.50

**AULA IV**

## The increasing burden of STIs

Chairs: S. Cecere (Bologna), B. Suligoi (Roma)

16.40-16.45	<b>Introduction</b>	S. Cecere, Bologna; B. Suligoi, Roma
-------------	---------------------	--------------------------------------

**OC 73** 16.45-16.55 **A cross sectional study of sexually transmitted infections in a northern Italy STI clinic**

G. Mulé<sup>1</sup>, D. Tesoro<sup>1</sup>, A. De Bona<sup>1</sup>, L. Biasioli<sup>1</sup>, M. Mazzoccoli<sup>1</sup>, A. Copes<sup>1</sup>, L. Albertini<sup>1</sup>, A. Tavelli<sup>1</sup>, S. Cianciola<sup>1</sup>, E. Limoj<sup>1</sup>, M. Settembre<sup>1</sup>, F. Miraglia<sup>1</sup>, F. Bai<sup>2</sup>, C. Tincati<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G.C. Marchetti<sup>2</sup>  
<sup>1</sup>ASST Santi Paolo e Carlo, Milano, <sup>2</sup>Università Statale di Milano, Milano

**OC 74** 16.57-17.07 **Sexually Transmitted Infections In Men With Multidrug-Resistant Human Immunodeficiency Virus: Data From The PRESTIGIO Registry**

T. Clemente<sup>1,2</sup>, R. Lolatto<sup>2</sup>, R. Papaioannu Borjesson<sup>1,2</sup>, M. Fabbiani<sup>3</sup>, E. Manzillo<sup>4</sup>, E. Fronti<sup>5</sup>, S. Di Giambenedetto<sup>6,7</sup>, R. Gagliardini<sup>8</sup>, S. Rusconi<sup>9,10</sup>, M.M. Santoro<sup>11</sup>, A. Castagna<sup>1,2</sup>, V. Spagnuolo<sup>2</sup>, on behalf of the PRESTIGIO Study Group  
<sup>1</sup>Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>4</sup>Ospedale dei Colli, Napoli, Italy, <sup>5</sup>Unit of Infectious Diseases, AO-Universitaria, Parma, Italy, <sup>6</sup>Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, <sup>7</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>8</sup>National Institute for Infectious Diseases 'L. Spallanzani' IRCCS, Rome, Italy, <sup>9</sup>Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, Italy, <sup>10</sup>DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>11</sup>Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy

**OC 75** 17.09-17.19 **Temporal trends in incidence of bacterial sexually transmitted infections among PrEP users of Milano Checkpoint**

A. Tavelli<sup>1,2</sup>, R. Rossotti<sup>2,3</sup>, D. Calzavara<sup>1</sup>, A. Soria<sup>1,4</sup>, E. Caruso<sup>1</sup>, R. Repossi<sup>1,5</sup>, N. Frattini<sup>1,5</sup>, P. Vinti<sup>1</sup>, C. Muccini<sup>1,6</sup>, D. Tesoro<sup>1,7</sup>, G. Mulé<sup>1,7</sup>, D. Moschese<sup>1,8</sup>, A. Foschi<sup>1,8</sup>, L. Biasioli<sup>1,7</sup>, G. Lapadula<sup>1,2</sup>, S. Bossolasco<sup>1,6</sup>, A. De Bona<sup>1,7</sup>, A. d'Arminio Monforte<sup>1,2</sup>, M. Cernuschi<sup>1,5,6</sup>  
<sup>1</sup>Milano Check Point ETS, Milano, Italy, <sup>2</sup>Fondazione Icona, Milano, Italy, <sup>3</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, <sup>4</sup>Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>5</sup>ASA Milano ODV, Milano, Italy, <sup>6</sup>IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>7</sup>ASST Santi Paolo e Carlo, Milano, Italy, <sup>8</sup>ASST Fatebenefratelli Sacco, Milano, Italy

**OC 76** 17.21-17.31 **Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae isolates between 2012 and 2023: a single-center experience in Milan, Italy**

M.F. Lucente<sup>1</sup>, A.R. Raccagni<sup>1</sup>, L. Galli<sup>2</sup>, R. Lolatto<sup>2</sup>, M. Ripa<sup>1,2</sup>, G. Ponta<sup>1</sup>, R. Monardo<sup>1</sup>, F. Gona<sup>3</sup>, N. Clementi<sup>1,3</sup>, R. Burioni<sup>1,3</sup>, S. Carletti<sup>3</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, <sup>3</sup>Laboratory of Microbiology and Virology, San Raffaele Scientific Institute, Milan





**OC 77 17.33-17.43 Predictors of mpox duration and severity in an Italian multicenter cohort (Mpx-ICONA)**

*V. Mazzotta*<sup>1</sup>, *A. Tavelli*<sup>2</sup>, *D. Moschese*<sup>3</sup>, *A. Cozzi Lepri*<sup>4</sup>, *F.M. Fusco*<sup>5</sup>, *F. Colavita*<sup>6</sup>, *L. Biasioli*<sup>7</sup>, *A. Mondì*<sup>1</sup>, *F. Carletti*<sup>6</sup>, *A. Di Biagio*<sup>8</sup>, *D. Mileto*<sup>9</sup>, *G. Baldin*<sup>10</sup>, *S. Nozza*<sup>11</sup>, *L. Pipitò*<sup>12</sup>, *D. Tesoro*<sup>7</sup>, *N. Sangiovanni*<sup>5</sup>, *E. Nicastri*<sup>1</sup>, *G. Rizzardini*<sup>3</sup>, *F. Maggi*<sup>6</sup>, *A. d'Arminio Monforte*<sup>7</sup>, *A. Antinori*<sup>1</sup>, *S. Lanini*<sup>1</sup>

<sup>1</sup>Clinical and Research Department, INMI Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Division of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>4</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>5</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, P.O. "D. Cotugno", Azienda Ospedaliera dei Colli, Napoli, Italy, <sup>6</sup>Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Roma, Italy, <sup>7</sup>Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>8</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>9</sup>Laboratory of Clinical Microbiology Virology and Bioemergencies, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>10</sup>Fondazione Universitaria policlinico Gemelli, Roma, Italy, <sup>11</sup>Infectious Diseases Unit, San Raffaele Hospital, Vita-Salute San Raffaele University, Milano, Italy, <sup>12</sup>Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy

17.45-17.50 **Conclusion**

S. Cecere, Bologna; B. Suligoi, Roma

**ORAL COMMUNICATIONS** 16.40-17.50**AULA III****Vaccine in frail patients**

Chairs: S. Antinori (Milano), S. Nozza (Milano)

16.40-16.45 **Introduction**

S. Antinori, Milano; S. Nozza, Milano

**OC 78 16.45-16.55 Pneumococcal vaccination coverage among people living with HIV before and after the implementation of an on-site vaccination service at an HIV clinic: a retrospective observational study**

*M.L. Colombo*<sup>1,2</sup>, *A. Giacomelli*<sup>1</sup>, *M.V. Cossu*<sup>3</sup>, *G. Carrozzo*<sup>1,2</sup>, *A. Poloni*<sup>1,2</sup>, *G. Casalini*<sup>1,2</sup>, *B. Caloni*<sup>1,2</sup>, *S. Pagano*<sup>1,2</sup>, *M. Beltrami*<sup>1,2</sup>, *L. Oreni*<sup>1</sup>, *S. Antinori*<sup>1,2</sup>, *A.L. Ridolfo*<sup>1</sup>

<sup>1</sup>III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>Università degli Studi di Milano, DIBIC Luigi Sacco, Milan, Italy, <sup>3</sup>I Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy

**OC 79 16.57-17.07 SARS-CoV-2 mRNA vaccination and viro-immunological changes in PLWH**

*A. Vergori*<sup>1</sup>, *A. Cozzi-Lepri*<sup>2</sup>, *G. Marchetti*<sup>3</sup>, *A. Tavelli*<sup>4</sup>, *R. Gagliardini*<sup>1</sup>, *G. Lapadula*<sup>5</sup>, *N. Caroccia*<sup>6</sup>, *L. Taramasso*<sup>7</sup>, *A.M. Azzini*<sup>8</sup>, *S. Lanini*<sup>1</sup>, *F. Ceccherini-Silberstein*<sup>9</sup>, *M. Giannella*<sup>6</sup>, *E. Tacconelli*<sup>8</sup>, *A. d'Arminio Monforte*<sup>4</sup>, *A. Antinori*<sup>1</sup> on behalf of the VAX-ICONA Study Group

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>4</sup>Icona Foundation, Milan, Italy, <sup>5</sup>Clinic of Infectious Diseases, Foundation IRCCS San Gerardo dei Tintori -University of Milano Bicocca, Monza, Italy, <sup>6</sup>Infectious Diseases Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, <sup>7</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genova, Italy, <sup>8</sup>Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy, <sup>9</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

**OC 80 17.09-17.19 Specific humoral and T-cell response to three doses of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients**

*M. Guardiani*<sup>1</sup>, *M.A. Zingaropoli*<sup>1</sup>, *E. Tortellini*<sup>1</sup>, *F. Cogliati Dezza*<sup>1</sup>, *F. Dominelli*<sup>1</sup>, *P. Pasculli*<sup>1</sup>, *M. Garofalo*<sup>2</sup>, *A. Centofanti*<sup>3</sup>, *C. Carillo*<sup>3</sup>, *A. Gaeta*<sup>4</sup>, *C. Del Borgo*<sup>5</sup>, *A. Napoli*<sup>4</sup>, *F. Mengoni*<sup>1</sup>, *V. Vullo*<sup>1</sup>, *M.R. Ciardi*<sup>1</sup>, *G. Russo*<sup>1</sup>, *C.M. Mastroianni*<sup>1</sup>, *M. Lichtner*<sup>5,6</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome - Rome (Italy), <sup>2</sup>General Surgery and Organ Transplantation Unit, Sapienza University of Rome - Rome (Italy), <sup>3</sup>Division of Thoracic Surgery and Lung Transplant, Sapienza University of Rome - Rome (Italy), <sup>4</sup>Department of Molecular Medicine, Sapienza University of Rome - Rome (Italy), <sup>5</sup>Infectious Diseases Unit, Santa Maria (SM) Goretti Hospital, Sapienza University of Rome - Rome (Italy), <sup>6</sup>Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome - Rome (Italy)

**OC 81 17.21-17.31 Humoral and cell-mediated immune responses in elderly residing in a retirement house after 4 doses of anti-SARS-CoV-2 BNT162b2 vaccine**

*M. Tarkowski*<sup>1</sup>, *A. Bergna*<sup>1</sup>, *C. della Ventura*<sup>1</sup>, *A. Gabrielli*<sup>1</sup>, *B. Caimi*<sup>2</sup>, *A. Gatti*<sup>2</sup>, *C. Balotta*<sup>1</sup>, *A. Riva*<sup>1</sup>, *A. Lai*<sup>1</sup> CoVICIS EU Horizon grant nr 101046041

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>Azienda Servizi alla Persona, Istituti Milanesi Martinitt e Stelline e Pio Albergo Trivulzio, Milan, Italy



**OC 82 17.33-17.43 Assessment of SARS-CoV-2 specific T-cell responses using an in-house interferon-g release assay (IGRA) in people with HIV**

*L. Benedetti<sup>1</sup>, L. Ferrari<sup>2</sup>, A. Ruggiero<sup>3</sup>, C. Stefani<sup>3</sup>, N. Braccialarghe<sup>1</sup>, A. Imeneo<sup>1</sup>, C. Piubelli<sup>4</sup>, A. Matucci<sup>4</sup>, E. Teti<sup>2</sup>, L. Sarmati<sup>1,2</sup>, A.M. Geretti<sup>1,2,5</sup>, M. Iannetta<sup>1,2</sup>*

<sup>1</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy,

<sup>4</sup>Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, <sup>5</sup>School of Immunity and Microbial Sciences, King's College London, London, United Kingdom

17.45-17.50 **Conclusion**

S. Antinori, Milano; S. Nozza, Milano

**ORAL COMMUNICATIONS** 16.40-17.40**AULA II****Clinical outcome of SARS-CoV-2 infection**

Chairs: R. Gagliardini (Roma), R. Gulminetti (Pavia)

16.40-16.45 **Introduction**

R. Gagliardini, Roma; R. Gulminetti, Pavia

**OC 83 16.45-16.55 Association between vaccination status and disease severity in patients (pts) hospitalized for COVID-19: data from a national reference hospital**

*A. Mondì, L. Mastroianni, A. Navarra, S. Lanini, A. D'Annunzio, P. Galli, C. Cimaglia, A. Agresta, F. Vaia, E. Girardi, A. Antinori*  
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

**OC 84 16.57-17.07 Anti-spike SARS-CoV-2 antibody titer and risk of clinical progression in patients with COVID-19-related pneumonia**

*L. Mezzadri<sup>1</sup>, G. Lapadula<sup>1,2</sup>, G. Lo Cascio<sup>1</sup>, L. Antolini<sup>1</sup>, S. Malandrini<sup>2</sup>, P. Columpsi<sup>2</sup>, A. Rugova<sup>2</sup>, S. Limonta<sup>2</sup>, A. Cavallero<sup>2</sup>, P. Bonfanti<sup>1,2</sup>*  
<sup>1</sup>School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy, <sup>2</sup>Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

**OC 85 17.09-17.19 Vaccination against SARS-CoV-2 after the natural infection, is associated with a reduced risk of late-onset thrombotic and cardiovascular events (18-months analysis, on the "Surviving-COVID" Cohort, Bergamo)**

*S.V. Benatti<sup>1</sup>, S. Venturelli<sup>1</sup>, G. Crotti<sup>2</sup>, A. Ghirardi<sup>3</sup>, F. D'Aloia<sup>5</sup>, F. Binda<sup>1</sup>, M. Savardi<sup>4</sup>, M. Seghezzi<sup>1</sup>, G. Previtali<sup>1</sup>, P.A. Bonaffini<sup>1</sup>, A. Zucchi<sup>2</sup>, M. Rizzi<sup>1</sup>*

<sup>1</sup>ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>ATS Bergamo, Ufficio Epidemiologico, <sup>3</sup>Fondazione per la Ricerca Ospedale di Bergamo (FROM) - ETS, <sup>4</sup>Università degli Studi di Brescia, Facoltà di Informatica, <sup>5</sup>Università degli Studi di Milano-Bicocca, Scuola di Specializzazione in Malattie Infettive e Tropicali, Monza

**OC 86 17.21-17.31 Long-term assessment of anti-SARS-CoV-2 immunogenicity after a mRNA vaccine in PLWH**

*A. Vergori<sup>1</sup>, A. Cozzi-Leperi<sup>2</sup>, G. Matusali<sup>3</sup>, S. Cicalini<sup>1</sup>, E. Cimini<sup>4</sup>, S. Meschi<sup>3</sup>, V. Mazzotta<sup>1</sup>, F. Colavita<sup>3</sup>, M. Fusto<sup>1</sup>, S. Notari<sup>4</sup>, S. Lanini<sup>1</sup>, D. Lapa<sup>3</sup>, R. Gagliardini<sup>1</sup>, D. Mariotti<sup>3</sup>, G. Giannico<sup>1</sup>, E. Girardi<sup>5</sup>, F. Vaia<sup>6</sup>, C. Agrati<sup>4,7</sup>, F. Maggi<sup>3</sup>, A. Antinori<sup>1</sup>*

<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Institute of Global Health, University College London, CREME Center, London, United Kingdom, <sup>3</sup>Laboratory of Virology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>5</sup>Scientific Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>General Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>7</sup>Oncoematologia e Officina Farmaceutica, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy

17.33-17.40 **Conclusion**

R. Gagliardini, Roma; R. Gulminetti, Pavia




**SPECIAL SESSION** 08.30-09.00  
**ICAR CROI AWARDS 2023**
**AUDITORIUM ALDO MORO**

Chairs: G. Angarano (Bari), F. Ceccherini Silberstein (Roma), G. d'Ettorre (Roma)

This session is devoted to Young Italian Researchers - under 40 - who had an abstract accepted at CROI 2023. The following prizes will be announced and awarded:


**Two prizes for the best Clinical and Basic science Abstracts**

- **A Prevalence, incidence, and risk factors for falls in older people with and without HIV**  
S. Arsuffi, Brescia - MENTORS: F. Castelli, Brescia; E. Focà, Brescia
- **High RNAemia associates with skewed T-Cell response in PLWH hospitalized for COVID-19**  
M. Augello, Milano - MENTOR: G.C. Marchetti, Milano
- **Efficacy of 3TC+DTG vs 3-drug regimens in virologically suppressed PLWH**  
A. Borghetti, Roma - MENTOR: S. Di Giambenedetto, Roma
- **Mpox DNA clearance in semen over six months follow-up**  
C. Candela, Milano - MENTOR: A. Castagna, Milano
- **Increased burden of anal HPV-related potentially precancerous lesions in HIV+ women**
- **Efficacy of late HPV vaccination in young HIV+ MSM**  
E.N. Cavallari, Roma - MENTOR: G. d'Ettorre, Roma
- **Leukapheresis: a feasible tool to inform at risk through HIV reservoir study in children**  
N. Cotugno, Roma - MENTOR: P. Palma, Roma
- **The impact of early outpatient treatments for COVID-19: a retrospective study**  
M. Degli Antoni, Brescia - MENTOR: M.E. Quiros Roldan, Brescia
- **mRNA vaccines induces a higher antibodies response in children with previous COVID-19**  
C. Di Chiara, Padova - MENTOR: C. Giaquinto, Padova
- **Anemia as a predictor of poor clinical outcome in patients admitted for COVID-19**
- **Impact of the COVID-19 pandemic on Malaria services in Uganda: a time series analysis**  
F. Di Gennaro, Bari - MENTOR: A. Saracino, Bari
- **A joint analysis of two randomized controlled trials on enoxaparin for COVID-19**  
G. Dolci, Modena - MENTOR: C. Mussini, Modena
- **Effects of chemoradiation on expanded proviral clones in an elite controller**  
F. Dragoni, Siena - MENTORS: F.R. Simonetti, Baltimore, USA; Maurizio Zazzi, Siena
- **Mpox Virus in the pharynx of men having sex with men: a case series**  
S. Limonta, Monza - MENTOR: G. Lapadula, Monza
- **Inflammation but not IFN-I/III response is altered in children with long COVID**  
L. Maddaloni, Roma - MENTOR: C. Scagnolari, Roma
- **Screening approaches and clinical description of the anticholinergic burden in people with HIV**  
M. Mazzitelli, Padova - MENTOR: A.M. Cattelan, Padova



- **Neutralizing and T cell response against mpox virus after MVA-BN vaccine**
- **Comparison of subcutaneous versus intradermal route of administration of MVA vaccine**
- **Humoral and cellular immune response after 3 months from Mpox Virus infection**
- **SARS-CoV-2 Omicron viral load decrease after monoclonal antibodies or antivirals**
- **Incidence and predictors of clinical progression in an early treated COVID-19 Cohort**  
V. Mazzotta, Roma - MENTOR: A. Antinori, Roma
- **Mortality linked to higher inflammation in perinatallyinfected HIV+ kids**  
E. Morrocchi, Roma - MENTOR: P. Palma, Roma
- **Immunogenicity of MVA-BN vaccination with hybrid administration route**  
D. Moschese, Milano - MENTOR: G. Rizzardini, Milano
- **Multifaceted premature aging in adolescent/young adult with perinatal-acquired HIV**  
M.R. Petrara, Padova - MENTOR: A. De Rossi, Padova
- **Delayed positivization of non-lesion specimens among individuals with Mpox**  
A.R. Raccagni, Milano - MENTOR: V. Spagnuolo, Milano
- **Adaptive immunity dysregulation is associated to the development of long COVID**  
R. Rovito, Milano - MENTOR: G.C. Marchetti, Milano
- **Cap and metabolic profile worsening post-SRV in HCV-HIV people as a sign of steatosis**  
A. Siribelli, Milano - MENTOR: H.I. Hasson, Milano
- **DTG impact Zebrafish behaviour through dopaminergic pathways: rescue by folate**  
S. Storti, Brescia - MENTOR: M.E. Quiros Roldan, Brescia
- **The cerebrospinal fluid virome in virally suppressed people living with HIV**
- **Neurocognitive impairment negatively affects viral control in Art-Treated PWH**  
M. Trunfio, Torino - MENTOR: A. Calcagno, Torino
- **Neutralizing activity and T cell response after bivalent third booster dose in PLWH**  
A. Vergori, Roma - MENTOR: A. Antinori, Roma



## KEYNOTE LECTURES 09:00-10:30

## AUDITORIUM ALDO MORO

Chairs: G. Angarano (Bari), R. Cauda (Roma), A. Cossarizza (Modena)

### 09.00-09.30 **Mpox 2022: the story of another pandemics**

A. Antinori, Roma

The main features of the 2022 Mpox multi-country outbreak are characterized, in terms of epidemiological issues, peculiarities in sexual transmission, clinical aspects, diagnosis implications, and the course of the disease. Specific characteristics concerning the severity in HIV-infected persons with advanced disease were described, including the virologic compartmentalization, the immunologic signatures, and the complex pathogenesis of Mpox in the immunocompromised host. Therapeutic resources based on antivirals.

### 09.30-10.30 **COVID-19: virus vs immunocompromised host**

M.S. Clerici, Milano; C.F. Perno, Roma

Vaccination protocols and the decreased pathogenicity of the new variants of SARS-CoV-2 have changed the face of COVID-19, making it less of a concern. However, there is an exception: in patients with alterations of the immune response, COVID-19 can still be extremely dangerous. The peculiarities of the disease in these particular patients will be analyzed.





SPONSORED SYMPOSIUM 10.35-11.35

AUDITORIUM ALDO MORO

**Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV**

Chair: G. Nunnari (Messina)

Simposio promozionale di ViiV Healthcare

Long-acting regimens can help people living with HIV to overcome some challenges that have not yet been completely resolved. Today, we are one year from the reimbursement of Cabotegravir + Rilpivirine Long-acting, the first complete long-acting regimen indicated for the treatment of HIV in virologically suppressed patients. The goal of the symposium is to share new scientific evidence supporting the efficacy and safety of CAB+RPV LA, both from clinical trials and local experiences.

10.35-10.40 **Introduction**

G. Nunnari, Messina

10.40-11.00 **SOLAR study: the dawn of a new era**

G. Di Perri, Torino

11.00-11.30 **Round table: The experience starts with you**Discussants: N. Gianotti, Milano; C. Mussini, Modena;  
R. Rossotti, Milano; A. Saracino, Bari11.30-11.35 **Take home message**

G. Nunnari, Messina



ORAL COMMUNICATIONS 10.35-11.35

AULA V

**Bench studies of viral infections**

Chairs: S. Parisi (Padova), C. Scagnolari (Roma)

10.35-10.40 **Introduction**

S. Parisi, Padova; C. Scagnolari, Roma

**OC 87 10.40-10.50 Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V1061 polymorphism in B and non-B subtypes**

F. Giammarino<sup>1</sup>, A. de Salazar<sup>2</sup>, A. Fuentes<sup>2</sup>, L. Viñuela<sup>2</sup>, F. Saladini<sup>1</sup>, N. Bartolini<sup>1</sup>, C. Charpentier<sup>3</sup>, S. Lambert-Niclot<sup>4</sup>, G. Sterrantino<sup>5</sup>, G. Colao<sup>6</sup>, V. Micheli<sup>7</sup>, A. Bertoli<sup>8</sup>, L. Fabeni<sup>9</sup>, I. Malet<sup>10</sup>, E. Teyssou<sup>10</sup>, R. Delgado<sup>11</sup>, I. Falces<sup>12</sup>, A. Aguilera<sup>13</sup>, P. Gomes<sup>14</sup>, D. Paraskevis<sup>15</sup>, M.M. Santoro<sup>16</sup>, A.G. Marcelin<sup>10</sup>, F. Ceccherini-Silberstein<sup>16</sup>, M. Zazzi<sup>1</sup>, F. García<sup>2</sup>

<sup>1</sup>University of Siena, Department of Medical Biotechnologies, Siena, Italy, <sup>2</sup>Hospital Universitario Clinico San Cecilio, Clinical Microbiology, Granada, Spain, <sup>3</sup>AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France, <sup>4</sup>AP-HP, Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France, <sup>5</sup>University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy, <sup>6</sup>Careggi Hospital, Laboratory of Virology, Florence, Italy, <sup>7</sup>Sacco University Hospital, Department of Clinical Microbiology, Virology and Bioemergencies, Milan, Italy, <sup>8</sup>University Hospital "Tor Vergata", Laboratory of Virology, Rome, Italy, <sup>9</sup>"Lazzaro Spallanzani" - IRCCS, National Institute for Infectious Diseases, Virology and Biosafety Laboratories Unit, Rome, Italy, <sup>10</sup>AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Laboratoire de Virologie, Paris, France, <sup>11</sup>Hospital 12 de Octubre, Clinical Microbiology Service, Madrid, Spain, <sup>12</sup>Hospital La Paz, Clinical Microbiology Service, Madrid, Spain, <sup>13</sup>Complejo Hospitalario Santiago, Clinical Microbiology Service, Santiago de Compostela, Spain, <sup>14</sup>CiiEM. IUEM. Almada, Portugal and Centro Hospitalar Lisboa Ocidental - HEM, Laboratório de Biologia Molecular, LMCBM, SPC, Lisboa, Portugal, <sup>15</sup>National and Kapodistrian University of Athens, Department of Hygiene, Epidemiology and Medical Statistics, Athens, Greece, <sup>16</sup>University of Rome "Tor Vergata", Department of Experimental Medicine, Rome, Italy

**OC 88 10.52-11.02 The in vitro effects of dolutegravir and bictegravir on musculoskeletal cells**

A. Cazzaniga<sup>1</sup>, J.A.M. Maier<sup>1</sup>, S. Rusconi<sup>1,2</sup>

<sup>1</sup>Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, <sup>2</sup>Infectious Disease Unit, Legnano General Hospital, ASST Ovest Milanese

**OC 89 11.04-11.14 Pharmacokinetics of First-line Antitubercular Drugs in People Living with HIV and Controls in a Therapeutic Drug Monitoring Registry**

V. Pirriatore<sup>1</sup>, J. Cusato<sup>2</sup>, E. De Vivo<sup>2</sup>, P. Piccioni<sup>3</sup>, G. Rossi<sup>3</sup>, A. Trentalange<sup>4</sup>, G. Calleri<sup>1</sup>, S. Audagnotto<sup>4</sup>, G. Di Perri<sup>4</sup>, S. Bonora<sup>4</sup>, A. D'Avolio<sup>2</sup>, A. Calcagno<sup>4</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases Divisione A, Ospedale Amedeo di Savoia, ASL Città di Torino, Torino, <sup>2</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, <sup>3</sup>Unit of Pneumology at Ospedale Amedeo di Savoia, ASL Città di Torino, Torino, <sup>4</sup>Infectious Diseases, Department of Medical Sciences, University of Torino at Ospedale di Savoia, ASL Città di Torino, Torino



**OC 90 11.16-11.26 Extracellular vesicles designed to decoy or compete with spike binding to the human ACE2 receptor of SARS-CoV-2 highlight the diversity of Omicron spike***I. Pagani<sup>1</sup>, M. Schürz<sup>2</sup>, M.M. Neto<sup>3</sup>, N. Temperton<sup>3</sup>, N. Meisner-Kober<sup>2</sup>, E. Vicenzi<sup>1</sup>*<sup>1</sup>Viral Pathogenesis and Biosafety Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Chemical Biology and Biological Therapeutics, Department of Biosciences and Medical Biology, University of Salzburg, Austria, <sup>3</sup>Medway School of Pharmacy, University of Kent, United Kingdom11.28-11.35 **Conclusion**

S. Parisi, Padova; C. Scagnolari, Roma

**ORAL COMMUNICATIONS** 10.35-11.35**AULA IV****Liver, vessels and lipids**

Chairs: P. Blanc (Pistoia), A. Cingolani (Roma)

10.35-10.40 **Introduction**

P. Blanc, Pistoia; A. Cingolani, Roma

**OC 91 10.40-10.50 To TAF or not to TAF? What is the difference? Data from a real-life setting***N. Squillace<sup>1</sup>, L. Taramasso<sup>2</sup>, E. Ricci<sup>3</sup>, B. Menzaghi<sup>4</sup>, G. De Socio<sup>5</sup>, G. Orofino<sup>6</sup>, B.M. Celesia<sup>7</sup>, E. Sarchi<sup>8</sup>, S. Piconi<sup>9</sup>, G. Pellicano<sup>10</sup>, S. Rusconi<sup>11</sup>, F. Vichi<sup>12</sup>, A. Di Biagio<sup>2</sup>, P. Bonfanti<sup>1</sup>, for the CISAI Study Group*<sup>1</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, <sup>2</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, <sup>3</sup>Fondazione ASIA Onlus, Buccinasco (MI), <sup>4</sup>Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), <sup>5</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>6</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>7</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>8</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, <sup>9</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, <sup>10</sup>Infectious Diseases, G. Martino Hospital -University of Messina, Messina, <sup>11</sup>Infectious Diseases Unit, ASST Ovest Milanese, Legnano (MI) - DIBIC, University of Milan, <sup>12</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence**OC 92 10.52-11.02 LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study***G. Carrozzo<sup>1,2</sup>, B. Caloni<sup>1,2</sup>, A. Poloni<sup>1,2</sup>, S. Pagano<sup>1,2</sup>, M.L. Colombo<sup>1,2</sup>, M. Beltrami<sup>1,2</sup>, G. Casalini<sup>1,2</sup>, C. Gervasoni<sup>1</sup>, A.L. Ridolfo<sup>1</sup>, A. Giacomelli<sup>1</sup>, S. Antinori<sup>1,2</sup>*<sup>1</sup>III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>Università degli Studi di Milano, DIBIC Luigi Sacco, Milan, Italy**OC 93 11.04-11.14 Evaluation of intimal thickness and atheromatous plaques in HIV-experienced vs HIV-negative patients: data from the Archiprevalent cohort***S. Martini<sup>1</sup>, E.D. Ricci<sup>2</sup>, A. Masiello<sup>3</sup>, S. Zacà<sup>4</sup>, A. Castagna<sup>5</sup>, C. Muccini<sup>5</sup>, L. Galli<sup>5</sup>, B.M. Celesia<sup>6</sup>, S. Ferrara<sup>7</sup>, A. Tartaglia<sup>8</sup>, D. Angiletta<sup>4</sup>, P. Maggi<sup>1,3</sup>*<sup>1</sup>Università della Campania Luigi Vanvitelli, Naples, Italy, <sup>2</sup>Fondazione ASIA Onlus, Milan, Italy, <sup>3</sup>AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>4</sup>Chirurgia Vascolare ed Endovascolare "Aldo Moro", Università di Bari, Bari, Italy, <sup>5</sup>Università Vita e Salute San Raffaele, Milan, Italy, <sup>6</sup>Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy, <sup>7</sup>Università degli Studi, Foggia, Italy, <sup>8</sup>Azienda Ospedaliera Foggia-Italy, Foggia, Italy**OC 94 11.16-11.26 Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study***J. Milic<sup>1</sup>, S. Renzetti<sup>2</sup>, F. Motta<sup>1</sup>, J. Bischoff<sup>3</sup>, G. Besutti<sup>1</sup>, G. Mancini<sup>4</sup>, S. Esperti<sup>1</sup>, V. Menozzi<sup>1</sup>, D. Kablawi<sup>5</sup>, S. Calza<sup>2</sup>, C. Mussini<sup>1,4</sup>, J. Rockstroh<sup>3</sup>, G. Sebastiani<sup>5</sup>, G. Guaraldi<sup>1,4</sup>*<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>University of Brescia, Brescia, Italy, <sup>3</sup>University of Bonn, Bonn, Germany, <sup>4</sup>Clinic of Infectious Diseases, University Hospital of Modena, Modena, Italy, <sup>5</sup>McGill University, Montreal, Canada11.28-11.35 **Conclusion**

P. Blanc, Pistoia; A. Cingolani, Roma





ORAL COMMUNICATIONS 10.35-11.35

AULA III

**PACS: what to assess**

Chairs: G. Guaraldi (Modena), L. Sarmati (Roma)

10.35-10.40 **Introduction**

G. Guaraldi, Modena; L. Sarmati, Roma

**OC 95 10.40-10.50 Assessing health status dynamics in people with post-acute COVID-19 syndrome comparing patient reported outcome measures with physical functioning, sarcopenia and frailty***J. Milic<sup>1</sup>, M. Caccamo, F. Motta, M. Belli, L. Sighinolfi, V. Menozzi, M.D. Di Trapani, S. Esperti, C. Mussini, A. Montis, S. Caselli, G. Guaraldi*

University of Modena and Reggio Emilia, Modena, Italy

**OC 96 10.52-11.02 Frailty transitions in people with Post-Acute COVID Syndrome***J. Milic<sup>1</sup>, A. Spadoni<sup>1</sup>, S. Renzetti<sup>2</sup>, F. Motta<sup>1</sup>, A. Fisce<sup>1</sup>, F. Medioli<sup>1</sup>, A. Dessilani<sup>1</sup>, J. Conti<sup>1</sup>, A. Verduri<sup>1</sup>, B. Beghe<sup>1</sup>, E. Clini<sup>1</sup>, C. Mussini<sup>1</sup>, S. Calza<sup>2</sup>, G. Guaraldi<sup>1</sup>*<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>University of Brescia, Brescia, Italy**OC 97 11.04-11.14 12-month follow-up of the long COVID during three pandemic years***I.F. Bottalico, M. Poliseno, D. Capruzzi, G.A. Minafra, D.C. Cibelli, M. Rizzo, L. Barbera, F. De Gregorio, T.A. Santantonio, S. Lo Caputo*  
Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy**OC 98 11.16-11.26 A picture of psychological symptoms and coping strategies within post COVID-19 population***A.C. Brita<sup>1</sup>, G. Del Duca<sup>1</sup>, A. Lonigro<sup>2</sup>, M. Camici<sup>1</sup>, A. Vergori<sup>1</sup>, I. Mastrorosa<sup>1</sup>, A. Mondì<sup>1</sup>, C. Caligiuri<sup>1</sup>, V. Mazzotta<sup>1</sup>, S. Lanini<sup>1</sup>, C. Pinnetti<sup>1</sup>, A. Antinori<sup>1</sup>*<sup>1</sup>Clinical Department, Lazzaro Spallanzani National Institute for Infectious Diseases, IRCCS, Rome, Italy, <sup>2</sup>Department of Education, University of Roma Tre, Italy11.28-11.35 **Conclusion**

G. Guaraldi, Modena; L. Sarmati, Roma



SPECIAL SESSION 10:35-11:35

AULA I

**U=U: Impossibile Sbagliare**

Chairs: M. Farinella (Roma), F. Schloesser (Roma)

U=U represents the most revolutionary principle and the most effective tool to break down stigma and discrimination against people living with HIV (PLWH) and to improve acceptance of infection and break down self-stigma in PLWH themselves. For this, ICAR's Community Associations constructed a "prospective study to evaluate the impact of a U=U information campaign in two target populations": PLWH and the general population. In this first phase, the construction of the study will be explained and the communication campaign "U=U: No brainer" will be presented.

**10.35-11.35 Presentation of the communication campaign and methodologies of the impact assessment study**

D. Calzavara, Milano; N. Frattini, Milano





SYMPOSIUM 11.40-12.40

AUDITORIUM ALDO MORO

## The battle between the virus and the host: an ongoing dynamic process

Chairs: C. Agrati (Roma), A. Cossarizza (Modena)

The symposium is intended to address different topics concerning the delicate balance between protective and pathogenetic role of the immune system over viral infections. In particular, a comprehensive review of the most recent notions on early events (Type-I IFN-s) after HIV and SARS-CoV-2 infection will be provided. The role exerted by host immune factors and ART to contain HIV reservoir will be illustrated as well. The most novel technical approaches to gain exhaustive and more and more detailed information from biological specimens of infected patients will also be thoroughly reviewed during the symposium.

- |             |  |                     |
|-------------|--|---------------------|
| 11.40-11.55 | <b>Type I Interferon in HIV and SARS-CoV-2 infection: following the mechanistic thread</b> | C. Scagnolari, Roma |
| 11.55-12.10 | <b>Drivers for virus reservoir containment: ART or host immune responses</b>               | A. De Maria, Genova |
| 12.10-12.25 | <b>From bed to bench and return: what happens in between?</b>                              | S. De Biasi, Modena |
| 12.25-12.40 | <b>Discussion</b>  |                     |



ORAL COMMUNICATIONS 11.40-12.40

AULA V

## Innovative tools for diagnosis and monitoring of viral infections

Chairs: C. Alteri (Milano), C. Torti (Catanzaro)

- |             |                     |  |
|-------------|---------------------|--|
| 11.40-11.45 | <b>Introduction</b> | C. Alteri, Milano; C. Torti, Catanzaro |
|-------------|---------------------|--|

### OC 99 11.45-11.55 Preliminary evaluation on the relevance of CSF cell-free mitochondrial DNA in different setting of viral neuroinflammatory diseases

G. Chimienti<sup>1</sup>, A. Zingaropoli<sup>2</sup>, T. Latronico<sup>1</sup>, L. Trisolini<sup>1</sup>, P. Pasculli<sup>2</sup>, C.M. Mastroianni<sup>2</sup>, M.R. Ciardi<sup>2</sup>, G.M. Liuzzi<sup>1</sup><sup>1</sup>Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, Bari, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

### OC 100 11.57-12.07 Serum Antibody Fingerprinting for SARS-CoV-2 Variants by Label-Free Microarray Biosensor

T. Carzaniga<sup>1</sup>, L. Casiraghi<sup>1</sup>, G. Nava<sup>1</sup>, G. Zanchetta<sup>1</sup>, T. Inzani<sup>1</sup>, M. Chiari<sup>2</sup>, V. Bollati<sup>3</sup>, S. Epis<sup>4</sup>, C. Bandi<sup>4</sup>, A. Lai<sup>5</sup>, G. Zehender<sup>5</sup>, T. Bellini<sup>1</sup>, M. Buscaglia<sup>1</sup><sup>1</sup>Department of Medical Biotechnologies and Translational Medicine, Università degli Studi di Milano, Segrate, Italy, <sup>2</sup>Istituto di Scienze e Tecnologie Chimiche "Giulio Natta", National Research Council of Italy (SCITEC-CNR), Milano, Italy, <sup>3</sup>Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy, <sup>4</sup>Department of Biosciences, Università degli Studi di Milano, Milano, Italy, <sup>5</sup>Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milano, Italy

### OC 101 12.09-12.19 Molecular diagnosis of human Monkeypox virus in the 2022 outbreak: preliminary evaluation of novel real-time qualitative PCR assays

V. De Pace<sup>1</sup>, G. Guarona<sup>2</sup>, G. Garzillo<sup>2</sup>, M. Ferraris<sup>1</sup>, V. Chessa<sup>1</sup>, S. Varesano<sup>2</sup>, M. Lucente<sup>1</sup>, A. Di Biagio<sup>2,3</sup>, E. Costa<sup>2</sup>, A. Orsi<sup>1,2</sup><sup>1</sup>Hygiene Laboratory Unit, IRCCS, Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>3</sup>Infectious Diseases, IRCCS San Martino Hospital-IST, Genoa, Italy

### OC 102 12.21-12.31 Kinetic of TTV DNA load in peripheral blood lymphomonocytes in early treated acute HIV infections

I. Abbate<sup>1</sup>, G. Rozera<sup>1</sup>, E. Cimino<sup>2</sup>, F. Carletti<sup>1</sup>, E. Tartaglia<sup>2</sup>, M. Rubino<sup>2</sup>, S. Pittalis<sup>3</sup>, R. Esvan<sup>3</sup>, R. Gagliardini<sup>4</sup>, A. Mondì<sup>4</sup>, V. Mazzotta<sup>4</sup>, A. Antinori<sup>4</sup>, V. Puro<sup>3</sup>, E. Girardi<sup>5</sup>, F. Vaia<sup>6</sup>, F. Maggi<sup>1</sup><sup>1</sup>Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Laboratory of Cellular Immunology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>AIDS Referral Center, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>4</sup>Clinical and Research Infectious Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>5</sup>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>6</sup>General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

- |             |                   |  |
|-------------|-------------------|--|
| 12.33-12.40 | <b>Conclusion</b> | C. Alteri, Milano; C. Torti, Catanzaro |
|-------------|-------------------|--|







ORAL COMMUNICATIONS 11.40-12.40

**The experience of PrEP in Italy**

AULA IV

Chairs: E. Focà (Brescia), F.P. Maraglino (Roma)

11.40-11.45 **Introduction**

E. Focà, Brescia; F.P. Maraglino, Roma

**OC 103 11.45-11.55 PrEP in Italy: increased coverage despite significant barriers to access***M. Falaguasta<sup>1</sup>, M. Stizioli<sup>1</sup>, P. Vinti<sup>1</sup>, F. Leserri<sup>2</sup>, G.M. Corbelli<sup>2</sup>*<sup>1</sup>PrEP in Italia, <sup>2</sup>Plus Roma**OC 104 11.57-12.07 Daily or On Demand Oral HIV Pre-exposure Prophylaxis: a Comparison of Users' Characteristics and Sexually Transmitted Infection Features***C. Quarta<sup>1</sup>, I. Miglio<sup>1</sup>, C.M. Tettoni<sup>1</sup>, M. Quaranta<sup>1</sup>, S. Taurian<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>, A. Calcagno<sup>1</sup>, M. Tutone<sup>2</sup>, P. Sales<sup>2</sup>, A. Lucchini<sup>2</sup>*<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, <sup>2</sup>Sexual Health Clinic, ASL Città di Torino, Italy Affiliation**OC 105 12.09-12.19 Confidence in the "Undetectable Equals Untransmittable" (U=U) paradigm among PrEP users***S. Venturelli<sup>1</sup>, D. Ripamonti<sup>1</sup>, A.S. Tran<sup>2</sup>, L. Comi<sup>1</sup>, F. Borghi<sup>1</sup>, F. Maggiolo<sup>1</sup>, M. Rizzi<sup>1</sup>*<sup>1</sup>UOC Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>2</sup>University of Milan, Milano, Italy**OC 106 12.21-12.31 MDPV awareness and preparedness among PrEP users: a community survey***A. Bianchi<sup>1,2</sup>, D. Moschese<sup>1,3</sup>, D. Calzavara<sup>1</sup>, R. Rossotti<sup>1,4</sup>, D. Zagato<sup>2</sup>, A. Antonino<sup>1,2</sup>, A. Tavelli<sup>5</sup>, E. Caruso<sup>1</sup>, I. Khatat<sup>1</sup>, P. Vinti<sup>1</sup>, P. Testoni<sup>1,2</sup>, M. Cernuschi<sup>1,2,6</sup>*<sup>1</sup>Milano Check Point ETS - Milan, Italy, <sup>2</sup>ASA Milano ODV - Milan, Italy, <sup>3</sup>ASST Fatebenefratelli Sacco - Milan, Italy, <sup>4</sup>ASST Grande Ospedale Metropolitano Niguarda - Milan, Italy, <sup>5</sup>Fondazione ICONA - Milan, Italy, <sup>6</sup>IRCCS Ospedale San Raffaele - Milan, Italy12.33-12.40 **Conclusion**

E. Focà, Brescia; F.P. Maraglino, Roma



ORAL COMMUNICATIONS 11.40-12.40

**Virological topics in SARS-CoV-2 infection**

AULA III

Chairs: S. Carbonara (Bari), I. Vicenti (Siena)

11.40-11.45 **Introduction**

S. Carbonara, Bari; I. Vicenti, Siena

**OC 107 11.45-11.55 A heparan sulfate proteoglycan binding tetrapeptide successfully inhibits SARS-CoV-2 Omicron replication***C. Biba, L. Depau, L. Fiaschi, J. Brunetti, I. Varasi, C. Falciani, M. Zazzi, I. Vicenti, L. Bracci*

Department of Medical Biotechnologies, University of Siena, Siena

**OC 108 11.57-12.07 Synergistic effects of antivirals and monoclonal antibodies in vitro against SARS-CoV-2 Wild Type B.1 strain and BQ.1.1 Omicron sublineage***L. Fiaschi, C. Biba, I. Varasi, N. Bartolini, C. Paletti, F. Giammarino, F. Saladini, M. Zazzi, I. Vicenti*

University of Siena, Department of Medical Biotechnologies, Siena, Italy

**OC 109 12.09-12.19 In vitro modelling to monitor pathogenic implications of RSV and SARS-CoV-2 co-infection***C. Yanetti<sup>1</sup>, S. Zecchini<sup>1</sup>, G. Cappelletti<sup>1</sup>, M. Garziano<sup>2</sup>, I. Saulle<sup>2</sup>, S. Strizzi<sup>1</sup>, F. Limanaqi<sup>1</sup>, C. Fenizia<sup>2</sup>, M. Clerici<sup>3</sup>, D. Trabattoni<sup>1</sup>, M. Biasin<sup>1</sup>*<sup>1</sup>Università degli Studi di Milano, Department of Biomedical and Clinical Sciences, Milan, <sup>2</sup>Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, <sup>3</sup>IRCCS, Fondazione Don Carlo Gnocchi, Milan**OC 110 12.21-12.31 Efficacy and SARS CoV-2 viral decay in nasopharynx, saliva and plasma in high-risk vaccinated patients treated with monoclonal antibodies (mAb)***F. Bai<sup>1</sup>, T. Beringheli<sup>1</sup>, R. Rovito<sup>1</sup>, M. Marsiglia<sup>2</sup>, V. Bono<sup>1</sup>, S. Bianchi<sup>2</sup>, E. Borghi<sup>2</sup>, G. Marchetti<sup>1</sup>*<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, <sup>2</sup>Microbiology Laboratory, Department of Health Sciences, University of Milan12.33-12.40 **Conclusion**

S. Carbonara, Bari; I. Vicenti, Siena




**PARALLEL SESSION** 11.40-12.40

**Meeting Prestigio Registry**
**AULA I**

Chair: A. Castagna (Milano)

The PRESTIGIO REGISTRY opens its doors to the ICAR community. The meeting will be an opportunity to share the updated profile of the Registry, as well as to present the achievements, ongoing initiatives and research projects to all participating centers.

11.40-11.55	<b>PRESTIGIO Registry Update</b>	A. Castagna, Milano
11.55-12.10	<b>Publications</b>	L. Galli, Milano
12.10-12.25	<b>Current initiatives and research projects</b>	V. Spagnuolo, Milano
12.25-12.40	<b>Questions and Answers</b>	E. Carini, Milano; R. Lolatto, Milano


**SYMPOSIUM** 12.45-13.45

**Clinical COVID-19**
**AUDITORIUM ALDO MORO**

Chairs: G. Guaraldi (Modena), L. Sarmati (Roma)

The symposium will present virological and clinical paradigms in the prophylaxis and treatment of SARS-CoV-2 infection. In a multidisciplinary approach we will invite a psychiatrist to discuss immune-inflammatory pathways leading to psychopathology and neurocognitive impairment in LongCOVID with a focus on target for treatment. It will end with a round table comparing different models of care in the management of people with LongCOVID highlighting unmet clinical needs and research opportunities.

12.45-13.00	<b>Paradigms of a prophylax and early treatment in COVID-19</b>	M. Andreoni, Roma
13.00-13.15	<b>Psychopathology and neurocognitive impairment in Long COVID: immunopsychiatry of Long COVID</b>	F. Benedetti, Milano
13.15-13.45	<b>Round table</b>	
13.15-13.25	<b>Introduction Lecture "Challenges in Long-COVID care: Italian experiences and best practices"</b>	G. Onder, Roma
13.25-13.45	<b>Discussion</b>	Moderator: G.C. Marchetti, Milano Discussants: M. Andreoni, Roma; F. Benedetti, Milano; A.M. Cattelan, Padova; G. Guaraldi, Modena; G. Onder, Roma


**SPECIAL SESSION** 12:45-13:45

**Drug pipeline: a glimpse of the future**
**AULA V**

Chairs: C. Mussini (Modena), C.F. Perno (Roma), S. Vella (Roma)

An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of antiviral drug and vaccines development in the next decade

12.45-12.50	<b>Introduction</b>	C. Mussini, Modena; C.F. Perno, Roma; S. Vella, Roma
12.50-12.55	<b>E. Bissio</b> , Global Director Medical Affairs (HIV) at MSD	
12.55-13.00	<b>G.M. Prandi</b> , Director Medical Affairs, Vaccines, MSD Italy	
13.00-13.10	<b>M. Gartland</b> , Vice President, Early Development Lead, Pipeline at ViiV Healthcare	
13.10-13.20	<b>F. Rogatto</b> , Executive Director of Global HIV Medical Affairs – Franchise & Strategic Implementation at Gilead Sciences	
13.20-13.25	<b>F. Gkalapi</b> , Medical Lead Vaccines Europe – Belgium at GSK	
13.25-13.30	<b>S. Salehi</b> , Medical Director, Global Medical Affairs at GSK	
13.30-13.45	<b>Q&amp;A and Discussion</b>	C. Mussini, Modena; C.F. Perno, Roma; S. Vella, Roma





ORAL COMMUNICATIONS 12.45-13.45

AULA IV

**Education and knowledge to reduce the burden of HIV and STIs**

Chairs: N. Frattini (Milano), R. Galipò (Roma)

12.45-12.50 **Introduction**

N. Frattini, Milano; R. Galipò, Roma

**OC 111 12.50-13.00 Community based voluntary counselling and testing (CBVCT) services for HIV and other sexual transmitted diseases offered during the pandemic**

A. Nappo<sup>1</sup>, P. Piselli<sup>1</sup>, C. Cimaglia<sup>1</sup>, L. Cosmaro<sup>2</sup>, M. Farinella<sup>3</sup>, L. Rancilio<sup>4</sup>, M. Stagnitta<sup>5</sup>, S. Mattioli<sup>6</sup>, V. Calvino<sup>7</sup>, D. Calzavara<sup>8</sup>, P. Testoni<sup>9</sup>, D. Masci<sup>10</sup>, P. Meli<sup>11</sup>, J. Testa<sup>12</sup>, I. Pennini<sup>13</sup>, M. Errico<sup>14</sup>, A. Caraglia<sup>15</sup>, E. Girardi<sup>1</sup> for the Working Group of the project "The impact of COVID-19 on the processes and outcomes of care of people with HIV"

<sup>1</sup>INMI L. Spallanzani, Rome, Italy, <sup>2</sup>LILA Milano, Milan, Italy, <sup>3</sup>Circolo di Cultura Omosessuale "Mario Mieli, Rome, Italy, <sup>4</sup>CARITAS Ambrosiana, Milan, Italy, <sup>5</sup>CNCA, Rome, Italy, <sup>6</sup>PLUS, Bologna, Italy, <sup>7</sup>ANLAIDS Onlus-ETS, Rome, Italy, <sup>8</sup>Milano Checkpoint, Milan, Italy, <sup>9</sup>Associazione Solidarietà AIDS, Milan, Italy, <sup>10</sup>Villa Maraini, Rome, Italy, <sup>11</sup>CICA, Bergamo, Italy, <sup>12</sup>Italian Society of Migration Medicine - SIMM, Rome, Italy, <sup>13</sup>Arcigay, Bologna, Italy, <sup>14</sup>NPS Italia, Naples, Italy, <sup>15</sup>Ministero della Salute, Rome, Italy

**OC 112 13.02-13.12 Knowledge, Attitudes and Practices regarding HIV and other Sexually Transmitted Infections among High School Students in Southern Italy: a cross-sectional survey**

A. Belati<sup>1</sup>, F.V. Segala<sup>1</sup>, C.R. Santoro<sup>1</sup>, I. Bottalico<sup>2</sup>, C. Pellegrino<sup>1</sup>, R. Novara<sup>1</sup>, G. Guido<sup>1</sup>, L. Frallonardo<sup>1</sup>, L. De Santis<sup>1</sup>, M. Cormio<sup>1</sup>, M. Camporeale<sup>1</sup>, S. Cotugno<sup>1</sup>, S. Di Gregorio<sup>1</sup>, V. Totaro<sup>1</sup>, N. Catucci<sup>3</sup>, A. De Giosa<sup>3</sup>, R. Giusto<sup>3</sup>, F. Di Gennaro<sup>1</sup>, S. Lo Caputo<sup>2</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Infection Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>3</sup>CAMA LILA Bari, Italy

**OC 113 13.14-13.24 Knowledge reduces stigma and generates awareness. The experience of the #cHIVuoleconoscere project in Bergamo**

I. Mercurio<sup>1</sup>, P. Meli<sup>1</sup>, D. Meli<sup>1</sup>, F. Maggiolo<sup>2</sup>, E. Zanetti<sup>3</sup>, C. Pellegris<sup>3</sup>, I. Fontana<sup>4</sup>, S. Zuppardo<sup>5</sup>, F. Tognoli<sup>6</sup>

<sup>1</sup>Don Giuseppe Monticelli Società Cooperativa Sociale, <sup>2</sup>ASST Papa Giovanni XXIII, <sup>3</sup>Associazione Comunità Emmaus, <sup>4</sup>Ufficio Scolastico Territoriale di Bergamo, Italy, <sup>5</sup>Istituto Istruzione Superiore Caterina Caniana, <sup>6</sup>Liceo Don Lorenzo Milani

**OC 114 13.26-13.36 Just LILA - A pilot project and promotional campaign to promote self-testing**

M.L. Cosmaro<sup>1</sup>, G. Dessi<sup>2</sup>, G. Di Pasquale<sup>3</sup>, G. Giupponi<sup>2</sup>, M. Oldrini<sup>1</sup>, S. Penon<sup>1</sup>, C. Perone<sup>4</sup>, P. Perone<sup>2</sup>, D. Savarino<sup>1</sup>

<sup>1</sup>Fondazione LILA Milano, Italy, <sup>2</sup>LILA Nazionale Onlus, Como, Italy, <sup>3</sup>Diversity Lab, Milano, Italy, <sup>4</sup>Cliccaqui, Roma, Italy

13.38-13.45 **Conclusion**

N. Frattini, Milano; R. Galipò, Roma



ORAL COMMUNICATIONS 12.45-13.45

AULA III

**Real world evidence in different treatment setting**

Chairs: A. Di Biagio (Genova), M. Polisenò (Foggia)

12.45-12.50 **Introduction**

A. Di Biagio, Genova; M. Polisenò, Foggia

**OC 115 12.50-13.00 Adherence to and forgiveness to imperfect adherence of FTC/TAF/RPV**

F. Maggiolo<sup>1</sup>, L. Taramasso<sup>2</sup>, L. Comi<sup>1</sup>, G. Brucci<sup>2</sup>, D. Valenti<sup>1,3</sup>, E. Di Filippo<sup>1</sup>, A. Di Biagio<sup>4</sup>

<sup>1</sup>UOC Infectious Diseases I ASST Papa Giovanni XXII, Bergamo, Italy, <sup>2</sup>IRCCS Ospedale Policlinico San Martino di Genova, Genova, Italy, <sup>3</sup>FROM foundation, Bergamo, Italy, <sup>4</sup>Department of Health Sciences, Clinic of Infectious Diseases, University of Genoa, Genoa, Italy

**OC 116 13.02-13.12 Adherence to and forgiveness to imperfect adherence of B/F/TAF**

F. Maggiolo<sup>1</sup>, L. Taramasso<sup>2</sup>, L. Comi<sup>1</sup>, G. Brucci<sup>2</sup>, D. Valenti<sup>1,3</sup>, E. Di Filippo<sup>1</sup>, A. Di Biagio<sup>4</sup>

<sup>1</sup>UOC Infectious Diseases I ASST Papa Giovanni XXII, Bergamo, Italy, <sup>2</sup>IRCCS Ospedale Policlinico San Martino di Genova, Genova, Italy, <sup>3</sup>FROM Foundation, Bergamo, Italy, <sup>4</sup>Department of Health Sciences, Clinic of Infectious Diseases, University of Genoa, Genoa, Italy



**OC 117 13.14-13.24 Antiretroviral therapy prescription in older people living with HIV: cross-sectional study on multidrug regimens (MDR) and less drug regimens (LDR) in GEPO cohort**S. Nozza<sup>1</sup>, B. Fioretti<sup>2</sup>, S. Calza<sup>3</sup>, G. Guaraldi<sup>4</sup>, J. Milic<sup>4</sup>, G.V. De Socio<sup>5</sup>, A. Riva<sup>6</sup>, G. Orofino<sup>7</sup>, G. Di Perri<sup>8</sup>, A. Calcagno<sup>8</sup>, E. Focà<sup>2</sup><sup>1</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Infectious Diseases, University of Brescia and Spedali Civili Hospital, Brescia, Italy, <sup>3</sup>Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>4</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena e Reggio Emilia, Italy, <sup>5</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, <sup>6</sup>3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy, <sup>7</sup>Unit of Infectious Diseases, Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy, <sup>8</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy**OC 118 13.26-13.36 Reasons for choosing a doravirine (DOR) based versus an INSTI-based regimen in ART-naïve and ART-experienced patients in real-world setting: data from the Icona Cohort**A. Saracino<sup>1</sup>, M. Ponzano<sup>2</sup>, F. Bovis<sup>2</sup>, E. Quiros-Roldan<sup>3</sup>, M. Fabbiani<sup>4</sup>, N. Squillace<sup>5</sup>, S. Rusconi<sup>6</sup>, M. Ferrara<sup>7</sup>, S. Lo Caputo<sup>8</sup>, A. Tavelli<sup>9</sup>, A. Antinori<sup>10</sup>, A. d'Arminio Monforte<sup>9</sup><sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, <sup>3</sup>Clinic of Infectious Diseases, University of Brescia, Brescia, Italy, <sup>4</sup>Clinic of Infectious Diseases, Azienda Ospedaliera Universitaria Senese, Siena, Italy, <sup>5</sup>Infectious Diseases Clinic, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy, <sup>6</sup>Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC Luigi Sacco, Università degli Studi di Milano, Legnano, Italy, <sup>7</sup>Department of Infectious Diseases, University of Torino and "Amedeo di Savoia" Hospital, Turin, Italy, <sup>8</sup>Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>9</sup>Icona Foundation, Milan, Italy, <sup>10</sup>Clinical and Research Infectious Diseases Department, National Institute of Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy13.38-13.45 **Conclusion**

A. Di Biagio, Genova; M. Polisenò, Foggia

**PARALLEL SESSION** 12.50-14.00**HIV Outcomes in Europe****AULA I**

Chairs: M. Cascio (Milano), A. d'Arminio Monforte (Milano)

HIV Outcomes is a European initiative born in 2016, thanks to the support of the members of the European Parliament, bringing together patient organisations, clinicians, academics, public institutions and the private sector to think about a new way of addressing the needs of HIV-positive people, to guarantee that they can live longer, in good health and fully participate in society. HIV Outcomes aims to sensitise policy makers and to implement actions that lead to a patient-centric health system that also includes a change in the clinical approach. Improving the quality of life of people living with HIV means improving the sustainability of European health systems through the sharing of best practices and innovative approaches to care. In 2017 HIV Outcomes presented its 5 Recommendations on the health, well-being and long-term care of people living with HIV to the European Parliament. In 2020, to bring the right attention on HIV of Italian political decision-makers, being at the same time members of the European Parliament, and by healthcare professionals, HIV Outcomes Italia was then created. The ultimate aim is to disseminate the recommendations and vision of HIV Outcomes Europe at national level. In 2022, the Policy Asks, developed together with national initiatives "Enhancing long-term health and well-being among people living with HIV" were presented to the European Parliament.

12.50-13.00	<b>Presentation of the initiative</b>	A. d'Arminio Monforte, Milano
13.00-13.10	<b>Policy Asks</b>	M. Cascio, Milano
13.10-13.15	<b>The involvement of the Institutions</b>	S. Milano, Milano
13.15-13.20	<b>The work done, Delphi on Recommendations and initial Institutions engagement</b>	A. d'Arminio Monforte, Milano
13.20-13.25	<b>Abstract on Surveys on Residential care Homes and Hospitals</b>	L. Broganzoli, Milano
13.25-13.40	<b>The way forward on Ageing</b>	A. d'Arminio Monforte, Milano; M. Cascio, Milano
13.40-14.00	<b>Questions and Answers</b>	





SYMPOSIUM 14.00-15.00

AUDITORIUM ALDO MORO

**Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection**

Chairs: A. Bandera (Milano), G. Nunnari (Messina)

HIV infection has taken on clinical connotations in the last two decades that are certainly different from what was observed at the beginning of the HIV epidemic. These changes have been induced by the universal use of antiretroviral therapy in our latitudes, although where therapy is not universally available, some clinical pictures may appear different and more similar to what was previously observed. The aim of this symposium is, on the one hand, to bring back the attention especially of young physicians to the classical clinical aspects of HIV infection by focusing on syndromic aspects in different situations of universal availability of ART, especially in terms of late presentation; on the other hand, it is intended to focus attention on particular clinical situations, toward which the availability of new treatments could change the natural history and prognosis of the diseases themselves, such as progressive multifocal leucoencephalopathy and HIV-related neoplasms.

- 14.00-14.20 **Syndromic approach to main opportunistic infections in HIV. Focus on limited resources - vs rich resources countries** C. Pinnetti, Roma
- 14.20-14.40 **Progressive multifocal leucoencephalopathy. Update on diagnostics and therapeutic approaches** P.M. Cinque, Milano
- 14.40-15.00 **New insights into innovative anti-cancer therapies and their application in HIV-related cancers** E. Vaccher, Aviano PN



ORAL COMMUNICATIONS 14.00-15.00

AULA V

**Body and mind**

Chairs: T. Bini (Milano), G. Rizzardini (Milano)

- 14.00-14.05 **Introduction** T. Bini, Milano; G. Rizzardini, Milano

**OC 119 14.05-14.15 BMI vs body composition changes to predict metabolic outcomes in people with HIV**

L. Taramasso<sup>1</sup>, M. Simion<sup>2</sup>, J. Milic<sup>1</sup>, F. Bovis<sup>1</sup>, F. Motta<sup>2</sup>, G. Besutti<sup>3</sup>, G. Mancini<sup>4</sup>, A. Dessiliani<sup>2</sup>, M. Del Monte<sup>2</sup>, A. Mazzocchi<sup>2</sup>, L. Sighinolfi<sup>2</sup>, M. Ponzano<sup>1</sup>, A. Di Biagio<sup>1</sup>, M. Bassetti<sup>1</sup>, C. Mussini<sup>2,4</sup>, G. Guaraldi<sup>2,4</sup>

<sup>1</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Radiology Unit, Azienda USL-IRCCS di Reggio Emilia, <sup>4</sup>Infectious Diseases Unit, Policlinico di Modena, Università Degli Studi di Modena e Reggio Emilia, Modena, Italy

**OC 120 14.17-14.27 Prevalence, incidence and risk factors for sarcopenic obesity in people with HIV**

J. Milic<sup>1</sup>, S. Cantergiani<sup>1</sup>, S. Renzetti<sup>2</sup>, F. Motta<sup>1</sup>, C. Mussini<sup>1</sup>, S. Calza<sup>2</sup>, G. Sebastiani<sup>3</sup>, G. Guaraldi<sup>1</sup>

<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>University of Brescia, Brescia, Italy, <sup>3</sup>McGill University, Montreal, Canada

**OC 121 14.29-14.39 Plasma and CSF biomarkers of CNS involvement during primary HIV infection**

A. Calcagno<sup>1</sup>, M. Antonucci<sup>2</sup>, P. Cinque<sup>3</sup>, G. Marchetti<sup>4</sup>, D. Bernasconi<sup>5</sup>, M. Trunfio<sup>1</sup>, E. Bruzzesi<sup>6</sup>, S. Rusconi<sup>7,8</sup>, A. Gabrieli<sup>9</sup>, A. Muscatello<sup>9</sup>, A. Antinori<sup>10</sup>, D. Ripamonti<sup>11</sup>, R. Gulminetti<sup>12</sup>, J. Cusato<sup>13</sup>, S. Nozza<sup>3</sup> for the INACTION Study Group

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, <sup>2</sup>ASL Città di Torino, Amedeo di Savoia Hospital, Turin, Italy, <sup>3</sup>Unit of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy, <sup>4</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>5</sup>Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, <sup>6</sup>Vita-Salute San Raffaele University, Milan, <sup>7</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, <sup>8</sup>Dipartimento di Scienze Biomediche e Cliniche (DIBIC), University of Milan, Milan, <sup>9</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, <sup>10</sup>INMI L. Spallanzani, Rome, <sup>11</sup>Papa Giovanni XXIII Hospital, Bergamo, <sup>12</sup>Infectious Diseases Unit, Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, <sup>13</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy



**OC 122 14.41-14.51 The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: 3-months findings from a randomized study**

*B. Rossetti<sup>1,2</sup>, M. Ferrara<sup>3</sup>, L. Taramasso<sup>4</sup>, F. Bai<sup>5</sup>, F. Lombardi<sup>6</sup>, N. Ciccarelli<sup>7</sup>, M. Durante<sup>8</sup>, F. Alladio<sup>3</sup>, I. Rancan<sup>1,8</sup>, F. Montagnani<sup>1,8</sup>, A. Di Biagio<sup>9</sup>, A. d'Arminio Monforte<sup>5</sup>, M. Zazzi<sup>8</sup>, M. Fabbiani<sup>1</sup> for DOBINeuro study group*

<sup>1</sup>Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, <sup>2</sup>Infectious Disease Department, USL SUDEST Toscana, Misericordia Hospital, Grosseto, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>4</sup>Infectious Diseases Clinic, Department of Internal Medicine, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>5</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, <sup>6</sup>Infectious Diseases Unit, UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>7</sup>Department of Psychology, Catholic University, Milan, Italy, <sup>8</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>9</sup>Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

14.53-15.00 **Conclusion**

T. Bini, Milano; G. Rizzardini, Milano



**ORAL COMMUNICATIONS** 14.00-15.00

**AULA IV**

**PACS: clinical outcome**

Chairs: G. Cenderello (Sanremo IM), D. Ripamonti (Bergamo)

14.00-14.05 **Introduction**

G. Cenderello, Sanremo IM; D. Ripamonti, Bergamo

**OC 123 14.05-14.15 Long COVID phenotypes and association with SARS CoV-2 variants in the EUCARE-POSTCOVID study**

*F. Bai<sup>1</sup>, S. De Benedittis<sup>1</sup>, A. Tavelli<sup>1</sup>, M.M. Santoro<sup>2</sup>, F. Ceccherini-Silberstein<sup>2</sup>, M. Iannetta<sup>3</sup>, Y. Shimoni<sup>4</sup>, S. Ravid<sup>4</sup>, T. Kozlovski<sup>4</sup>, F. Köning<sup>5</sup>, N. Pfeifer<sup>5</sup>, E. Shamsara<sup>5</sup>, M. Parczewski<sup>6</sup>, A. Cozzi-Lepri<sup>7</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>*

<sup>1</sup>Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, <sup>2</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Roma, Lazio, Italy, <sup>3</sup>Infectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Rome, Italy, <sup>4</sup>Healthcare Informatics, IBM Research-Haifa, Mount Carmel Haifa, Israel, <sup>5</sup>Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany, <sup>6</sup>Department of Infectious Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland, <sup>7</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

**OC 124 14.17-14.27 Implication of Human Endogenous Retroviruses in development, progression and long-term sequelae of COVID-19: towards a personalized medicine**

*A. Minutolo<sup>1</sup>, V. Petrone<sup>1</sup>, M. Fanelli<sup>1</sup>, C. Maracchioni<sup>1</sup>, M. Giudice<sup>1</sup>, R. Chirico<sup>1</sup>, C. Cipriani, L. Coppola<sup>2</sup>, E. Teti<sup>2</sup>, C. Sorace<sup>2</sup>, M. Zordan<sup>2,3</sup>, P. Vitale<sup>2,3</sup>, V. Malagnino<sup>2,3</sup>, M. Iannetta<sup>2,3</sup>, M. Andreoni<sup>2,3</sup>, H. Perron<sup>4</sup>, S. Grelli<sup>1,5</sup>, E. Balestrieri<sup>1</sup>, L. Sarmati<sup>2,3</sup>, C. Matteucci<sup>1</sup>*

<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, Italy, <sup>3</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>4</sup>Geneuro – Innovation, Lyon-France, <sup>5</sup>Virology Unit, Policlinic of Tor Vergata, Rome, Italy

**OC 125 14.29-14.39 Impact of long-COVID on daily working activity in non-elderly patients: a cross sectional study**

*A.I. Ritacco, D.F. Bavaro, F.V. Segala, L. Piccolomo, V. Giliberti, A. Amendolara, A. Lugli, D. Cassano, G. Manco Cesari, G. Romita, M. De Filippis, G. Brindicci, F. Di Gennaro, A. Saracino*

Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari "Aldo Moro", Bari, Italy

**OC 126 14.41-14.51 Symptom clusters and risk factors for Long COVID syndrome in hospitalized patients at 6 months of follow up**

*V. Cogliandro<sup>1</sup>, N. Squillace<sup>1</sup>, E. Rossi<sup>2</sup>, M.C. Ferrara<sup>3</sup>, A. Monzani<sup>4</sup>, M. Pozzi<sup>5</sup>, V. Salvarani<sup>6</sup>, L. Valagussa<sup>7</sup>, I.C. Caramma<sup>1</sup>, A. Cappelletti<sup>1</sup>, L. Bonaffini<sup>1</sup>, C. Ferrarese<sup>8,9</sup>, G. Foti<sup>5,9</sup>, M. Lettino<sup>7,9</sup>, F. Luppi<sup>4</sup>, M.G. Strepparava<sup>6,9</sup>, G. Bellelli<sup>3,9</sup>, P. Bonfanti<sup>1,9</sup>*

<sup>1</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>2</sup>Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, <sup>3</sup>Acute Geriatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>4</sup>Respiratory Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>5</sup>Anesthesia and Intensive Care Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>6</sup>Clinical Psychology Unit, Department of Mental Health, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>7</sup>Cardiology Division, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>8</sup>Neurology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>9</sup>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

14.53-15.00 **Conclusion**

G. Cenderello, Sanremo IM; D. Ripamonti, Bergamo





ORAL COMMUNICATIONS 14.00-15.00

AULA III

**Viruses, resistance and drugs**

Chairs: B. Bruzzone (Genova), F. Saladini (Siena)

14.00-14.05 **Introduction**

B. Bruzzone, Genova; F. Saladini, Siena

**OC 127 14.05-14.15 Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry***D. Armenia<sup>1</sup>, V. Spagnuolo<sup>2</sup>, M.C. Bellocchi<sup>3</sup>, L. Galli<sup>2</sup>, L. Duca<sup>3</sup>, G. Marchegiani<sup>3</sup>, T. Clemente<sup>2</sup>, L. Carioti<sup>3</sup>, R. Lolatto<sup>2</sup>, L. Calza<sup>4</sup>, B.M. Celesia<sup>5</sup>, A. Cascio<sup>6</sup>, D. Francisci<sup>7</sup>, A. Saracino<sup>8</sup>, C. Torti<sup>9</sup>, M. Zazzi<sup>10</sup>, A. Castagna<sup>2</sup>, M.M. Santoro<sup>3</sup> on behalf of the PRESTIGIO Registry*<sup>1</sup>Saint Camillus International University of Health Sciences, Rome, Italy, <sup>2</sup>Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, Italy, <sup>3</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>4</sup>Policlinico Sant'Orsola-Malpighi, Bologna, Italy, <sup>5</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, <sup>6</sup>Infectious and Tropical Diseases Unit -Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, <sup>7</sup>Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>8</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>9</sup>Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy, <sup>10</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy**OC 128 14.17-14.27 HIV-1 persistence in people living with HIV who started antiretroviral therapy in acute or chronic infection: insight into molecular mechanisms***E. Bruzzesi<sup>1</sup>, G. Spinozzi<sup>2</sup>, L. Rudilosso<sup>2</sup>, P. Gallina<sup>2</sup>, G. Amodio<sup>2</sup>, A. Castagna<sup>1</sup>, S. Gregori<sup>2</sup>, E. Montini<sup>2</sup>, A. Calabria<sup>2</sup>, S. Nozza<sup>1</sup>, D. Cesana<sup>2</sup>*<sup>1</sup>Vita-Salute San Raffaele University, <sup>2</sup>San Raffaele Telethon Institute for Gene Therapy (Sr-TIGET), San Raffaele Scientific Institute, Milan, Italy**OC 129 14.29-14.39 Comparison of different interpretation tools for HIV-1 resistance detected through Next Generation Sequencing in Italian clinical routine***D. Armenia<sup>1</sup>, L. Carioti<sup>2</sup>, V. Micheli<sup>3</sup>, T. Allice<sup>4</sup>, C. Bonura<sup>5</sup>, B. Bruzzone<sup>6</sup>, F. Bracchitta<sup>3</sup>, F. Cerutti<sup>4</sup>, G. Giammanco<sup>5</sup>, N. Randazzo<sup>6</sup>, A. Bonifacio<sup>7</sup>, I. Bon<sup>8</sup>, A. Bertoli<sup>9</sup>, M. Vatteroni<sup>10</sup>, G. Ibba<sup>11</sup>, F. Novazzi<sup>12</sup>, M.R. Lipsi<sup>13</sup>, N. Cuomo<sup>14</sup>, I. Vicenti<sup>15</sup>, F. Ceccherini-Silberstein<sup>2</sup>, B. Rossetti<sup>16</sup>, A. Bezenchek<sup>17</sup>, F. Saladini<sup>15</sup>, M. Zazzi<sup>15</sup>, M.M. Santoro<sup>2</sup>, on behalf of the NGS Network*<sup>1</sup>UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, <sup>2</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>3</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco - University of Milan, Milan, Italy, <sup>4</sup>Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy, <sup>5</sup>Azienda Ospedaliera Universitaria Policlinico "P. Giaccone" - Università degli Studi di Palermo, Palermo, Italy, <sup>6</sup>Hygiene Unit, Ospedale Policlinico San Martino, Genoa, Italy, <sup>7</sup>Section of Experimental and Clinical Pathology, Department of Precision and Regenerative Medicine and Ionic Area, University of Bari, Bari, Italy, <sup>8</sup>Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, <sup>9</sup>Virology Unit, Polyclinic of "Tor Vergata", Rome, Italy, <sup>10</sup>Virology Unit, AOU Pisana, Pisa, Italy, <sup>11</sup>Microbiology and Virology Unit, Diagnostic Department, AOU Sassari, Sassari, Italy, <sup>12</sup>Department of Medicine and Surgery, University of Insubria, Varese, Italy, <sup>13</sup>Microbiology and Virology Unit, Policlinico Riuniti Foggia Hospital, Foggia, Italy, <sup>14</sup>U.O.C. Microbiologia e Virologia, P.O. "D.Cotugno" - AO dei Colli - Napoli, Italy, <sup>15</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>16</sup>Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, <sup>17</sup>IPRO-InfarmaPRO S.r.l., Rome, Italy, EuResist Network GEIE, Rome, Italy**OC 130 14.41-14.51 Pharmacokinetic of tecovirimat in plasma and semen of Mpox patients***M. Tempestilli<sup>1</sup>, A. Mondì<sup>1</sup>, C. Pinnetti<sup>1</sup>, A. D'Avolio<sup>2</sup>, V. Mazzotta<sup>1</sup>, G. Matusali<sup>1</sup>, D. Mariotti<sup>1</sup>, O. Forini<sup>1</sup>, A. Beccacece<sup>1</sup>, A. De Nicolò<sup>2</sup>, P. Faccendini<sup>1</sup>, E. Cimini<sup>1</sup>, F. Maggi<sup>1</sup>, E. Girardi<sup>1</sup>, E. Nicastri<sup>1</sup>, F. Vaia<sup>1</sup>, A. Antinori<sup>1</sup>*<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>University of Turin, Turin, Italy14.53-15.00 **Conclusion**

B. Bruzzone, Genova; F. Saladini, Siena




**ORAL COMMUNICATIONS** 14.00-15.00

**AULA II**
**Mpox and Immunopathogenic mechanisms**

Chairs: F. Maggi (Roma), V. Mazzotta (Roma)

 14.00-14.05 **Introduction**

F. Maggi, Roma; V. Mazzotta, Roma

**OC 131 14.05-14.15 Humoral and cellular immune response after eight months from Mpox virus infection**

 V. Mazzotta<sup>1</sup>, G. Matusali<sup>2</sup>, E. Cimini<sup>3</sup>, F. Colavita<sup>2</sup>, R. Casetti<sup>3</sup>, C. Pinnetti<sup>1</sup>, A. Mondì<sup>1</sup>, A. Bettini<sup>2</sup>, Bordini<sup>4</sup>, G. Grassi<sup>3</sup>, G. Prota<sup>5</sup>, S. Vita<sup>6</sup>, N. Nicastrì<sup>6</sup>, E. Girardi<sup>7</sup>, C. Agrati<sup>4</sup>, F. Vaia<sup>8</sup>, F. Maggi<sup>2</sup>, A. Antinori<sup>1</sup>
<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Laboratory of Virology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>3</sup>Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>Unit of Pathogen Specific Immunity Department of Pediatric Hematology and Oncology, IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy, <sup>5</sup>Laboratory of Microbiology, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>Emerging Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>7</sup>Scientific Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>8</sup>General Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

**OC 132 14.17-14.27 Neutralizing and T cell immunogenicity after MVA-BN vaccination for mpox according to previous smallpox vaccination, HIV status, and administration route**

 V. Mazzotta<sup>1,2</sup>, A. Cozzi Lepri<sup>3</sup>, G. Matusali<sup>1</sup>, E. Cimini<sup>1</sup>, S. Lanini<sup>1</sup>, C. Aguglia<sup>1,4</sup>, F. Colavita<sup>1</sup>, S. Notari<sup>1</sup>, R. Gagliardini<sup>1</sup>, S. Meschi<sup>1</sup>, A. Oliva<sup>1</sup>, S. Vita<sup>1</sup>, P. Piselli<sup>1</sup>, V. Mondillo<sup>1</sup>, G. Montagnari<sup>1,4</sup>, E. Nicastrì<sup>1</sup>, A. Siddu<sup>5</sup>, G. Rezza<sup>5</sup>, A. Barca<sup>6</sup>, E. Girardi<sup>1</sup>, F. Vaia<sup>1</sup>, F. Maggi<sup>1</sup>, A. Antinori<sup>1</sup> and the Mpox Vaccine Lazio Study Group

<sup>1</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>4</sup>University of Rome Tor Vergata, Rome, Italy, <sup>5</sup>Italian Ministry of Health, <sup>6</sup>Department of Health of Lazio Region

**OC 133 14.29-14.39 Interferon-gamma (IFN-g), But Not Tumor Necrosis Factor-alpha (TNF-a) Induces the Polarization of Human Monocyte-Derived Macrophage (MDM) into M1 Cells Restricting HIV-1 Replication**

 C. Mazzei<sup>1</sup>, V.S. Ibbá<sup>1</sup>, S. Ghezzi<sup>1</sup>, G. Poli<sup>1,2</sup>
<sup>1</sup>San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Human Immuno-Virology Group, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, School of Medicine, Milan, Italy

**OC 134 14.41-14.51 Effect of sera from HIV-1-exposed seronegative subjects, long term non progressors, HIV-1+ and HIV-1- individuals on CCR5 expression and R5 HIV-1 infectivity in human primary macrophages and CD4+ T lymphocytes**

 I. Farina<sup>1</sup>, C. Pastori<sup>2</sup>, R. Bona<sup>1</sup>, C.M. Galluzzo<sup>1</sup>, R. Amici<sup>1</sup>, C. Purificato<sup>1</sup>, M.C. Gauzzi<sup>1</sup>, M. Andreotti<sup>1</sup>, L. Lopalco<sup>2</sup>, L. Fantuzzi<sup>1</sup>
<sup>1</sup>National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, <sup>2</sup>Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy

 14.53-15.00 **Conclusion**

F. Maggi, Roma; V. Mazzotta, Roma


**PARALLEL SESSION** 14.05-15.35

**AULA I**
**Investigator Meeting of EDOLAS Study**

Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression

 14.05-14.10 **Welcome**

A. Antinori, Roma; F. Maggiolo, Bergamo

 14.10-14.15 **Introduction**

A. Antinori, Roma; F. Maggiolo, Bergamo

 14.15-14.30 **Protocol and enrolments**

R. Gagliardini, Roma

 14.30-14.50 **Discussion**

 14.50-15.30 **Meeting with investigators of the Edolas substudies**

 15.30-15.35 **Conclusions**

A. Antinori, Roma







SYMPOSIUM 15.05-16.05

AUDITORIUM ALDO MORO

**Chemsex emergency - what happens in real life**

Chairs: M. Cernuschi (Milano), D. Zagato (Milano)

Chemsex, or the use of recreational substances during sex, is a widespread practice within the MSM community. Numerous cohort studies on HIV-positive MSM or PrEP users show that the prevalence of the phenomenon is increasing and the substances used are constantly evolving. The chemsex emergency is often spoken of with emphasis on the health and addiction issues related to drug use, but also with a good deal of ignorance leading to stigmatisation of users. The symposium aims to shed light on this practice, providing information on the type of substances most commonly used, the contribution of peer practitioners in the field who, within community associations, offer support to chemsex users, and finally the fundamental role of PrEP in reducing the risk of HIV infection in contexts where other prevention tools would be of doubtful effectiveness.

- 15.05-15.20 **Old and new psychotropic substances in chemsex practice** M. Lanza, Milano
- 15.20-15.40 **Recreational Chemsex Vs problematic Chemsex** F. Leserri, Roma; M. Manfredini, Milano
- 15.40-15.50 **Chemsex & PrEP** S. Nozza, Milano
- 15.50-16.05 **Discussion**



ORAL COMMUNICATIONS 15.05-16.05

AULA V

**Outcomes in treatment experienced PLWH**

Chairs: A.M. Cattelan (Padova), A. Moznich (Milano)

- 15.05-15.10 **Introduction** A.M. Cattelan, Padova; A. Moznich, Milano

**OC 135 15.10-15.20 Effectiveness of switch to bicitgravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed persons living with HIV (PLWH): 96-week data from the Icona cohort**

A. d'Arminio Monforte<sup>1</sup>, A. Tavelli<sup>2</sup>, A. Cingolani<sup>3</sup>, L. Taramasso<sup>4</sup>, C. Mussini<sup>5</sup>, S. Piconi<sup>6</sup>, A. Calcagno<sup>7</sup>, G. Orofino<sup>8</sup>, S. Cicalini<sup>9</sup>, A. Castagna<sup>10</sup>, F. Ceccherini-Silberstein<sup>11</sup>, A. Gori<sup>12</sup>, G. Guaraldi<sup>5</sup>, A. Antinori<sup>9</sup> for the Icona Foundation Study Group

<sup>1</sup>Icona Foundation, University of Milan, Milan, Italy, <sup>2</sup>Icona Foundation, Milan, Italy, <sup>3</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Department of Safety and Bioethics, Infectious Diseases Unit, Rome, Italy, <sup>4</sup>Ospedale Policlinico San Martino IRCCS, University of Genoa, Unit of Infectious Diseases, Genoa, Italy, <sup>5</sup>Azienda Ospedaliero Universitaria di Modena, University of Modena and Reggio Emilia, Infectious and Tropical Diseases Unit, Modena, Italy, <sup>6</sup>ASST Lecco, Infectious Diseases Unit, Lecco, Italy, <sup>7</sup>Ospedale Amedeo di Savoia, University of Turin, Unit of Infectious Diseases, Department of Medical Sciences, Turin, Italy, <sup>8</sup>Ospedale Amedeo di Savoia, ASL Città di Torino, Division A of Infectious Diseases, Turin, Italy, <sup>9</sup>National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Clinical Department, HIV/AIDS Unit, Rome, Italy, <sup>10</sup>IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Infectious Diseases Unit, Milan, Italy, <sup>11</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, <sup>12</sup>IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Department of Pathophysiology and Transplantation, Clinic of Infectious Diseases, Milan, Italy

**OC 136 15.22-15.32 Effectiveness of bicitgravir/emtricitabine/tenofovir alafenamide(BIC/FTC/TAF) as switch strategy in virologically suppressed: real world data from monocentric cohort**

R.A. Passerotto<sup>1</sup>, F. Lamanna<sup>1</sup>, D. Farinacci<sup>2</sup>, A. Dusina<sup>3</sup>, A. D'Angelillo<sup>1</sup>, A. Cicullo<sup>4</sup>, G. Baldin<sup>3</sup>, I. Mozzetta<sup>3</sup>, E. Visconti<sup>3</sup>, S. Di Giambenedetto<sup>1,3</sup>, A. Borghetti<sup>3</sup>

<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>2</sup>UOC Medicina Protetta - Malattie Infettive - ASL Viterbo, Viterbo, Italy, <sup>3</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy, <sup>4</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italy

**OC 137 15.34-15.44 Use of tenofovir alafenamide/emtricitabine/bicitgravir (B/F/TAF) in treatment-experienced people living with HIV. Real-life data from Infectious Disease Unit of Alessandro Manzoni Hospital in Lecco**

V. Morena, F. Conti, S. Pontiggia, C. Molteni, L. Bradanini, A. Pandolfo, S. Piconi  
Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco (LC), Italy

**OC 138 15.46-15.56 Safety and efficacy of doravirine-based regimens in People Living With HIV: a real-life multicentric study**

C. Micali<sup>1</sup>, Y. Rusotto<sup>2</sup>, G.F. Pellicanò<sup>3</sup>, L. Panella<sup>4</sup>, A. Albanese<sup>5</sup>, L. Santoro<sup>2</sup>, S. Sofia<sup>6</sup>, G. Pantò<sup>6</sup>, M. Coco<sup>2</sup>, A. Guarneri<sup>2</sup>, C. Iacobello<sup>6</sup>, M.S. Paternò Raddusa<sup>2</sup>, G. Ceccarelli<sup>7</sup>, A. Marino<sup>7</sup>, B.M. Celesia<sup>8</sup>, B.S. Cacopardo<sup>7</sup>, A. Montineri<sup>9</sup>, C. Frasca<sup>9</sup>, A. Colpani<sup>10</sup>, A. De Vito<sup>10</sup>, G. Madeddu<sup>10</sup>, A. Alibrandi<sup>11</sup>, E. Venanzi Rullo<sup>2</sup>, G. Nunnari<sup>2</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina,



Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>3</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", University of Messina, Messina, Italy, <sup>4</sup>"Cutroni Zodda" Hospital, Barcellona Pozzo di Gotto, Messina, Italy, <sup>5</sup>"Papardo" Hospital, Messina, Italy, <sup>6</sup>"Azienda Ospedaliera per l'Emergenza Cannizzaro", Unit of Infectious Diseases, Catania, Italy, <sup>7</sup>Unit of Infectious Diseases, ARNAS Garibaldi, Nesima Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, <sup>8</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, <sup>9</sup>G. Rodolico - San Marco Hospital, Catania, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>11</sup>Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina, Italy

15.58-16.05 **Conclusion**

A.M. Cattelan, Padova; A. Moznich, Milano



ORAL COMMUNICATIONS 15.05-16.05

AULA IV

## Clinical approach to COVID-19 in vulnerable populations

Chairs: F. Di Gennaro (Bari), C. Gervasoni (Milano)

15.05-15.10 **Introduction**

F. Di Gennaro, Bari; C. Gervasoni, Milano

### OC 139 15.10-15.20 Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis

G. Guido<sup>1</sup>, F. Di Gennaro<sup>1</sup>, L. Frallonardo<sup>1</sup>, F. V. Segala<sup>1</sup>, R. De Nola<sup>2</sup>, G.R. Damiani<sup>2</sup>, E. De Vita<sup>1</sup>, V. Totaro<sup>1</sup>, M. Barbagallo<sup>3</sup>, G. Liuzzi<sup>4</sup>, E. Nicastrì<sup>4</sup>, A. Vimercati<sup>2</sup>, E. Cicinelli<sup>2</sup>, N. Veronese<sup>3</sup>, A. Saracino<sup>1</sup>

<sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area - (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Clinic of Obstetrics & Gynaecology, University of "Aldo Moro," Bari, Italy, <sup>3</sup>Geriatrics Section, Department of Internal Medicine, University of Palermo, Palermo, Italy, <sup>4</sup>National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), Rome, Italy

### OC 140 15.22-15.32 SARS-CoV2 infection in patients with Hematological Malignancies in the omicron era: hospitalization, need for mechanical ventilation and mortality in seronegative and seropositive population

V. Todisco<sup>1</sup>, Y. Menozzi<sup>1</sup>, M. Pellegrino<sup>1</sup>, S. Cantergiani<sup>1</sup>, A. Spadoni<sup>1</sup>, F. Romani<sup>1</sup>, F. Bettelli<sup>2</sup>, A. Santoro<sup>1</sup>, C. Mussini<sup>1</sup>, E. Franceschini<sup>1</sup>

<sup>1</sup>Malattie Infettive - Azienda Ospedaliero Universitaria Policlinico di Modena, Italy, <sup>2</sup>Ematologia - Azienda Ospedaliero Universitaria Policlinico di Modena, Italy

### OC 141 15.34-15.44 Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth and after a ninemonths follow-up

A. Proto<sup>1</sup>, S. Agliardi<sup>2</sup>, S. Renica<sup>3</sup>, A. Pani<sup>2</sup>, G. Gazzaniga<sup>2</sup>, R. Giossi<sup>2</sup>, M. Senatore<sup>2</sup>, F. di Ruscio<sup>3</sup>, C. Vismara<sup>4</sup>, D. Campisi<sup>4</sup>, F. Scaglione<sup>2</sup>, S. Martinelli<sup>1</sup>

<sup>1</sup>Neonatology and Neonatal Intensive Care Unit, Niguarda Hospital, Milan, Italy, <sup>2</sup>Postgraduate School of Clinical Pharmacology and Toxicology, Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy, <sup>3</sup>Postgraduate School of Microbiology and Virology, Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy, <sup>4</sup>Microbiology Unit, Niguarda Hospital, Milan, Italy

### OC 142 15.46-15.56 Safety of Antiviral therapy in fragile SARS COV 2 paediatric patients

S. Bernardi<sup>1</sup>, M. Di Giuseppe<sup>1</sup>, L. Romani<sup>1</sup>, F. Calo' Carducci<sup>1</sup>, L. Cursi<sup>1</sup>, L. Lancella<sup>1</sup>, S. Mercadante<sup>1</sup>, C. Tripiciano<sup>1</sup>, M. De Luca<sup>1</sup>, S. Chiurchiù<sup>1</sup>, A. Krzysztofak<sup>1</sup>, R. Adoriso<sup>1</sup>, A. Amodeo<sup>1</sup>, G. Paglietti<sup>1</sup>, L. Colagrossi<sup>1</sup>, R. Scutari<sup>1</sup>, C. Di Maio<sup>1</sup>, C. Russo<sup>1</sup>, P. Palma<sup>1</sup>, V. Santilli<sup>1</sup>, E. Manno<sup>1</sup>, B. Rivalta<sup>1</sup>, A. Campana<sup>1</sup>, D. Perrotta<sup>1</sup>, A. Antinori<sup>2</sup>, E. Nicastrì<sup>2</sup>, P. Merli<sup>1</sup>, B. Lucarelli<sup>1</sup>, F. Galaverna<sup>1</sup>, M. Becilli<sup>1</sup>, T. Corsetti<sup>1</sup>, F. Tangari<sup>1</sup>, C.F. Perno<sup>1</sup>, Villani<sup>1</sup>, M. Raponi<sup>1</sup>, F. Locatelli<sup>1</sup>, L. Vallesi<sup>1</sup>

<sup>1</sup>Bambino Gesù Children's Hospital, Rome, Italy, <sup>2</sup>INMI National Institute Infectious Disease Lazzaro Spallanzani, Rome, Italy

15.58-16.05 **Conclusion**

F. Di Gennaro, Bari; C. Gervasoni, Milano



ORAL COMMUNICATIONS 15.05-16.05

AULA III

## Emerging issues in HIV-1 infection

Chairs: B.M. Celesia (Catania), G. Giupponi (Como)

15.05-15.10 **Introduction**

B.M. Celesia, Catania; G. Giupponi, Como

### OC 143 15.10-15.20 Impact of COVID-19 in time to linkage to care (LtC) and ART initiation in the ICONA cohort

P. Piselli<sup>1</sup>, A. De Vito<sup>2</sup>, A. Tavelli<sup>3</sup>, C. Cimaglia<sup>1</sup>, A. Nappo<sup>1</sup>, M. Farinella<sup>4</sup>, L. Rancilio<sup>5</sup>, L. Cosmaro<sup>6</sup>, C. Muccini<sup>7</sup>, C. Santoro<sup>8</sup>, D. Segala<sup>9</sup>, M. Trizzino<sup>10</sup>, A. Caraglia<sup>11</sup>, A. d'Arminio Monforte<sup>3</sup>, A. Antinori<sup>1</sup>, E. Girardi<sup>1</sup>, G. Madeddu<sup>2</sup> for the ICONA Foundation Study Group and for the Working Group of the project "The impact of COVID-19 on the processes and outcomes of care of people with HIV"

<sup>1</sup>INMI L. Spallanzani IRCCS, Rome, <sup>2</sup>University of Sassari, Sassari, <sup>3</sup>Icona Foundation, Milan, <sup>4</sup>Circolo Mario Mieli, Rome, <sup>5</sup>Caritas Ambrosiana, Milan, <sup>6</sup>LILA, Milan, <sup>7</sup>IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, <sup>8</sup>University of Bari, Bari, <sup>9</sup>AOU di Ferrara, University of Ferrara, Ferrara, <sup>10</sup>AOU Policlinico "P. Giaccone", Palermo, <sup>11</sup>Minister of Health, Rome



**OC 144 15.22-15.32 Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network**

*A. Giacomelli<sup>1</sup>, R. Gagliardini<sup>2</sup>, A. Tavelli<sup>3</sup>, S. De Benedittis<sup>4</sup>, V. Mazzotta<sup>5</sup>, G. Rizzardini<sup>5</sup>, A. Mondì<sup>2</sup>, D. Barbanotti<sup>4</sup>, S. Antinori<sup>1</sup>, A. Vergori<sup>2</sup>, A. Gori<sup>6</sup>, M. Menozzi<sup>7</sup>, L. Taramasso<sup>8</sup>, F.M. Fusco<sup>9</sup>, A. De Vito<sup>10</sup>, G. Mancarella<sup>11</sup>, G. Marchetti<sup>4</sup>, A. d'Arminio Monforte<sup>3</sup>, A. Antinori<sup>2</sup>, A. Cozzi-Lepri<sup>12</sup> on behalf of COVID-19 ICONA study group*

<sup>1</sup>III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>2</sup>Clinical and Research Infectious Diseases Department, National Institute of Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Icona Foundation, Milan, Italy, <sup>4</sup>ASST Santi Paolo e Carlo, San Paolo Hospital, Unit of Infectious Diseases, Department of Health Sciences, University of Milan, Milan, Italy, <sup>5</sup>I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>6</sup>II Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy, <sup>7</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy, <sup>8</sup>Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>9</sup>UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, P.O. "D. Cotugno", Naples, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, <sup>11</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>12</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK

**OC 145 15.34-15.44 Patient reported outcomes in older people living with/without HIV in the GEPO cohort**

*A. Calcagno<sup>1</sup>, M. Sandri<sup>2</sup>, J. Milic<sup>3</sup>, M. Ferrara<sup>1</sup>, S. Nozza<sup>4</sup>, S. Arsuffi<sup>5</sup>, T. Lucchi<sup>6</sup>, G.V. De Socio<sup>7</sup>, G. Orofino<sup>8</sup>, C. Mussi<sup>9</sup>, A. Riva<sup>10</sup>, G. Guaraldi<sup>3</sup>, S. Calza<sup>2</sup>, G. Di Perri<sup>1</sup>, E. Focà<sup>3</sup>*

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, <sup>2</sup>Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>3</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>4</sup>Unit of Infectious Diseases, San Raffaele Scientific Institute, Milan, <sup>5</sup>Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy, <sup>6</sup>Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>7</sup>Unit of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>8</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, ASL Città di Torino, Italy, <sup>9</sup>Centro di Valutazione e Ricerca Gerontologica, Chair of Geriatrics, University of Modena and Reggio Emilia, Modena, Italy, <sup>10</sup>Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy

**OC 146 15.46-15.56 Implementing an Electronic Patient-Reported Outcomes (ePROs) system in PLWH management: experience of Icona cohort**

*A. Tavelli<sup>1</sup>, L. Cosmaro<sup>2</sup>, N. Gianotti<sup>3</sup>, R. Gagliardini<sup>4</sup>, V.G. Calvino<sup>5</sup>, F. Bai<sup>6</sup>, G. Guaraldi<sup>7</sup>, F. Vichi<sup>8</sup>, I. Fanti<sup>1</sup>, M. Cernuschi<sup>9</sup>, A. Antinori<sup>4</sup>, A. d'Arminio Monforte<sup>6</sup>, A. Cingolani<sup>10</sup>*

<sup>1</sup>ICONA Foundation, Milano, <sup>2</sup>Fondazione LILA Milano, Milano <sup>3</sup>Hospital San Raffaele, Milano, <sup>4</sup>INMI "L.Spallanzani", Roma, <sup>5</sup>Anlaidi Onlus-ETS, Roma, <sup>6</sup>San Paolo Hospital, Milano, <sup>7</sup>University of Modena and Reggio Emilia, Modena, <sup>8</sup>Santa Maria Annunziata Hospital, Firenze, <sup>9</sup>Associazione Solidarietà Aids, Milano, <sup>10</sup>Fondazione A. Gemelli IRCCS, Roma

15.58-16.05 **Conclusion**

B.M. Celesia, Catania; G. Giupponi, Como

**ORAL COMMUNICATIONS** 15.05-16.05**AULA II****Novel clinical and epidemiological aspects of viral hepatitis**

Chairs: G. Lapadula (Monza), T.A. Santantonio (Foggia)

15.05-15.10 **Introduction**

G. Lapadula, Monza; T.A. Santantonio, Foggia

**OC 147 15.10-15.20 HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication**

*L. Duca<sup>1</sup>, A. Olivero<sup>2</sup>, L. Piermatteo<sup>1,3</sup>, S. D'Anna<sup>1</sup>, G. Torre<sup>1</sup>, E. Teti<sup>4</sup>, A. Di Lorenzo<sup>4</sup>, V. Malagnino<sup>4</sup>, M. Iannetta<sup>4</sup>, L. Baiocchi<sup>5</sup>, S. Francioso<sup>5</sup>, I. Lenci<sup>5</sup>, F. Ceccherini-Silberstein<sup>1</sup>, M. Milella<sup>6</sup>, A. Saracino<sup>6</sup>, A. Ciancio<sup>2</sup>, L. Sarmati<sup>4</sup>, M. Rizzetto<sup>2</sup>, G.P. Caviglia<sup>2</sup>, V. Svicher<sup>1,3</sup>, R. Salpini<sup>1</sup>*

<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Department of Medical Sciences, University of Turin, Turin, Italy, <sup>3</sup>Department of Biology, University of Rome Tor Vergata, Rome, Italy, <sup>4</sup>Department of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy, <sup>5</sup>Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, <sup>6</sup>Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro," Bari, Italy

**OC 148 15.22-15.32 Management of antiviral prophylaxis in patients with resolved HBV infection receiving immunosuppressive treatment**

*C. Sorace<sup>1</sup>, L. Campogiani<sup>1</sup>, G. De Simone<sup>1</sup>, N. Braccialarghe<sup>1</sup>, C. Aguglia<sup>1</sup>, E. Teti<sup>1</sup>, L. Sarmati<sup>2</sup>, A.M. Geretti<sup>2</sup>*

<sup>1</sup>Clinical Infectious Disease, Tor Vergata Hospital, Rome, Italy, <sup>2</sup>Clinical infectious disease, Department of System Medicine, Tor Vergata University, Rome, Italy



**OC 149 15.34-15.44 HDV infection is stable in Central Italy across the last two decades and is characterized by the circulation of multiple HDV subgenotypes 1 with a different pro-inflammatory potential**

R. Salpini<sup>1</sup>, L. Piermatteo<sup>1,2</sup>, G. Torre<sup>1</sup>, S. D'Anna<sup>1</sup>, S. Khan<sup>1</sup>, L. Duca<sup>1</sup>, A. Bertoli<sup>1,3</sup>, V. Malagnino<sup>4</sup>, P. Paba<sup>3</sup>, M. Ciotti<sup>3</sup>, I. Lenci<sup>5</sup>, S. Francioso<sup>5</sup>, C. Paquazzi<sup>6</sup>, M. Lichtner<sup>7</sup>, C. Mastroianni<sup>7</sup>, F. Santopaolo<sup>8</sup>, G. De Sanctis<sup>9</sup>, M. Marignani<sup>6</sup>, A. Pellicelli<sup>10</sup>, G. Galati<sup>11</sup>, A. Moretti<sup>12</sup>, G. Colucci<sup>13</sup>, K. Casinelli<sup>14</sup>, L. Caterini<sup>15</sup>, N. Iapadre<sup>16</sup>, G. Parruti<sup>17</sup>, I. Vecchiet<sup>18</sup>, M. Paoloni<sup>19</sup>, S. Grelli<sup>3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, L. Sarmati<sup>4</sup>, V. Svicher<sup>1</sup>

<sup>1</sup>Tor Vergata University, Department of Experimental Medicine, Rome, Italy, <sup>2</sup>Tor Vergata University, Department of Biology, Rome, Italy, <sup>3</sup>Tor Vergata University Hospital, Virology Unit, Rome, Italy, <sup>4</sup>Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, <sup>5</sup>Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, <sup>6</sup>S.Andrea Hospital, Rome, Italy, <sup>7</sup>La Sapienza University, Rome, Italy, <sup>8</sup>Internal Medicine and Gastroenterology-Hepatology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>9</sup>"Umberto I" University Hospital, Rome, Italy, <sup>10</sup>Liver and Transplant Unit, San Camillo Forlanini Hospital, Rome, Italy, <sup>11</sup>Internal Medicine and Hepatology Unit, University Campus Bio-Medico, Rome, Italy, <sup>12</sup>San Filippo Neri Hospital, Rome, Italy, <sup>13</sup>Nuovo Regina Margherita Hospital, Spaziani Hospital, Rome, Italy, <sup>14</sup>Infectious Disease Unit, Spaziani Hospital, Frosinone, Italy, <sup>15</sup>Belcolle Hospital, Viterbo, Italy, <sup>16</sup>San Salvatore Hospital, L'Aquila, Italy, <sup>17</sup>Pescara General Hospital, Pescara, Italy, <sup>18</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, <sup>19</sup>Infectious Diseases Unit, Avezzano General Hospital, Avezzano, Italy

**OC 150 15.46-15.56 Prevalence and outcome of Hepatitis Delta virus (HDV) infection among Persons Living with HIV (PLWH) in Italy: the Delta-Icna study**

M. Puoti<sup>1,2</sup>, R. Salpini<sup>3</sup>, A. Tavelli<sup>4</sup>, L. Piermatteo<sup>3</sup>, S. D'Anna<sup>3</sup>, S. Carrara<sup>5</sup>, V. Malagnino<sup>6</sup>, V. Mazzotta<sup>7</sup>, G. Brancaccio<sup>8</sup>, G.B. Gaeta<sup>9</sup>, G. Marchetti<sup>10,11</sup>, E. Rosselli Del Turco<sup>12,13</sup>, C.F. Perno<sup>14</sup>, V. Svicher<sup>3</sup>, A. d'Arminio Monforte<sup>4</sup> for Icna Foundation Study Group

<sup>1</sup>University of Milano Bicocca, School of Medicine, Milan, Italy, <sup>2</sup>ASST GOM Niguarda, Infectious Diseases, Italy, <sup>3</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Italy, <sup>4</sup>Icna Foundation, Milano, Italy, <sup>5</sup>INMI, Unity of Microbiology and Biobank, Roma, Italy, <sup>6</sup>University of Rome Tor Vergata, Department of Medicine of Systems, Clinical Infectious Diseases, Rome, Italy, <sup>7</sup>INMI, Clinical and Research Infectious Diseases Department, Rome, Italy, <sup>8</sup>University of Padua, Department of Molecular Medicine, Padua, Italy, <sup>9</sup>University L. Vanvitelli, Infectious Diseases Unit, Naples, Italy, <sup>10</sup>ASST Santi Paolo e Carlo, Clinic of Infectious Diseases, Milano, Italy, <sup>11</sup>University of Milano, Department of Health Sciences, Milano, Italy, <sup>12</sup>Alma Mater Studiorum Bologna University, Department of Medical and Surgical Sciences, Bologna, Italy, <sup>13</sup>IRCCS Azienda Ospedaliero Universitaria S. Orsola- Malpighi, Infectious Diseases Unit, Bologna, Italy, <sup>14</sup>Bambino Gesù Pediatric Hospital, Rome, Italy

15.58-16.05 **Conclusion**

G. Lapadula, Monza; T.A. Santantonio, Foggia


**SPECIAL SESSION 16:10-16:30**  
**ICAR 2023 AWARDS**  
**and Closing remarks**
**AUDITORIUM ALDO MORO**

Chairs: F. Ceccherini Silberstein (Roma), M. Formisano (Taranto), S. Lo Caputo (Foggia), F. Maggiolo (Bergamo), C.M. Mastroianni (Roma), A. Saracino (Bari)

ICAR and SIMIT support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.


**ICAR 2023 Scientific Committee Awards: Three prizes for the best Clinical, Basic science and Social sciences Abstracts**

F. Maggiolo, Bergamo


**SIMIT Special Awards: Five prizes for the best Oral Communications in: Clinical HIV, Clinical Hepatitis Virus, Clinical SARS-CoV-2, Virology and Immunopathogenesis, Epidemiology and Social sciences**

C.M. Mastroianni, Roma

**Closing remarks**

F. Ceccherini Silberstein, Roma; M. Formisano, Taranto; S. Lo Caputo, Foggia; A. Saracino, Bari



15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



DIGITAL  
**POSTER**  
**EXHIBITION**

**Antiretroviral therapy**

- P 1 HIV-1 RNA levels in semen of people on “short-cycle” antiretroviral therapy**  
M. Lanzafame<sup>1</sup>, A. Delama<sup>1</sup>, D. Fait<sup>1</sup>, L. Collini<sup>2</sup>, S. Vento<sup>3</sup>  
<sup>1</sup>Unit of Infectious Diseases, Ospedale Santa Chiara, Trento, Italy, <sup>2</sup>Unit of Microbiology, Ospedale Santa Chiara, Trento, Italy, <sup>3</sup>Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia
- P 2 Efficacy and safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in people living with HIV-1 aged over 65 years**  
L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, D. Riccucci<sup>1</sup>, C. Rigamonti<sup>1</sup>, D. Marzolla<sup>1</sup>, I. Bon<sup>2</sup>, P. Viale<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, <sup>2</sup>Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy
- P 3 Real-world data on the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): 24-month results of the Italian BICStaR cohort**  
A. Saracino<sup>1</sup>, S. Rusconi<sup>2</sup>, D. Canetti<sup>3</sup>, V. Esposito<sup>4</sup>, E. Quiros-Roldan<sup>5</sup>, B. Candelaes<sup>6</sup>, G. Marchetti<sup>7</sup>, M. Andreoni<sup>8</sup>, A. Antinori<sup>9</sup>, A. Marongiu<sup>10</sup>, L. Albini<sup>11</sup>, R. Caldera<sup>11</sup>, G. Forcina<sup>11</sup>, G. Di Perri<sup>12</sup>  
<sup>1</sup>Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Italy, <sup>2</sup>Infectious Diseases Unit, ASST Ovest Milanese - University of Milan, Milan, Italy, <sup>3</sup>Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli, Naples, Italy, <sup>5</sup>Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Italy, <sup>6</sup>Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, <sup>7</sup>Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, “ASST Santi Paolo e Carlo”, Milan, Italy, <sup>8</sup>Infectious Diseases Clinic, University Hospital “Tor Vergata”, Rome, Italy, <sup>9</sup>HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, <sup>10</sup>Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK, <sup>11</sup>Gilead Sciences Srl, Milan, Italy, <sup>12</sup>Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy
- P 4 Probability of starting 2DR vs 3DR regimens in ART-naïve and ART-experienced PLWH before and after the COVID-19 pandemic**  
A. Vergori<sup>1</sup>, N. Gianotti<sup>2</sup>, A. Tavelli<sup>3</sup>, C. Tincati<sup>4</sup>, A. Giacomelli<sup>5</sup>, E. Matteini<sup>6</sup>, G. Lapadula<sup>7</sup>, F. Bai<sup>8</sup>, L. Sarmati<sup>9</sup>, A. d’Arminio Monforte<sup>3</sup>, A. Antinori<sup>1</sup>, A. Cozzi-Leperi<sup>9</sup>, on behalf of the ICONA Foundation Study Group  
<sup>1</sup>HIV/AIDS Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, Roma, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Icona Foundation, Milano, Italy, <sup>4</sup>Clinica di Malattie Infettive, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo-Presidio Ospedaliero San Paolo, Università degli Studi di Milano, Milano, Italy, <sup>5</sup>III Infectious Disease Unit, ASST-Fatebenefratelli Sacco, Milano, Italy, <sup>6</sup>Dipartimento di Sicurezza e Bioetica - Università Cattolica del Sacro Cuore, Roma, Italy, <sup>7</sup>IRCCS Fondazione San Gerardo, Monza, Università di Milano Bicocca, Milano, Italy, <sup>8</sup>Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Roma, Italy, <sup>9</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK
- P 5 Physical activity, oxidative stress and antiretroviral therapy in people living with HIV: a multidisciplinary pilot study in people switching to double therapy**  
J. Cusato<sup>1</sup>, A. Mulasso<sup>2</sup>, M. Ferrara<sup>3</sup>, A. Palermi<sup>1</sup>, A. Manca<sup>1</sup>, M. Antonucci<sup>3</sup>, G. Bianco<sup>1</sup>, D. Maiese<sup>1</sup>, F. Chiara<sup>4</sup>, J. Mula<sup>1</sup>, E.D. De Vivo<sup>1</sup>, M.G. Maddalone<sup>1</sup>, G. Accardo<sup>5</sup>, M.C. Tettoni<sup>3</sup>, S. Cuomo<sup>2</sup>, L. Marinaro<sup>3</sup>, S. Bonora<sup>2</sup>, G. Di Perri<sup>3</sup>, C. Lupo<sup>2</sup>, A. Rainoldi<sup>2</sup>, A. D’Avolio<sup>1</sup>  
<sup>1</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>Department of Medical Sciences, NeuroMuscularFunction | Research Group, University of Turin, Italy, <sup>3</sup>ASL Città di Torino, Amedeo di Savoia Hospital, Turin, Italy, <sup>4</sup>Laboratory of Clinical Pharmacology S.Luigi A.O.U., Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole, Orbassano, Turin, Italy, <sup>5</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- P 6 Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a pregnant woman with drug resistant HIV-1 infection: A case report**  
A. Giaccone<sup>1</sup>, A. Maddaloni<sup>1</sup>, P. Bellopede<sup>1</sup>, M. Talamo<sup>1</sup>, S. Parente<sup>1</sup>, A. Gallicchio<sup>1</sup>, S. Susini<sup>2</sup>, I. Gentile<sup>2</sup>, A. Franco<sup>1</sup>  
<sup>1</sup>AORN Ospedali dei Colli, Ospedale D. Cotugno, U.O.C. Malattie Infettive dell’Età Geriatrica, Napoli, <sup>2</sup>AOU Federico II, U.O.C. Malattie infettive, Napoli
- P 7 To enDORse Doravirine use in antiretroviral treatment?**  
C. Papalini<sup>1</sup>, B. Canovari<sup>2</sup>, F. Lagi<sup>3</sup>, G. Formica<sup>4</sup>, K. Sterrantino<sup>4</sup>, F. Barchiesi<sup>2</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Clinica Malattie Infettive, Ospedale Santa Maria della Misericordia, Università degli studi di Perugia, Perugia, <sup>2</sup>Clinica Malattie Infettive, Ospedale San Salvatore, Ospedali Riuniti Marche Nord, Pesaro, <sup>3</sup>SOD Malattie Infettive e tropicali, AOU Careggi, Firenze, <sup>4</sup>Dipartimento medicina sperimentale e clinica, Università degli studi di Firenze, Firenze
- P 8 Effectiveness of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced patients**  
S. Tordi, G. De Socio, D. Altobelli, S. Benedetti, A. Gidari, A. Zoffoli, D. Francisci  
Clinica di Malattie Infettive, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia
- P 9 Immuno-virological stability in patient with Multi-drug-Resistant HIV and history of poliallergy and intolerance to several antiretroviral drugs**  
R. Riccardi, D. Riccucci, L. Calza  
Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy IRCCS S.Orsola Hospital
- P 10 Long-acting cabotegravir-rilpivirine in highly experienced PLWHIV: the role of Directly Observed Treatment (DOT) in overcoming barriers to adherence**  
A. Ciccullo<sup>1</sup>, M. Petrucci<sup>2</sup>, F. Onorati<sup>2</sup>, V. Iannone<sup>3</sup>, A. Borghetti<sup>2</sup>, E. Visconti<sup>2</sup>, S. Di Giambenedetto<sup>2,3</sup>  
<sup>1</sup>Infectious Diseases Unit, San Salvatore Hospital, L’Aquila, <sup>2</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, <sup>3</sup>Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Infectious Diseases Unit, Roma
- P 11 Satisfaction, clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in a real-life cohort of people living with HIV**  
M. Mazzitelli, L. Sasset, D. Leoni, S. Gardin, E. Agostini, A.M. Cattelan  
Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy
- P 12 Clinical and economic evaluation of dual therapies in cART-experienced HIV positive patients**  
S. Palantone<sup>1</sup>, M. Allegrini<sup>2</sup>, T. Calamia<sup>1</sup>, S. Minniti<sup>2</sup>  
<sup>1</sup>Pharmacy, P.O. Perrino (ASL BR), Brindisi, Italy, <sup>2</sup>Infectious Diseases Unit, P.O. Perrino (ASL BR), Brindisi, Italy
- P 13 HIV-DNA trend in ART-experienced PLWH switching to injectable long-acting antiretroviral therapies with CAB+RPV: 12-week results in a real-life setting**  
F. Lombardi<sup>1</sup>, F. Onorati<sup>1</sup>, M. Petrucci<sup>1</sup>, A. Sanfilippo<sup>2</sup>, V. Iannone<sup>2</sup>, D. Farinacci<sup>2</sup>, A. Dusina<sup>1</sup>, A. Carbone<sup>2</sup>, A. Borghetti<sup>1</sup>, A. Ciccullo<sup>3</sup>, S. Di Giambenedetto<sup>1,2</sup>  
<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive, <sup>2</sup>Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive, <sup>3</sup>Unità di Malattie infettive, Ospedale San Salvatore, L’Aquila, Italia
- P 14 Efficacy and safety of a switch to doravirine and dolutegravir combination in HIV-1-infected patients in a single Italian center: a cohort data analysis**  
F. Lagi<sup>1</sup>, G. Formica<sup>2</sup>, F. Ducci<sup>2</sup>, S.T. Kiro<sup>2</sup>, M. Pozzi<sup>1</sup>, M. Meli<sup>1</sup>, M. Pittorru<sup>3</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>2</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, <sup>2</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, <sup>3</sup>Dipartimento del Farmaco - Azienda ASL Toscana Centro
- P 15 Comparing efficacy, safety, and tolerability of 3TC/DTG, TAF/3TC/DOR, and TAF/FTC/BIC in switch strategy of virologically suppressed HIV-infected people**  
D. Farinacci<sup>1</sup>, A. Ciccullo<sup>2</sup>, A. D’angelillo<sup>1,3</sup>, V. Iannone<sup>3</sup>, A. Carbone<sup>3</sup>, E. Visconti<sup>4</sup>, G. Baldin<sup>4</sup>, A. Borghetti<sup>4</sup>, S. Di Giambenedetto<sup>3,4</sup>  
<sup>1</sup>UOC Medicina Protetta-Malattie Infettive, ASL Viterbo, Italy, <sup>2</sup>Ospedale San Sebastiano, L’Aquila, Italy, <sup>3</sup>Università Cattolica del Sacro Cuore, Roma, Italy, <sup>4</sup>Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Roma, Italy

- P 16 Risk of failure in dual therapy versus triple therapy in viro-suppressed HIV patients switched to CAB or DTV dual regimens: a systematic review and meta-analysis**  
V. Zollo<sup>1</sup>, S. Martini<sup>1</sup>, M. Pisaturo<sup>1</sup>, L. Onorato<sup>1</sup>, A. Russo<sup>1</sup>, M.G. Palamone<sup>1</sup>, M. Russo<sup>1</sup>, P. Maggi<sup>1,2</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano, Caserta, Italy
- P 17 Significant CD4+ T-cell increase in Women Living With HIV (WLWH) switching to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): multi-center real-world retrospective longitudinal study**  
M. Ceccarelli<sup>1,2,3</sup>, A. De Vito<sup>4</sup>, G. Pantò<sup>5</sup>, A. Albanese<sup>6</sup>, G.F. Pellicano<sup>7,8</sup>, M.C. Frasca<sup>9</sup>, M.S. Paternò Raddusa<sup>2,10</sup>, A. Colpani<sup>4</sup>, A.E. Campanella<sup>5,10</sup>, L. Santoro<sup>6,10</sup>, Y. Rusotto<sup>10,8</sup>, L. Todaro<sup>9,10</sup>, E. Venanzi Rullo<sup>8,10</sup>, M. Coco<sup>5,10</sup>, S.A. Sofia<sup>5</sup>, C. Micali<sup>3,8</sup>, A. Marino<sup>1,2,11</sup>, C. Iacobello<sup>5</sup>, A. Montineri<sup>2</sup>, B.S. Cacopardo<sup>2,1</sup>, G. Madeddu<sup>4</sup>, B.M. Ceslasia<sup>2</sup>, G. Nunnari<sup>2,1</sup>  
<sup>1</sup>University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy, <sup>2</sup>ARNAS "Garibaldi", "Nesima" Hospital, Unit of Infectious Diseases, Catania, Italy, <sup>3</sup>University of Messina, Department of Biomedical and Dental Sciences and of Morphological and Functional Imaging, Messina, Italy, <sup>4</sup>University of Sassari, Medical, Surgical, and Experimental Sciences, Sassari, Italy, <sup>5</sup>AOE "Cannizzaro", Unit of Infectious Diseases, Catania, Italy, <sup>6</sup>"Papardo" Hospital, Unit of Infectious Diseases, Messina, Italy, <sup>7</sup>University of Messina, "G. Barresi" Department of Human and Pediatric Pathology, Messina, Italy, <sup>8</sup>"G. Martino" University Hospital, Unit of Infectious Diseases, Messina, Italy, <sup>9</sup>"G. Rodolico - S. Marco" University Hospital, Unit of Infectious Diseases, Catania, Italy, <sup>10</sup>University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, <sup>11</sup>University of Catania, Department of Biomedical and Biotechnological Sciences, Catania, Italy
- P 18 Virological rebound and the use of dietary supplements in people living with HIV: results of a survey**  
S. Esperiti, M. Del Monte, B. Fontana, I. Baldisserotto, A. Dessilani, A. Cervo, V. Borghi, C. Mussini  
Malattie Infettive, Azienda Ospedaliera-Universitaria di Modena, Università di Modena e Reggio Emilia Modena
- P 19 INSTI resistance mutations emerging while on DTG/3TC dual therapy**  
F. Conti, V. Morena, C. Molteni, L. Bradanini, A. Pandolfo, S. Pontiggia, S. Picconi  
Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco (LC), Italy
- P 20 Real-life experience of doravirine-based regimens in a cohort living with HIV**  
N. Braccialarghe<sup>1</sup>, L.V. Rindi<sup>1</sup>, L. Ansaldo<sup>1</sup>, D. Zaçe<sup>1</sup>, M. Compagno<sup>2</sup>, E. Teti<sup>2</sup>, A.M. Geretti<sup>1,2,3</sup>, L. Sarmati<sup>1,2</sup>  
<sup>1</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>School of Immunity and Microbial Sciences, King's College London, London, United Kingdom
- P 21 Efficacy and safety of dolutegravir/lamivudine in a patient with HIV following sleeve gastrectomy**  
G. De Simone<sup>1</sup>, M. Tempestilli<sup>3</sup>, E. Teti<sup>1</sup>, M. Compagno<sup>1</sup>, L. Sarmati<sup>1</sup>, A.M. Geretti<sup>2</sup>  
<sup>1</sup>Infectious Diseases Unit, Tor Vergata Hospital, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>3</sup>Laboratory of Cellular Immunology and Clinical Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
- P 22 A retrospective cohort analysis to evaluate the barriers and facilitators encountered by HIV-positive patients undergoing HAART regimen and clinical outcomes**  
D. Cicetti, R. Caprara, G. Pierfelice, L. Appolloni, G. Pensalfine, S. Vitale, A. Stancari  
IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Clinical Pharmacy, Bologna
- P 23 Fostemsavir, a new antiretroviral molecule for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: data from clinical practice**  
P.F. Salvo<sup>1</sup>, R. Jo Steiner<sup>1</sup>, A. Sanfilippo<sup>1</sup>, G. Baladin<sup>2</sup>, E. Visconti<sup>2</sup>, A. D'angelillo<sup>3</sup>, A. Ciccullo<sup>4</sup>, F. Raffaelli<sup>2</sup>, A. Dusina<sup>2</sup>, S. Di Giambenedetto<sup>1,2</sup>, A. Borghetti<sup>2</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, <sup>3</sup>UOC Medicina Protetta - ASL Viterbo, Viterbo, <sup>4</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila
- P 24 Experience with the use of prolonged-release injectable CAB/RPV in outpatients**  
N. Bobbio<sup>1</sup>, E. Blasi Vacca<sup>1</sup>, S. Boni<sup>1</sup>, F. Del Puente<sup>1</sup>, M. Feasi<sup>1</sup>, A. Parisini<sup>1</sup>, R. Prinapori<sup>1</sup>, D. Fiorellino<sup>2</sup>, S. Puppo<sup>2</sup>, A. Zunino<sup>3</sup>, C. Fraguaglia<sup>3</sup>, F. Filaurio<sup>3</sup>, B. Mainero<sup>3</sup>, E. Pontali<sup>1</sup>  
<sup>1</sup>MD Department of Infectious Diseases, E.E.O.O. Galliera, Genoa, <sup>2</sup>Professional Nurse Department of Infectious Diseases, E.E.O.O. Galliera, Genoa, <sup>3</sup>Pharmacists of the Hospital Pharmacy, E.E.O.O. Galliera, Genoa
- P 25 Efficacy, tolerability, safety and adherence to dolutegravir/lamivudine as first-line regimen in the real life setting**  
M. Quaranta<sup>1</sup>, M. Ferrara<sup>1</sup>, M.C. Ottino<sup>1</sup>, A. Serra<sup>1</sup>, V. Maccario<sup>1</sup>, E. Drappero<sup>1</sup>, G. Orofino<sup>2</sup>, O. Bargiacchi<sup>3</sup>, P. Bigliano<sup>4</sup>, D. Vitullo<sup>5</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>, S. Bonora<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences Infectious Diseases, University of Turin, Torino, <sup>2</sup>Amedeo di Savoia Hospital Divisione A, Turin, Italy, <sup>3</sup>Infectious Diseases Unit, University Hospital Maggiore della Carità, Novara, Italy, <sup>4</sup>Unit of Infectious Diseases, Cardinal Massaia Hospital, Asti, Italy, <sup>5</sup>Division of Infectious and Tropical Diseases, Department of S. Croce e Carle Hospital, Cuneo, Italy
- P 26 Acceptability of long-acting injectable antiretroviral therapy (LAI-ART) in people living with HIV**  
S. Arsuffi<sup>1</sup>, C. Mazzi<sup>1</sup>, S. Calza<sup>2</sup>, I. Izzo<sup>1</sup>, I. El Hamad<sup>1</sup>, R. Fazio<sup>4</sup>, G. Piccardi<sup>4</sup>, C. Anzoni<sup>1</sup>, M. Migliorati<sup>1</sup>, D. Laurenda<sup>1</sup>, I. Polesini<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, <sup>2</sup>Università degli Studi di Brescia, <sup>3</sup>Unità di Biostatistica e Biomatematica e Unità di Bioinformatica, Dipartimento di Medicina Molecolare e Traslationale, Università degli Studi di Brescia, <sup>4</sup>Unità Operativa Farmacia Aziendale, ASST Spedali Civili di Brescia
- P 27 Will Lenacapavir save us? Compassionate use in heavily treatment-experienced patients with multi-drug resistant HIV infection: a narrative description of the Italian experience**  
M.C. Ottino<sup>1</sup>, G. Orofino<sup>1</sup>, A. Soria<sup>2</sup>, A. Ranzani<sup>2</sup>, M. Feasi<sup>3</sup>, G. De Socio<sup>4</sup>, G. Lapadula<sup>5</sup>, E. Teti<sup>6</sup>, S. Martini<sup>7</sup>  
<sup>1</sup>Osp. Amedeo di Savoia, Torino, <sup>2</sup>IRCCS Fondazione San Gerardo dei Tintori, Monza, <sup>3</sup>EO Ospedali Galliera, Genova, <sup>4</sup>AO di Perugia, <sup>5</sup>Università di Milano, Bicocca, <sup>6</sup>Policlinico Tor Vergata, Roma, <sup>7</sup>Università degli studi della Campania, Luigi Vanvitelli
- P 28 Real Life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine: new era of ART**  
S. Spampinato<sup>1</sup>, A.G. Saia<sup>1</sup>, Y. Rusotto<sup>1</sup>, C. Micali<sup>1</sup>, M. Ceccarelli<sup>2</sup>, E. Venanzi Rullo<sup>1</sup>, G.F. Pellicano<sup>3</sup>, G. Nunnari<sup>2</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Hospital, Catania, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Human and Pediatric Pathology "Gaetano Barresi", University of Messina, Messina, Italy
- P 29 Bicitegravir versus Dolutegravir-based regimen in the setting of Rapid ART Initiation: 48-week analysis in a one clinical center**  
A. Cervo, V. Borghi, M. Menozzi, M. Digaetano, M.D. Di Trapani, I. Baldisserotto, G. Cuomo, C. Mussini  
Infectious Diseases Unit, Hospital University of Modena
- P 30 Outcome of DRV/cobicistat-based regimens in HIV-infected people who experienced virological failure**  
F. Alberton<sup>1,2</sup>, L. Galli<sup>1</sup>, R. Lolatto<sup>1</sup>, C. Candela<sup>1,2</sup>, N. Gianotti<sup>1</sup>, D. Canetti<sup>1</sup>, M. Chiurlo<sup>1,2</sup>, M. Ranzenigo<sup>1,2</sup>, M. Strano<sup>1,2</sup>, A. Uglietti<sup>3</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Infectious Disease, IRCCS San Raffaele Scientific Institute, Milano, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milano, Italy, <sup>3</sup>Medical Affairs, Janssen-Cilag Italy
- P 31 The impact of Doravirine on lipid metabolism: a real-life study**  
G. Valentini, M. Trizzino, L. Pipitò, M. Alfonso, A. Mancuso, A. Cascio  
Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
- P 32 Cardiovascular risk and ARV: an observational study of PLWH with PI based regimen versus INSTI and NNRTI based regimens**  
N. Leoni, A. Leonardi, S. Perra, L. Maitta, M.F. Nurchi, S. Bergamin, M. Buffa, G. Caligaris, G. Sanna, F. Cabras, A. Bolliri, M. Garau, G. Angioni  
UOC Malattie Infettive e Tropicali, SS Trinità, Cagliari

- P 33 Long-acting injectable CAB/RPV vs DTG/RPV: two sides of similar two-drugs regimens**  
 C. Bartalucci<sup>1,2</sup>, F. Baldi<sup>1,2</sup>, E. Ricci<sup>3</sup>, G. Orofino<sup>4</sup>, B. Menzaghi<sup>5</sup>, N. Squillace<sup>6</sup>, F. Vichi<sup>7</sup>, G.F. Pellicanò<sup>8</sup>, S. Ferrara<sup>9</sup>, E. Sarchi<sup>10</sup>, E. Pontali<sup>11</sup>, G.V. De Socio<sup>12</sup>, G. Cenderello<sup>13</sup>, O. Bargiacchi<sup>14</sup>, M.A. Carleo<sup>15</sup>, F. Lagi<sup>16</sup>, S. Piconi<sup>17</sup>, S. Martini<sup>18</sup>, B.M. Celesia<sup>19</sup>, A. Cascio<sup>20</sup>, R. Gulminetti<sup>21</sup>, G. Madeddu<sup>22</sup>, P. Bonfanti<sup>23</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>DISSAL - University of Genova - Genoa, Italy, <sup>2</sup>IRCCS Ospedale Policlinico San Martino - Genoa, Italy, <sup>3</sup>Fondazione Asia Onlus, Buccinasco (MI), <sup>4</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, <sup>5</sup>Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), Italy, <sup>6</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>7</sup>SOC 1 USL CENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, <sup>8</sup>Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, <sup>9</sup>Malattie Infettive Univ. AOU Policlinico Foggia, <sup>10</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>11</sup>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, <sup>12</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, <sup>13</sup>SC Malattie Infettive, ASL1 Imperiese, Sanremo, Italy, <sup>14</sup>Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, <sup>15</sup>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, <sup>16</sup>Infectious and Tropical Disease Unit, AOU Careggi, Florence, Italy, <sup>17</sup>Infectious Diseases, Azienda Ospedaliera di Lecco, Lecco, Italy, <sup>18</sup>UOC Malattie Infettive - Università degli studi della Campania, Luigi Vanvitelli, <sup>19</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, <sup>20</sup>Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, <sup>21</sup>Infectious Diseases Unit, Department of Medical Science and Infectious Diseases - Fondazione IRCCS Policlinico San Matteo - University of Pavia - Italy, <sup>22</sup>Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, <sup>23</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy
- P 34 Dual therapy vs triple therapy in experienced PLWH: a multicentre one-year long observational study**  
 Y. Rusotto<sup>1</sup>, A. G. Saia<sup>1</sup>, E.V. Rullo<sup>1</sup>, G. F. Pellicanò<sup>2</sup>, G. Nunnari<sup>1,3</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>2</sup>Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", University of Messina, Messina, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Nesima Hospital, University of Catania, Catania, Italy
- P 35 Safe switch to dual therapy in HIV vertically transmitted young patients**  
 G. Meraviglia<sup>1</sup>, C. Russo Artimagnella<sup>2</sup>, A. Sala<sup>1</sup>, L. Taramasso<sup>2</sup>, S. Rusconi<sup>3</sup>, A. Di Biagio<sup>2</sup>, V. Giacometti<sup>1</sup>  
<sup>1</sup>Pediatric Infectious Diseases Unit, Department of Pediatrics, ASST Fatebenefratelli-Sacco, Luigi Sacco Hospital, Università degli Studi di Milano, Italy, <sup>2</sup>Infectious Diseases Unit, Department of Internal Medicine, IRCCS Policlinico San Martino Hospital, Genoa, Italy, <sup>3</sup>Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital and DIBIC "Luigi Sacco", Università degli Studi di Milano, Italy
- P 36 PWH pioneers of cabotegravir and rilpivirine long-acting therapy in SCOLTA: who are they?**  
 C. Bartalucci<sup>1,2</sup>, F. Baldi<sup>1,2</sup>, E. Ricci<sup>3</sup>, G. Orofino<sup>4</sup>, B. Menzaghi<sup>5</sup>, S. Ferrara<sup>6</sup>, G.F. Pellicanò<sup>7</sup>, N. Squillace<sup>8</sup>, E. Sarchi<sup>9</sup>, E. Pontali<sup>10</sup>, G. Cenderello<sup>11</sup>, O. Bargiacchi<sup>12</sup>, F. Vichi<sup>13</sup>, M.A. Carleo<sup>14</sup>, A. Cascio<sup>15</sup>, G.V. De Socio<sup>16</sup>, P. Bonfanti<sup>17</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>DISSAL - University of Genova - Genoa, Italy, <sup>2</sup>IRCCS Ospedale Policlinico San Martino - Genoa, Italy, <sup>3</sup>Fondazione ASIA Onlus, Buccinasco (MI), <sup>4</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, <sup>5</sup>Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), Italy, <sup>6</sup>S.C. Malattie Infettive Universitarie AOU OO.RR. Foggia, <sup>7</sup>Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy, <sup>8</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>9</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>10</sup>Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, <sup>11</sup>SC Malattie Infettive, ASL1 Imperiese, Sanremo, Italy, <sup>12</sup>Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy, <sup>13</sup>SOC 1 USL CENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, <sup>14</sup>Infectious diseases and gender medicine Unit - PO Cotugno, AO dei Colli, Napoli, <sup>15</sup>Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy, <sup>16</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, <sup>17</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy
- P 37 CD4 and CD4/CD8 ratio gain in PLWH treated with fostemsavir: results from the PRESTIGIO Registry**  
 R. Papaioannu Borjesson<sup>1</sup>, L. Galli<sup>2</sup>, R. Gagliardini<sup>3</sup>, M. Feasi<sup>4</sup>, M. Ferrara<sup>5</sup>, S. di Giambenedetto<sup>6,7</sup>, F. Lagi<sup>8</sup>, G. Marchetti<sup>9</sup>, M. Malena<sup>10</sup>, A. Cervo<sup>11</sup>, A. M. Cattelan<sup>12</sup>, F. Maggiolo<sup>13</sup>, M. Fabbiani<sup>14</sup>, V. Spagnuolo<sup>2</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, <sup>3</sup>National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, <sup>4</sup>Ente Ospedaliero Ospedali Galliera, Genova, <sup>5</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, <sup>6</sup>Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, <sup>7</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, <sup>8</sup>Department of Clinical and Experimental Medicine, University of Florence, <sup>9</sup>Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, <sup>10</sup>Infectious Diseases Unit, AULSS9 Scaligera, Verona, <sup>11</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, <sup>12</sup>Azienda Ospedale-Università Padova, <sup>13</sup>Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, <sup>14</sup>Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena
- P 38 Clinical Trials versus Real-Life: Similarities and Differences of patients receiving LA CAB/RPV in a large clinical centre**  
 M. Piscaglia<sup>1,4</sup>, D. Moschese<sup>1</sup>, G. Pozza<sup>2,4</sup>, A. Giacomelli<sup>2</sup>, A. Ridolfo<sup>2</sup>, F. Caruso<sup>3,4</sup>, F. Petri<sup>3,4</sup>, L. Galli<sup>3,4</sup>, C. Atzori<sup>3</sup>, P.R. Meraviglia<sup>3</sup>, A.F. Capetti<sup>1</sup>, S. Antinori<sup>2,4</sup>, A. Gori<sup>3,4</sup>, G. Rizzardini<sup>1</sup>, M.V. Cossu  
<sup>1</sup>Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>3</sup>II Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>4</sup>University of Milano, Milan, Italy
- P 39 "Test and treat strategy": evaluation data from a multicenter Italian cohort**  
 A. Carbone<sup>1</sup>, V. Iannone<sup>1</sup>, L. Oreni<sup>2</sup>, P. Fusco<sup>3</sup>, M. Fabbiani<sup>4</sup>, V. Borghi<sup>5</sup>, A. Giacomelli<sup>2</sup>, S. Antinori<sup>2</sup>, C. Mussini<sup>5</sup>, C. Torti<sup>3</sup>, M. Tumbarello<sup>4</sup>, S. Di Giambenedetto<sup>1,6</sup>, G. Baldin<sup>6</sup>  
<sup>1</sup>Istituto di Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, <sup>3</sup>Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, <sup>5</sup>Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali, Modena, <sup>6</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma
- P 40 Antiretroviral therapy is associated with Sexual Dysfunction and paresthesias**  
 V. Vola, E. Gentilini Cacciola, P. Vassalini, A. Lazzaro, G. d'Ettore, C.M. Mastroianni  
 Policlinico Umberto I, Università La Sapienza, Roma
- P 41 Rescue therapy with Ibalizumab in HIV MDR patient**  
 S. Martini<sup>1</sup>, N. Cuomo<sup>2</sup>, M. Pisaturo<sup>1</sup>, A. Cascone<sup>1</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>UOC Malattie infettive Università degli studi della Campania Luigi Vanvitelli, Napoli, <sup>2</sup>AORN dei COLLI, Unità di Malattie Infettive ospedale Cotugno, Napoli
- P 42 Analysis of determinants of c-ART switch strategies in PLWH in post-COVID-19 era: results from a real-life retrospective study from a tertiary University center in Italy**  
 E. Zappulo, N. Esposito, A. Truono, M.E. Forte, G. Di Filippo, M. Cotugno, S. Mercinelli, I. Gentile  
 Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy
- P 43 Immune reconstitution and safe metabolic profile after the switch to bictegravir/emtricitabine/tenofovir alafenamide fumarate among virologically controlled PLWH: a 96 week update from BICTEL cohort**  
 J. Morcos<sup>1</sup>, A. Lazzaro<sup>1</sup>, D. Bianchini<sup>1</sup>, E. Gentilini Cacciola<sup>1</sup>, I. Mezzaroma<sup>2</sup>, M. Falciano<sup>1</sup>, C. Andreoni<sup>1</sup>, C. Fimiani<sup>1</sup>, L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, G. Bugani<sup>1</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, <sup>2</sup>Department of Translational and Precision Medicine; Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy



- P 44 CMV re-activation in patients on triple ART switching to B/F/TAF or DTG/3TC: a substudy of the DEBATE Trial**  
A. Cossarizza<sup>1</sup>, A. Cozzi-Leperi<sup>2</sup>, A. Paolini<sup>1</sup>, A. Neroni<sup>1</sup>, S. De Biasi<sup>1</sup>, M. Mattioli<sup>1</sup>, D. Lo Tartaro<sup>1</sup>, R. Borella<sup>1</sup>, L. Fidanza<sup>1</sup>, L. Gibellini<sup>1</sup>, E. Santacroce<sup>1</sup>, B. Beghetto<sup>3</sup>, E. Roncaglia<sup>3</sup>, G. Nardini<sup>3</sup>, J. Milic<sup>3</sup>, M. Menozzi<sup>4</sup>, G. Cuomo<sup>4</sup>, M. Di Gaetano<sup>4</sup>, G. Orlando<sup>4</sup>, M. Sarti<sup>5</sup>, M. Lichtner<sup>6</sup>, V. Borghi<sup>4</sup>, G. Guaraldi<sup>3,4</sup>, C. Mussini<sup>3,4</sup>  
<sup>1</sup>Chair of Pathology and Immunology, University of Modena and Reggio Emilia School of Medicine, Modena, Italy, <sup>2</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, <sup>3</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Italy, <sup>5</sup>Clinical Pathology Department, Virology Section, Azienda Ospedaliero-Universitaria Policlinico of Modena, Italy, <sup>6</sup>Clinic of Infectious Diseases, University La Sapienza, Rome, Italy
- Clinical HIV**
- P 45 Clinical/therapeutic correlates of anxiety and depression in people living with HIV**  
A. Calcagno<sup>1</sup>, M. Trunfo<sup>1</sup>, F. Portesani<sup>1</sup>, E. Vuaran<sup>1</sup>, D. Vai<sup>1</sup>, G. Guastamacchia<sup>2</sup>, M.C. Tettani<sup>1</sup>, M. Ferrara<sup>1</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Ospedale Amedeo di Savoia, Turin, Italy, <sup>2</sup>Unit Of Neurology, Ospedale Maria Vittoria, Turin, Italy
- P 46 HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG**  
V. Malagnino<sup>1,2</sup>, T. Mulas<sup>1</sup>, M. Basso<sup>4</sup>, Y. Abi Aad<sup>3</sup>, J.P. Vincensini<sup>3</sup>, M. Brucker<sup>3</sup>, G. Battagin<sup>6</sup>, E. Teti<sup>1</sup>, M. Iannetta<sup>1,2</sup>, S.G. Parisi<sup>4</sup>, K. Lacombe<sup>3,5</sup>, L. Sarmati<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Policlinico Tor Vergata of Rome, <sup>2</sup>Department of Medicine of Systems, Tor Vergata University of Rome, <sup>3</sup>GHU APHP. Sorbonne Université, Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France, <sup>4</sup>Dipartimento di Medicina Molecolare, Università degli Studi di Padova, <sup>5</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, <sup>6</sup>UOC Malattie Infettive, Ospedale di Vicenza
- P 47 Prevalence and risk factors for sleep disturbances in PLWH: preliminary results from an observational study**  
G. Bruno<sup>1</sup>, M. Giotta<sup>2</sup>, S. Perelli<sup>1</sup>, V. Spada<sup>3</sup>, M.A. Purgatorio<sup>1</sup>, N. Bartolomeo<sup>2</sup>, G.B. Buccoliero<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, San Giuseppe Moscati Hospital, Taranto, Azienda Sanitaria Locale Taranto, Italy, <sup>2</sup>Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Italy, <sup>3</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy
- P 48 Impact of SARS-CoV2 pandemic on immune, viral and metabolic status in an Umbrian PLWH cohort**  
D. Altobelli, C. Papalini, D. Francisci  
Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy
- P 49 Cerebrospinal fluid drain infection caused by pandrug-resistant Staphylococcus epidermidis treated with ceftaroline in combination with fosfomycin and vancomycin in a PLWHIV with AIDS-defining illness**  
E. Rando<sup>1</sup>, P. Del Giacomo<sup>2</sup>, G. Maiuro<sup>2</sup>, A. Dusina<sup>2</sup>, E. Matteini<sup>1</sup>, E. Magrini<sup>1</sup>, F. Sanmartini<sup>1</sup>, A. Carbone<sup>1</sup>, A. Cingolani<sup>2</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>2</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- P 50 A Case of Central Nervous System Infection Diagnosed as Frontotemporal Dementia**  
E. Staffilano, L. Carani, F. Vischia, D. Vai, D. Imperiale, G. Orofino, A. Calcagno, G. Calleri  
Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino
- P 51 Cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of virologically suppressed PLWHIV**  
A. Cicullo<sup>1</sup>, V. Iannone<sup>2</sup>, D. Farinacci<sup>3</sup>, R.J. Steiner<sup>2</sup>, F. Lombardi<sup>2</sup>, V. Massaroni<sup>2</sup>, V. Delle Donne<sup>2</sup>, G. Baldin<sup>4</sup>, A. Borghetti<sup>4</sup>, S. Di Giambenedetto<sup>2,4</sup>  
<sup>1</sup>UOC Malattie Infettive, Ospedale S. Salvatore, L'Aquila, Italia, <sup>2</sup>Università Cattolica del Sacro Cuore, <sup>3</sup>UOC Medicina Protetta - Malattie Infettive, ASL Viterbo, Italia, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico A. Gemelli IRCCS, Roma, Italia
- P 52 Aging and HIV: between gaps and perspectives**  
G. Guaraldi<sup>1,2,3</sup>, G. Rizzardini<sup>4</sup>, G. Marchetti<sup>5</sup>, A. Gori<sup>6,7</sup>, L. Broggonzoli<sup>8</sup>, J. Milic<sup>1,2</sup>, C. Falcinella<sup>5</sup>, P. Saltini<sup>9,7</sup>, R. Iardino<sup>8</sup>  
<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>4</sup>Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>5</sup>Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>6</sup>II Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>7</sup>Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy, <sup>8</sup>The Bridge Foundation (Fondazione The Bridge), Milano, Italy, <sup>9</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
- P 53 Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predictive of post-treatment control (PCT)**  
F. Sironi<sup>1</sup>, S. Dispinseri<sup>1</sup>, R. Chimienti<sup>1</sup>, R. Dell'Acqua<sup>2</sup>, S. Nozza<sup>2</sup>, A. Castagna<sup>2</sup>, G. Scarlatti<sup>1</sup>, M. Malnati<sup>1</sup>  
<sup>1</sup>Viral Evolution and Transmission Unit, DIBIT, IRCCS San Raffaele, Milan, Italy, <sup>2</sup>Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
- P 54 Viro-immunologic pre-treatment predictors of suboptimal viral suppression at 48 weeks of antiretroviral therapy**  
G. Bozzi<sup>1</sup>, P. Saltini<sup>1,3</sup>, M. Centazzo<sup>2</sup>, G.M. Butta<sup>2</sup>, A. Liparoti<sup>1,3</sup>, C. Bobbio<sup>1</sup>, A. Muscatello<sup>1</sup>, A. Gori<sup>1,3</sup>, L. Manganaro<sup>2,3</sup>, A. Bandera<sup>1,3</sup>  
<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milan, Italy, <sup>2</sup>Virology Unit, INGM-Istituto Nazionale di Genetica Molecolare - Milan, Italy, <sup>3</sup>University of Milan - Milan, Italy
- P 55 Cryptococcal meningitis as the first clinical presentation of HIV infection**  
C. Frisenda, C. Febo, A. Zarroli, G. Castrignanò, E. D'Arcangelo, S. Di Giovine, C. Ucciferri, K. Falasca, J. Vecchiet  
Clinica Malattie Infettive, Università "G. d'Annunzio" Chieti
- P 56 Prognostic factors of CD4 recovery after 12 months of treatment in a cohort of HIV-1 positive patients**  
M.A. Carleo<sup>1</sup>, S. Martini<sup>2</sup>, A. Russo<sup>2,3</sup>, A. Cascone<sup>2</sup>, V. Rizzo<sup>1</sup>, A. Guida<sup>1</sup>, P. Rosario<sup>1</sup>, V. Zollo<sup>3</sup>, M. Di Lorenzo<sup>1</sup>, M. Pisaturo<sup>2,3</sup>, V. Esposito<sup>1</sup>, N. Coppola<sup>2,3</sup>  
<sup>1</sup>Infectious Diseases and Gender Medicine Unit, PO Cotugno, AO dei Colli, Naples, <sup>2</sup>AOU Vanvitelli, Naples, <sup>3</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples
- P 57 Survival of HIV/HCV co-infected individuals received liver transplantation in the post-DAA era in Modena**  
A. Cervo<sup>1</sup>, G. Dolci<sup>1</sup>, E. Franceschini<sup>1</sup>, J. Milic<sup>2</sup>, F. Casari<sup>1</sup>, E. Ghidoni<sup>1</sup>, G.P. Guerrini<sup>3</sup>, N. De Maria<sup>4</sup>, B. Catellani<sup>2</sup>, P. Magistri<sup>3</sup>, F. Di Benedetto<sup>3</sup>, C. Mussini<sup>1,2</sup>, G. Guaraldi<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Clinic, University Hospital of Modena, Modena, <sup>2</sup>University of Modena and Reggio Emilia, Modena, <sup>3</sup>Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena, Modena, <sup>4</sup>Gastroenterology Unit, University Hospital of Modena, Modena
- P 58 Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort**  
P. Fusco<sup>1</sup>, P. Nasta<sup>2</sup>, E. Quiros-Roldan<sup>2</sup>, A. Tondinelli<sup>3</sup>, C. Costa<sup>4</sup>, C. Fornabaio<sup>5</sup>, N. Mazzini<sup>6</sup>, M. Prosperi<sup>7</sup>, C. Torti<sup>1</sup>, G. Carosi<sup>6</sup>  
<sup>1</sup>Infectious Diseases Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy, <sup>2</sup>University Division of Infectious and Tropical Diseases, University of Brescia and Brescia ASST Spedali Civili Hospital, Brescia, Italy, <sup>3</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>4</sup>Infectious Diseases Unit, S. Maria Annunziata Hospital, Florence, Italy, <sup>5</sup>Infectious Diseases Unit, Cremona ASST Hospital, Cremona, Italy, <sup>6</sup>M.I.S.I. Foundation, Brescia, Italy, <sup>7</sup>Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA

- P 59** **Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report**  
F. Lamanna<sup>1</sup>, R.A. Passerotto<sup>1</sup>, A. Carbone<sup>1</sup>, R.J. Steiner<sup>1</sup>, V. Iannone<sup>1</sup>, P.F. Salvo<sup>1</sup>, A. Ciccullo<sup>2</sup>, G. Baldin<sup>3</sup>, A. Borghetti<sup>3</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>2</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, <sup>3</sup>Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy
- P 60** **Tubercular rhombencephalitis and ocular syphilis, with possible central nervous system compartmentalization, in a newly diagnosed AIDS patient**  
M. Moccione, V. Barchi, D. Kontogiannis, G. Muratore, D. Zace, D. Benvenuto, A. Cekrezi, A. Imeneo, M.L. Giacalone, T. Mulas, L. Coppola, M. Iannetta, L. Campogiani, L. Sarmati  
Department of System Medicine, Infectious Diseases Unit, Tor Vergata University, Rome, Italy
- P 61** **Identikit of the HIV patient with acute pathology: epidemiology and clinical characteristics of HIV patients hospitalized in the last year in an Italian University Hospital**  
P. Mantini<sup>1</sup>, S. Mazzanti<sup>1,2</sup>, V. Barocci<sup>1</sup>, B. Candelaresi<sup>1,2</sup>, S. Olivieri<sup>1,2</sup>, F. Pallotta<sup>1,2</sup>, I. Luchetti<sup>1,2</sup>, G. Cesaretti<sup>1,2</sup>, F. Ginevri<sup>1,2</sup>, A. Ivanovitz<sup>1,2</sup>, V. Perticarioli<sup>1,2</sup>, A. Di Fortunato<sup>1,2</sup>, A. Ficala<sup>1,2</sup>, A. Iannacone<sup>1,2</sup>, G. Gelo Signorino<sup>1,2</sup>, L. Brescini<sup>1,2</sup>, A. Giacometti<sup>1,2</sup>  
<sup>1</sup>Azienda Ospedaliero Universitaria delle Marche Ospedali Riuniti Ancona, Ancona, <sup>2</sup>Università politecnica delle Marche Facoltà di Medicina e Chirurgia, Ancona
- P 62** **A case of PCP in a patient with undiagnosed HIV infection**  
A. Zarroli, C. Febo, C. Frisenda, S. Di Giovine, E. D'Arcangelo, G. Castrignanò, K. Falasca, C. Ucciferri, J. Vecchiet  
Ospedale SS. Annunziata, Chieti
- P 63** **An unusual increase in Kaposi Sarcoma diagnosis in naïve PLWH in the last year in our area. Did the doctors forget this cancer or is it just another late gift of the pandemic?**  
B. Bellocchi<sup>1,2</sup>, L. Todaro<sup>1,2</sup>, E. Pistarò<sup>1,2</sup>, A. Guarneri<sup>1,2</sup>, M.S. Paternò Raddusa<sup>1,2</sup>, V. Boscia<sup>1</sup>, A. Onorante<sup>1</sup>, B. Santi Cacopardo<sup>3</sup>, M. Ceccarelli<sup>3</sup>, G. Nunnari<sup>3</sup>, B.M. Celesia<sup>1</sup>  
<sup>1</sup>ARNAS Garibaldi, Unit of Infectious Diseases, Catania, Italy, <sup>2</sup>University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, <sup>3</sup>University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy
- P 64** **Reasons for long-acting treatment refusal despite eligibility in a cohort of people living with HIV**  
S. Gardin, M. Mazzitelli, L. Sasset, D. Leoni, E. Agostini, A.M. Cattelan  
Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy
- P 65** **Progressive disseminated histoplasmosis in patients living with HIV: case series and review of literature in non-endemic areas**  
D. Kontogiannis<sup>1</sup>, D. Zace<sup>1</sup>, D. Benvenuto<sup>1</sup>, M. Moccione<sup>1</sup>, G. Muratore<sup>1</sup>, M.L. Giacalone<sup>1</sup>, V. Barchi<sup>1</sup>, L. Carnevale<sup>1</sup>, G. Montagnari<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, T. Mulas<sup>1</sup>, L. Coppola<sup>1</sup>, L. Campogiani<sup>1</sup>, R. Petrucci<sup>2</sup>, C. Seghetti<sup>3</sup>, M. Sebastiani<sup>4</sup>, K. Casinelli<sup>4</sup>, A. Ferlosio<sup>3</sup>, C. D'Agostini<sup>5</sup>, L. Sarmati<sup>1,6</sup>, M. Iannetta<sup>1,6</sup>  
<sup>1</sup>Department of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy, <sup>2</sup>Laboratory of Clinical Microbiology, Policlinico Tor Vergata, Rome, Italy, <sup>3</sup>Anatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy, <sup>4</sup>Infectious Disease Clinic, F. Spaziani Hospital, Frosinone FR, <sup>5</sup>Department of Experimental Medicine, Tor Vergata University, Rome, Italy, <sup>6</sup>Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy
- P 66** **A case of HIV-2 infection in an African man resident in Italy for a long time**  
D. Benvenuto<sup>1</sup>, F. De Maria<sup>1</sup>, G. Muratore<sup>1</sup>, A. Imeneo<sup>1</sup>, D. Kontogiannis<sup>1</sup>, D. Zace<sup>1</sup>, M. Moccione<sup>1</sup>, M.L. Giacalone<sup>1</sup>, A. Cavasio<sup>1</sup>, V. Barchi<sup>1</sup>, R. Iannazzo<sup>1</sup>, B. Massa<sup>1</sup>, L. Carnevale<sup>1</sup>, G. Montagnari<sup>1</sup>, A. Cekrezi<sup>1</sup>, F. Nina<sup>1</sup>, L. Minardi<sup>1</sup>, V. D'Aquila<sup>1</sup>, A. Lodi<sup>1</sup>, T. Mulas<sup>1</sup>, L. Coppola<sup>1</sup>, L. Campogiani<sup>1</sup>, V. Malagnino<sup>1</sup>, E. Teti<sup>1</sup>, L. Sarmati<sup>1,2</sup>, M. Iannetta<sup>1,2</sup>  
<sup>1</sup>Department of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, Rome, Italy, <sup>2</sup>Infectious Disease Clinic, Policlinico Tor Vergata, Rome, Italy
- P 67** **EBV-related smooth muscle leiomyosarcoma, disseminated non tuberculous mycobacterial infection and Kaposi's sarcoma in AIDS: a case report**  
M.C. Chionsini<sup>1</sup>, D. Santoro<sup>1</sup>, N. Dentale<sup>2</sup>, A. Cascavilla<sup>2</sup>, L. Marconi<sup>2</sup>, M. Tadolini<sup>1,2</sup>  
<sup>1</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, <sup>2</sup>Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- P 68** **The two sides of doravirine-based regimens: a descriptive study focusing on kidney function and lipidic profile**  
M. Menozzi<sup>1</sup>, M. Mazzitelli<sup>2</sup>, B. Fontana<sup>1</sup>, M. Albertini<sup>1</sup>, M.D. Di Trapani<sup>1</sup>, A.M. Cattelan<sup>2</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup>Infectious Disease Department, University Hospital of Modena, Italy, <sup>2</sup>Infectious Disease Unit, Padova University Hospital, Italy
- P 69** **Serodiscordant twins: a case report of vertical HIV transmission and a minireview of the literature**  
M. Alfonzo<sup>1</sup>, M. Trizzino<sup>1</sup>, G. Boncori<sup>1</sup>, G. Valentini<sup>1</sup>, L. Pipitò<sup>1</sup>, C. Colomba<sup>1,2</sup>, A. Cascio<sup>1</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy, <sup>2</sup>Division of Pediatric Infectious Diseases, "G. Di Cristina" Hospital, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy
- P 70** **Extracerebral toxoplasmosis in AIDS: a rare case of T. gondii myositis**  
G. Lingua<sup>1</sup>, A. Crocetta<sup>1</sup>, A. Bernardi<sup>1</sup>, C. Bobba<sup>1</sup>, R. Balbiano<sup>2</sup>, V. Pirriatore<sup>2</sup>, A.M. Caputo<sup>2</sup>, M. Chiriotto<sup>2</sup>, S. Bonora<sup>3</sup>, G. Calleri<sup>2</sup>  
<sup>1</sup>Dipartimento Scienze Mediche, Malattie Infettive e Tropicali, Università degli Studi di Torino, Torino, <sup>2</sup>S.C. Malattie Infettive Divisione A, A.O Ospedale Amedeo di Savoia, A.S.L. Città di Torino, Torino, <sup>3</sup>Dipartimento Scienze Mediche, Malattie Infettive e Tropicali, Università degli Studi di Torino, Clinica Universitaria A.O Ospedale Amedeo di Savoia, Torino
- P 71** **Varicella-zoster virus is an important but often forgotten pathogen in people living with HIV**  
R.A. Cavasio<sup>1</sup>, C. Sorace<sup>1</sup>, L. Alborghetti<sup>1</sup>, T. Mulas<sup>2</sup>, L. Ferrari<sup>2</sup>, G. De Simone<sup>2</sup>, A. Crea<sup>2</sup>, M. Compagno<sup>2</sup>, E. Teti<sup>2</sup>, A.M. Geretti<sup>1,2,3</sup>, and the Tor Vergata Hospital group  
<sup>1</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Infectious Diseases Clinic Policlinico Tor Vergata University Hospital, Rome, Italy, <sup>3</sup>School of Immunity and Microbial Sciences, King's College London, London, United Kingdom
- P 72** **Should echo-doppler of the supra aortic vessels be considered as a screening test in all patients or only in those with a significant cardiovascular risk prediction by Framingham score?**  
G. Bruno, M.T. Tassone, H. Morrone, P. Fusco, S. Rotundo, C. Costa, C. Tori  
Department of Medical and Surgical Sciences, Chair of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro, Italy
- P 73** **Next generation sequencing in the HIV-infected naïve patient: a single centre performance evaluation**  
M. Cerchiaro<sup>1,2</sup>, M. Bavastro<sup>1,2</sup>, C. Russo Artimagnella<sup>1,2</sup>, L. Labate<sup>1,2</sup>, F. Stefanelli<sup>3</sup>, V. Ricucci<sup>3</sup>, M. Lucente<sup>3</sup>, B. Bruzzone<sup>3</sup>, S. Cardaci<sup>1</sup>, L. Taramasso<sup>1</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>3</sup>Hygiene Laboratory Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy
- P 74** **Demographical, clinical, and immunological characteristics of c-ART naïve patients and risk factors of advanced disease across the years: preliminary results from a tertiary University hospital in Italy**  
E. Zappulo, A. Truono, A. d'Agostino, M. Faiella, M.E. Forte, F. Licciardi, E. Trucillo, I. Vecchietti, N. Esposito, S. Mercinelli, G. Di Filippo, M. Cotugno, I. Gentile  
Department of Clinical Medicine and Surgery - Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy

- P 75 Characterization and role of HIV-DNA minority mutations in a long-term treated paediatric patients cohort**  
L. Colagrossi<sup>1</sup>, S. Bernardi<sup>2</sup>, R. Scutari<sup>3,4</sup>, K. Yu La Rosa<sup>1</sup>, A. Granaglia<sup>1</sup>, V. Fini<sup>1</sup>, L. Forqué Rodriguez<sup>1</sup>, L. Coltella<sup>1</sup>, S. Ranno<sup>1</sup>, G. Linardos<sup>1</sup>, V.C. Di Maio<sup>1</sup>, L. Gentile<sup>1</sup>, M. Di Giuseppe<sup>2</sup>, F. Leone<sup>2</sup>, C. Russo<sup>1</sup>, C.F. Perno<sup>1</sup>  
<sup>1</sup>Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, <sup>2</sup>Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Bambino Gesù Children's Hospital, Rome, Italy, <sup>3</sup>Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>4</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- P 76 Evaluation of the clinical presentation of naïve HIV patients in the pre-Covid era vs those enrolled in the Covid era: data from a Neapolitan multicenter cohort**  
S. Martini<sup>1</sup>, A. Russo<sup>1,2</sup>, M.A. Carleo<sup>3</sup>, A. Cascone<sup>1</sup>, M. Pisaturo<sup>1,2</sup>, V. Esposito<sup>3</sup>, N. Coppola<sup>1,2</sup>  
<sup>1</sup>UOC Infectious Diseases, University of Campania, Luigi Vanvitelli, Napoli, <sup>2</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, Luigi Vanvitelli, Napoli, <sup>3</sup>Infectious Diseases and Gender Medicine Unit, AO dei Colli, PO Cotugno, Napoli
- P 77 Management and outcome of pregnancy in HIV-infected women in a northern Italian hospital**  
C. Russo<sup>1,2</sup>, G. Cattaraccio<sup>1,2</sup>, A. Allodi<sup>3</sup>, C. Arioni<sup>3</sup>, C. Gustavino<sup>4</sup>, A. Ferraiolo<sup>4</sup>, L. Taramasso<sup>1</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>DISSAL - University of Genova - Genoa, Italy, <sup>2</sup>IRCCS Ospedale Policlinico San Martino, Infectious Disease Unit - Genova, Italy, <sup>3</sup>IRCCS Ospedale Policlinico San Martino, Neonatal Department - Genova, Italy, <sup>4</sup>IRCCS Ospedale Policlinico San Martino, Gynecology Department - Genova, Italy

## Comorbidities

- P 78 Incidence and outcome of TB/HIV co-infection in a rural area of Senegal: a 13-year retrospective study**  
M. Giglia<sup>1,2,3</sup>, G. Menotti<sup>1,2,3</sup>, T. Matucci<sup>1,4</sup>, N. Riccardi<sup>1,4</sup>, B. Granozzi<sup>1,2,3</sup>, M.D. Yacine<sup>5</sup>, M. Ndiaye<sup>6</sup>, G. Besozzi<sup>1</sup>, M. Tadolini<sup>1,2,3</sup>  
<sup>1</sup>Stop TB Italia, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, <sup>3</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, <sup>4</sup>Clinic of Infectious Diseases and Tropical Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, <sup>5</sup>Ministry of Health, Dakar, Senegal, <sup>6</sup>Health Care Centre of Diofior, Diofior, Senegal
- P 79 Prevalence and type of sleep disturbances in a modern cohort of people living with HIV**  
M. Mazzitelli<sup>1</sup>, M. Trunfo<sup>2,3</sup>, A. Milinkovic<sup>4</sup>, E. Castelli<sup>1</sup>, L. Sasset<sup>1</sup>, D. Leoni<sup>1</sup>, V. Scaglione<sup>1</sup>, A.M. Cattelan<sup>1</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, <sup>2</sup>Infectious Diseases Unit, Department of Medical Sciences, University of Turin at Amedeo di Savoia Hospital, Turin, Italy, <sup>3</sup>HIV Neurobehavioral Research Program and Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, CA, <sup>4</sup>Chelsea and Westminster Foundation Trust, SW10 9NH, London, United Kingdom
- P 80 Improvement in insulin sensitivity after the switch from dolutegravir/lamivudine or bicitegravir/emtricitabine/tenofovir alafenamide to doravirine/tenofovir disoproxil fumarate/lamivudine in HIV-infected patients with weight gain**  
L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Giglia<sup>1</sup>, S. Cretella<sup>1</sup>, I. Bon<sup>2</sup>, P. Viale<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, <sup>2</sup>Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy
- P 81 Complete remission of polyarteritis nodosa using etanercept in a HIV positive patient: a case report**  
M. Gilio<sup>1</sup>, G. Tramontano<sup>2</sup>, M. Frontuto<sup>1</sup>, D. Palazzo<sup>1</sup>, N. Bertolini<sup>3</sup>, C. Acierno<sup>1</sup>, F. Picaro<sup>1</sup>, A. Erezanu<sup>1</sup>, S. Morella<sup>1</sup>, M. Purgatorio<sup>1</sup>, G. De Stefano<sup>1</sup>  
<sup>1</sup>San Carlo Regional Hospital, Division of Infectious Diseases, Potenza, Italy, <sup>2</sup>Asl3 Genovese, Rheumatology, Genova, Italy, <sup>3</sup>Federico II University Hospital, Rheumatology, Napoli, Italy
- P 82 Liver fibrosis assesment by fibrosis4 index and correlation with cardiovascular risk in people living with HIV**  
C. Bertoni<sup>1,2</sup>, D. Ceccarelli<sup>2</sup>, L. Galli<sup>2</sup>, H. Hasson<sup>2</sup>, A. Siribelli<sup>1,2</sup>, R. Lolatto<sup>2</sup>, A. Castagna<sup>1,2</sup>, C. Uberti-Foppa<sup>1,2</sup>, G. Morsica<sup>2</sup>  
<sup>1</sup>Vita-Salute University, Milan, Italy, <sup>2</sup>Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy
- P 83 Metabolic, hormonal, vascular and psychological characterization of Erectile Dysfunction in young man living with HIV: preliminary results of a cross-sectional ongoing study**  
G. Tiecco<sup>1</sup>, M. Di Gregorio<sup>1</sup>, C. Colangelo<sup>1</sup>, P. Facondo<sup>2</sup>, A. Delbarba<sup>3</sup>, S. Storti<sup>1</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>  
<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Endocrinology and Metabolism, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>3</sup>Unit of Endocrinology and Metabolism, ASST Spedali Civili di Brescia, Brescia, Italy
- P 84 Sleep disorders and antiretroviral therapy: a real-life study**  
L. Pipitò<sup>1,2</sup>, M. Trizzino<sup>2</sup>, G. Valenti<sup>1,2</sup>, G. Bongiorno<sup>1</sup>, M. Piccione<sup>1,2</sup>, A. Cascio<sup>1,2</sup>  
<sup>1</sup>Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro," University of Palermo, Palermo, Italy, <sup>2</sup>Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the fight against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy
- P 85 Erectile Dysfunction in young men with vertically acquired HIV infection: a retrospective study**  
G. Tiecco<sup>1</sup>, C. Colangelo<sup>1</sup>, M. Di Gregorio<sup>1</sup>, P. Facondo<sup>2</sup>, A. Delbarba<sup>3</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>  
<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Endocrinology and Metabolism, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>3</sup>Unit of Endocrinology and Metabolism, ASST Spedali Civili di Brescia, Brescia, Italy
- P 86 Polypharmacy and aging in people living with HIV: 6 years of experience in a multidisciplinary outpatient clinic**  
D. Cattaneo<sup>1,2</sup>, L. Oreni<sup>2</sup>, P. Meraviglia<sup>2</sup>, D. Minisci<sup>3</sup>, N. Astuti<sup>2</sup>, S. Antinori<sup>2</sup>, A. Gori<sup>2</sup>, C. Gervasoni<sup>1,2</sup>  
<sup>1</sup>Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy, <sup>2</sup>Department of Infectious Diseases, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy, <sup>3</sup>Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- P 87 Evaluation of lipid profile and intima media thickness in HIV experienced patients treated with PI-based regimens vs PI-sparing regimens**  
M.G. Palamone, S. Martini, M. Pisaturo, A. Russo, V. Zollo, M.T. Russo, P. Maggi, N. Coppola  
Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli" Naples, Italy
- P 88 Vertebral osteomyelitis from Mycobacterium avium complex in ID acquired, six years after immunological recovery**  
V. Gennaro<sup>1</sup>, C. Montrucchio<sup>2</sup>, T. De Blasi<sup>2</sup>, M. Chiriotto<sup>2</sup>, G. Orofino<sup>2</sup>, G. Calleri<sup>2</sup>  
<sup>1</sup>Dipartimento Scienze Mediche, Malattie Infettive e Tropicali, Università degli Studi di Torino, Torino, <sup>2</sup>S.C. Malattie Infettive div.A, Ospedale Amedeo di Savoia, A.S.L. Città di Torino, Torino
- P 89 Liver enzyme variation after switching to Emtricitabine/Tenofovir Alafenamide/Bicitegravir is associated with Glucose increase in a real-life cohort**  
N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, P. Maggi<sup>3</sup>, B. Menzaghi<sup>4</sup>, G.V. De Socio<sup>5</sup>, G. Orofino<sup>6</sup>, B.M. Cesia<sup>7</sup>, A. Bandera<sup>8</sup>, F. Vichi<sup>9</sup>, A. Di Biagio<sup>10</sup>, L. Taramasso<sup>10</sup>, S. Piconi<sup>11</sup>, E. Sarchi<sup>12</sup>, L. Valsecchi<sup>13</sup>, G.F. Pellicano<sup>14</sup>, G. Cenderello<sup>15</sup>, P. Bonfanti<sup>1</sup>, for the CISAI Study Group  
<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS San Gerardo Hospital-University of Milano-Bicocca, Monza, <sup>2</sup>Fondazione ASIA Onlus, Buccinasco (MI), Italy, <sup>3</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>4</sup>Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), <sup>5</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>6</sup>Division I of Infectious and Tropical Diseases, ASL Città di Torino, <sup>7</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>8</sup>Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>9</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, <sup>10</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, <sup>11</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, <sup>12</sup>Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, <sup>13</sup>1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>14</sup>Infectious Diseases, G. Martino Hospital -University of Messina, Messina, Italy, <sup>15</sup>Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy

- P 90 Weight gain in PLWH: role of multidisciplinary approach**  
M.A. Carleo<sup>1</sup>, F.M. Fusco<sup>2</sup>, M. Di Lorenzo<sup>1</sup>, M. Vitale<sup>1</sup>, L. Santoro<sup>1</sup>, S. Mascolo<sup>1</sup>, V. Rizzo<sup>1</sup>, A. Guida<sup>1</sup>, O. Tambaro<sup>2</sup>, F. Borrelli<sup>2</sup>, P. Rosario<sup>1</sup>, R. Viglietti<sup>2</sup>, V. Esposito<sup>1</sup>  
<sup>1</sup>Infectious Diseases and Gender Medicine Unit, AO dei Colli, PO Cotugno, Napoli, <sup>2</sup>Infectious Diseases and Immunodeficiencies Unit, AO dei Colli, PO Cotugno, Napoli
- P 91 Correlating Qualitative/Quantitative Quantiferon- Tb Gold Plus Results And Cd4+/Cd8+ Count: A Retrospective Study In A HIV Cohort**  
A. Tavano, E. Asperges, P. Cambieri, M. Corbella, P. Guidicini, E. Bono, R. Gulminetti, L. Maiocchi, B. Mariani, S. Novati, L. Pagnucco, P. Sacchi, V. Zuccaro, R. Bruno  
Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo - Pavia (Italy), Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo - Pavia (Italy), Department of Clinical, Surgical, Diagnostics and Pediatric Sciences. University of Pavia - Pavia (Italy), Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milano (Italy)
- P 92 Is CAP (Controlled Attenuation Parameter) a useful test in the management of older HIV positive patients?**  
E.P. Drago, M. Poliseo, A. Narducci, C. Grillo, F. De Gregorio, S. Ferrara, T.A. Santantonio, S. Lo Caputo  
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia
- P 93 Psychological well-being in a cohort of people living with HIV: a single center study**  
D. D'Elia<sup>1</sup>, A. Londero<sup>1</sup>, M. Garzitto<sup>2</sup>, M. Colizzi<sup>2</sup>, C. Tascini<sup>1</sup>  
<sup>1</sup>Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, <sup>2</sup>Unit of Psychiatry, Department of Medicine (DAME), University of Udine, Udine, Italy
- P 94 NAFLD In People Living With HIV (PLHIV): risk factors associated with steatosis confirmed by fibroscan**  
N.B. Bana<sup>1</sup>, N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, P. Vitiello<sup>3</sup>, P. Maggi<sup>4</sup>, F. Colucci<sup>4</sup>, A. Di Biagio<sup>5,6</sup>, L.A. Nicolini<sup>5</sup>, K. Falasca<sup>7</sup>, E. Salomoni<sup>8</sup>, P. Bonfanti<sup>1</sup>  
<sup>1</sup>Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Università Milano-Bicocca, Monza, <sup>2</sup>Fondazione ASIA Onlus, Buccinasco (MI), <sup>3</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio (VA), <sup>4</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, <sup>5</sup>Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, <sup>6</sup>Department of Health Science (Dissal), University of Genoa, Genoa, Italy, <sup>7</sup>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. D'Annunzio", Chieti, Pescara, <sup>8</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence
- P 95 Correlation between bone and microvascular damage in patients with HIV**  
A. Masiello<sup>1</sup>, A. Boccia<sup>2</sup>, A. Limone<sup>2</sup>, F. Simeone<sup>1</sup>, A. Iodice<sup>1</sup>, P. Maggi<sup>1</sup>  
<sup>1</sup>UOC Malattie Infettive, AORN "S. Anna e S. Sebastiano" Caserta, <sup>2</sup>UOC Malattie Infettive, Università della Campania "L. Vanvitelli" Napoli
- P 96 A Nocardia From Nowhere**  
A.L. Croci, A. Cascavilla, M. Giglia, G. Beci, L. Calza  
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
- P 97 Salmonella enteritidis spondylodiscitis in a liver transplanted HIV-HBV-HCV-HDV patient: a case report**  
A. Iannaccone, M. Cimatti, A. Ficola, S. Mazzanti, M. Tavio, A. Giacometti  
UNIVPM - Azienda Ospedaliera Universitaria delle Marche, Ancona
- P 98 Not all that's indolent can't hurt: an aggressive case of EBV-positive mucocutaneous ulcer (EBVMCU) in an HIV naive patient**  
P. Valsecchi<sup>1</sup>, E. Asperges<sup>1</sup>, M. Sambo<sup>2</sup>, V. Zuccaro<sup>1</sup>, P. Sacchi<sup>1</sup>, R. Bruno<sup>1,3</sup>  
<sup>1</sup>Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>2</sup>Infectious and Tropical Diseases Unit, Siena University Hospital, Siena, Italy, <sup>3</sup>Department of Clinical Surgical Diagnostic & Pediatric Sciences, University of Pavia, Italy
- P 99 A multidisciplinary approach for an uncommon case of infective endocarditis**  
A. Cornelli<sup>1</sup>, C. Monari<sup>2</sup>, L. Alessio<sup>2</sup>, S. De Pascalis<sup>2</sup>, G. Cimmino<sup>3</sup>, M. Torella<sup>3</sup>, N. Coppola<sup>1,2</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Studies of Campania Luigi Vanvitelli, <sup>2</sup>AOU Vanvitelli, Naples, <sup>3</sup>Department of Translational Medical Sciences, University of Studies of Campania Luigi Vanvitelli
- P 100 The impact on body weight and body mass index of glucagon-like peptide 1 receptor agonists in diabetic people living with HIV**  
M. Bottanelli<sup>1,2</sup>, L. Galli<sup>2</sup>, R. Lolatto<sup>2</sup>, M. Guffanti<sup>2</sup>, A. Danise<sup>2</sup>, G. Mori<sup>1,2</sup>, C. Maci<sup>1,2</sup>, C. Bertoni<sup>1,2</sup>, F. Badalucco Ciotta<sup>1,2</sup>, V. Spagnuolo<sup>2</sup>, A. Castagna<sup>1,2</sup>, C. Muccini<sup>2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy
- P 101 Cancer in People Living With HIV: study of the outpatient population at Tor Vergata Hospital**  
V. D'Aquila<sup>1</sup>, C. Sorace<sup>1</sup>, N. Braccialarghe<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, T. Mulas<sup>1</sup>, M. Compagno<sup>1</sup>, E. Teti<sup>1</sup>, V. Malagnino<sup>2</sup>, L. Sarmati<sup>2</sup>  
<sup>1</sup>Clinical Infectious Diseases, Tor Vergata Hospital, Rome, Italy, <sup>2</sup>Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 102 Cancers of the skin and mucous membranes in HIV-infected patients compared to the general population**  
G. Ciccarese<sup>1</sup>, S. Ferrara<sup>2</sup>, E. Drago<sup>2</sup>, C. Grillo<sup>2</sup>, F. Sanguedolce<sup>3</sup>, C. Pizzulli<sup>2</sup>, M. Mastrolonardo<sup>2</sup>, T. Santantonio<sup>2</sup>, S. Lo Caputo<sup>2</sup>  
<sup>1</sup>Unit of Dermatology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>2</sup>Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>3</sup>Department of Pathology, University of Foggia, Foggia, Italy
- P 103 Prevalence of metabolic syndrome in a cohort of people living with HIV: lifestyle and risk factors analysis**  
A. Narducci, M. Poliseo, C. Grillo, M. Caggese, E. Colletti, M. Calabrese, S. Ferrara, T.A. Santantonio, S. Lo Caputo  
Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
- P 104 Efficacy and safety of dolutegravir + lamivudine in patients in onco-haematological treatment**  
L. Pagnucco, A. Tavano, R. Gulminetti, P. Sacchi, S. Novati, R. Bruno  
Infectious Diseases Unit, Department of Medical Science and Infectious Diseases Fondazione IRCCS Policlinico San Matteo - University of Pavia
- P 105 Statins and Aspirin use in people living with HIV (PLWH): gap between European AIDS Clinical Society guidelines and clinical practice**  
C. Giarratana<sup>1,2</sup>, A. Bandiera<sup>1,2</sup>, S. Pulvirenti<sup>1,2</sup>, C. Gullotta<sup>1,2</sup>, R. Ippolito<sup>1,2</sup>, A.E. Campanella<sup>1,2</sup>, B. Bellocchi<sup>1,2</sup>, R. Bruno<sup>1,3</sup>, A. Onorante<sup>1</sup>, B.S. Cacopardo<sup>1,3</sup>, G. Nunnari<sup>1,3</sup>, M. Ceccarelli<sup>1,3</sup>, B.M. Ceselia<sup>1</sup>  
<sup>1</sup>ARNAS Garibaldi, U.O. di Malattie Infettive, Catania, <sup>2</sup>Università degli Studi di Messina, Dipartimento di Medicina Clinica e Sperimentale, Messina, <sup>3</sup>Università di Catania, Dipartimento di Medicina Clinica e Sperimentale, Catania
- P 106 Evaluation of intimal media thickness in HIV-experienced patients treated with triple therapy vs patients treated with dual therapy: multicenter cohort data**  
M.T. Russo<sup>1</sup>, S. Martini<sup>1</sup>, A. Masiello<sup>2</sup>, N. Coppola<sup>1</sup>, P. Maggi<sup>1,2</sup>  
<sup>1</sup>Università della Campania Luigi Vanvitelli, Naples, Italy, <sup>2</sup>AORN Sant'Anna e San Sebastiano, Caserta, Italy
- P 107 Peritoneal-pleural tuberculosis in a HIV positive and cirrhotic patient**  
A. Cilli, F. Malerba, M. Tadolini, L. Calza, P. Viale  
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
- P 108 Depressive disorder and vitamin D in a group of HIV patients in cART: dual therapy versus triple therapy**  
L. Maffa<sup>1</sup>, F. Mucedola<sup>1</sup>, S. Maffa<sup>2</sup>, C. Ucciferri<sup>1</sup>, J. Vecchiet<sup>1</sup>, K. Falasca<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases - Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara- Italy, <sup>2</sup>Department of Pharmacy, University "G. D'Annunzio", Chieti, Pescara, Italy
- P 109 Male breast cancer in a patient with HIV-HCV coinfection: a case report**  
N. Amarasinghe, L. Pagnucco, R. Gulminetti, R. Pesare, R. Bruno  
Infectious Diseases Unit, Department of Medical Science and Infectious Diseases Fondazione IRCCS Policlinico San Matteo - University of Pavia, Italy

## COVID-19

- P 110 Scaling up COVID 19 response among adolescents and young people in Limbe health district of Cameroon**  
A. Fontu, J. Esame, I.B. Beloli, T. Ewet Adeola, N. Eucharla  
Alliance for Community Initiative, Reach-out Cameroon
- P 111 Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study**  
M. Mazzitelli<sup>1</sup>, M. Trunfo<sup>2</sup>, L. Sasset<sup>1</sup>, V. Scaglione<sup>1</sup>, A. Ferrari<sup>1</sup>, D. Mengato<sup>3</sup>, S. Gardin<sup>1</sup>, N. Bonadiman<sup>1</sup>, L. Calandrino<sup>1</sup>, E. Agostini<sup>1</sup>, A.M. Cattelan<sup>1,4</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, <sup>2</sup>Infectious Disease Unit, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Torino, Torino, Italy, <sup>3</sup>Hospital Pharmacy Department, Padua University Hospital, Padua, Italy, <sup>4</sup>University of Padua, Padua, Italy
- P 112 Prognostic value of creatinine levels at admission on disease progression and mortality in patients with COVID-19. An observational retrospective study**  
A. Russo<sup>1</sup>, M. Pisaturo<sup>1</sup>, C. Monari<sup>1</sup>, F. Ciminelli<sup>1</sup>, P. Maggi<sup>2</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, R. Pisapia<sup>9</sup>, A.S. Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticciello<sup>17</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania L. Vanvitelli, Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit, University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy
- P 113 Long-covid characterization in a cohort of patients from Campania: prospective cohort study results**  
F. Caruso, C. Monari, A. Russo, L. Onorato, P. Grimaldi, C. Curatolo, R. Palladino, M. Pisaturo, N. Coppola  
UOC Malattie Infettive; Università degli Studi della Campania "Luigi Vanvitelli"
- P 114 Risk factors for acute kidney injury (AKI) in patients hospitalized with COVID-19: results of a retrospective cohort study**  
F. Ambrisi<sup>1</sup>, F. Spatola<sup>1</sup>, R. Nevola<sup>2</sup>, A. Russo<sup>1</sup>, S. Imbriani<sup>2</sup>, C. Aprea<sup>2</sup>, D. Beccia<sup>2</sup>, C. Brin<sup>2</sup>, G. Cirigliano<sup>2</sup>, M. Del Core<sup>2</sup>, K. Gjeloshi<sup>2</sup>, L. Agnese Meo<sup>2</sup>, A. Padula<sup>2</sup>, R. Ranieri<sup>2</sup>, C. Ricozzi<sup>2</sup>, L. Rinaldi<sup>2</sup>, R. Ruocco<sup>2</sup>, C. Ruosi<sup>2</sup>, P. Sommese<sup>2</sup>, A. Villani<sup>2</sup>, M. Pisaturo<sup>1</sup>, N. Coppola<sup>1</sup>, L.E. Adinolfi<sup>2</sup>  
<sup>1</sup>Infectious Diseases Unit, COVID Center, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>2</sup>Internal Medicine Unit, COVID Center, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
- P 115 The impact of co-infections and antibiotic use in SARS-CoV-2 hospitalized patients at Policlinico Tor Vergata Hospital, Rome, Italy**  
A. Di Lorenzo, R. Iannazzo, L. Campogiani, A. Imeneo, G. Alessio, V. D'Aquila, B. Massa, I. Fato, V. Malagnino, E. Teti, M. Andreoni, M. Iannetta, L. Sarmati  
Infectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Rome, Italy
- P 116 Predictors of SARS-CoV-2 infection in treatment-experienced PLWHIV: case-control study**  
V. Iannone<sup>1</sup>, P.F. Salvo<sup>1</sup>, F. Lombardi<sup>2</sup>, A. Ciccullo<sup>3</sup>, F. Lamanna<sup>1</sup>, R.A. Passerotto<sup>1</sup>, G. Placidi<sup>2</sup>, V. Massaroni<sup>4</sup>, S. Di Giambenedetto<sup>1,2</sup>, A. Borghetti<sup>2</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Malattie Infettive, Roma, <sup>2</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, <sup>3</sup>Ospedale San Salvatore, L'Aquila, <sup>4</sup>Università Cattolica del Sacro Cuore, Roma
- P 117 Delta variant as a strong predictor of long COVID incidence and neuropsychiatric symptomatology: data from a large, multicenter, prospective cohort study**  
L. Frallonardo<sup>1</sup>, N. Veronese<sup>2</sup>, F.V. Segala<sup>1</sup>, M. Cormio<sup>1</sup>, G. Romita<sup>1</sup>, A. Parisi<sup>2</sup>, E. Marrone<sup>2</sup>, M.E. Ciuppa<sup>2</sup>, A. La Carrubba<sup>2</sup>, L. Carruba<sup>2</sup>, A. Licata<sup>2</sup>, G. Cavallaro<sup>3</sup>, V. Pagliuso<sup>3</sup>, T. Maino<sup>3</sup>, S. Lollo<sup>3</sup>, L. Latino<sup>4</sup>, L.T. Solimeo<sup>4</sup>, A. Ianniello<sup>4</sup>, D. Montalbò<sup>4</sup>, D.F. Bavaro<sup>1</sup>, M.L. Fiorella<sup>3</sup>, M. Barbagallo<sup>1</sup>, F. Di Gennaro<sup>1</sup>, A. Saracino<sup>1</sup>  
<sup>1</sup>Department of Precision and Regenerative Medicine and Ionian Area - (DiMePre-J), University of Bari "Aldo Moro", Bari - Italy, <sup>2</sup>Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy, <sup>3</sup>Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Italy, <sup>4</sup>Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
- P 118 Impact of COVID-19 on the long-term outcome among PLWH: a real-life study**  
M. Degli Antoni<sup>1</sup>, G. Maifredi<sup>2</sup>, S. Storti<sup>1</sup>, F. Viola<sup>1</sup>, M. Di Gregorio<sup>1</sup>, G. Tiecco<sup>1</sup>, I. Izzo<sup>1</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>  
<sup>1</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, <sup>2</sup>ATS Brescia (Brescia Health Protection Agency), Brescia
- P 119 COVID-19 in immunocompromised patients: what is the role of passive and active immunisation?**  
L. Coppola<sup>1</sup>, M. Iannetta<sup>1,2</sup>, L. Campogiani<sup>1</sup>, M. Compagno<sup>1</sup>, V. Malagnino<sup>1,2</sup>, E. Teti<sup>1</sup>, D. Zaccà<sup>2</sup>, L. Alborghetti<sup>1</sup>, A. Cekrezi<sup>2</sup>, L. Sarmati<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Clinic, Policlinico Tor Vergata, Rome Italy, <sup>2</sup>Department of System Medicine, Tor Vergata University, Rome, Italy
- P 120 Factors associated with anti-spike SARS-CoV2 antibody titer among patients hospitalized with COVID-19-related pneumonia**  
G. Lo Cascio<sup>1</sup>, G. Lapadula<sup>1,2</sup>, L. Mezzadri<sup>1</sup>, L. Antolini<sup>1</sup>, M. Rossi<sup>2</sup>, E. Colella<sup>2</sup>, E. Pollastrì<sup>2</sup>, A. Ranzani<sup>2</sup>, S. Malandrino<sup>2</sup>, A. Cavallero<sup>2</sup>, P. Bonfanti<sup>1,2</sup>  
<sup>1</sup>School of Medicine, University of Milano-Bicocca, Milan, Italy, <sup>2</sup>IRCCS Fondazione "San Gerardo dei Tintori", Monza, Italy
- P 121 Epidemiological and clinical factors related to late negativization of SARS-CoV 2 swab**  
P. Grimaldi<sup>1</sup>, M. Pisaturo<sup>1</sup>, A. Russo<sup>1</sup>, P. Maggi<sup>1</sup>, R. Astorri<sup>1</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, V. Sangiovanni<sup>5</sup>, A. Russomando<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, C. Rescigno<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, G. Russo<sup>13</sup>, R. Parrella<sup>14</sup>, G. Dell'Aquila<sup>15</sup>, M. Gambardella<sup>16</sup>, A. Ponticciello<sup>17</sup>, N. Coppola<sup>1</sup> on behalf of CoviCam group  
<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit, University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>III Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, <sup>14</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>15</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>16</sup>Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, <sup>17</sup>Pneumology Unit, AORN Caserta, Italy
- P 122 Early treatment of COVID-19 in out-patient setting: a single-center retrospective study**  
E. Binetti, F. Ciccone, A. Falletta, S. Trapani, S. Lobello, C. Leanza, M.A. Albanese, I. De Angelis, C. Ajassa, C.M. Mastroianni  
Sapienza Università di Roma, Rome
- P 123 Glucocorticoids in diabetic COVID-19 patients: efficacy and safety of Deflazacort**  
A. Di Gasbarro<sup>1</sup>, C. Ucciferri<sup>1</sup>, G. Taraschi<sup>1</sup>, K. Falasca<sup>1</sup>, J. Vecchie<sup>2</sup>  
<sup>1</sup>Università G. D'Annunzio, Chieti, <sup>2</sup>Clinica di Malattie Infettive, P.O. S.S. Annunziata, Chieti
- P 124 Post-COVID-19 Syndrome: a retrospective study of our center's patients**  
G. Taraschi<sup>1</sup>, A. Di Gasbarro<sup>1</sup>, C. Ucciferri<sup>1</sup>, K. Falasca<sup>1</sup>, J. Vecchie<sup>2</sup>  
<sup>1</sup>Università degli Studi G.D'Annunzio, Chieti, <sup>2</sup>Clinica di Malattie Infettive e Tropicali, P.O. S.S. Annunziata, Chieti

- P 125 Impact of SARS-CoV2 infection in PLWH in the vaccine era**  
L. Comi<sup>1</sup>, S. Venturelli<sup>1</sup>, E. Di Filippo<sup>1</sup>, D. Valenti<sup>1,2</sup>, F. Maggiolo<sup>1</sup>  
<sup>1</sup>UOC Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>FROM Foundation, ASST Papa Giovanni XXIII, Bergamo
- P 126 Incidence and burden of long COVID in Africa: a systematic review and meta-analysis**  
R. Novara<sup>1</sup>, F.V. Segala<sup>1</sup>, F. Di Gennaro<sup>1</sup>, S. Cotugno<sup>1</sup>, G. Guido<sup>1</sup>, R. Papagni<sup>1</sup>, A. Colpani<sup>2</sup>, A. De Vito<sup>2</sup>, M. Barbagallo<sup>3</sup>, G. Madeddu<sup>2</sup>, S. Babudieri<sup>2</sup>, G. Putoto<sup>4</sup>, N. Veronese<sup>3</sup>, A. Saracino<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), University of Bari "Aldo Moro", Bari, Italy, <sup>2</sup>Unit of Infectious and Tropical diseases, Department of Medicine, Surgery and Pharmacy - University of Sassari, Sassari, Italy, <sup>3</sup>Geriatrics Section, Department of Internal Medicine, University of Palermo, Palermo, Italy, <sup>4</sup>Operational Research Unit, Doctors with Africa CUAMM, Italy
- P 127 Vaccination against SARS-CoV2: are antibodies predictive of protection?**  
S. Dispinseri<sup>1</sup>, I. Marzino<sup>2</sup>, M. Tolazzi<sup>1</sup>, A. Cara<sup>3</sup>, D. Negri<sup>4</sup>, P. Cinque<sup>5</sup>, R. Vercesi<sup>5</sup>, V. Lampasona<sup>2</sup>, G. Scarlatti<sup>1</sup>  
<sup>1</sup>Viral Evolution and Transmission Unit, IRCCS San Raffaele, Milan, Italy, <sup>2</sup>Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy, <sup>3</sup>National Center for Global Health, Istituto Superiore Di Sanità, Rome, Italy, <sup>4</sup>Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy, <sup>5</sup>Unit of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
- P 128 Survival stratification according to soluble urokinase plasminogen activator receptor (suPAR) levels of COVID-19 hospitalised patients**  
M. Maggi<sup>1</sup>, G. Gazzaniga<sup>1</sup>, M. Senatore<sup>2</sup>, A. Pani<sup>3</sup>, F. Scaglione<sup>2,3</sup>  
<sup>1</sup>Postgraduate School of Clinical Pharmacology and Toxicology-Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, <sup>2</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, <sup>3</sup>Chemical-Clinical Analysis Department, Niguarda Hospital, Milan
- P 129 Does remdesivir affect renal function in SARS-CoV2 infected patients? Real life data in a single center in Perugia**  
E. Svizzeretto<sup>1</sup>, D. Altobelli<sup>1</sup>, E. Baranello<sup>1</sup>, L. Curci<sup>1</sup>, G. Gonnelli<sup>1</sup>, D. Francisci<sup>1</sup>  
Clinica delle Malattie Infettive, Azienda Ospedaliera di Perugia, Università degli Studi di Perugia
- P 130 Which is the efficacy of Sotrovimab in reducing disease progression and death during the Omicron era? Answer from a real-life study**  
A. De Vito<sup>1</sup>, F.R.P. Ieva<sup>2</sup>, L. Diella<sup>3</sup>, A. Colpani<sup>1</sup>, R. Papale<sup>2</sup>, A. Belati<sup>3</sup>, S. Babudieri<sup>1</sup>, L. De Santis<sup>3</sup>, T. Santantonio<sup>2</sup>, A. Saracino<sup>3</sup>, S. Lo Caputo<sup>2</sup>, G. Madeddu<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Italy, <sup>2</sup>S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy, <sup>3</sup>Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRE-J), University of Bari "Aldo Moro", Bari, Italy
- P 131 Treatment with nirmatrelvir/ritonavir prevented hospitalizations and deaths in patients diagnosed with COVID-19 at a residential care facility in Milan, Italy**  
M. Franzetti<sup>1</sup>, L. Pezzati<sup>1,2</sup>, A. Gatti<sup>3</sup>, F. Salmoiraghi<sup>3</sup>, E. Magni<sup>3</sup>, N. Antonioti<sup>3</sup>, S. Baruffi<sup>3</sup>, G. Esposti<sup>3</sup>, C. Balotta<sup>3</sup>, B. Caimi<sup>3</sup>, S. Rusconi<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, ASST Ovest Milanese, Legnano, Milan, <sup>2</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, <sup>3</sup>Azienda Servizi alla Persona, Istituti Milanese Martinitt e Stelline e Pio Albergo Trivulzio, Milan
- P 132 Oldest old outpatients with mild-moderate SARS-CoV-2 infection treated with monoclonal antibodies: a real life single center study**  
N. Bonadiman<sup>1</sup>, M. Basso<sup>2</sup>, V. Scaglione<sup>2</sup>, S. Gardin<sup>1</sup>, M. Canova<sup>1</sup>, E. Agostini<sup>1</sup>, A.M. Catelan<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, Department of Medicine, Azienda Ospedale Università Padova, Padova, Italy, <sup>2</sup>Department of Molecular Medicine, University of Padova, Padova, Italy
- P 133 Relationship between ultrasensitive SARS-CoV-2 viraemia, inflammatory parameters and lymphocyte stimulation test**  
A. Imeneo<sup>1</sup>, G. Alessio<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, L. Benedetti<sup>1</sup>, L. Piermatteo<sup>2</sup>, F. Ceccherini-Silberstein<sup>2</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>, M. Iannetta<sup>1</sup>  
<sup>1</sup>Department of Systems Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Department of Experimental Medicine, Tor Vergata University, Rome, Italy
- P 134 SARS CoV 2 infection in a patient affected by cerebral amyloid angiopathy: case report and literature commentary**  
A.M. Spera, A. Campagna, C. D'Amore, V. Fortunato, S. Madonna, A. Masullo, M. Onofrio, G. Parrella, R. Verrioli  
Infectious Disease Unit, AOU OO RR San Giovanni di Dio e Ruggi d'Aragona, Salerno
- P 135 Remdesivir-nirmatrelvir combination: in vitro activity and a case report**  
A. Gidari<sup>1,2</sup>, S. Sabbatini<sup>3</sup>, E. Schiaroli<sup>1</sup>, S. Bastianelli<sup>1</sup>, S. Pierucci<sup>1</sup>, C. Busti<sup>1</sup>, L.M. Saraca<sup>1</sup>, L. Capogrossi<sup>1</sup>, M.B. Pasticcini<sup>1,2</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>2</sup>Clinic of Infectious Diseases, "Santa Maria" Hospital, Terni, Italy, <sup>3</sup>Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy
- P 136 Correlation between IgM and IgG anti-Sars-Cov-2 and clinical Covid stadiation**  
A. Di Fraia, M. Pisaturo, M. Starace, C. Minichini, L. Occhiello, A. Russo, N. Coppola  
Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
- P 137 Immunogenicity of primary two dose cycle and three dose of mRNA vaccine in treated solid cancer patients**  
A. Gabrieli<sup>1</sup>, A. Riva<sup>1</sup>, N. La Verde<sup>2</sup>, D. Dalu<sup>2</sup>, C. Della Ventura<sup>1</sup>, S. Cona<sup>2</sup>, M. Tarkowski<sup>1</sup>, L. Ruggieri<sup>2</sup>, C. Fasola<sup>2</sup>, M. De Monte<sup>2</sup>, A. Bergna<sup>1</sup>, C. Buonomo<sup>2</sup>, A. Lai<sup>1</sup>, D. Chizzonti<sup>2</sup>  
<sup>1</sup>Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy, <sup>2</sup>Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
- P 138 Clinical efficacy of two doses of mRNA-based vaccines COVID-19 for solid cancer patients on treatment**  
A. Gabrieli<sup>1</sup>, A. Riva<sup>1</sup>, N. La Verde<sup>2</sup>, D. Dalu<sup>2</sup>, C. Della Ventura<sup>1</sup>, S. Cona<sup>2</sup>, M. Tarkowski<sup>1</sup>, L. Ruggieri<sup>2</sup>, C. Fasola<sup>2</sup>, M. De Monte<sup>2</sup>, A. Bergna<sup>1</sup>, C. Buonomo<sup>2</sup>, A. Lai<sup>1</sup>, D. Chizzonti<sup>2</sup>  
<sup>1</sup>Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy, <sup>2</sup>Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
- P 139 Incidence of Post-COVID conditions in people treated with molnupiravir: a single-center experience**  
A. De Vito, P. Filigheddu, A. Colpani, G. Moi, B. Zauli, M. Fois, A. Bitti, M.C. Meloni, C.M. Panu Napodano, A. Muredda, I. Maida, V. Fiore, S. Babudieri, G. Madeddu  
Unit of Infectious Diseases, Department of Medicine, Surgery, Pharmacy, University of Sassari, Italy
- P 140 SARS-CoV-2 infection and solid organ transplant recipients: a single center experience**  
F. Peracchi<sup>1,2</sup>, M. Merli<sup>2</sup>, R. Rossotti<sup>2</sup>, M. Puoti<sup>1,2</sup>, G. Travi<sup>2</sup>  
<sup>1</sup>University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy, <sup>2</sup>Division of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda Milan, Italy
- P 141 Keystone bacterial species of altered blood and oral microbiota profile during SARS-CoV-2 infection**  
L. Santinelli<sup>1</sup>, L. Sorrentino<sup>2</sup>, M. Fracella<sup>2</sup>, L. Maddaloni<sup>1</sup>, F. Frasca<sup>2</sup>, A. Davria<sup>2</sup>, G. Radocchia<sup>1</sup>, V. Iebba<sup>3</sup>, G. Bugani<sup>1</sup>, C. Lofaro<sup>1</sup>, E. Binetti<sup>1</sup>, A. Pierangeli<sup>2</sup>, G. Antonelli<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, S. Schippa<sup>1</sup>, G. d'Ettore<sup>1</sup>, C. Scagnolari<sup>2</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, <sup>2</sup>Laboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia, Sapienza University, Rome, <sup>3</sup>Department of Medical Sciences, University of Trieste, Trieste, Italy
- P 142 Latina score for discrimination between progressor and non progressor SARS-CoV-2 infected patients**  
P. Zuccalà<sup>1</sup>, D. Alunni Fegatelli<sup>2</sup>, C. Del Borgo<sup>1</sup>, R. Marocco<sup>1</sup>, B. Kertusha<sup>1</sup>, T. Tieghi<sup>1</sup>, A. Gasperini<sup>2</sup>, A. Parente<sup>2</sup>, P. Fabietti<sup>1</sup>, G. Mancarella<sup>2</sup>, S. Garattini<sup>2</sup>, A. Spagnolo<sup>2</sup>, M. Lichtner<sup>2</sup>  
<sup>1</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>2</sup>Department of Public Health, microbiology and Infectious Diseases, Sapienza University of Rome, Polo Pontino, Latina, Italy

- P 143 A retrospective cohort study to understand the impact of the drugs indicated in the early treatment of Sars-CoV-2 disease and the risk of hospitalization**  
D. Cicetti<sup>1,2</sup>, G. Pierfelice<sup>1,2</sup>, G. Pensalfine<sup>1,2</sup>, R. Caprara<sup>1,2</sup>, S. Vitale<sup>1,2</sup>, S. Cavara<sup>3</sup>, L. Appolloni<sup>1,2</sup>, A. Stancari<sup>1</sup>  
<sup>1</sup>IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Clinical Pharmacy, Bologna, <sup>2</sup>IRCCS University Hospital Company - S.Orsola-Malpighi Polyclinic - Department of Infectious Disease, Bologna, <sup>3</sup>Alma Mater Studiorum University of Bologna – Course of study in Pharmacy
- P 144 Impact of COVID pandemic and COVID disease on aging trajectories in older nursing homes residents in Italy**  
B. Manni<sup>1</sup>, F. Romani<sup>2</sup>, J. Milic<sup>2</sup>, S. Renzetti<sup>3</sup>, G. Dolci<sup>4</sup>, S. Braglia<sup>1</sup>, C. Mussi<sup>2,4</sup>, S. Calza<sup>5</sup>, A. Fabbo<sup>1</sup>, G. Guaraldi<sup>2,4</sup>  
<sup>1</sup>Geriatric Service - Cognitive Disorders and Dementia Unit, Health Authority and Services of Modena, Italy, <sup>2</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy, <sup>4</sup>Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, <sup>5</sup>Geriatric Clinic, Biomedical Science, Metabolism and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy, <sup>6</sup>Department of Molecular and Translational Medicine, University of Brescia, Italy
- P 145 Use of a rapid molecular multiplex real time PCR test for the detection of SARS-CoV-2, influenza A/B and respiratory syncytial virus**  
C. Orlandi, M. Magnani, A. Casabianca  
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Italy
- P 146 Active metabolite of Erdosteine (MET-1) inhibits SARS-CoV-2 infection and modulates inflammatory state in A549 cells**  
S. Strizzi<sup>1</sup>, F. Danzo<sup>2</sup>, C. Vanetti<sup>1</sup>, M. Biasin<sup>1</sup>, D. Radovanovic<sup>2</sup>, P. Santus<sup>2</sup>, D. Trabattoni<sup>1</sup>  
<sup>1</sup>Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Division of Respiratory Diseases, University Hospital "L. Sacco", Milan, Italy
- P 147 SARS-CoV-2 infection in Chimeric Antigen receptor T cell patients**  
E. Metafuni<sup>1</sup>, I. Pansini<sup>2</sup>, F. Sorà<sup>1,2</sup>, E. Galli<sup>1</sup>, A. Cingolani<sup>3,4</sup>, M. Fantoni<sup>3,4</sup>, F. Fronzidi<sup>4</sup>, S. Giammarco<sup>1</sup>, R. Santangelo<sup>1,5</sup>, N. Piccirillo<sup>1,2</sup>, L. Teofili<sup>1,2</sup>, E. Maiolo<sup>1</sup>, S. Hohaus<sup>1,2</sup>, P. Chiusolo<sup>1,2</sup>, S. Sica<sup>1,2</sup>  
<sup>1</sup>Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (IT), <sup>2</sup>Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome (IT), <sup>3</sup>Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome (IT), <sup>4</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (IT), <sup>5</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (IT)
- P 148 Alpha-synuclein multimer/monomer ratio is an important determinant of Type-I Interferon response against SARS-CoV-2 infection**  
F. Limanaqi<sup>1,2</sup>, S. Zecchin<sup>1</sup>, I. Saulle<sup>1,2</sup>, S. Strizzi<sup>3</sup>, C. Vanetti<sup>3</sup>, M. Garziano<sup>1,2</sup>, G. Cappelletti<sup>2</sup>, D. Parolin<sup>2</sup>, S. Caccia<sup>2</sup>, D. Trabattoni<sup>2</sup>, C. Fenizia<sup>1,2</sup>, M. Clerici<sup>1,3</sup>, M. Biasin<sup>2</sup>  
<sup>1</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>2</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>3</sup>IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
- P 149 Early SARS-CoV-2 Treatment in Solid Organ Transplant recipients: a Single-Centre Retrospective Cohort Study during the Omicron era**  
E. Milozzi<sup>1</sup>, V. Mazzotta<sup>1</sup>, A. Caioli<sup>1</sup>, E. Biliotti<sup>1</sup>, L. Loiacono<sup>1</sup>, A. Rianda<sup>1</sup>, R. Libertone<sup>1</sup>, A. Mariano<sup>1</sup>, D.R. Donno<sup>1</sup>, P. De Paolis<sup>2</sup>, A. Antinori<sup>1</sup>, G. D'Offizi<sup>1</sup>  
<sup>1</sup>INMI L. Spallanzani, Rome, <sup>2</sup>A.O.S. Camillo-Forlanini, Rome
- P 150 Characterization of the second, third and fourth wave of COVID 19 occurring in Campania: results of a cohort study**  
R. Palladino<sup>1</sup>, A. Russo<sup>1</sup>, M. Pisaturo<sup>1</sup>, P. Maggi<sup>2</sup>, F.G. Numis<sup>3</sup>, I. Gentile<sup>4</sup>, C. Sagnelli<sup>1</sup>, V. Sangiovanni<sup>5</sup>, V. Esposito<sup>6</sup>, R. Punzi<sup>7</sup>, G. Calabria<sup>8</sup>, R. Pisapia<sup>9</sup>, A. Salomone Megna<sup>10</sup>, A. Masullo<sup>11</sup>, E. Manzillo<sup>12</sup>, R. Parrella<sup>13</sup>, G. Dell'Aquila<sup>14</sup>, A. Ponticciello<sup>15</sup>, C. Camaioni<sup>2</sup>, N. Coppola<sup>1</sup> Covicamp group  
<sup>1</sup>Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, <sup>2</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>3</sup>Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, <sup>4</sup>Infectious disease unit, University Federico II, Naples, Italy, <sup>5</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>6</sup>IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>7</sup>Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>8</sup>IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>9</sup>First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>10</sup>Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, <sup>11</sup>Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, <sup>12</sup>VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>13</sup>Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, <sup>14</sup>Infectious Diseases Unit, AO Avellino, Italy, <sup>15</sup>Pneumology Unit, AORN Caserta, Italy
- P 151 Anti-SARS-CoV-2 humoral and cellular immune responses in health care workers 4 months after a 4th vaccination with the Pfizer-BioNTech bivalent vaccine**  
C. Stefani<sup>1</sup>, M. Iannetta<sup>2</sup>, L. Benedetti<sup>2</sup>, A. Matucci<sup>2</sup>, L. Ferrari<sup>2</sup>, L. Sarmati<sup>2</sup>, D. Zipeta<sup>1</sup>, C. Piubelli<sup>2</sup>, A.M. Geretti<sup>1,4,5</sup>, A. Ruggiero<sup>1</sup>, EVAN-COV Study Group  
<sup>1</sup>Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, <sup>2</sup>Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy, <sup>4</sup>Infectious Diseases Unit, Fondazione PTV, University of Rome Tor Vergata, Rome, Italy, <sup>5</sup>School of Immunity and Microbial Sciences, King's College London, London, United Kingdom
- P 152 Analysis of T cell receptor repertoire in vaccinated and unvaccinated COVID-19 patients**  
E. Vecchio<sup>1</sup>, S. Rotundo<sup>2</sup>, C. Veneziano<sup>1</sup>, L. Berardelli<sup>2</sup>, S. Palma Gullì<sup>2</sup>, S. Mongiardì<sup>2</sup>, A. Abatino<sup>3</sup>, I. Aversa<sup>3</sup>, R. Gallo<sup>3</sup>, C. Giordano<sup>3</sup>, A. Russo<sup>2</sup>, E.M. Treccarichi<sup>2</sup>, C. Torti<sup>2</sup>, C. Palmieri<sup>3</sup>  
<sup>1</sup>Interdepartmental Centre of Services, "Magna Graecia" University of Catanzaro, Italy, <sup>2</sup>Department of Medical and Surgical Sciences, Chair of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro, Italy, <sup>3</sup>Department of Experimental and Clinical Medicine, University "Magna Graecia", Catanzaro, Italy
- P 153 Risk factors of prolonged SARS-CoV-2 infection in patients with mild symptoms, a retrospective analysis**  
F. Milite, A. Russo, M. Pisaturo, S. De Pascalis, C. Sagnelli, N. Coppola  
Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
- P 154 Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5 in booster vaccinated immunocompromised patients at the Infectious Diseases Clinic of Perugia**  
E. Schiaroli<sup>1</sup>, A. Gidari<sup>1</sup>, G. Brachelente<sup>2</sup>, G. Bicchieraro<sup>3</sup>, R. Spaccapelo<sup>4</sup>, S. Bastianelli<sup>1</sup>, S. Pierucci<sup>1</sup>, C. Busti<sup>1</sup>, C. Pallotto<sup>1</sup>, L. Malincarne<sup>1</sup>, B. Camilloni<sup>2</sup>, G.V. De Socio<sup>1</sup>, A. Villa<sup>2</sup>, A. Mencacci<sup>5</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>2</sup>Clinical Pathology and Ematology, Santa Maria della Misericordia Hospital, Perugia, Italy, <sup>3</sup>Genomics and Genetics Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>4</sup>Functional Genomic Center (C.U.R.Ge.F.), Department of Medicine and Surgery, Genomics and Genetics section Department of Medicine and Surgery, University of Perugia, <sup>5</sup>Microbiology and Clinical Microbiology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- P 155 A refine analysis on SARS-CoV-2 omicron variability in infected immunocompromised individuals**  
M.C. Bellocchi<sup>1</sup>, L. Carioti<sup>1</sup>, G. Marchegiani<sup>1</sup>, L. Coppola<sup>2</sup>, M. Iannetta<sup>2</sup>, L. Duca<sup>1</sup>, A. Di Lorenzo<sup>2</sup>, L. Alborghetti<sup>2</sup>, L. Piermatteo<sup>1</sup>, V. Malagnino<sup>2</sup>, L. Benedetti<sup>1</sup>, M.M. Santoro<sup>1</sup>, M. Andreoni<sup>2</sup>, L. Sarmati<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>  
<sup>1</sup>University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>University Hospital of Rome Tor Vergata, Rome, Italy
- P 156 A data-driven identification of PASC clusters to predict recovery**  
F. Motta<sup>1</sup>, V. Guidetti<sup>1</sup>, J. Milic<sup>1</sup>, A. Cattelan<sup>2</sup>, S. Cavinato<sup>2</sup>, M. Belli<sup>3</sup>, V. Menozzi<sup>1</sup>, M.D. Di Trapani<sup>1</sup>, S. Esperti<sup>1</sup>, G. Mancini<sup>3</sup>, C. Mussini<sup>1,3</sup>, F. Mandreoli<sup>1</sup>, G. Guaraldi<sup>1,3</sup>  
<sup>1</sup>Università degli Studi di Modena e Reggio Emilia, Modena, Italy, <sup>2</sup>Azienda Ospedale Università Padova, Padova, Italy, <sup>3</sup>Azienda Ospedaliero Universitaria di Modena, Modena, Italy

- P 157 Combination therapy to eradicate sarscov2 infection in a patient treated with CAR-T**  
M. Pisaturo<sup>1,2,3</sup>, A. Russo<sup>1,2,3</sup>, A. dell'Aquila<sup>3</sup>, I. Palma<sup>3</sup>, N. Carro<sup>3</sup>, P. Medusa<sup>3</sup>, C. Ricozzi<sup>3</sup>, S. Imbriani<sup>3</sup>, C. Sagnelli<sup>1,2,3</sup>, K. Gjelošić<sup>3</sup>, N. Coppola<sup>1,2,3</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Università degli studi della Campania Luigi Vanvitelli, <sup>2</sup>AOU Vanvitelli, Naples, <sup>3</sup>Covid 19 UNIT, Vanvitelli
- P 158 The hypothesis of dysergic diathesis in long-COVID syndrome and in SARS-Cov2 post-vaccination reactions: preliminary data from a prospective cohort study**  
D. Recinelli, E. Mazzotta, G. Rapacchiale, S. Coladonato, M. Bondanese, G. Ferrandu, S. Ianniruberto, F. Trave, D. Silletta, C. De Flaviis, E. Polliti, G. Parruti  
Infectious Disease Unit, Pescara's General Hospital
- P 159 Active role of Telefono Verde AIDS and IST in the communication on COVID-19 pandemic in Italy**  
E. Fanales Belasio, P. Gallo, R. Valli, R. dalla Torre, M. Schwarz, A. D'Agostini, A. Colucci  
Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione del Dipartimento Malattie Infettive – Istituto Superiore di Sanità, Rome, Italy
- P 160 SARS-CoV-2 seroprevalence and associated factors in young people living with HIV attending Youth-friendly Health services in the Sofala province, Mozambique**  
V. Casigliani<sup>1,2</sup>, R. Benoni<sup>1,3</sup>, A. Zin<sup>3</sup>, K. Chhaganlal<sup>4</sup>, H. Guambe Dos Anjos<sup>5</sup>, A. Merolle<sup>1</sup>, N. Ronzoni<sup>1</sup>, D. Giannini<sup>1</sup>, D. Donà<sup>3</sup>, C. Di Chiara<sup>3</sup>, G. Putato<sup>6</sup>, C. Giaquinto<sup>3</sup>  
<sup>1</sup>Doctors with Africa CUAMM, Beira, Mozambique, <sup>2</sup>Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, <sup>3</sup>Department of Women's and Children's Health, University of Padua, Padua, <sup>4</sup>Faculty of Medical Health Sciences, Universidade Católica de Moçambique, Beira, Mozambique, <sup>5</sup>UNICEF Mozambique, Maputo, Mozambique, <sup>6</sup>Operational Research Unit, Doctors with Africa CUAMM, Padua, Italy
- P 161 Are there any differences in effectiveness between available antivirals and monoclonal antibodies treatments in paucisymptomatic SARS-CoV-2 infected patients? A real life experience**  
L. Galli<sup>2</sup>, A. Lai<sup>1</sup>, A. Bergna<sup>1</sup>, C. della Ventura<sup>1</sup>, A. Riva<sup>1,2</sup>, L. Cordier<sup>2</sup>, G. Scaglione<sup>2</sup>, V. Colombo<sup>2</sup>, D. Bernasconi<sup>2</sup>, S. Landonio<sup>2</sup>, S. Sollima<sup>2</sup>, M. Corbellino<sup>2</sup>, G. Dedivittis<sup>2</sup>, G. Casalini<sup>2</sup>, S. Passerini<sup>2</sup>, M. Matone<sup>2</sup>, G. Rizzardini<sup>2</sup>, A. Gori<sup>2</sup>, S. Antinori<sup>1,2</sup>, D. Visigalli<sup>3</sup>, G. Zehender<sup>1</sup>, M. Schiavini<sup>2</sup>  
<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, <sup>2</sup>Infectious Diseases Department, L Sacco Hospital, Milan, Italy, <sup>3</sup>Pharmacy Unit, L Sacco Hospital, Milan, Italy
- P 162 Monoclonal antibodies (mAbs) and antiviral drugs for SARS-CoV2 treatment in patients with oncohematological disease**  
S.G. De Maria, S. Corazza, A. Grimaldi, A. Gasperin, D. Di Trento, S. Garattini, A. Carraro, V. Belvisi, B. Kertusha, A. Parente, P. Zuccalà, P. Fabietti, R. Marocco, C. Del Borgo, N. Cenfra, A. Romeo, M. Lichtner  
Università di Roma La Sapienza, Ospedale S.M. Goretti Latina
- P 163 Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and lung involvement in acute and post-acute SARS-CoV-2 infection**  
M.A. Zingaropoli<sup>1</sup>, T. Latronico<sup>2</sup>, P. Pasculli<sup>1</sup>, G.G. Masci<sup>3</sup>, R. Merz<sup>1</sup>, F. Ciccone<sup>1</sup>, F. Dominelli<sup>1</sup>, C. Del Borgo<sup>4</sup>, M. Lichtner<sup>4,5</sup>, F. Iafrate<sup>3</sup>, G. Galardo<sup>6</sup>, F. Pugliese<sup>7</sup>, V. Panebianco<sup>3</sup>, P. Ricci<sup>3,8</sup>, C. Catalano<sup>9</sup>, M.R. Ciardi<sup>1</sup>, G.M. Liuzzi<sup>2</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, Rome, Italy, <sup>2</sup>Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari "Aldo Moro", Bari, Italy, <sup>3</sup>Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>4</sup>Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza, University of Rome, Latina, Italy, <sup>5</sup>Department of Neurosciences Mental Health and Sensory Organs, Sapienza University of Rome, Italy, <sup>6</sup>Medical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy, <sup>7</sup>Department of Specialist Surgery and Organ Transplantation "Paride Stefanini", Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>8</sup>Unit of Emergency Radiology, Policlinico Umberto I, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>9</sup>Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
- P 164 Risk-factors for mortality of COVID-19 in hematologic patients: a multivariate analysis in Galliera hospital COVID-19 cohort**  
S. Boni, A. Parisini, F. Del Puente, E. Blasi Vacca, R. Prinapori, M. Feasi, N. Bobbio, E. Pontali  
S.C. Malattie Infettive Ente Ospedaliero Galliera Genova
- P 165 Remdesivir 3-day course reduces the risk of disease progression in a real-life matched cohort**  
A. De Vito<sup>1</sup>, A. Bitti<sup>1</sup>, L. Saderi<sup>2</sup>, M. Puci<sup>2</sup>, A. Colpani<sup>1</sup>, B. Zauli<sup>1</sup>, V. Fiore<sup>1</sup>, M. Fois<sup>1</sup>, M.C. Meloni<sup>1</sup>, G. Moi<sup>1</sup>, I. Maida<sup>1</sup>, S. Babudieri<sup>1</sup>, G. Sotgiu<sup>2</sup>, G. Madeddu<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Italy, <sup>2</sup>Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy
- P 166 SARS-CoV2 infection in dialysis patients: early treatment impact on clinical outcome**  
S. Corazza, S.G. De Maria, A. Grimaldi, S. Garattini, A. Carraro, D. Di Trento, A. Gasperin, V. Belvisi, T. Tieghi, P. Cirillo, B. Kertusha, A. Parente, P. Zuccalà, R. Marocco, Del Borgo, P. Fabietti, M. De Masi, M. Lichtner  
Sapienza, U.O.C. Malattie Infettive Santa Maria Goretti, Latina
- P 167 Sotrovimab vs Tixagevimab/Cilgavimab in outpatients with COVID-19: Clinical practice**  
F.R.P. Ieva, R. Papale, M.C. Polisenò, F. De Gregorio, C. Muscatello, G.A. Minafra, T.A. Santantonio, S. Lo Caputo  
Infectious Disease Unit, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy
- P 168 A comparative focus between immunocompromised and immunocompetent patients with COVID19 infection receiving early antiviral therapy in a real-world scenario**  
S. Garattini<sup>1,2</sup>, C. Bortignon<sup>1</sup>, A. Carraro<sup>1,2</sup>, D. Di Trento<sup>1,2</sup>, A. Gasperin<sup>1,2</sup>, A. Grimaldi<sup>1,2</sup>, S.G. De Maria<sup>1,2</sup>, S. Corazza<sup>1,2</sup>, V. Belvisi<sup>2</sup>, B. Kertusha<sup>2</sup>, A. Parente<sup>1,2</sup>, P. Zuccalà<sup>2</sup>, P. Fabietti<sup>2</sup>, E. Tortellini<sup>1,3</sup>, M.S. Guardiani<sup>1,3</sup>, A. Spagnoli<sup>1,3</sup>, R. Marocco<sup>2</sup>, C. Del Borgo<sup>2</sup>, D. Alunni Fegatelli<sup>1,3</sup>, M. Lichtner<sup>1,2,3</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, Santa Maria (SM) Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>3</sup>Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy
- P 169 The impact of cognitive reserve on neurocognitive impairment during long-COVID-19**  
G. Del Duca<sup>1</sup>, A.C. Brita<sup>1</sup>, A. Lonigro<sup>2</sup>, M. Camici<sup>1</sup>, I. Mastrorosa<sup>1</sup>, A. Vergori<sup>1</sup>, A. Mondì<sup>1</sup>, C. Pinnetti<sup>1</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup>Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, <sup>2</sup>Department of Education, University of Roma Tre, Italy
- P 170 Recurrent COVID-19 infection in a patient with post-remission onco-hematological diseases**  
A. Fulgione<sup>1</sup>, M. Pisaturo<sup>1,3</sup>, A. Russo<sup>1,3</sup>, A. dell'Aquila<sup>3</sup>, I. Palma<sup>3</sup>, N. Carro<sup>3</sup>, P. Medusa<sup>3</sup>, S. de Pascalis<sup>2</sup>, L. Alessio<sup>2</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania "Luigi Vanvitelli", <sup>2</sup>AOU Vanvitelli, Naples, <sup>3</sup>Covid 19 UNIT, Vanvitelli
- P 171 Is it possible to identify predictive factors for COVID-19 severe disease and mortality in the post-vaccine era? A real-life single cohort Italian experience**  
C. Fusetti<sup>1,2</sup>, A. Foschi<sup>1</sup>, M. Colaneri<sup>1</sup>, L. Cordier<sup>1</sup>, F. Borgonovo<sup>1,2</sup>, F. Petri<sup>1,2</sup>, M. Matone<sup>1,2</sup>, M. Gerbi<sup>1,2</sup>, M. Piscaglia<sup>1,2</sup>, D. Bernasconi<sup>1</sup>, I. Faggion<sup>1</sup>, G. Gubertini<sup>1</sup>, A. Gori<sup>1,2</sup>, G. Rizzardini<sup>1</sup>, M. Schiavini<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco – Milan (Italy), <sup>2</sup>University of Milan – Milan (Italy)
- P 172 The impact and outcome of early treatment for COVID-19 in transplanted patients: a real life study**  
A. Grimaldi, S.G. De Maria, S. Corazza, S. Garattini, A. Carraro, D. Di Trento, A. Gasperin, V. Belvisi, T. Tieghi, B. Kertusha, A. Parente, P. Zuccalà, R. Marocco, Del Borgo, P. Fabietti, M. De Masi, M. Lichtner  
Università Roma "La Sapienza"



- P 173 Risk Factors Associated with Long COVID: A Retrospective Study**  
P. Pasculli<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, F. Ciccone<sup>1</sup>, F. Paribeni<sup>1</sup>, G. Masci<sup>3</sup>, R. Merz<sup>1</sup>, F. Dominelli<sup>1</sup>, G. Siccardiv, S. Pellegrini<sup>1</sup>, M. Pasculli<sup>3</sup>, G. Galardo<sup>2</sup>, C.M. Mastroianni<sup>1</sup>, M.R. Ciardi<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Medical Emergency Unit, Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy, <sup>3</sup>Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
- P 174 Real-World Use of Sotrovimab in outpatients and hospitalized COVID-19 during Omicron pandemic wave**  
C. Muscatiello<sup>1,3</sup>, F. Cuccaro<sup>2</sup>, S. Bruno<sup>3</sup>, L. Montemurro<sup>3</sup>, A. Calamo<sup>3</sup>, A. Giannelli<sup>2</sup>, M. Mazzola<sup>3</sup>, S. Carbonara<sup>3</sup>  
<sup>1</sup>Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>2</sup>Epidemiology and Statistics Unit, Barletta, Local Health Unit BT, Italy, <sup>3</sup>Infectious Diseases Unit, V. Emanuele II Hospital, Bisceglie, Local Health Unit BT, Italy
- P 175 Sotrovimab treatment in Severe COVID-19**  
C. Muscatiello<sup>1,3</sup>, F. Cuccaro<sup>2</sup>, S. Bruno<sup>3</sup>, L. Montemurro<sup>3</sup>, M. Altamura<sup>3</sup>, G. Infante<sup>3</sup>, R. Losappio<sup>3</sup>, S. Carbonara<sup>3</sup>  
<sup>1</sup>Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, <sup>2</sup>Epidemiology and Statistics Unit, Barletta, Local Health Unit BT, Italy, <sup>3</sup>Infectious Diseases Unit, V. Emanuele II Hospital, Bisceglie, Local Health Unit BT, Italy
- P 176 A SARS-CoV-2 cluster in patients with onco-hematological disease**  
A. Gasperin<sup>1</sup>, D. Di Trento<sup>1</sup>, S.G. De Maria<sup>1</sup>, M. Lichtner<sup>1,3</sup>, S. Perrone<sup>2</sup>, E. Ortu La Barbera<sup>2</sup>, C. Del Borgo<sup>1</sup>, A. Carraro<sup>1</sup>, T. Tieghi<sup>1</sup>, B. Kertusha<sup>1</sup>, P. Fabietti<sup>1</sup>, V. Belvisi<sup>1</sup>, R. Marocco<sup>1</sup>, M. De Masi<sup>1</sup>, A. Grimaldi<sup>1</sup>, S. Corazza<sup>1</sup>, S. Garattini<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, SM Goretti Hospital, Latina, <sup>2</sup>Hematology Operative Unit, SM Goretti Hospital, Latina, <sup>3</sup>Department of Public Health and Infectious Diseases, "La Sapienza" University, Rome
- P 177 SARS-CoV-2 infection in oncohematological patients: a real-world experience**  
F. Izzo<sup>1</sup>, S. Garattini<sup>1</sup>, S. Di Bari<sup>2</sup>, L. Bresciani<sup>2</sup>, A. Carraro<sup>1</sup>, A. Gasperin<sup>1</sup>, D. Di Trento<sup>1</sup>, G. Mancarella<sup>1</sup>, A. Parente<sup>1</sup>, A. Grimaldi<sup>1</sup>, S. Corazza<sup>1</sup>, S.G. De Maria<sup>1</sup>, A. Destro<sup>1</sup>, B. Kertusha<sup>1</sup>, T. Tieghi<sup>1</sup>, C. Del Borgo<sup>1</sup>, P. Cirillo<sup>1</sup>, C. Pasquazzi<sup>2</sup>, A. Teggi<sup>2</sup>, M. Lichtner<sup>1</sup>  
<sup>1</sup>Dept of Public Health and Infectious Disease, "Santa Maria Goretti" Hospital, Sapienza University of Rome, Latina, Latium, Italy, <sup>2</sup>Dept of Public Health and Infectious Disease, "Sant'Andrea" Hospital, Sapienza University of Rome, Rome, Latium, Italy
- P 178 Characterization and monitoring of post-acute sequelae of SARS-CoV-2 infection (PASC) through a voice assistant platform: an ecological prospective study**  
A. Caselgrandi<sup>1</sup>, J. Milic<sup>2</sup>, L. Gozzi<sup>2</sup>, S. Renzetti<sup>3</sup>, F. Motta<sup>4</sup>, M. Pacchioni<sup>5</sup>, M. Orsini<sup>5</sup>, E. Mescoli<sup>2</sup>, L. Sighinolfi<sup>2</sup>, M. Belli<sup>2</sup>, V. Menozzi<sup>6</sup>, M.D. Di Trapani<sup>6</sup>, S. Esperti<sup>6</sup>, F. Mediolio<sup>6</sup>, G. Mancini<sup>6</sup>, A. Verduri<sup>6</sup>, B. Beghe<sup>7,8</sup>, E. Clini<sup>7,8</sup>, S. Calza<sup>9</sup>, C. Mussini<sup>2,6</sup>, G. Guaraldi<sup>2,6</sup>  
<sup>1</sup>School of Medicine and Surgery, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Italy, <sup>3</sup>Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy, <sup>4</sup>Department of Physics, Informatics and Mathematics, University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>DataRiver Srl, Modena, Italy, <sup>6</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>7</sup>Respiratory Unit, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, <sup>8</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena, and Reggio Emilia, Modena, Italy, <sup>9</sup>Department of Molecular and Translational Medicine, University of Brescia, Italy
- P 179 Importance of use of antiviral and monoclonal therapies in patients at risk of developing severe disease and complications from SARS-CoV2 infection: experience of COVID-DH of Pescara Civil Hospital**  
D.A. Silleta, G. Rapacchiale, D. Recinelli, E. Mazzotta, M. Bondanese, S. Colanato, S. Ianniruberto, G. Ferrandu, F. Trave, C. De Flavis, M. Giulianelli, D. Pietrantonio, G. Aventaggiato, G. Parruti  
Infectious Disease Unit, Pescara's General Hospital
- P 180 The clinical management of fully vaccinated patients at high risk of disease progression with symptomatic COVID-19 infection at ASST Lecco: Real-life experience**  
L. Bradanini<sup>1</sup>, S. Pontiggia<sup>1</sup>, M. Bottanelli<sup>2</sup>, R. Monardo<sup>2</sup>, F. Badalucco Ciotta<sup>2</sup>, D. Tuoli<sup>1</sup>, V. Morena<sup>1</sup>, F. Conti<sup>1</sup>, C. Molteni<sup>1</sup>, A. Pandolfo<sup>1</sup>, A. Castagna<sup>2</sup>, S. Piconi<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, <sup>2</sup>Università Vita-Salute San Raffaele, Milan, Italy
- P 181 Evaluation of the immune response to SARS-CoV-2 vaccination one year after the booster dose in oncology patients**  
R. Campagna<sup>1</sup>, F. Dominelli<sup>2</sup>, M.A. Zingaropoli<sup>2</sup>, F. Ciurlini<sup>3</sup>, V. Picone<sup>4</sup>, E. Cortesi<sup>4</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>  
<sup>1</sup>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, <sup>2</sup>Department of Public Health and Infectious diseases, Sapienza University of Rome, <sup>3</sup>Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, <sup>4</sup>Medical Oncology Department, Policlinico Umberto I, Sapienza University of Rome
- P 182 SARS-CoV-2 infection in patients with haematological malignancies: in search of lost timing?**  
R. Astorri<sup>1,2</sup>, N. Carro<sup>2</sup>, A. Dell'Aquila<sup>2</sup>, P. Medusa<sup>2</sup>, I. Palma<sup>2</sup>, S. Imbriani<sup>2</sup>, K. Gjeloghi<sup>2</sup>, C. Ricozzi<sup>2</sup>, Russo<sup>1,2</sup>, C. Sagnelli<sup>1,2</sup>, M. Pisaturo<sup>1,2</sup>, N. Coppola<sup>1,2</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, Naples, Italy, <sup>2</sup>Vanvitelli COVID-19 Unit, University of Campania L. Vanvitelli, Naples, Italy

## Epidemiology and Prevention

- P 183 Convenient&Quick - Let's do it in Pharmacies**  
R. Galipò<sup>1</sup>, R. Bellagamba<sup>1,2</sup>, E. Farinola<sup>1</sup>, P. Ferri<sup>1</sup>, A. Palummiri<sup>1</sup>  
<sup>1</sup>Anlaid Lazio, Rome, <sup>2</sup>INMI Spallanzani, Rome
- P 184 Sexually Transmitted Infections' (STIs) screening offered by not-for-profit sector entities during the COVID-19 pandemic: a descriptive observational study of the population accessing a LGBT+ dedicated service**  
R. Piccirillo, B. Allegretti, G. Alicino, S. Carotenuto, A. Cioffi, G. Cioffi, V. Coluccino, G. D'Ambrosio, B. Diana, F. Merolle, N. Piazza  
Rain Arcigay Caserta ODV, Caserta, Università degli studi di Palermo dipartimento di Igiene e medicina Preventiva, Palermo
- P 185 The future impact of SARS-CoV-2 on sexually transmitted diseases spread**  
I. Uccella<sup>1</sup>, E. Anzalone<sup>1</sup>, S. Viri<sup>1</sup>, C. Gargiulo<sup>2</sup>, R. Pulselli<sup>2</sup>, C. Sias<sup>2</sup>  
<sup>1</sup>UOSD AIDS, F. Spaziani Hospital, Frosinone, Italy, <sup>2</sup>Clinical Pathology, F. Spaziani Hospital, Frosinone, Italy
- P 186 Human papillomavirus vaccine uptake before and after the implementation of an on-site vaccination service at an HIV clinic in Milan, Italy: a retrospective observational study**  
A. Giacomelli<sup>1</sup>, M.L. Colombo<sup>1,2</sup>, M.V. Cossu<sup>3</sup>, D. Moschese<sup>3</sup>, G. Carrozza<sup>1,2</sup>, A. Poloni<sup>1,2</sup>, G. Casalini<sup>1,2</sup>, G. Pozza<sup>1,2</sup>, L. Oreni<sup>1</sup>, S. Antinori<sup>1,2</sup>, A.L. Ridolfo<sup>1</sup>  
<sup>1</sup>III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>Università degli Studi di Milano, DIBIC Luigi Sacco, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- P 187 Incidence of HCV and HIV in the female prison population: Analysis of two Italian centers**  
V. Manca<sup>1</sup>, V. Fiore<sup>1</sup>, N. Geremia<sup>2</sup>, I. Maida<sup>1</sup>, S. Babudieri<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Clinical Medicine, "Ospedale dell'Angelo", Venezia, Italy

- P 188 Detection of asymptomatic Mpox virus infection in high-risk men who have sex with men: a prospective analysis**  
R. Rossotti<sup>1,2</sup>, D. Calzavara<sup>2</sup>, M. Cernuschi<sup>2,3</sup>, F. D'Amico<sup>1</sup>, D. Moschese<sup>2,4</sup>, A. De Bona<sup>2,5</sup>, S. Bossolasco<sup>2,3</sup>, D. Tesoro<sup>2,5</sup>, C. Muccini<sup>2,3</sup>, A. d'Arminio Monforte<sup>6</sup>  
<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>2</sup>Milano Checkpoint, Milan, Italy, <sup>3</sup>San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>ASST Fatebenefratelli Sacco, Milan, Italy, <sup>5</sup>ASST Santi Paolo e Carlo, Milan, Italy, <sup>6</sup>University of Milan, Milan, Italy
- P 189 Life expectancy and determinants of increased risk of death in PLWH**  
F. Maggiolo<sup>1</sup>, L. Comi<sup>1</sup>, D. Valenti<sup>1,2</sup>, R. Teocchi<sup>3</sup>, E. Di Filippo<sup>1</sup>, S. Venturelli<sup>1</sup>  
<sup>1</sup>UOC Infectious Diseases, <sup>2</sup>FROM foundation, <sup>3</sup>Informatics department, ASST Papa Giovanni XXII, Bergamo Italy
- P 190 Use of MVA-BN vaccine in the context of the current Mpox outbreak: early experience of an infectious and tropical diseases unit in Florence, Italy**  
F. Lagi<sup>1</sup>, G. Formica<sup>2</sup>, S. Gaggioli<sup>2</sup>, V. Petrini<sup>2</sup>, P. Corsi<sup>1</sup>, A. Di Felice<sup>2</sup>, C. Fiorelli<sup>1</sup>, C. Malcontenti<sup>1</sup>, E. Francalanci<sup>2</sup>, G. Modì<sup>2</sup>, M. Trotta<sup>1</sup>, S.T. Kirois<sup>2</sup>, E. Gazzarri<sup>3</sup>, I. Macri<sup>3</sup>, N. Zocco<sup>3</sup>, A. Bartoloni<sup>1,2</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, <sup>2</sup>Department of Experimental and Clinical Medicine, University of Florence, Florence Italy, <sup>3</sup>Cooperativa Sociale C.A.T. Street unit Vivian Love, project S.A.T.I.S., Florence, Italy
- P 191 Outbreak of HIV among people who inject drugs discovered through phylogenetic analysis: are we seeing just the top of the iceberg?**  
A. Soria<sup>1</sup>, M. Carboti<sup>1,2</sup>, B. Monti<sup>1,3</sup>, G. Papatratto<sup>4</sup>, M. Tallarita<sup>1</sup>, M. Sciabica<sup>1</sup>, S. Malandrini<sup>1</sup>, E. Chiesa<sup>1</sup>, P. Fortuna<sup>1</sup>, N. Squillace<sup>1</sup>, E. Colella<sup>1</sup>, P. Columpsi<sup>1</sup>, G. Bozzi<sup>5</sup>, C. Alteri<sup>6</sup>, L. Tavoschi<sup>4</sup>, G. Lapadula<sup>1,3</sup>, P. Bonfanti<sup>1,3</sup>  
<sup>1</sup>Fondazione IRCCS San Gerardo dei Tintori, Monza, <sup>2</sup>University of Pavia, Pavia, <sup>3</sup>University of Milano-Bicocca, Monza, <sup>4</sup>University of Pisa, Pisa, <sup>5</sup>Fondazione IRCCS Ca' Granda Policlinico, Milan, <sup>6</sup>University of Milan, Milan
- P 192 Evaluation of the acceptance of salivary rapid HIV tests in the IDU population afferent to the Ser.D. of Treviso**  
M.C. Rossi<sup>1</sup>, F. Farina<sup>1</sup>, G. Berto<sup>2</sup>, S. Pavanello<sup>2</sup>, E. Marzola<sup>2</sup>, G.M. Mauro<sup>2</sup>, M. Piccinini<sup>2</sup>, V. Pagnotta<sup>2</sup>, E. Favero<sup>2</sup>, A. Bertocco<sup>2</sup>, L. Sutto<sup>2</sup>, R. Manera<sup>2</sup>  
<sup>1</sup>ANLAIDS Treviso, Treviso, <sup>2</sup>Unità Dipartimentale per le Dipendenze, Azienda ULSS 2 "Marca Trevigiana", Treviso
- P 193 Lack of antibody protection for HBV in young people undergoing non-occupational Post-Exposure Prophylaxis (PEP) for HIV in a large tertiary hospital in Milan, Italy**  
G. Bozzi<sup>1</sup>, A. Liparoti<sup>1,2</sup>, M. Fava<sup>1,2</sup>, G. Ancona<sup>1</sup>, C. Bobbio<sup>1</sup>, N. Iannotti<sup>1</sup>, B. Mariani<sup>1</sup>, A. Muscatello<sup>1</sup>, A. Bandera<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, <sup>2</sup>Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy
- P 194 High Prevalence of HIV Infection and Late Diagnoses by HIV indicator conditions guided screening in the Emergency Department: Preliminary Results from the INDI Study**  
D. Barbanotti<sup>1</sup>, A. Santoro<sup>1</sup>, C. Tincati<sup>1</sup>, A. Tavelli<sup>1</sup>, L. Colombo<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, <sup>2</sup>Emergency Department, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, University of Milan, Italy
- P 195 Highlights from an ongoing anal cancer prevention protocol for people living with HIV at the Infectious and Tropical Diseases Unit of Padua University Hospital**  
D. Leoni<sup>1</sup>, C. Ruffolo<sup>2</sup>, M. Mazzitelli<sup>1</sup>, L. Sasseti<sup>1</sup>, M. Scarpa<sup>2</sup>, A. Masini<sup>2</sup>, S. Gardin<sup>1</sup>, S. Pucciarelli<sup>2</sup>, A.M. Cattelan<sup>1</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, <sup>2</sup>General Surgery 3 Unit, Padua University Hospital, Padua, Italy
- P 196 Strategies to reduce vaccine hesitancy. First step: know your population. A single center in-dept analysis of PLWHA adherence to vaccination schedule**  
G. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, M.C. Ottino<sup>2</sup>, A. Ianniello<sup>1</sup>, E. Remani<sup>3</sup>, G. Lo Moro<sup>4</sup>, F. Bert<sup>4</sup>, G.D. Greco<sup>5</sup>, G. Calleri<sup>1</sup>  
<sup>1</sup>Divisione A Mal Inf e Trop, Ospedale Amedeo di Savoia, Torino, <sup>2</sup>Dipartimento di Scienze Mediche, Università di Torino, <sup>3</sup>Farmacia Ospedaliera, Ospedale Amedeo di Savoia, Torino, <sup>4</sup>Dipartimento di Salute Pubblica, Università di Torino, <sup>5</sup>SSD SISP Emergenze infettive e Prevenzione, ASL Città di Torino
- P 197 Retrospective analysis of accidental and occupational exposures, post-exposure prophylaxis (PEP) prescription and surveillance program in a large Hospital, Northern Italy**  
S. Arsuffi<sup>1</sup>, D. Minisci<sup>1</sup>, B. Fioretti<sup>1</sup>, F. Pennati<sup>1</sup>, I. Izzo<sup>1</sup>, S. Di Iuglio<sup>1</sup>, I. Polesini<sup>1</sup>, D. Bonetta<sup>1</sup>, I. El Hamad<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>  
Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- P 198 HPV vaccination coverage in MSM living with HIV: a retrospective monocentric study in Northern Italy**  
D. Laurenda<sup>1</sup>, D. Castelli<sup>1</sup>, I. Izzo<sup>1</sup>, I. Polesini<sup>1</sup>, F. Gaffurini<sup>1</sup>, E. Focà<sup>1</sup>, P. Zanotti<sup>1</sup>, S. Arsuffi<sup>1</sup>, M. Migliorati<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>  
Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- P 199 Do we think enough about strongyloidiasis, schistosomiasis and Chagas disease among HIV-positive migrant patients? Screening ratio and seroprevalence in a tertiary health-care center in Italy**  
A. Barbiero<sup>1</sup>, R. Paggi<sup>1</sup>, C. Malcontenti<sup>2</sup>, M. Pozzi<sup>2</sup>, F. Lagi<sup>2</sup>, A. Mantella<sup>1,3</sup>, S. Tekle Kirois<sup>1</sup>, A. Bartoloni<sup>1,2,3</sup>, L. Zammarchi<sup>1,2,3</sup>  
<sup>1</sup>Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Firenze, <sup>2</sup>SOD Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria Careggi, Firenze, <sup>3</sup>Centro di Riferimento Regionale per le Malattie Tropicali, Azienda Ospedaliera Universitaria Careggi, Firenze
- P 200 Monkeypox vaccination in a cohort of people on pre-exposure prophylaxis (PrEP) or living with HIV infection (PLWH): a retrospective observational study from the Umbria region, Italy**  
G. Quartini<sup>1</sup>, G. Genga<sup>2</sup>, C. Vernelli<sup>1</sup>, B. Tiri<sup>1</sup>, C. Pallotto<sup>2</sup>, M.B. Pasticci<sup>1</sup>, D. Francisci<sup>2</sup>  
<sup>1</sup>Infectious Disease Clinic, Ospedale Santa Maria Terni, Università degli Studi di Perugia, Terni, <sup>2</sup>Infectious Disease Clinic, Ospedale Santa Maria della Misericordia, Università degli Studi di Perugia, Perugia
- P 201 HIV Testing in the Emergency Department: an effective strategy to increase new diagnoses**  
F. Romano<sup>1</sup>, A. Lazzaro<sup>1</sup>, A. Falletta<sup>1</sup>, L. Santinelli<sup>1</sup>, F. Cancelli<sup>1</sup>, F. Biamonte<sup>2</sup>, L. Zinamosca<sup>2</sup>, G. Della Grotta<sup>2</sup>, C. Marinelli<sup>2</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. Galardo<sup>2</sup>, G. d'Ettore<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, <sup>2</sup>Medical Emergency Unit, Sapienza University of Rome, Rome, Italy
- P 202 HPV vaccination days in HIV and STI outpatient clinic**  
A. Carraro<sup>1,2</sup>, E. Tortellini<sup>2</sup>, S. Guardiani<sup>2</sup>, S. Garattini<sup>2</sup>, S. Corazza<sup>2</sup>, A. Destro<sup>2</sup>, R. Marocco<sup>1</sup>, V. Belvisi<sup>1</sup>, F. Dominelli<sup>1</sup>, C. Falvino<sup>1</sup>, C. Giambi<sup>3</sup>, A. Zerbetto<sup>3</sup>, M. Lichtner<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, <sup>3</sup>Prevention Unit, ASL Latina, Latina
- P 203 Missed opportunities in HIV diagnosis: to recognize sentinel conditions for HIV to reduce late presentation in an urban setting in northern Italy**  
M. Bavastro<sup>1,2</sup>, M. Cerchiaro<sup>1,2</sup>, L. Labate<sup>1,2</sup>, C. Russo Artimagnella<sup>1,2</sup>, S. Cardaci<sup>1</sup>, L. Crupi<sup>1,2</sup>, G. Brucci<sup>1,2</sup>, L. Taramasso<sup>1</sup>, M. Bassetti<sup>1,2</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

## Hepatitis and other viral infections

- P 204 An Occult hepatitis B virus Infection Reactivation in an HIV/HCV Coinfected patient during an Immune Reconstitution Inflammatory Syndrome**  
S. Zaltron, A. Cambianica, M. Di Gregorio, C. Colangelo, S. Storti, G. Tiecco, E. Quiros-Roldan  
Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy, Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy
- P 205 Human Orf: an under-recognized and under-reported viral infection**  
L. Rossi<sup>1</sup>, G. Tiecco<sup>1</sup>, M. Salvi<sup>1</sup>, M. Venturini<sup>2</sup>, F. Castelli<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>  
<sup>1</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Section of Dermatology, University of Brescia, Brescia, Italy
- P 206 Evaluation of the effectiveness of a population-based health policy to increase HCV treatment coverage: an interrupted time series analysis**  
L. Ceccarelli<sup>1,2</sup>, C. Seghieri<sup>2</sup>, C. Tortù<sup>2</sup>, L. Tavoschi<sup>3</sup>  
<sup>1</sup>Università di Bologna, Bologna, <sup>2</sup>Scuola Superiore Sant'Anna, Pisa, <sup>3</sup>Università di Pisa, Pisa
- P 207 Evaluation of anti-Mpox IgG development in infected patients**  
D. Farinacci<sup>1</sup>, F. Lombardi<sup>2</sup>, A. Ciccullo<sup>3</sup>, G. Baldin<sup>4</sup>, E. Visconti<sup>4</sup>, A. Borghetti<sup>4</sup>, S. Di Giambenedetta<sup>2,4</sup>  
<sup>1</sup>UOC Medicina Protetta – Malattie Infettive, ASL Viterbo, <sup>2</sup>Università Cattolica Del Sacro Cuore, Roma, <sup>3</sup>Ospedale San Salvatore, L'Aquila, <sup>4</sup>Fondazione Policlinico Universitario "A. Gemelli", Roma
- P 208 Performance evaluation of HIV-2 RNA plasma quantification using a commercial RUO RT-PCR assay**  
F. Salari, A. Rizzo, F. Bracchitta, L. Morelli, A. Tamoni, F. De Poli, M. Cuomo, M. R. Gismondo, V. Micheli  
Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, "L. Sacco" University Hospital, Milan, Italy
- P 209 Inherited chromosomally integrated HHV6: a case report**  
G. D'Aguzzo<sup>1</sup>, F. Savalli<sup>1</sup>, G. Consuelo<sup>1</sup>, P. Miraglia<sup>1</sup>, M.C. Morsellino<sup>1</sup>, S. Cianchino<sup>1</sup>, G. Colomba<sup>2</sup>, G. Di Quattro<sup>2</sup>, P. Colletti<sup>1</sup>  
<sup>1</sup>Department of Infection Diseases, Paolo Borsellino Hospital (Marsala), <sup>2</sup>Microbiology Department, Villa Sofia-Cervello Hospital (Palermo)
- P 210 Early HCV treatment during RCHOP therapy in subjects with non Hodgkin lymphoma**  
R. Palladino<sup>1</sup>, G. Stornaivolo<sup>2</sup>, M. Stanzione<sup>2</sup>, C. Liagkou<sup>1</sup>, M. Pisaturo<sup>1</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Dipartimento di salute mentale, fisica e medicina preventiva, Università degli studi della Campania L. Vanvitelli, Napoli, <sup>2</sup>AOU Vanvitelli, Napoli
- P 211 Hepatic flare and immune reconstitution in Hepatitis B Virus-Human Immunodeficiency Virus coinfecting patients**  
A.M.A. Crea<sup>1</sup>, L. Campogiani<sup>1</sup>, T. Mulas<sup>1</sup>, M. Compagno<sup>1</sup>, A. Di Lorenzo<sup>1</sup>, E. Teti<sup>1</sup>, V. Malagnino<sup>1,2</sup>, M. Andreoni<sup>2</sup>, L. Sarmati<sup>1,2</sup>, M. Iannetta<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit-Policlinico Tor Vergata, Rome, Italy, <sup>2</sup>Department of System medicine-Tor Vergata University, Rome, Italy
- P 212 Tuscany Region: Epidemiology of Hepatitis C**  
M.P. Tramonti Fantozzi<sup>1</sup>, L. Ceccarelli<sup>1,2</sup>, D. Petri<sup>1</sup>, A. Agostini<sup>1</sup>, R. Berni<sup>3</sup>, C. Bianco<sup>4</sup>, S. Chigiotti<sup>5</sup>, P. Colombatto<sup>6</sup>, S. Iacopini<sup>7</sup>, E. Mariabelli<sup>8</sup>, S. Modica<sup>7</sup>, S. Moneta<sup>7</sup>, G. Ottaviano<sup>5</sup>, F. Panza<sup>9</sup>, P. Pierotti<sup>8</sup>, A. Porretta<sup>1</sup>, D. Redi<sup>4</sup>, B. Rossetti<sup>5</sup>, C. Stasi<sup>10</sup>, P. Blanc<sup>8</sup>, M.R. Brunetto<sup>6</sup>, M. Fabbiani<sup>9</sup>, S. Luchi<sup>7</sup>, C. Nencioni<sup>2</sup>, C. Silvestri<sup>2</sup>, D. Tacconi<sup>1</sup>, A.L. Zignego<sup>10</sup>, L. Tavoschi<sup>1</sup>  
<sup>1</sup>Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy, <sup>2</sup>Infectious Diseases Unit, Department of Medical and Surgical Sciences, Policlinico Sant'Orsola Malpighi, University of Bologna, Bologna, Italy, <sup>3</sup>Epidemiology Unit, Tuscany Regional Health Agency, Florence, Italy, <sup>4</sup>Division of Infectious Diseases, Arezzo Hospital, Arezzo, Italy, <sup>5</sup>Division of Infectious Diseases, AUSL Toscana Sud Est, Grosseto Hospital, Grosseto, Italy, <sup>6</sup>Hepatology Unit, University Hospital of Pisa, Pisa, Italy, <sup>7</sup>Division of Infectious Diseases and Hepatology, San Luca Hospital, AUSL Toscana Nord Ovest, Lucca, <sup>8</sup>Division of Infectious Diseases 1-2 AUSL Toscana Centro, Firenze, Italy, <sup>9</sup>Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy, <sup>10</sup>Careggi University Hospital, Florence, Italy
- P 213 Patient with HCV/HBV-related cirrhosis and colon cancer: a difficult patient to treat**  
C. Liagkou<sup>1</sup>, G. Stornaivolo<sup>2</sup>, M. Stanzione<sup>2</sup>, R. Palladino<sup>1</sup>, M. Pisaturo<sup>1</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Dipartimento di salute mentale, fisica e medicina preventiva, Università degli studi della Campania L. Vanvitelli, Napoli, <sup>2</sup>AOU Vanvitelli, Napoli
- P 214 Pathways underlying HDV persistence act independently from the extent of HBV reservoir and are sustained by an abundant production of HBsAg derived from integrated HBV-DNA**  
R. Salpini<sup>1</sup>, S. D'Anna<sup>1</sup>, L. Piermatteo<sup>1,2</sup>, E. Teti<sup>3</sup>, A. Di Lorenzo<sup>3</sup>, G. Brancaccio<sup>4</sup>, G. Torre<sup>1</sup>, V. Malagnino<sup>3</sup>, M. Iannetta<sup>3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C. Pasquazzi<sup>5</sup>, U. Cillo<sup>6</sup>, A. Vitale<sup>6</sup>, E. Gringeri<sup>6</sup>, M. Magrofuoco<sup>6</sup>, M. Pacenti<sup>7</sup>, L. Baiocchi<sup>8</sup>, S. Francioso<sup>9</sup>, I. Lenci<sup>8</sup>, A.M. Geretti<sup>8</sup>, M.L. Abate<sup>2</sup>, M. Milella<sup>10</sup>, A. Saracino<sup>10</sup>, A. Olivero<sup>9</sup>, G.B. Gaeta<sup>11</sup>, L. Sarmati<sup>3</sup>, M. Rizzetto<sup>9</sup>, G.P. Caviglia<sup>9</sup>, V. Svicher<sup>1,2</sup>  
<sup>1</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, <sup>2</sup>Department of Biology, University of Rome Tor Vergata, Rome, Italy, <sup>3</sup>Department of Medicine and Surgery, Infectious Disease Clinic, University of Rome Tor Vergata, Rome, Italy, <sup>4</sup>Infectious Diseases Unit, Department of Molecular Medicine, University of Padova, Padova, Italy, <sup>5</sup>Sant'Andrea Hospital, Rome, Italy, <sup>6</sup>Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy, <sup>7</sup>Microbiology and Virology Unit, Padova University Hospital, Padova, Italy, <sup>8</sup>Hepatology Unit, Policlinico Tor Vergata, Rome, Italy, <sup>9</sup>Department of Medical Sciences, University of Turin, Turin, Italy, <sup>10</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>11</sup>Infectious Disease Unit, University L. Vanvitelli, Naples, Italy
- P 215 Kinetics of the three HBsAg isoforms along with HDV-RNA predict virological response in CHD patients treated with bulevirtide up to 96 weeks**  
S. D'Anna<sup>1</sup>, R. Salpini<sup>1</sup>, E. Degasperi<sup>2</sup>, L. Duca<sup>1</sup>, M.P. Anolli<sup>2</sup>, L. Piermatteo<sup>1,3</sup>, D. Sambarino<sup>2</sup>, M. Borghi<sup>2</sup>, F. Facchetti<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, R. Perbellini<sup>2</sup>, P. Lampertico<sup>2,4</sup>, V. Svicher<sup>1,3</sup>  
<sup>1</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, <sup>2</sup>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, <sup>3</sup>University of Rome Tor Vergata, Department of Biology, Rome, Italy, <sup>4</sup>CRC "A. M. and A. Migliaiavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
- P 216 Identification of novel molecular targets for therapeutic reconstitution of HBV-specific CD8 T cell reactivity in chronic hepatitis B virus infection**  
I. Montali<sup>1</sup>, C. Ceccatelli Berti<sup>1</sup>, M. Morselli<sup>2</sup>, C. Boni<sup>3</sup>, A. Penna<sup>3</sup>, D. Laccabue<sup>1,3</sup>, A. Vecchi<sup>3</sup>, M. Rossi<sup>1</sup>, C. Tiezzi<sup>1,3</sup>, V. Reverberi<sup>3</sup>, A. Montali<sup>1</sup>, S. Doselli<sup>2</sup>, A. Alfieri<sup>2</sup>, D. Sambarino<sup>4</sup>, P. Lampertico<sup>4,5</sup>, M. Massari<sup>6</sup>, G. Missale<sup>1,3</sup>, C. Ferrari<sup>1,3</sup>, P. Fiscaro<sup>3</sup>  
<sup>1</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy, <sup>2</sup>Laboratory of Biochemistry and Molecular Biology, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy, <sup>3</sup>Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy, <sup>4</sup>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, <sup>5</sup>CRC "A. M. and A. Migliaiavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, <sup>6</sup>Unit of Infectious Diseases, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- P 217 Ecthyma gangrenosum with facial and oral localization in a young neutropenic woman with recent Dengue infection**  
F. Catania<sup>1</sup>, F. Damiano<sup>1,2</sup>, I.M. Izzi<sup>1,2</sup>, F. Raffaelli<sup>2</sup>, F. Frondizi<sup>1</sup>, E. Matteini<sup>1</sup>, F. Sangiorgi<sup>1</sup>, G. Scoppettuolo<sup>2</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore - Rome (Italy), <sup>2</sup>Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy)
- P 218 HCV relapse after sofosbuvir/velpatasvir/voxilaprevir in a patient with chronic lymphocytic leukemia: speculations on a potential cause**  
C. Fusetti<sup>1,2</sup>, C. Magni<sup>1</sup>, D. Moschese<sup>1</sup>, R. Giorgi<sup>1</sup>, S. Merli<sup>1</sup>, F. Petri<sup>1,2</sup>, M.V. Cossu<sup>1</sup>, G. Gubertini<sup>1</sup>, G. Rizzardini<sup>1</sup>, A. Gori<sup>1,2</sup>  
<sup>1</sup>Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco - Milan, Italy, <sup>2</sup>University of Milan, Milan - Italy

- P 219 Preliminary results of a Case Finding and Linkage to Care program for high-risk HCV infected individuals**  
F.G. Spatola<sup>1</sup>, M. Pisaturo<sup>1</sup>, P. Grimaldi<sup>1</sup>, S. Capuano<sup>1</sup>, A. Russo<sup>1</sup>, F. Ambrisi<sup>1</sup>, F. Milite<sup>1</sup>, B. Morello<sup>1</sup>, F. Sautariello<sup>1</sup>, C. Sagnelli<sup>1</sup>, M. Stanzione<sup>2</sup>, G. Stornaiuolo<sup>2</sup>, P. Caruso<sup>3</sup>, K. Esposito<sup>4</sup>, M.R. Rizzo<sup>3</sup>, F. Simonelli<sup>4</sup>, P. Bucci<sup>1</sup>, S. Galderisi<sup>1</sup>, N. Coppola<sup>1</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli" - Napoli (Italy), <sup>2</sup>AOU Luigi Vanvitelli - Napoli (Italy), <sup>3</sup>Department of Advanced Medical and Surgical Sciences (DAMSS) University of Campania "L. Vanvitelli" - Napoli (Italy), <sup>4</sup>Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "L. Vanvitelli" - Napoli (Italy)
- P 220 Long-term mortality after HCV eradication among PLWH**  
A. Siribelli<sup>2</sup>, S. Diotallevi<sup>2</sup>, L. Galli<sup>2</sup>, G. Morsica<sup>2</sup>, R. Lolatto<sup>2</sup>, C. Bertoni<sup>2</sup>, E. Messina<sup>2</sup>, C. Tassan Din<sup>2</sup>, M. Ripa<sup>1,2</sup>, C. Uberti-Foppa<sup>1,2</sup>, A. Castagna<sup>1,2</sup>, H. Hasson<sup>2</sup>  
<sup>1</sup>Vita-Salute University, Milan, Italy, <sup>2</sup>Unit of Infectious Diseases, San Raffaele Hospital, Milan, Italy
- P 221 A pilot intervention for HCV elimination among MSM in Rome: results from a program of micro-elimination of HCV**  
P. Piselli<sup>1</sup>, M. Giuliani<sup>2</sup>, M. Farinella<sup>3</sup>, F. Leserri<sup>4</sup>, F. Angeli<sup>5</sup>, R. Galipò<sup>6</sup>, C. Cimaglia<sup>1</sup>, A. Nappo<sup>1</sup>, N. Orchi<sup>1</sup>, A. Latini<sup>2</sup>, F. Carducci<sup>3</sup>, O. Bruzzi<sup>1</sup>, S. Foracappa<sup>2</sup>, E. Piscitelli<sup>1</sup>, D. Tonnini<sup>1</sup>, E. Gennaro<sup>1</sup>, S. Pittalis<sup>1</sup>, R. Esvan<sup>1</sup>, A. Faticoni<sup>1</sup>, G. De Carli<sup>1</sup>, F. Gili<sup>1</sup>, A. Genovese<sup>3</sup>, S. Meschi<sup>1</sup>, A.R. Garbuglia<sup>1</sup>, A. Amendola<sup>1</sup>, S. Cicalini<sup>1</sup>, M. De Palo<sup>1</sup>, E. Grilli<sup>1</sup>, E. Biliotti<sup>1</sup>, M. Marra<sup>3</sup>, G.M. Corbelli<sup>4</sup>, P. Ferri<sup>6</sup>, A. Cristaudo<sup>2</sup>, F. Maggi<sup>1</sup>, G. D'Offizi<sup>1</sup>, A. Antinori<sup>1</sup>, V. Puro<sup>1</sup>, E. Girardi<sup>1</sup>  
<sup>1</sup>INMI "L. Spallanzani" IRCCS, Rome, <sup>2</sup>Istituto Dermatologico San Galliciano, IRCCS, Rome, <sup>3</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, <sup>4</sup>Plus Roma - Checkpoint, Rome, <sup>5</sup>ARCIGAY Roma, Rome, <sup>6</sup>ANLAIDS Lazio APS, Rome
- P 222 Integration of hepatitis C and addiction treatment in people who injects drugs. The San Patrignano HCV-free and drug-free experience**  
P. Piselli<sup>1</sup>, A. Boschini<sup>2</sup>, S. Duehren<sup>2</sup>, A. Nappo<sup>1</sup>, C. Smacchia<sup>2</sup>, G. Scarfò<sup>1</sup>, C. Pagliardini<sup>2</sup>, C. Cimaglia<sup>1</sup>, E. Girardi<sup>1</sup>  
<sup>1</sup>Clinical Epidemiology Unit, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome - Italy, <sup>2</sup>Medical Center, Comunità di S. Patrignano, Coriano (RN), Italy
- P 223 Acute viral hepatitis from HBV due to immune-reconstitution in a patient with pleural tuberculosis receiving treatment**  
L. Ansaldo<sup>1</sup>, C. Sorace<sup>1</sup>, M.L. Minardi<sup>1</sup>, A. Lodi<sup>1</sup>, F. Barreca<sup>1</sup>, M. Compagno<sup>1</sup>, E. Teti<sup>1</sup>, L. Sarmati<sup>1,2</sup>, A.M. Geretti<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Policlinico Tor Vergata, Roma, Italia, <sup>2</sup>Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 224 A case of congenital CMV infection due to pre-conceptional maternal primary infection: serologic pitfalls in Valacyclovir Era**  
M. Maffezzoni<sup>1</sup>, I. Gallazzi<sup>1</sup>, M. Furione<sup>2</sup>, A. Sarasini<sup>2</sup>, C. Fornara<sup>2</sup>, F. Brillo<sup>3</sup>, A. Ricciardi<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo - University of Pavia - Italy, <sup>2</sup>Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>3</sup>Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
- P 225 Anti-HBV therapy in hemodialytic patient: a not easy approaches**  
R. Pesare, L. Pagnucco, R. Gulminetti, N. Amarasinghe, R. Bruno  
Infectious Diseases Unit, Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo - University of Pavia - Italy
- P 226 Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia. Updated data**  
L. Dentì<sup>1</sup>, C. Marcia<sup>1</sup>, E. Bozzi<sup>1</sup>, G. Alagna<sup>2</sup>, A. Muredda<sup>1</sup>, C. Panu Napodano<sup>1</sup>, M.A. Seazzu<sup>1</sup>, S. Uzzau<sup>3</sup>, S. Babudieri<sup>1</sup>, I. Maida<sup>1</sup>  
<sup>1</sup>S.C. Malattie Infettive e Tropicali, Sassari, <sup>2</sup>U.O.C. Medicina Interna, Sassari, <sup>3</sup>S.C. Microbiologia e Virologia, Sassari
- P 227 Acute HBV hepatitis leading to liver failure: when to treat?**  
A. Gizzi, F. Guida Marascia, M. Abbott, S. Agrenzano, G. Pipitone, G. Ciusa, F. Onorato, A. Ficalora, C. Iaria  
UOC Malattie Infettive e Tropicali, ARNAS Civico, Palermo

## Immunopathogenesis and Vaccines

- P 228 High frequency of type I Interferon autoantibodies in a cohort of middle-aged people with HIV: a retrospective pilot study**  
L. Imberti<sup>1</sup>, G. Tiecco<sup>2</sup>, A. Sottini<sup>3</sup>, V. Quaresima<sup>3</sup>, F. Castelli<sup>2</sup>, E. Quiros-Roldan<sup>2</sup>  
<sup>1</sup>Section of Microbiology, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>2</sup>Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, <sup>3</sup>Clinical Chemistry Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy
- P 229 Viral blips and virologic failures following mpox MVA-BN vaccination among people living with HIV**  
A.R. Raccagni<sup>1</sup>, S. Diotallevi<sup>2</sup>, R. Lolatto<sup>2</sup>, M.F. Lucente<sup>1</sup>, C. Candela<sup>1</sup>, N. Gianotti<sup>2</sup>, B. Trentacapilli<sup>1</sup>, D. Canetti<sup>2</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy
- P 230 How COVID-19 asymptomatic infection influence response to BNT162b2 vaccine among Persons Living with HIV (PLWH): data from patients in charge at Cotugno Hospital, Naples, Italy**  
F.M. Fusco, M.A. Carleo, N. Sangiovanni, M. D'Abbraccio, R. Viglietti, O. Tambaro, F. Borrelli, R. Pisapia, V. Rizzo, A. Guida, P. Rosario, M. Di Lorenzo, N. Cuomo, V. Esposito, V. Sangiovanni  
"D. Cotugno" hospital, AOS dei Colli, Naples, Italy
- P 231 Gut microbiome influences the reservoir in acute, cART-treated HIV**  
C. Tincati<sup>1</sup>, V. Bono<sup>1</sup>, M. Augello<sup>1</sup>, R. Rovito<sup>1</sup>, S. Rusconi<sup>2</sup>, A. Gabrieli<sup>2</sup>, A. Giacomelli<sup>3</sup>, A. Muscatello<sup>4</sup>, S. Dispinseri<sup>5</sup>, A. d'Arminio Monforte<sup>1</sup>, A. Calcagno<sup>6</sup>, S. Nozza<sup>7</sup>, A. Gori<sup>8</sup>, G. Marchetti<sup>1</sup> for the Inaction (Italian Network of Acute HIV Infection) Study Group  
<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>2</sup>UOC Malattie Infettive, Ospedale Civile di Legnano, DIBIC, University of Milan, ASST Ovest Milanese, Legnano, <sup>3</sup>Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, <sup>4</sup>Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, <sup>5</sup>Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, <sup>6</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin
- P 232 Association between SARS-CoV-2 RNAemia and systemic inflammation in people with HIV hospitalized for acute COVID-19 pneumonia**  
M. Augello<sup>1</sup>, V. Bono<sup>1</sup>, R. Rovito<sup>1</sup>, C. Tincati<sup>1</sup>, S. Bianchi<sup>2</sup>, L. Taramasso<sup>3</sup>, A. Di Biagio<sup>3,4</sup>, A. Callegaro<sup>5</sup>, F. Maggiolo<sup>6</sup>, E. Borghi<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>2</sup>Microbiology and Clinical Microbiology, Department of Health Sciences, University of Milan, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, San Martino Policlinico Hospital, <sup>4</sup>Department of Health Sciences, University of Genoa, Genoa, Italy, <sup>5</sup>Biobank Unit and Microbiology and Virology Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>6</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy
- P 233 Heavily Treatment-Experienced (HTE) People Living with HIV (PLWH) with Vertical Transmission and Detectable Viremia do not Display Increased Peripheral Inflammation Markers: Data from the Prestigio Registry**  
C. Tincati<sup>1</sup>, V. Bono<sup>1</sup>, V. Spagnuolo<sup>2</sup>, L. Galli<sup>2</sup>, A. di Biagio<sup>3</sup>, M. Augello<sup>1</sup>, R. Rovito<sup>1</sup>, E. Garlassi<sup>4</sup>, M.C. Moialti<sup>5</sup>, E. Focà<sup>6</sup>, A. Castagna<sup>2</sup>, G. Marchetti<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive, San Paolo Hospital, University of Milan, Milan, Italy, <sup>2</sup>Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Department of Infectious Disease, IRCCS AOU San Martino IST, (DISSAL), University of Genoa, Italy, <sup>4</sup>Malattie Infettive Arcispedale S. Maria Nuova-IR-CSS, Reggio Emilia, Italy, <sup>5</sup>Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>6</sup>Division of Infectious and Tropical Diseases, ASST Spedali Civili Hospital, University of Brescia, Brescia, Italy

- P 234 Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience**  
B. Trentacapilli<sup>1</sup>, G. Catalano<sup>1</sup>, L. Galli<sup>2</sup>, R. Lolatto<sup>2</sup>, A.R. Raccagni<sup>1</sup>, S. Nozza<sup>1,2</sup>, A.C. D'Amelio<sup>3</sup>, G. Ponta<sup>1</sup>, V. Spagnuolo<sup>1,2</sup>, M. Cernuschi<sup>2</sup>, N. Gianotti<sup>2</sup>, A. Castagna<sup>1,2</sup>, D. Canetti<sup>2</sup>  
<sup>1</sup>Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milano, Italy, <sup>3</sup>Public Health School, San Raffaele Scientific Institute, Milano, Italy
- P 235 Determinants of recorded SARS-CoV-2 vaccine uptake among ART-compliant people living with HIV**  
G. Alessio, A. Imeneo, A. Di Lorenzo, L. Ferrari, T. Mulas, M. Compagno, V. Malagnino, M. Iannetta, E. Teti, L. Sarmati, A.M. Geretti  
Fondazione PTV, University of Rome Tor Vergata, Rome, Italy
- P 236 Targeting Nef as the Primary Driver of HIV Persistence and Immune Escape**  
C. Brosgart, M. Curlin, R. Ogden  
Immgenuity, Inc., Dover Delaware
- P 237 Tolerability of Shingrix in patients with multiple sclerosis and other neurological diseases on immune modulating treatments**  
I. Fato, G. Alessio, D. Landi, F. Napoli, A. Imeneo, L. Benedetti, B. Massa, V. Barchi, C. Picarelli, F. Angelone, A.C. Epifani, A. Di Lorenzo, G. Mataluni, C. Gabri Nicoletti, G.A. Marfia, L. Sarmati, M. Iannetta  
Fondazione PTV, University of Rome Tor Vergata, Rome, Italy
- P 238 Antibody response to the third dose of SARS-CoV-2 mRNA vaccine in PLWH on ART at 12 months after its administration**  
E. Tortellini<sup>1</sup>, M.A. Zingaropoli<sup>1</sup>, G. Mancarella<sup>1,2</sup>, R. Marocco<sup>2</sup>, A. Carraro<sup>1,2</sup>, S. Garattini<sup>1,2</sup>, M. Jhamour<sup>2</sup>, M. Guardiani<sup>1</sup>, F. Dominelli<sup>1</sup>, V. Perri<sup>1</sup>, P. Pasculli<sup>1</sup>, A. Napoli<sup>1</sup>, A. Gaeta<sup>1</sup>, F. Mengoni<sup>1</sup>, P. Zuccalà<sup>2</sup>, V. Belvisi<sup>2</sup>, B. Kertusha<sup>1,2</sup>, A. Parente<sup>1,2</sup>, C. Del Borgo<sup>2</sup>, V. Vullo<sup>1</sup>, M.R. Ciardi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, M. Lichtner<sup>2,3</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, <sup>3</sup>Department of NESMOS, Sapienza University of Rome, Rome, Italy, <sup>4</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
- P 239 Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement**  
C. Pinnetti<sup>1</sup>, V. Bordoni<sup>2,3</sup>, A. Vergori<sup>1</sup>, A. Mondì<sup>1</sup>, V. Mazzotta<sup>1</sup>, I. Mastroianni<sup>1</sup>, S. Notari<sup>2</sup>, E. Cimini<sup>3</sup>, O. Forini<sup>3</sup>, S. Grisetti<sup>1</sup>, R. Gagliardini<sup>1</sup>, M. Camici<sup>1</sup>, A. Antinori<sup>1</sup>, C. Agrati<sup>2,3</sup>  
<sup>1</sup>Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Oncoematologia e Officina Farmaceutica, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, <sup>3</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
- P 240 Herpes zoster prevention through administration of recombinant zoster vaccine (RZV) in a cohort of PLWH in Rome**  
P.F. Salvo<sup>1</sup>, E. Tamburrini<sup>1,2</sup>, A. Dusina<sup>2</sup>, S. Martinelli<sup>3</sup>, R.A. Passerotto<sup>1</sup>, F. Lamanna<sup>1</sup>, V. Iannone<sup>1</sup>, E. Visconti<sup>2</sup>, P. Laurenti<sup>3,4</sup>, F. Lombardi<sup>2</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, <sup>3</sup>Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, <sup>4</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
- P 241 Serum and Plasma Biomarkers of Central Nervous System Involvement Measured Through Single Molecule Array in PLWH and controls**  
J. Cusato<sup>1</sup>, M. Antonucci<sup>2</sup>, M. Trunfo<sup>3</sup>, D. Imperiale<sup>4</sup>, E. Vuaran<sup>3</sup>, A. Palermi<sup>1</sup>, G. Di Perri<sup>3</sup>, A. D'Avolio<sup>1</sup>, S. Bonora<sup>3</sup>, A. Calcagno<sup>3</sup>  
<sup>1</sup>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy, <sup>3</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, <sup>4</sup>Unit of Neurology, Maria Vittoria Hospital, ASL Città di Torino, Turin, Italy
- P 242 Immunization coverage in older people living with HIV in a large Hospital, Northern Italy**  
S. Arsuffi, A. Cambianica, I. Izzo, I. Polesini, F. Gaffurini, D. Castelli, P. Zanotti, F. Pennati, D. Laurenda, E. Quiros-Roldan, F. Castelli, E. Focà  
Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- P 243 Immune responses to vaccination in HIV vertically-infected patients: a long term evaluation**  
A. Zin<sup>1</sup>, D. Mengato<sup>2</sup>, A. Francavilla<sup>3</sup>, L. Chiusaroli<sup>1</sup>, C. Giaquinto<sup>1</sup>, D. Donà<sup>1</sup>, O. Rampon<sup>1</sup>  
<sup>1</sup>Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, Padua, Italy, <sup>2</sup>Hospital Pharmacy Department, University Hospital of Padua, Padua, Italy, <sup>3</sup>Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy
- P 244 Compliance with immunisation amongst HIV-infected patients and clinicians vaccines offer rates in the HIV Outpatient Clinic of the Valle d'Aosta Region**  
M. Colafigli<sup>1</sup>, N. Pagani<sup>1</sup>, J. Ledakowicz<sup>1</sup>, G. Doveri<sup>2</sup>, S. Magnani<sup>1</sup>  
<sup>1</sup>SS Malattie Infettive, Ospedale Regionale U. Parini, Aosta, <sup>2</sup>Dipartimento Scienze Mediche, Ospedale Regionale U. Parini, Aosta
- P 245 The impact of HIV-1 infection and sexual orientation on the intestinal microbiota composition in HIV-1 serodiscordant couples**  
G. Bugani<sup>1</sup>, V. Iebba<sup>2</sup>, L. Santinelli<sup>1</sup>, L. Maddaloni<sup>1</sup>, A. Lazzaro<sup>1</sup>, C.M. Lofaro<sup>1</sup>, M. Fracella<sup>3</sup>, L. Sorrentino<sup>3</sup>, G. Coia<sup>1</sup>, G. Ceccarelli<sup>1</sup>, G. Antonelli<sup>3</sup>, C.M. Mastroianni<sup>1</sup>, C. Scagnolari<sup>3</sup>, G. d'Ettore<sup>1</sup>  
<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome - Rome (Italy), <sup>2</sup>Department of Medical Sciences, University of Trieste, Trieste (Italy), <sup>3</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome (Italy)
- P 246 Idiopathic CD4 Lymphocytopenia: novel insights into the immunological functions of CD4 T cells**  
A. Lisco, A.M. Ortega-Villa, M.V. Anderson, A. Mateja, A.F. Freeman, V. Sheikh, I. Sereti  
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

## PrEP

- P 247 Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)**  
S. Mattioli<sup>1</sup>, L. Badia<sup>2</sup>, M. Pedone<sup>1</sup>, S. Cecere<sup>1</sup>, R. Masina<sup>1</sup>, A. Leo<sup>1</sup>, F. Pavone<sup>1</sup>, L. Cinti<sup>1</sup>, S. Lo Bianco<sup>1</sup>  
<sup>1</sup>Plus Rete Persone LGBT+ Sieropositive aps, <sup>2</sup>Azienda Unità Sanitaria Locale di Imola
- P 248 The Anlaid's forum may identify new subjects to be addressed for PrEP**  
A. Venturelli, C. Balotta, R. Galipò, G.V. Calvino, B. Marchini  
Anlaid's Onlus, Rome, Italy
- P 249 Pre-Exposure Prophylaxis (PrEP) usage in a MSM adult population: organizational procedures, issues and observations**  
A. Franco<sup>1</sup>, P. Bellopede<sup>1</sup>, R.M. Franco<sup>1</sup>, A. Gallicchio<sup>1</sup>, A. Giaccone<sup>1</sup>, A. Maddaloni<sup>1</sup>, S. Parente<sup>1</sup>, S. Susini<sup>1</sup>, M. Talamo<sup>1</sup>, A. Bianchi<sup>2</sup>, V. Iodice<sup>2</sup>, A. Lanzardo<sup>2</sup>, A. Marocco<sup>2</sup>, M. Sardo<sup>2</sup>, I. Vecchietti<sup>2</sup>, E. Manzillo<sup>2</sup>  
<sup>1</sup>UOC di Malattie Infettive dell'età Geriatrica AORN "Ospedali dei Colli", Napoli, <sup>2</sup>UOC di Immunodeficienze e Malattie dell'Emigrazione AORN "Ospedali dei Colli", Napoli
- P 250 High Propensity to Switch to Long-acting Injectable PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men**  
A.R. Raccagni<sup>1</sup>, M.F. Lucente<sup>1</sup>, C. Candela<sup>1</sup>, R. Lolatto<sup>2</sup>, L. Galli<sup>2</sup>, B. Trentacapilli<sup>1</sup>, G. Ponta<sup>1</sup>, E. Messina<sup>2</sup>, N. Gianotti<sup>2</sup>, A. Castagna<sup>1,2</sup>, S. Nozza<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy

- P 251 Is hypophosphatemia a real contraindication for PrEP? Let's ask the renal tubule**  
G. Guglielmetti<sup>1</sup>, O. Bargiacchi<sup>2</sup>, S. Prenna<sup>1</sup>, F. Rinaldi<sup>2</sup>, A. Barco<sup>2</sup>, V. Cantaluppi<sup>1</sup>  
<sup>1</sup>Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, University of Eastern Piedmont, "Maggiore della Carità" University Hospital, Novara, Italy, <sup>2</sup>Infectious Diseases Unit, "Maggiore della Carità" University Hospital, Novara, Italy
- P 252 Pre-exposure prophylaxis (PrEP): achieved results and what remains to be done**  
L. Coppola<sup>1</sup>, M. Iannetta<sup>1,2</sup>, L. Campogiani<sup>1</sup>, M. Compagno<sup>1</sup>, V. Malagnino<sup>1,2</sup>, E. Teti<sup>1</sup>, L. Ferrari<sup>1</sup>, T. Mulas<sup>1</sup>, A.R. Cavasio<sup>1,2</sup>, N. Braccialarghe<sup>1,2</sup>, L. Sarmati<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Clinic, Policlinico Tor Vergata, Rome Italy, <sup>2</sup>Department of System Medicine, Tor Vergata University, Rome, Italy
- P 253 High interest in long-acting injectable cabotegravir (CAB-LA) among "on demand" PrEP users**  
S. Venturelli<sup>1</sup>, D. Ripamonti<sup>1</sup>, A.S. Tran<sup>2</sup>, L. Comi<sup>1</sup>, F. Borghi<sup>1</sup>, F. Maggiolo<sup>1</sup>, M. Rizzi<sup>1</sup>  
<sup>1</sup>UOC Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy, <sup>2</sup>University of Milan, Milano, Italy
- P 254 PrEP in Eastern Piedmont: STIs and renal safety**  
F. Rinaldi, O. Bargiacchi, A. Barco, M. Sciarra, A. Rossati, P.L. Garavelli  
Infectious Diseases Unit, University Hospital "Maggiore della Carità" Novara
- P 255 Reasons for leaving a PrEP community-based service: our experience in Bologna, Italy**  
C. Patrucco<sup>1</sup>, A. Pozzi<sup>1</sup>, S. Mattioli<sup>2</sup>, S. Cecere<sup>2</sup>, M. Casarini<sup>1</sup>, P. Fai<sup>1</sup>, D. Marzolla<sup>1</sup>, B. Nuti<sup>1</sup>, L. Piazza<sup>1</sup>, I. Sartini<sup>1</sup>, D. Testi<sup>4</sup>, V. Gaspari<sup>2</sup>, L. Badia<sup>5</sup>  
<sup>1</sup>Alma Mater Studiorum University of Bologna, Infectious Disease Department, S.Orsola-Malpighi Hospital, <sup>2</sup>Plus aps, PrEP Point Plus Bologna, <sup>3</sup>Alma Mater Studiorum University of Bologna, Dermatology Department, S.Orsola-Malpighi Hospital, <sup>4</sup>Arcispedale S.Anna, Cona, Ferrara, Infectious Disease Department, <sup>5</sup>Azienda USL di Imola, Infectious Disease Department
- P 256 A descriptive analysis of serum creatinine variation in users assuming TDF-PrEP: a possible role of age and comedication**  
M. Albertini, M. Menozzi, E. Martini, M.D. Di Trapani, A. Soffritti, B. Fontana, C. Mussini  
Infectious Disease Department, University Hospital of Modena, Italy
- P 257 Pre-exposure prophylaxis for HIV and risk of recurrent sexually transmitted infections**  
D. Farinacci<sup>1</sup>, P.F. Salvo<sup>2</sup>, R.J. Steiner<sup>2</sup>, A. Ciccullo<sup>3</sup>, V. Iannone<sup>2</sup>, R.A. Passerotto<sup>2</sup>, A. Dusina<sup>4</sup>, A. Borghetti<sup>4</sup>, S. Di Giambenedetto<sup>2,4</sup>, G. Baldin<sup>4</sup>  
<sup>1</sup>UOC Medicina Protetta-Malattie Infettive, ASL Viterbo, <sup>2</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>3</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS

## Social and behavioural science, marginalized groups, community aspects and community surveys

- P 258 Impact of peer education on sexual health knowledge among adolescents and young persons in the Buea subdivision of the South West region of Cameroon: through VCT campaigns**  
K. Eric Marot, G.T. Ayissi Bella, P. Kuete Tape, R. Ngome  
Vision in Action, Presse Jeune Développement, Cameroon National Association for Family Welfare, Alliance for Community Initiative
- P 259 Chems & le Holograms**  
A. Infante  
Policlinico Tor Vergata Roma
- P 260 THE M.A.NNA project (Maometto Alla moNtagNa)**  
S. Dell'Isola<sup>1</sup>, S. Aviani<sup>2</sup>, A.M. Ialungo<sup>1</sup>, E. Rastrelli<sup>1</sup>, G. Starnini<sup>1</sup>, L. Caterini<sup>2</sup>  
<sup>1</sup>UOC Medicina protetta-Malattie infettive Ospedale Belcolle, Viterbo, <sup>2</sup>UOC Malattie Infettive ASL Ospedale Belcolle, Viterbo
- P 261 Young people and HIV - Millennials on HIV/AIDS/STI and emerging needs**  
R. Galipò<sup>1,3</sup>, M. Bolletta<sup>10</sup>, M. Bononi<sup>4</sup>, L. Butini<sup>7</sup>, V. Calvino<sup>1</sup>, L. Cipriani<sup>9</sup>, P. Costa<sup>6</sup>, S. De Balzo<sup>2</sup>, A. De Faveri<sup>8</sup>, S. Negri<sup>5</sup>, A. Palummieri<sup>1</sup>, B. Marchini<sup>1</sup>  
<sup>1</sup>Anlaidi Onlus, Roma, <sup>2</sup>Anlaidi Campania, Napoli, <sup>3</sup>Anlaidi Lazio, Roma, <sup>4</sup>Anlaidi Liguria, Genova, <sup>5</sup>Anlaidi Lombardia, Milano, <sup>6</sup>Anlaidi Mantova, Mantova, <sup>7</sup>Anlaidi Marche, Ancona, <sup>8</sup>Anlaidi Torino, Torino, <sup>9</sup>Anlaidi Treviso, Treviso, <sup>10</sup>Anlaidi Umbria, Perugia
- P 262 Bringing HIV prevention to schools: data analysis**  
F. Rossi<sup>1</sup>, A. Bianchi<sup>1</sup>, P.M. Testoni<sup>1</sup>, D. Zagato<sup>1</sup>, M. Cernuschi<sup>2</sup>  
<sup>1</sup>ASA Associazione Solidarietà ODV, Milano, Italy, <sup>2</sup>San Raffaele Hospital, Milano, Italy
- P 263 The non-Italian MSM population within the Rome Checkpoint HIV and STD screening context**  
F. Angeli  
Arcigay Roma, Roma
- P 264 IO C'ENTRO HIV CheckPoint in Genova, Italy: results of first year experience towards future objectives and new operational strategies**  
E. Terragna, S. Tunesi, A. Chinelli, C. Tosi, G. Notore, U. De Santis, M. Feasi, S. Puppo, D. Fiorellino, E. Pontali, M. Viscoli  
Anlaidi sezione regionale Ligure Odv, Genova, S.C. Malattie Infettive Ospedale Galliera, Genova, Dipartimento di ricerca traslazionale e delle nuove tecnologie in medicina e chirurgia, Università di Pisa, UOC Malattie infettive, AON SS Antonio e Biagio e Cesare Arrigo, Alessandria
- P 265 Things change. Latest U=U communication campaign of LILA Cagliari**  
G. Dessi, V. Mascia, B. Mucci, A. Pontis  
LILA Cagliari OdV, Cagliari
- P 266 Supporting Quality of Life: complexities and goals in the experience of a Mindfulness group in a community site**  
A. Bianchi<sup>1</sup>, P. Testoni<sup>1</sup>, A. Antonino<sup>1</sup>, M. Cernuschi<sup>1,2</sup>  
<sup>1</sup>ASA Associazione Solidarietà AIDS ODV, Milan, Italy, <sup>2</sup>San Raffaele Hospital, Milan, Italy
- P 267 One year experience of the Ancona Checkpoint: first analysis of COBATEST data of population**  
S. Caucci<sup>1,3</sup>, L. Saracini<sup>2,3</sup>, P. Pauri<sup>2</sup>, L. Butini<sup>4</sup>  
<sup>1</sup>Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, <sup>2</sup>Ass. Opere Caritative Francescane, Ancona, <sup>3</sup>Ancona Checkpoint, Ancona, <sup>4</sup>Immunology Laboratory, Azienda Ospedaliero Universitaria delle Marche, Ancona
- P 268 Prisoners living with HIV. Retrospective analysis the cascade of care in two penitentiaries in Northern Italy**  
A. Cambianica<sup>1</sup>, F. Pennati<sup>1</sup>, A. Faustinelli<sup>1</sup>, I. El Hamad<sup>1</sup>, F. Roda<sup>2</sup>, I. Rossetti<sup>2</sup>, B. Fioretti<sup>1</sup>, S. Arsuffi<sup>1</sup>, S. Fiorentini<sup>3</sup>, E. Quiros Roldan<sup>1</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>  
<sup>1</sup>Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Prison Health ASST Spedali Civili Hospital, Brescia, Italy, <sup>3</sup>Unit of Microbiology and Virology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- P 269 Fifth year of mono symptomatic therapeutical group for chemsex addiction, a roundup**  
G. Fracca, M. Manfredini  
ASA Associazione Solidarietà AIDS Onlus, Milano
- P 270 Mapping the Status of Services in the Field of Sexual Health and HIV Management in Thirty-One Provincial Capitals of Italy**  
C. Urciuoli, M. Costacurta, M. Marocco, I. Pennini  
Arcigay, Bologna

- P 271 Taking it to the Streets: HIV Prevention for Drug Users through Outreach Units in Rome in 2022**  
G. Rodoquino<sup>1</sup>, D. Masci<sup>1</sup>, B. Colardace<sup>1</sup>, P. Sammarco<sup>1</sup>, T. Di Giovanni<sup>1</sup>, F. Alessi<sup>2</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>, M. Zaccarelli<sup>1</sup>  
<sup>1</sup>Street Unit and HIV/Infectious Diseases Unit, Villa Maraini Foundation, Italian Red Cross, Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome
- P 272 Breaking barriers to HIV and HCV screening among migrants in Rome**  
D. Masci<sup>1</sup>, P. Sammarco<sup>1</sup>, T. Di Giovanni<sup>1</sup>, G. Rodoquino<sup>1</sup>, G.D'Etto<sup>2</sup>, A. Tullio<sup>1</sup>, B. Colardace<sup>1</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>, M. Zaccarelli<sup>1</sup>  
<sup>1</sup>HIV/Infectious Diseases Unit & Street Unit, Villa Maraini Foundation, Italian Red Cross, Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome
- P 273 Transgender and HIV: a case for an inclusive clinical record**  
L. Brogonzoli<sup>1</sup>, M. Errico<sup>2</sup>, A. Moznich<sup>2</sup>, M. Cascio<sup>2</sup>, M. Formisano<sup>2</sup>  
<sup>1</sup>Fondazione The Bridge, Milano, <sup>2</sup>NPS Italia aps, Milano
- P 274 U=U. Cosa sai, cosa non sai**  
A. Zottino<sup>2</sup>, M. Cascio<sup>1</sup>, M. Errico<sup>1</sup>, G.P.Turchi<sup>2</sup>, N. Giovannelli<sup>2</sup>, D. Manfredotti<sup>2</sup>, M. Pellizzato<sup>2</sup>, G. Balcan<sup>2</sup>, V. Landi<sup>2</sup>, A. Moznich<sup>1</sup>  
<sup>1</sup>NPS Italia Aps, Milano, <sup>2</sup>Università di Padova, Padova
- P 275 LILA testing services in 2022: observations from experiences of our network**  
S. Bellini<sup>1</sup>, G. Dessi<sup>1</sup>, A. Leoni<sup>2</sup>, E. Sosio<sup>2</sup>  
<sup>1</sup>LILA Nazionale Onlus, Como, <sup>2</sup>Fondazione LILA Milano Onlus, Milano
- P 276 The Relationship as Outcome Indicator: Person-Based Approach in Rome**  
P. Sammarco, D. Masci, T. Di Giovanni, G.Rodoquino, B. Colardace, R. Sista, E. Rossi, M. Barra, M. Zaccarelli  
HIV/Infectious Diseases Unit & Street Unit, Villa Maraini Foundation, Italian Red Cross, Rome
- P 277 "Resilience" – Study on the psychological and practical impact of COVID-19 on the quality of life of people living with HIV**  
S. Penon<sup>1</sup>, M.L. Cosmaro<sup>1</sup>, S. Curridori<sup>1</sup>, M. Oldrini<sup>1</sup>, D. Savarino<sup>1</sup>, S. Mazzilli<sup>2</sup>  
<sup>1</sup>Fondazione LILA Milano, <sup>2</sup>Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
- P 278 Conscious sexuality and young people: let's talk about HIV**  
A. De Faveri<sup>1</sup>, V. Simeone<sup>2</sup>  
<sup>1</sup>Anlaidis Torino, Torino, <sup>2</sup>Anlaidis Torino, Torino
- P 279 How much does stigma weigh in a more informed setting? An online survey**  
D. Calzavara<sup>1</sup>, R. Rossotti<sup>1,2</sup>, G. Federico<sup>3</sup>, D. Iannacone<sup>3</sup>, D. Buselli<sup>3</sup>, S. Bossolasco<sup>1,4</sup>, E. Caruso<sup>1</sup>, M. Cernuschi<sup>1,4,5</sup>  
<sup>1</sup>Milano Check Point ETS, Milano, <sup>2</sup>Grande Ospedale Metropolitano Niguarda, Milano, <sup>3</sup>Gay.it, Milano, <sup>4</sup>IRCCS Ospedale San Raffaele, Milano, <sup>5</sup>ASA Milano ODV, Milano
- P 280 Difficult to reach, fragile key populations at high risk: the Bergamo Leaves No One Behind Project**  
D. Meli<sup>1</sup>, P. Meli<sup>1</sup>, I. Mercurio<sup>1</sup>, F. Maggiolo<sup>2</sup>, E. Ris<sup>3</sup>, M. Gotti<sup>3</sup>, F. Defendi<sup>4</sup>, Stefano<sup>4</sup>, M. Del Vecchio<sup>5</sup>, E. Recanatì<sup>5</sup>, A. Sarzi Sartori<sup>6</sup>, M. Vitali<sup>7</sup>, N. Butta<sup>8</sup>  
<sup>1</sup>Don Giuseppe Monticelli Società Cooperativa Sociale, <sup>2</sup>ASST Papa Giovanni XXIII, <sup>3</sup>La Melarancia ODV, <sup>4</sup>Fondazione Opera Diocesana Patronato San Vincenzo, <sup>5</sup>Cooperativa di Bessimo Onlus, <sup>6</sup>Fondazione Opera Bonomelli Onlus, <sup>7</sup>Caritas Bergamasca, <sup>8</sup>Arcigay Bergamo Cives
- P 281 The two faces / directions of the Bergamo Check Point: young people and key populations**  
P. Meli<sup>1</sup>, D. Meli<sup>1</sup>, C. Pellegrini<sup>2</sup>, F. Maggiolo<sup>3</sup>, S. Venturelli<sup>3</sup>, I. Mercurio<sup>4</sup>, N. Butta<sup>5</sup>, R. Carissoli<sup>5</sup>, F. Radici<sup>5</sup>  
<sup>1</sup>Don Giuseppe Monticelli Società Cooperativa Sociale, <sup>2</sup>Associazione Comunità Emmaus, <sup>3</sup>ASST Papa Giovanni XXIII, <sup>4</sup>Croce Rossa Italiana – Comitato di Bergamo, <sup>5</sup>Arcigay Bergamo Cives
- P 282 Foreigners and their requests to LILA helpline from 2018 to 2022: a comparative analysis**  
A. Castellari<sup>1</sup>, A. De Giosa<sup>2</sup>, S. Penon<sup>3</sup>, M.G. Di Benedetto<sup>1</sup>  
<sup>1</sup>LILA ONLUS, Como, <sup>2</sup>LILA Bari, Bari, <sup>3</sup>LILA Milano, Milano
- P 283 NO ONE LEFT BEHIND - Omphalos LGBTI+ experience, Perugia, Italy. A community-based HIV testing before and after the challenging covid-19 pandemic period (2020). It's time to strengthen the dialogue about sexual health**  
A. Zoffoli<sup>1</sup>, E. Albertini<sup>2</sup>, P. Diana<sup>2</sup>, A. Gidari<sup>1</sup>, G. Gonnelli<sup>1</sup>, S. Tordi<sup>1</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Clinica delle Malattie Infettive, Azienda Ospedaliera di Perugia, Università degli Studi di Perugia, <sup>2</sup>Omphalos LGBTI+, Gruppo Salute
- P 284 To drink or not to drink. Data from real life and implication for dietitian counselling for PLWHA**  
D. Penoncelli<sup>2</sup>, A. Pezzana<sup>2</sup>, A. Ianniello<sup>1</sup>, M. Guastavigna<sup>1</sup>, M.C. Ottino<sup>1</sup>, G. Orofino<sup>1</sup>, G. Calleri<sup>1</sup>  
<sup>1</sup>SC Malattie Infettive e Tropicali I, Ospedale Amedeo di Savoia, ASL Città di Torino, <sup>2</sup>SC Nutrizione Clinica, Ospedale Amedeo di Savoia, ASL Città di Torino
- P 285 Association between Locus of Control, Health Locus of Control, Coping and Resilience in an Italian cohort of people living with HIV**  
V. Massaroni<sup>1</sup>, V. Delle Donne<sup>1</sup>, R. Jo Steiner<sup>1,2</sup>, R. Passerotto<sup>1,2</sup>, A. Dusina<sup>2</sup>, G. Baladin<sup>2</sup>, P.F. Salvo<sup>1,2</sup>, F. Lamanna<sup>1,2</sup>, S. Di Giambenedetto<sup>1,2</sup>, A. Borghetti<sup>2</sup>  
<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- P 286 The role of emotion dysregulation in patient health engagement and HIV-related symptom distress in an Italian cohort of people living with HIV**  
V. Delle Donne<sup>1</sup>, V. Massaroni<sup>1</sup>, P.F. Salvo<sup>1,2</sup>, V. Iannone<sup>1,2</sup>, D. Farinacci<sup>2</sup>, A. Ciccullo<sup>3</sup>, A. Borghetti<sup>2</sup>, A. Carbone<sup>1,2</sup>, S. Di Giambenedetto<sup>1,2</sup>, F. Lombardi<sup>2</sup>  
<sup>1</sup>Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, <sup>3</sup>UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila; Italy
- P 287 Searching for HCV infection: involvement of Therapeutical Communities is mandatory!**  
A. Floriani<sup>1</sup>, J. Sechi<sup>2</sup>, C.M. Bruno<sup>2</sup>, V. Vivaldi<sup>3</sup>, M. Gladioro<sup>3</sup>, M. Ciccone<sup>4</sup>, G. Lizzio<sup>4</sup>, D. Fiorellino<sup>5</sup>, N. Bobbio<sup>5</sup>, F. Del Puente<sup>5</sup>, M. Feasi<sup>5</sup>, E. Pontali<sup>5</sup>  
<sup>1</sup>SERD Interno C.C. Genova-Marassi ASL3 Genovese, Genova, <sup>2</sup>C.T. San Benedetto, Genova, <sup>3</sup>C.T. Ma.Ris, Isola del Cantone (GE), <sup>4</sup>C.T. CEIS 'Trasta', Genova, <sup>5</sup>S.C. Malattie Infettive, E.O. Ospedali Galliera, Genova
- P 288 HIV and HCV awareness and knowledge among the general population in Brescia, Northern Italy**  
F. Viola, S. Aruffi, B. Formenti, P. Magro, I. Polesini, E. Focà, F. Castelli, E. Quiros-Roldan for FAST-TRACT CITY Brescia Group  
Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- P 289 Late-presenter person living with HIV in detention institute. Case report**  
A. D'Angelillo<sup>1</sup>, D. Farinacci<sup>1</sup>, E. Rastrelli<sup>1</sup>, C. Lupan<sup>1</sup>, A. Sanvito<sup>3</sup>, A.M. Ialungo<sup>1</sup>, C. Viti<sup>3</sup>, G. Starnini<sup>1</sup>  
<sup>1</sup>UOC Medicina Protetta-Malattie Infettive, Belcolle Hospital, Viterbo, Italy, <sup>2</sup>UOS Medicina Penitenziaria Territoriale, ASL Viterbo, Italy, <sup>3</sup>UOC Otorinolaringoiatria, Belcolle Hospital, Viterbo, Italy
- P 290 A friendly, rapid testing and counseling approach to improve linkage to care: a two year experience at Checkpoint and Hospital center**  
G. Mancarella<sup>1</sup>, S. Garattini<sup>1</sup>, A. Gasperin<sup>1</sup>, A. Destro<sup>1</sup>, F. Izzo<sup>1</sup>, L. De Martino<sup>1</sup>, D. Di Trento<sup>1</sup>, S. Corazza<sup>1</sup>, S. De Maria<sup>1</sup>, A. Parente<sup>1</sup>, A. Grimaldi<sup>1</sup>, L. Battisti<sup>1</sup>, S. Cacace<sup>1</sup>, A. Carraro<sup>2</sup>, R. Marocco<sup>2</sup>, V. Rossi<sup>2</sup>, M. D'Achille<sup>2</sup>, A. Petrillo<sup>3</sup>, V. Vitale<sup>3</sup>, A. Girardi<sup>3</sup>, M. Lichtner<sup>1</sup>  
<sup>1</sup>Università la Sapienza, Latina, <sup>2</sup>Infectious disease department, Latina, <sup>3</sup>Arcigay - Sei come sei, Latina

- P 291 Comprehensive Sexuality Education (CSE) in Italian secondary schools: preliminary results of EduForIST2 pilot activity**  
A. Chinelli<sup>1</sup>, R. Galipò<sup>2</sup>, P. Meli<sup>3</sup>, S. Bellini<sup>4</sup>, N. Catucci<sup>5</sup>, M. Farinella<sup>6</sup>, L. Rancilio<sup>7</sup>, A. Camposeragna<sup>8</sup>, G. Papparatto<sup>1</sup>, A. Musco<sup>9</sup>, E. Torri<sup>1</sup>, M. Ubbiali<sup>10</sup>, M.C. Salfa<sup>11</sup>, B. Suligo<sup>11</sup>, A. Caraglia<sup>12</sup>, D. Martinelli<sup>12</sup>, L. Tavoschi<sup>1</sup>  
<sup>1</sup>Dipartimento di ricerca traslazionale e delle nuove tecnologie in medicina e chirurgia, Università di Pisa, <sup>2</sup>ANLAIDS, Roma, <sup>3</sup>CICA, Bergamo, <sup>4</sup>LILA, Firenze, <sup>5</sup>LILA, Bar, <sup>6</sup>Circolo di cultura omosessuale Mario Mieli, Roma, <sup>7</sup>Caritas Ambrosiana, Milano, <sup>8</sup>CNCA, Roma, <sup>9</sup>Dipartimento di Scienze Mediche e Chirurgiche, Università di Foggia, <sup>10</sup>Dipartimento di Scienze Umane, Università di Verona, <sup>11</sup>Centro operativo AIDS, Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Roma, <sup>12</sup>Direzione Generale della prevenzione sanitaria, Ministero della Salute, Roma
- P 292 Web Listening to identify the information needs of different targets and detected the barriers to the modification of the HIV behaviors**  
A. Colucci<sup>1</sup>, A. D'Ari<sup>2</sup>, F. Furiozzi<sup>2</sup>, P. Gallo<sup>1</sup>, M. Mirabile<sup>2</sup>, G. Santolini<sup>2</sup>, E. Fanales Belasio<sup>1</sup>, R. Dalla Torre<sup>1</sup>, A. D'Agostini<sup>1</sup>, E. Fedele<sup>2</sup>, T. Bertani<sup>2</sup>, M. Schwarz<sup>2</sup>, R. Valli<sup>1</sup>, L. Bertinato<sup>3</sup>, S. Iavicoli<sup>2</sup>  
<sup>1</sup>Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione Dipartimento Malattie Infettive – Istituto Superiore di Sanità, Rome, Italy, <sup>2</sup>Direzione Generale della Comunicazione e dei Rapporti Europei ed Internazionali – Ministero della Salute, Rome, Italy, <sup>3</sup>Segreteria Scientifica Presidenza - Istituto Superiore di Sanità, Rome, Italy
- P 293 Impact of COVID-19 on the management of their disease in People living with HIV: preliminary results of semi-structured interviews**  
A. Camposeragna<sup>1</sup>, L. Cosmaro<sup>2</sup>, P. Piselli<sup>3</sup>, C. Cimaglia<sup>3</sup>, A. Nappo<sup>3</sup>, M. Farinella<sup>4</sup>, L. Rancilio<sup>5</sup>, S. Mattioli<sup>6</sup>, V. Calvino<sup>7</sup>, D. Zagato<sup>8</sup>, D. Masci<sup>9</sup>, P. Meli<sup>10</sup>, J. Testa<sup>11</sup>, N. Piazza<sup>12</sup>, M. Errico<sup>13</sup>, A. Caraglia<sup>14</sup>, E. Girardi<sup>1</sup> for the Working Group of the project "The impact of COVID-19 on the processes and outcomes of care of people with HIV"  
<sup>1</sup>CNCA, Rome, <sup>2</sup>LILA Milano, Milan, <sup>3</sup>INMI L. Spallanzani, Rome, <sup>4</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, <sup>5</sup>CARITAS Ambrosiana, Milan, <sup>6</sup>PLUS, Bologna, <sup>7</sup>ANLAIDS Onlus-ETS, Rome, <sup>8</sup>Associazione Solidarietà AIDS odv, Milan, <sup>9</sup>Villa Maraini, Rome, <sup>10</sup>CICA, Bergamo, <sup>11</sup>Italian Society of Migration Medicine - SIMM, Rome, <sup>12</sup>Arcigay, Bologna, <sup>13</sup>NPS Italia, Naples, <sup>14</sup>Ministero della Salute, Rome
- P 294 The role of the psycho-social team of the C.A.M.A. ODV, in 25 years of activity in the "Home treatment of people suffering from AIDS and related pathologies" - Interventions in implementation of the Presidential Decree 09.14.1991 and Ministerial Decree 09.13.1991**  
A. Calluso, N. Catucci, M. Di Tullio, R. Giusto, S. Louidice, C. Michelucci, I. Lanera, M. Potenza, A. Scavo, P. Tomascchio  
C.A.M.A (Centro Assistenza Malati Aids) OdV ETS
- P 295 The prevention of Sexually transmitted infections (STIs) in new migrant populations. Data from the Perugia Outpatients Clinic**  
M. Ramadori, V. Suriani, S. Tordi, A. Bernardelli  
USL Umbria 1
- P 296 Quality of pre- and post-COVID-19 healthcare: the point of view of women living with HIV**  
A. Bove<sup>1</sup>, M. Cernuschi<sup>2</sup>, A. Cervo<sup>3</sup>, C. Pinnetti<sup>4</sup>, A. Perziano<sup>5</sup>, M. Errico<sup>6</sup>, G.V. Calvino<sup>7</sup>, M. Giglia<sup>8</sup>, M. Guastavigna<sup>9</sup>, D. Canetti<sup>10</sup>, A. Di Biagio<sup>11</sup>, M.L. Cosmaro<sup>12</sup>, A. Cingolani<sup>13</sup> for Icona Foundation Study Group  
<sup>1</sup>Circolo di Cultura Omosessuale Mario Mieli, Roma, <sup>2</sup>Associazione Solidarietà Aids, Milano, <sup>3</sup>Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, <sup>4</sup>Clinical and Research Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>5</sup>Associazione Arcobaleno AIDS, Torino, <sup>6</sup>Network Persone Sieropositive, Milano, <sup>7</sup>Anlaids Onlus-ETS, Roma, <sup>8</sup>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, <sup>9</sup>Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, <sup>10</sup>Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, <sup>11</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>12</sup>Fondazione LILA Milano, Milano, <sup>13</sup>Infectious Diseases Unit, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
- ## STIs, Sexually transmitted infections
- P 297 Ureaplasma urealyticum: a controversial pathogen to treat. The experience from a difficult-to-reach population**  
A. Colpani<sup>1</sup>, A. Donisi<sup>2</sup>, A. De Vito<sup>1</sup>, N. Geremia<sup>3</sup>, B. Zauli<sup>1</sup>, V. Fiore<sup>1</sup>, S. Babudieri<sup>1</sup>, G. Madeddu<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, <sup>2</sup>Migration Health Unit, Primary Health Care Department, AUSL Piacenza, Piacenza, <sup>3</sup>Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale "Dell'Angelo", Venice, Italy
- P 298 Reduction of sexual risky behavior and vaccination do not explain decreased incidence of Mpox among PrEP users attending a community-based facility**  
R. Rossotti<sup>1,2</sup>, D. Calzavara<sup>2,3</sup>, M. Cernuschi<sup>2,3</sup>, A. De Bona<sup>2,4</sup>, A. Tavelli<sup>5</sup>, S. Bossolasco<sup>2,3</sup>, C. Muccini<sup>2,3</sup>, D. Tesoro<sup>2,4</sup>, D. Moschese<sup>2,6</sup>, G. Mule<sup>2,4</sup>, A. d'Arminio Monforte<sup>7</sup>  
<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>2</sup>Milano Checkpoint, Milan, Italy, <sup>3</sup>San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>ASST Santi Paolo e Carlo, Milan, Italy, <sup>5</sup>ICONA Foundation, Milan, Italy, <sup>6</sup>ASST Fatebenefratelli Sacco, Milan, Italy, <sup>7</sup>University of Milan, Milan, Italy
- P 299 Monkeypox in a woman with HIV infection: a case report**  
S.M. Susini<sup>1</sup>, A. Maddaloni<sup>2</sup>, P. Bellopede<sup>2</sup>, M. Talamo<sup>2</sup>, S. Parente<sup>2</sup>, A. Giaccone<sup>2</sup>, A. Gallicchio<sup>2</sup>, A.R. Buonomo<sup>1</sup>, I. Gentile<sup>1</sup>, A. Franco<sup>2</sup>  
<sup>1</sup>AOU Federico II, U.O.C. Malattie Infettive e Tropicali, Napoli, <sup>2</sup>AORN Ospedale dei Colli, Ospedale D. Cotugno, U.O.C. Malattie Infettive dell'Età Geriatrica, Napoli
- P 300 Doxycycline oral treatment for latent syphilis: evaluation of outcomes and tolerability**  
M.L. Colombo<sup>1,2</sup>, D. Moschese<sup>3</sup>, A. Rizzo<sup>4</sup>, F. Petri<sup>5</sup>, G. Carrozzo<sup>1,2</sup>, M.V. Cossu<sup>3</sup>, G. Rizzardini<sup>3</sup>, A. Gori<sup>2,5</sup>, S. Antinori<sup>1,2</sup>  
<sup>1</sup>III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>2</sup>Università degli Studi di Milano, DIBIC Luigi Sacco, Milan, Italy, <sup>3</sup>I Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>4</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, <sup>5</sup>II Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
- P 301 Luetic infection in the present day: characteristics of a cohort of patients diagnosed with syphilis in the Roman suburbs**  
M. Zordan, M. Compagno, A. Di Lorenzo, L. Ansaldo, D. Checchi, L. Ferrari, E. Teti, M. Iannetta, L. Sarmati  
Roma, Università di Tor Vergata
- P 302 Prevalence of Human Papillomavirus (HPV) in the Oral swabs of patients at University Hospital of Bari**  
D. Nesta<sup>1</sup>, V. De Laurentis<sup>1</sup>, E. Milano<sup>2</sup>, M. Lorusso<sup>1</sup>, S. Piccolo<sup>1</sup>, L. Capozzi<sup>1</sup>, M. Mastria<sup>1</sup>, S. Garzone<sup>1</sup>, E.M. Ranieri<sup>1</sup>, S. Stolfi<sup>1</sup>, F. Romanelli<sup>1</sup>, S. Denicolò<sup>1</sup>, L. Nisi<sup>1</sup>, M.T. Montagna<sup>3</sup>, A. Saracino<sup>2</sup>, A. Mosca<sup>1</sup>, R. Del Prete<sup>1</sup>, A. Visceglia<sup>1</sup>, L. Ronga<sup>1</sup>  
<sup>1</sup>UOC Microbiology and Virology, University "Aldo Moro", Bari, <sup>2</sup>Clinic of Infectious Diseases, University "Aldo Moro", Bari, <sup>3</sup>Department of Biomedical Sciences and Human Oncology, Section of Hygiene, University "Aldo Moro", Bari
- P 303 Prevalence of seven sexually transmitted pathogens in oral cavity and the impact of a new dedicated ambulatory for STI and Pre-Exposure Prophylaxis (PrEP) in Bari**  
M. Lorusso<sup>1</sup>, L. Ronga<sup>1</sup>, E. Milano<sup>2</sup>, V. De Laurentis<sup>1</sup>, M. Mastria<sup>1</sup>, S. Garzone<sup>1</sup>, F. Indraccolo<sup>1</sup>, S. Stolfi<sup>1</sup>, F. Romanelli<sup>1</sup>, S. Denicolò<sup>1</sup>, L. Nisi<sup>1</sup>, M.T. Montagna<sup>3</sup>, A. Saracino<sup>2</sup>, A. Mosca<sup>1</sup>, R. Del Prete<sup>1</sup>  
<sup>1</sup>UOC Microbiology and Virology, University "Aldo Moro", Bari, <sup>2</sup>Clinic of Infectious Diseases, University "Aldo Moro", Bari, <sup>3</sup>Department of Biomedical Sciences and Human Oncology, Section of Hygiene, University "Aldo Moro", Bari
- P 304 Neisseria meningitidis in PrEP users: sexual transmission and isolation of an ESBL positive strain**  
G. Gamboni<sup>1</sup>, C. Pallotto<sup>1</sup>, C. Papalini<sup>1</sup>, A. Repetto<sup>2</sup>, F. Allegrucci<sup>2</sup>, E. Schiaroli<sup>1</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, <sup>2</sup>Department of Medicine and Surgery, Medical Microbiology Section, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy



- P 305 HIV and Syphilis rapid tests among University students: a prevention and awareness campaign towards sexually transmitted infections**  
F. De Gregorio, M. Niglio, C. Grillo, R. Papale, M. Caggese, F.R.P. Ieva, A. Narducci, E.P. Drago, T.A. Santantonio, S. Lo Caputo  
Infectious Disease Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
- P 306 Distinct mucosal Interferon response to MPXV, HIV and HPV infections in anal cells from MSM**  
M. Fracella<sup>1</sup>, L. Maddaloni<sup>2</sup>, A. D'Auria<sup>1</sup>, F. Frasca<sup>1</sup>, L. Santinelli<sup>2</sup>, C. Bitossi<sup>1</sup>, N. Cavallari<sup>2</sup>, P. Mazzetti<sup>3</sup>, A. Pierangeli<sup>1</sup>, C.M. Mastroianni<sup>2</sup>, M. Pistello<sup>3</sup>, G. Antonelli<sup>1</sup>, G. D'Efforre<sup>2</sup>, C. Scagnolari<sup>1</sup>  
<sup>1</sup>Laboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Virology Section and Retrovirus Centre, Department of Biomedicine, University of Pisa, Pisa, Italy
- P 307 Rapid increase in syphilis diagnoses in Rome during the first quarter of 2023**  
C. Stingone, M. Giuliani, L. Gianserra, M.G. Donà, E. Giuliani, F. Pimpinelli, A. Latini  
San Gallicano Dermatological Institute IRCCS of Rome, Italy
- P 308 When it rains, it pours: early treatment with tecovirimat of myopericarditis associated with monkeypox infection in a person with HIV and previously undiagnosed Lyme disease**  
G. Formica<sup>2</sup>, F. Lagi<sup>1</sup>, A. Rostagno<sup>2</sup>, A. Milia<sup>3</sup>, S. Pradella<sup>4</sup>, G. Guazzini<sup>3</sup>, S. Tekle Kiros<sup>2</sup>, P. Corsi<sup>1</sup>, A. Bartoloni<sup>1,2</sup>, F. Pieralli<sup>3</sup>  
<sup>1</sup>Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, <sup>2</sup>Department of Clinical and experimental medicine, University of Florence, Florence, Italy, <sup>3</sup>Intermediate Care Unit, Careggi University Hospital, Florence, Italy, <sup>4</sup>Department of Radiology, Careggi University Hospital, Florence, Italy
- P 309 Neisseria gonorrhoeae in a localized septic arthritis: an unusual aetiology**  
M. Zagarrigo, S. Tedeschi, E. Zamparini, A. Cascavilla, G. Fornaro, A. Zuppiroli, P. Viale  
Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
- P 310 Analysis of STIs incidence and risk factors in a cohort of MSM attending a PrEP community-based center and the STD outpatient clinic of the Dermatology Department of S.Orsola-Malpighi Hospital in Bologna. One year follow-up data from SEX-CHECK-PLUS study**  
P. Fait<sup>1</sup>, M. Casarini<sup>1</sup>, D. Marzolla<sup>1</sup>, S. Cretella<sup>1</sup>, D. Testi<sup>1</sup>, B. Nuti<sup>1</sup>, A. Pozzi<sup>1</sup>, C. Patrucco<sup>1</sup>, L. Piazza<sup>1</sup>, I. Sartini<sup>1</sup>, L. Rapparini<sup>2</sup>, S. Mattioli<sup>3</sup>, M. Pedone<sup>3</sup>, S. Cecere<sup>3</sup>, L. Badia<sup>4</sup>, V. Gaspari<sup>2</sup>  
<sup>1</sup>Alma Mater Studiorum University, Infectious Disease Department, S.Orsola-Malpighi Hospital, Bologna, <sup>2</sup>Alma Mater Studiorum University, Dermatology Department, S. Orsola-Malpighi Hospital, Bologna, <sup>3</sup>Plus aps, PrEP Point Plus, Bologna, <sup>4</sup>Infectious Disease Department, Azienda USL di Imola
- P 311 Syphilis in PrEP users and PLWH attending an outpatient clinic of a large clinical centre in Rome**  
R.J. Steiner<sup>1</sup>, P.F. Salvo<sup>1</sup>, D. Zjalic<sup>2</sup>, D. Farinacci<sup>3</sup>, C. Savoia<sup>2</sup>, G. Baldin<sup>4</sup>, A. Ciccullo<sup>5</sup>, A. D'angelillo<sup>3</sup>, F. Lamanna<sup>1</sup>, S. Di Giambenedetto<sup>1,4</sup>, A. Borghetti<sup>4</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, <sup>2</sup>Sezione di Igiene, Dipartimento di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, <sup>3</sup>UOC Medicina Protetta - ASL Viterbo, Viterbo, <sup>4</sup>UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, <sup>5</sup>Malattie Infettive, Ospedale San Salvatore, L'Aquila
- P 312 A case of otic involvement in secondary syphilis**  
M. Abbott, A. Gizzi, F. Guida Marascia, D. Spicola, A. Sanfilippo, C. Buscemi, F. Di Lorenzo, C. Iaria  
UOC Malattie Infettive e Tropicali, ARNAS Civico, Palermo
- P 313 Case Report: A novel presentation of Neurosyphilis in a HIV-uninfected patient with fronto-temporal-parietal cerebral atrophy**  
E. Matteini<sup>1</sup>, A. Dusina<sup>1</sup>, F. Sanmartin<sup>1</sup>, A. Carbone<sup>1</sup>, E. Rando<sup>1</sup>, G. Maiuro<sup>1</sup>, A. Cingolani<sup>1</sup>, V. Guglielmi<sup>2</sup>, P. Del Giacomo<sup>1</sup>  
<sup>1</sup>Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome (IT), <sup>2</sup>Fondazione Pol. A. Gemelli IRCCS, Neurology Unit, Rome (IT)
- P 314 Effectiveness of the mpox vaccination campaign and vaccine safety profile – experience of a STI clinic during 2022 epidemic**  
D. Tesoro<sup>1</sup>, G. Mulè<sup>1</sup>, D. Barbanotti<sup>1</sup>, R. Castoldi<sup>1</sup>, L. Biasioli<sup>1</sup>, S. Pettenuzzo<sup>1</sup>, N. Gemignani<sup>1</sup>, F. Molà<sup>1</sup>, L.B. Lundgren<sup>1</sup>, A. De Bona<sup>1</sup>, A. d'Arminio Monforte<sup>2</sup>, G.C. Marchetti<sup>1</sup>  
<sup>1</sup>ASST Santi Paolo e Carlo, Milano, <sup>2</sup>Fondazione ICONA
- P 315 The impact of COVID-19 pandemic on STI trends and at-risk sexual behaviors. A national multicenter study**  
M. Giuliani<sup>1</sup>, A. Latini<sup>1</sup>, C. Negri<sup>2</sup>, C. Colli<sup>3</sup>, M. Grandolfo<sup>4</sup>, M.G. Donà<sup>1</sup>, C. Stingone<sup>1</sup>, E. Giuliani<sup>1</sup>, M. Farinella<sup>5</sup>, A. Caraglia<sup>6</sup>  
<sup>1</sup>Istituto Dermatologico San Gallicano, IRCCS, Rome, <sup>2</sup>Centro CMST/AIDS Gorizia Monfalcone, <sup>3</sup>Centro MTS UCO Clinica Dermatologica ASU Giuliano-Isoncina, <sup>4</sup>Centro MST Clinica Dermatologica Università di Bari, <sup>5</sup>Circolo di Cultura Omosessuale "Mario Mieli", Rome, <sup>6</sup>Ministero della Salute, Rome

## Virology and Pharmacology

- P 316 Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study**  
I. Vicenti<sup>1</sup>, S. Piemontese<sup>2</sup>, L. Fiaschi<sup>1</sup>, C. Biba<sup>1</sup>, A. Cervo<sup>3</sup>, I. Varasi<sup>1</sup>, F. Saladini<sup>1</sup>, G. Leonardi<sup>4</sup>, C.F. Perno<sup>5</sup>, C. Mussini<sup>6</sup>, M. Zazzi<sup>1</sup>, V. Borghi<sup>6</sup>  
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, <sup>2</sup>Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, Milan, <sup>3</sup>Infectious Diseases Unit, Department of Health Promotion Sciences and Mother and Child Care "Giuseppe D'Alessandro" (PROMI-SE), University of Palermo, Palermo, <sup>4</sup>Hematology Unit and Chair, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria Di Modena, University of Modena and Reggio Emilia, Modena, <sup>5</sup>Multimodal Research Area, Unit of Microbiology and Diagnostics in Immunology, Bambino Gesù Children's Hospital, IRCCS, Rome, <sup>6</sup>UO of infectious Diseases, University of Modena and Reggio Emilia, Modena
- P 317 Safety evaluation of cabotegravir in zebrafish embryos**  
S. Ferretti<sup>1</sup>, D. Zizioli<sup>1</sup>, I. Zanella<sup>1</sup>, L. Mignani<sup>1</sup>, M. Degli Antoni<sup>2</sup>, F. Castelli<sup>2</sup>, E. Quiros-Roldan<sup>2</sup>  
<sup>1</sup>Department of Molecular and Translational Medicine, University of Brescia, Brescia, <sup>2</sup>University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia
- P 318 Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat**  
S. Pagano<sup>1</sup>, C. Gervasoni<sup>1,2</sup>, S. Antinori<sup>1</sup>, V. Micheli<sup>3</sup>, A. Gori<sup>2</sup>, D. Cattaneo<sup>1,2</sup>  
<sup>1</sup>Department of Infectious Diseases, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy, <sup>2</sup>Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy, <sup>3</sup>Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco University hospital, Milan, Italy
- P 319 Single-cell transcriptomics of CSF and PBMC in a primary HIV infection of a subject already affected by multiple sclerosis**  
C. Pinnetti<sup>1</sup>, F. Messina<sup>2</sup>, G. Rozera<sup>2</sup>, P. Spezia<sup>2</sup>, I. Mastrarosa<sup>1</sup>, A. Vergori<sup>1</sup>, A. Antinori<sup>1</sup>, E. Girardi<sup>3</sup>, F. Vaia<sup>3</sup>, F. Maggi<sup>2</sup>, I. Abbate<sup>2</sup>  
<sup>1</sup>Clinical and Research Infectious Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Department of Translational Research, Retrovirus Center - University of Pisa, <sup>4</sup>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>5</sup>General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

- P 320 Use of HIV genotype resistance test in Italy: a national survey**  
A. De Vito<sup>1</sup>, A. Bezenchek<sup>2</sup>, R. Scutarì<sup>3,4</sup>, L. Colagrossi<sup>4,5</sup>, G. Valentini<sup>6</sup>, M.C. Bellocchi<sup>7</sup>, L. Pipitò<sup>8</sup>, S. Ferrara<sup>9</sup>, S. Malandrino<sup>9</sup>, M. Tallarita<sup>9</sup>, A. Cozzi-Lepri<sup>10</sup>, F. Ceccherini Silberstein<sup>7</sup>, S. Lo Caputo<sup>8</sup>, S. Rusconi<sup>11</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, <sup>2</sup>PRO-InfornaPRO S.r.l., Rome, Italy; EuResist Network GEIE, Rome, Italy, <sup>3</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>4</sup>Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>5</sup>Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>6</sup>Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy, <sup>7</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>8</sup>S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy, <sup>9</sup>Microbiology and Virology Unit, ASST Ospedale San Gerardo, Monza, Italy, <sup>10</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>11</sup>Unit of Infectious Diseases, University of Milano and ASST Fatebenefratelli "L. Sacco" Hospital, Milan, Italy
- P 321 Evaluation of ELITE InGenius® integrated system for detection, quantification and monitoring of HIV-1 RNA in Cerebrospinal Fluid**  
P. Paba<sup>1</sup>, G. Costanza<sup>1</sup>, S. Grelli<sup>1,2</sup>  
<sup>1</sup>Unit of Virology, Policlinic of Tor Vergata, Rome, Italy, <sup>2</sup>Department of Experimental Medicine, the University of Rome Tor Vergata, Rome, Italy
- P 322 Comparison of developmental safety between doravirine and efavirenz in zebrafish (*Danio rerio*) embryos**  
S. Ferretti<sup>1</sup>, S. Storti<sup>2</sup>, D. Zizioli<sup>1</sup>, I. Zanella<sup>3</sup>, F. Castelli<sup>2</sup>, E. Quiras-Roldan<sup>2</sup>  
<sup>1</sup>Department of Molecular and Translational Medicine, University of Brescia, <sup>2</sup>Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, <sup>3</sup>Department of Molecular and Translational Medicine, University of Brescia and Clinical Chemistry Laboratory, ASST Spedali Civili di Brescia
- P 323 Large proportion of new HIV diagnoses in Northern Italy sustained by non-B subtypes with higher HIV DNA in the Effector Memory subset**  
G. Bozzi<sup>1</sup>, M. Centazzo<sup>1,2</sup>, P. Saltini<sup>1,3</sup>, G.M. Butta<sup>1,2</sup>, A. Liparoti<sup>1,3</sup>, C. Bobbio<sup>1</sup>, A. Muscatello<sup>1</sup>, A. Gori<sup>3</sup>, A. Bandera<sup>1,3</sup>, L. Mangano<sup>2,3</sup>  
<sup>1</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Infectious Diseases, Milano, Italy, <sup>2</sup>INGM - Istituto Nazionale di Genetica Molecolare - Milano, Virology Unit, Milano, Italy, <sup>3</sup>Unimi - Università degli Studi di Milano, Milano, Italy
- P 324 Does proviral DNA-NGS match historical genotype?**  
F. Stefanelli<sup>3</sup>, A. Chiara Russo<sup>1,2</sup>, L. Labate<sup>1,2</sup>, C. Fracalvieri<sup>3</sup>, M. Cerchiaro<sup>1,2</sup>, M. Bavastro<sup>1,2</sup>, L. Taramasso<sup>1</sup>, M. Bassetti<sup>1,2</sup>, B. Bruzzone<sup>3</sup>, A. Di Biagio<sup>1,2</sup>  
<sup>1</sup>Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>3</sup>Hygiene Laboratory Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy
- P 325 The effects of cognate peptide recognition on proviruses in expanded T cell clones in an Elite Controller**  
F. Dragoni<sup>1,2</sup>, A.K. Kwaa<sup>1</sup>, C.C. Garliss<sup>1</sup>, R.T. Veenhuis<sup>1</sup>, B.A. Woldemeskel<sup>1</sup>, A. Camilo-Contreras<sup>1</sup>, H. Raymond<sup>3</sup>, A.G. Dykema<sup>1</sup>, E.P. Scully<sup>1</sup>, A.M. Rosecrans<sup>1</sup>, K.N. Smith<sup>1</sup>, F.D. Bushman<sup>3</sup>, F.R. Simonetti<sup>1</sup>, J.N. Blankson<sup>1</sup>  
<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>2</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>3</sup>Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
- P 326 HIV Drug Resistance: Sanger Sequencing versus Next Generation Sequencing**  
N. Randazzo<sup>1</sup>, G. Garzillo<sup>2</sup>, M. Lucente<sup>1</sup>, G. Cendarello<sup>4</sup>, V. Bartolacci<sup>5</sup>, P. De Leo<sup>6</sup>, E. Pontali<sup>7</sup>, A. Di Biagio<sup>2,3</sup>, S. Artoli<sup>7</sup>, B. Bruzzone<sup>2</sup>  
<sup>1</sup>Hygiene Laboratory Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>2</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>3</sup>Infectious Diseases Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy, <sup>4</sup>Infectious Diseases Unit, Sanremo Hospital, Imperia, Italy, <sup>5</sup>Infectious Diseases Unit, S. Corona Hospital, Pietra Ligure, Italy, <sup>6</sup>Infectious Diseases Unit, San Paolo Hospital, Savona, Italy, <sup>7</sup>Infectious Diseases Unit, Galliera Hospital, Genoa, Italy, <sup>8</sup>Infectious Diseases Unit, S. Andrea, La Spezia, Italy
- P 327 A novel NanoBRET protease sensor to sense HIV-1 PR activity in living cells**  
M. Centazzo<sup>1,2</sup>, A.V.V. Djossou<sup>1</sup>, G. Alvisi<sup>1</sup>  
<sup>1</sup>Department of Molecular Medicine, University of Padova, Padova Italy, <sup>2</sup>Current address INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy
- P 328 Evaluation of a new automated real-time PCR commercial test for HIV-DNA quantification in PBMC and whole blood samples**  
T. Alice<sup>1</sup>, F. Cerutti<sup>1</sup>, M.G. Milia<sup>1</sup>, G. Gregori<sup>1</sup>, E. Burdino<sup>1</sup>, A. Pilone<sup>1</sup>, M. Cazzadore<sup>1</sup>, E. Scuccimarra<sup>1</sup>, M. Ferrara<sup>2</sup>, S. Bonora<sup>2</sup>, V. Ghisetti<sup>1</sup>  
<sup>1</sup>Laboratory of Microbiology and Virology, ASL Città di Torino, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Italy
- P 329 Evaluation of the HIV1 ELITE MGB assay for HIV-1 RNA quantification: comparison with the COBAS HIV-1 test**  
T. Alice, F. Cerutti, M.G. Milia, G. Gregori, B. Simoncelli, A. Ognibene, P. Tremante, A. Bottoni, S. Monteleone, V. Ghisetti  
Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy
- P 330 Ritonavir-boosted atazanavir dose escalation to overcome the drug-drug interaction with rifampicin: effectiveness on intracellular and plasma drug concentrations**  
A. De Nicolò<sup>1</sup>, E. De Vivo<sup>1</sup>, H. Mugerwa<sup>2</sup>, S. Nakabuye<sup>2</sup>, J. Namusanje<sup>2</sup>, J. Kobusingye<sup>2</sup>, P. Dent<sup>3</sup>, K. Gausi<sup>3</sup>, C. Waitt<sup>4</sup>, A. D'Avolio<sup>1</sup>  
<sup>1</sup>University of Turin, Dept. of Medical Sciences, <sup>2</sup>Joint Clinical Research Centre, Kampala, Uganda, <sup>3</sup>University of Cape Town, Cape Town, South Africa, <sup>4</sup>University of Liverpool, Dept. of Pharmacology and Therapeutics, Liverpool, UK
- P 331 The application of HIV-1 genotype resistance test: a multicentre Italian virology laboratory experience**  
R. Scutarì<sup>1,2</sup>, L. Colagrossi<sup>2,3</sup>, A. Bezenchek<sup>4</sup>, A. De Vito<sup>5</sup>, G. Valentini<sup>6</sup>, M.C. Bellocchi<sup>7</sup>, L. Pipitò<sup>8</sup>, S. Ferrara<sup>9</sup>, S. Malandrino<sup>9</sup>, M. Tallarita<sup>9</sup>, A. Cozzi-Lepri<sup>10</sup>, S. Lo Caputo<sup>8</sup>, S. Rusconi<sup>11</sup>, M. Zazzi<sup>12</sup>, F. Ceccherini-Silberstein<sup>7</sup>  
<sup>1</sup>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, <sup>2</sup>Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>3</sup>Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy, <sup>4</sup>PRO-InfornaPRO S.r.l., Rome, Italy; EuResist Network GEIE, Rome, Italy, <sup>5</sup>Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, <sup>6</sup>Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy, <sup>7</sup>Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, <sup>8</sup>S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy, <sup>9</sup>Microbiology and Virology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, <sup>10</sup>Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, London, UK, <sup>11</sup>Unit of Infectious Diseases, University of Milano and ASST Fatebenefratelli "L. Sacco" Hospital, Milan, Italy, <sup>12</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy

15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



**GENERAL**  
**INFORMATION**

## Congress Venue



### Università degli Studi Aldo Moro

Piazza Cesare Battisti, 3

70121 Bari

<https://www.uniba.it/it>

## How to reach the Conference Venue



### Railway Station

Bari: 350 m from station



### Bari-Karol Wojtyła International Airport

9.8 km from the airport (21 minutes by car)



### Car

Wide pay parking available near the Conference Venue

## Conference registration

To attend the Conference, participant must submit the registration form through **MyICAR on the Conference website [www.icar2023.it](http://www.icar2023.it)**.

After completing the form, you will receive an email with a link to confirm the activation of your personal account.

## Official languages

Italian and English. No simultaneous translation provided.



## Pre-conference advanced courses and Congress dates

**Pre-conference advanced courses:** Wednesday, June 14 from 15.00 to 17.30

**Conference:** from Wednesday, June 14 h. 18.00 to Friday, June 16 h. 16.30

---

## Conference Secretariat opening times

- **Wednesday, June 14** from 10.30 to 18.00
  - **Thursday, June 15** from 08.30 to 19.00
  - **Friday, June 16** from 08.30 to 17.00
- 

## Exhibition Area opening times

- **Wednesday, June 14** from 15.00 to 18.00
  - **Thursday, June 15** from 09.00 to 18.45
  - **Friday, June 16** from 09.00 to 16.30
- 

## Lunches

- **Thursday, June 15** from 12.00 to 14.30
- **Friday, June 16** from 12.00 to 14.30

In a dedicated area inside the **Università degli Studi Aldo Moro**.

---



## Instructions for Speakers


It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

A slides template for Speakers' presentations is available for download on the Conference website [www.icar2023.it](http://www.icar2023.it)

## Oral Communication Sessions



Selected abstract will be presented in Oral Communication Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 8/10 (power point) slides** resuming their abstract. Time allowed for presentation:

**10 minutes followed by 2 minutes for discussion.**

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

## Digital Poster Exhibition

All the posters can be viewed through dedicated monitors located at **Università degli Studi Aldo Moro**.

Don't forget to pick up the USB poster pendrive at the Gilead booth!



Con la sponsorizzazione non condizionante di Gilead Sciences



## Official events

### Quick test for HIV, HCV and Syphilis

Fontana Giardini P.zza Umberto I, in front of Università degli Studi Aldo Moro:

- **Wednesday, June 14** from 16.00 to 20.00
- **Thursday, June 15** from 11.00 to 14.00  
and from 16.00 to 20.00
- **Friday, June 16** from 11.00 to 18.00

Healthcare personnel will perform free rapid testing for HIV, HCV and Syphilis at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.

*Promosso da Cama Lila e Medici con l'Africa - Cuamm.  
Con il patrocinio della Città di Bari.  
In collaborazione con Abbot e Alifax*



### RaccontART - 9° Edition

Presentation of the finalist works and Winners' Awards

**Wednesday, June 14, Università degli Studi Aldo Moro**

● **Aula V** from 15.00 to 17.30

Three Winners

● **Teatro Petruzzelli** from 19.00 to 19.20

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS, Covid and STIs through various forms of expression. The winners will be awarded by the Jury composed of leading representatives of the national cultural, scientific and technical world.

*Con il supporto incondizionato di Gilead Sciences  
Con il patrocinio della Città di Bari*



## Mostra multimediale

### "Una storia positiva" di Simone Cerio

#### Contro lo Stigma e l'auto-Stigma

Andrea, Anthony, Maurizio e Angela sono i protagonisti di "Una storia positiva". Ognuno di loro ha subito lo stesso processo di discriminazione ed esclusione sociale per cause diverse ma, nonostante ciò, i quattro sono riusciti a ricostruire un tessuto familiare nuovo, fatto di protezione, confronti, tenerezze, supporti reciproci e amori. La loro è una famiglia allargata, dove ogni componente gioca un ruolo per l'altro: una coppia, in cui uno è sieropositivo e l'altro no, un amico e coinquilino che condivide le stesse problematiche di salute di uno dei due, ed infine una vicina di casa, mamma acquisita e spalla dei tre.


**Una storia positiva** per chi osserva da fuori e per chi allo stesso tempo è testimone diretto di come l'amore e la conoscenza sono gli unici strumenti che ci permettono di sviluppare un senso di appartenenza ed inclusione, sentimenti indispensabili a fronteggiare lo stigma.

Una Mostra itinerante che si snoda nel centro di Bari fino a raggiungere la sede museale al **Centro Polifunzionale Studenti** (Palazzo Ex Poste, Piazza Cesare Battisti 1, Bari): **dal 13 al 16 giugno**.



I punti della mostra itinerante:

- 1 Giardino "Fabrizio De Andrè", intersezione Molo di San Nicola con Lungomare Araldo di Crollalanza
- 2 Corso Cavour, prospiciente Teatro Petruzzelli
- 3 Via Sparano da Bari, adiacenze Chiesa San Ferdinando
- 4 Giardini di Piazza Umberto I, adiacenze fontana
- 5 Piazza Cesare Battisti, angolo Via Scipione Crisanzio
- 6 Piazza Cesare Battisti, angolo Via Domenico Nicolai



Sponsorizzato da ViiV Healthcare





## Special Awards

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 15th edition of ICAR awards as follows:

### ICAR-CROI Awards 2023

The absolute winners among the young Italian investigators who presented their work at CROI 2023

- **N. 1 Award** of € 1.000,00 for the best work in **Clinical**
- **N. 1 Award** of € 1.000,00 for the best work in **Basic Sciences**

**Winners will be announced during the ICAR-CROI Awards 2023 Session in Auditorium Aldo Moro on Friday June 16 from 08.30 to 09.00**



### ICAR 2023 Scientific Committee Awards

The 15th ICAR Chairs and Scientific Secretariat will announce the "Scientific Committee Awards": the ICAR awards to the best abstracts

- **N. 1 Award** of € 1.000,00 for the best **Clinical** abstract
- **N. 1 Award** of € 1.000,00 for the best **Basic Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Social Science** abstract

**Winners will be announced during the ICAR 2023 Special Awards Session in Auditorium Aldo Moro on Friday June 16 from 16.00**



### SIMIT Special Awards

The 15th ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards dedicated to Young Investigators, whose abstracts have been accepted as Oral Communications:

- **N. 1 Award** of € 2.000,00 for the best **Clinical HIV** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical Hepatitis Virus** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical SARS-CoV-2** abstract
- **N. 1 Award** of € 2.000,00 for the best **Virology and Immunopathogenesis** abstract
- **N. 1 Award** of € 2.000,00 for the best **Epidemiology and Social Science** abstract

Only young investigators under 45 years of age and regularly registered to SIMIT for years 2022 and 2023 will be selected.

**Abstracts will be evaluated at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2023 Special Awards Session in Auditorium Aldo Moro on Friday June 16 from 16.00**



## ICAR APP 2023

Designed to facilitate participation in ICAR 2023 and to respond to request for effective and high performance digital tools and supports. Two simple steps to access:


- 1. Download the ICAR App "ICAR Italian Conference"** for free from the main stores (Apple Store and Google Play) "Minimum system requirements required for the App: Android 8.0 and iOS 13"
- 2. Login App:** enter your personal login credentials (username and password) sent to you by the Organizing Secretariat Effetti

### Menu Functions

- 1. HOME:** Simple and immediate with a usability designed specifically for the Conference. Each menu item corresponds to a precise and useful feature.
- 2. PROGRAMMA SCIENTIFICO:** Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: these will be saved in My Agenda
- 3. MY AGENDA:** User can customize their own Agenda using this function. ICAR 2023 App will create the list of favorite selected sessions in a chronological order
- 4. PROGRAMME AT A GLANCE:** to quickly check Programme, rooms and sessions schedule
- 5. VOTAZIONE:** It allows user to vote when sessions require this functionality
- 6. RACCONTART:** To access the Art Contest, consult the works in competition, learn about participating schools, and much more
- 7. ABSTRACT:** All abstracts accepted, broken down by type of presentation (Oral, Poster) and Abstract Reviewers. From June 14, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs
- 8. ICAR AWARDS:** The official rewards that ICAR assign to young investigators and Community ambassadors
- 9. TEST RAPIDO HIV-HCV:** Where, when and at what times: all the appointments of the Quick test for HIV, HCV
- 10. ICAR SOCIAL:** Direct links to ICAR 2023 Social. Stay connect #ICAR2023
- 11. INFORMAZIONI GENERALI:** A menu item for the most useful and important links: Congress Venue, Transportation and much more...



Inquadra il QRcode  
e scarica l'App



Con la sponsorizzazione non condizionante di Janssen



## ICAR for Participants

### Community Village

A specific area of the **Università degli Studi Aldo Moro** dedicated to the Community Village: a meeting point for all participants to visit the booths of patient associations and meet the Community activists.



### Nice to ICAR YOU

The ICAR 2023 welcome point, in front of the **Università degli Studi Aldo Moro**: all registered participants can ask for all the informations and collect the ICAR 2023 T-shirt.



### POSTER 4 YOU

A free service for selected posters' Authors to create their own posters and record their comments. **ICAR Poster-4-you USB pendrive** can be requested showing the coupon at the Gilead Sciences booth.

*Con la sponsorizzazione non condizionante di Gilead Sciences*



### ICAR Web Repository

After the congress, on the official website **www.icar2023.it** you will find: ICAR 2023 web repository of abstracts, presentations, oral communications and accepted posters, podcasts and photo gallery.



### ICAR SOCIAL

Direct links to ICAR 2023 Social.

Stay connect #ICAR2023

[www.instagram.com/icarcongress](https://www.instagram.com/icarcongress)

[www.twitter.com/ICARcongress](https://www.twitter.com/ICARcongress)

[www.facebook.com/ICARcongress](https://www.facebook.com/ICARcongress)



Participants are hereby informed that in some spaces where the conference and ancillary activities will take place, photographs/video footage intended for online publication may be taken; participants will be notified through dedicated signage.



## CME Accreditation

### Conference

The 15th ICAR Conference has been accredited to the Italian Ministry of Health for 12,6 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
<b>Wednesday, June 14</b> 150-374173	<b>1,4</b>	<b>Medical Doctor</b> (all disciplines)
<b>Thursday, June 15</b> 150-374229	<b>6,3</b>	<b>Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist</b>
<b>Friday, June 16</b> 150-374237	<b>4,9</b>	

### Pre-conference advanced Courses

The 15th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professionals
<b>HIV infection in the migrant and refugee population</b> 150-382739	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Dermatology and Venereology; Gastroenterology; Infectious Diseases; Internal Medicine; Pharmacology and Clinical Toxicology; Microbiology and Virology; Clinical Pathology; Hygiene, Epidemiology and Public Health; <b>Healthcare Assistant, SSN Public Pharmacist, Professional Educator, Psychologist</b>
<b>Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer</b> 150-382780	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Dermatology and Venereology; Gastroenterology; Infectious Diseases; Internal Medicine; Pharmacology and Clinical Toxicology; Microbiology and Virology; Clinical Pathology; Hygiene, Epidemiology and Public Health; Psychotherapy; <b>Biologist Healthcare Assistant, SSN Public Pharmacist, Professional Educator, Psychologist, Nurse</b>
<b>Clinical virology: dealing with HIV infection today</b> 150-382792	<b>2</b>	<b>Medical Doctor</b> Allergology and Clinical Immunology; Dermatology and Venereology; Gastroenterology; Infectious Diseases; Internal Medicine; Pharmacology and Clinical Toxicology; Microbiology and Virology; Clinical Pathology; Hygiene, Epidemiology and Public Health; Psychotherapy; <b>Biologist Healthcare Assistant, SSN Public Pharmacist, Professional Educator, Psychologist, Nurse</b>



## CME Accreditation

### Obtaining credits

#### Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Fill in the assessment and approval questionnaires for each individual conference day within the **MyICAR reserved area** in the official website **www.icar2023.it**

#### Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Moderators will be given 1 credit for each moderation session.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

#### Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of the scientific work or each individual course and the completion of the assessment questionnaire (only one attempt will be allowed) and online approval, within its MyICAR reserved area.

#### CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

#### SVC Assobiomedica

The pre-conference courses and the Congress were assessed as compliant with the Ethics' Code by the Assobiomedica Conference Evaluation System (SVC).



## Registration fees

### Pre-conference advanced Courses

**Free of charge** (registrations available on a "first come, first served" basis). Included congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), CME registration, documentation.

### Conference

#### Conference registration fees (22% VAT not included)

<b>Physicians</b> (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 850,00
<b>Physicians &lt; 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse</b>	€ 400,00
<b>Students/PhD and Post-graduate medical trainees</b>	Free
<b>Members of HIV/AIDS Community</b>	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance), Opening Session, coffee break, lunches at the congress on 15 and 16 June, CME registration, Conference USB poster.

#### Daily Conference registration fees (22% VAT not included)

<b>Physicians</b> (all disciplines): Healthcare Assistant, Biologist, Professional Educator, SSN Public Pharmacist, Nurse, Medical Technician of Biomedical Laboratory, Psychologist, Psychotherapist	€ 350,00
<b>Physicians &lt; 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse</b>	€ 200,00
<b>Students/PhD and Post-graduate medical trainees</b>	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch of the day, CME registration, Conference USB poster.



15° CONGRESSO NAZIONALE

**BARI** 14-16 GIUGNO 2023  
UNIVERSITA' DEGLI STUDI ALDO MORO



**Italian Conference**  
on **AIDS** and **Antiviral**  
**Research**

Presidenza del Congresso:

F. Ceccherini Silberstein

M. Formisano

S. Lo Caputo

A. Saracino

From prevention to cure: ready for new challenges



**CONGRESS**  
**MAP**

A vibrant watercolor illustration of the Bari skyline, featuring various buildings, a lighthouse, and a church, set against a blue sea with white waves. The colors are bright and saturated, creating a lively and artistic representation of the city.




ICAR 2023  
Welcome area

Nice to  
ICAR  
you







**AREA ESPOSITIVA**

- 1 Abbott
- 2 janssen
- 3 ViiV Healthcare
- 4 GILEAD
- 5 GSK
- 12 ReAd files Fondazione Icona

**POP UP**

- 7 VIATRIS
- 8 VIATRIS
- 10 ELITechGroup EMPOWERING IVD

**AREA SPONSOR**

- 11 MSD

**TORRE LED**

- A VIATRIS
- B moderna
- C VIATRIS

**MONITOR POSTER 4 YOU**

- Y GILEAD



**DESK ASSOCIAZIONI**

- 12 VILLA MARAINI
- 13 MARIO MIELI
- 14 ARCOBALENO Aids ODV
- 15 ASA Onlus
- 16 EpaC Onlus
- 17 CAMA LILA
- 18 LILA
- 19 ARCIGAY
- 20 Milano Check Point
- 21 NADIR
- 22 NPS Italia Onlus
- 23 PLUS
- 24 C.I.C.A.
- 25 ANLAIDS

**ALTRI DESK**

- 26 ALIFAX
- 27 CUAMM



15° CONGRESSO NAZIONALE



Italian Conference  
on **AIDS** and **Antiviral**  
**Research**



effetti

## THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

### PLATINUM



### GOLD



### SILVER



### OTHERS

